Datasets:
bio-datasets
/
bigbio-ner-merged

Dataset card Viewer Files Community
answer
stringlengths
1
16.1k
id
stringlengths
7
56
instruction
stringlengths
106
72.6k
ner_tags
sequence
text
stringlengths
5
72.4k
tokens
sequence
types
sequence
Phospholipase A2 is a GENE-Y, p - bromophenacyl bromide is a CHEMICAL, arachidonyl trifluoromethyl ketone is a CHEMICAL, interleukin-2 is a GENE-Y, IL-2 is a GENE-Y, Phospholipase A2 is a GENE-Y, PLA2 is a GENE-Y, cytokine is a GENE-N, PLA2 is a GENE-Y, p - bromophenacyl bromide is a CHEMICAL, BPB is a CHEMICAL, arachidonyl trifluoromethyl ketone is a CHEMICAL, AACOCF3 is a CHEMICAL, interleukin-2 is a GENE-Y, IL-2 is a GENE-Y, BPB is a CHEMICAL, AACOCF3 is a CHEMICAL, phorbol 12-myristate 13-acetate is a CHEMICAL, IL-2 is a GENE-Y, IL-2 is a GENE-Y, BPB is a CHEMICAL, AACOCF3 is a CHEMICAL, IL-2 is a GENE-Y, PLA2 is a GENE-Y, BPB is a CHEMICAL, AACOCF3 is a CHEMICAL, PLA2 is a GENE-Y, BPB is a CHEMICAL, AACOCF3 is a CHEMICAL, IL-2 is a GENE-Y, PLA2 is a GENE-Y
22715_task0
Sentence: Phospholipase A2 inhibitors p-bromophenacyl bromide and arachidonyl trifluoromethyl ketone suppressed interleukin-2 (IL-2) expression in murine primary splenocytes. Phospholipase A2 (PLA2) has been postulated to play a role in the regulation of cytokine expression. Therefore, the objective of the present study was to investigate the effects of PLA2 inhibitors p-bromophenacyl bromide (BPB) and arachidonyl trifluoromethyl ketone (AACOCF3) on interleukin-2 (IL-2) expression in murine primary splenocytes. Pretreatment of the splenocytes with both BPB and AACOCF3 suppressed phorbol 12-myristate 13-acetate plus ionomycin-induced IL-2 secretion in a concentration-dependent manner. Inhibition > 90% of IL-2 secretion was observed at 1 microM BPB and 10 microM AACOCF3 compared to the respective vehicle control. Likewise, IL-2 steady-state mRNA expression was inhibited by both PLA2 inhibitors in a concentration-dependent fashion with > 90% inhibition at 1 microM BPB and 20 microM AACOCF3. Taken together, these data demonstrated that PLA2 inhibitors BPB and AACOCF3 are robust inhibitors of IL-2 expression at both the mRNA and protein levels in murine splenocytes. Moreover, these findings suggest that drugs and chemicals which inhibit PLA2 may have marked effects on T-cell function. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-N, GENE-Y, CHEMICAL
[ "B-GENE-Y", "I-GENE-Y", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Phospholipase A2 inhibitors p-bromophenacyl bromide and arachidonyl trifluoromethyl ketone suppressed interleukin-2 (IL-2) expression in murine primary splenocytes. Phospholipase A2 (PLA2) has been postulated to play a role in the regulation of cytokine expression. Therefore, the objective of the present study was to investigate the effects of PLA2 inhibitors p-bromophenacyl bromide (BPB) and arachidonyl trifluoromethyl ketone (AACOCF3) on interleukin-2 (IL-2) expression in murine primary splenocytes. Pretreatment of the splenocytes with both BPB and AACOCF3 suppressed phorbol 12-myristate 13-acetate plus ionomycin-induced IL-2 secretion in a concentration-dependent manner. Inhibition > 90% of IL-2 secretion was observed at 1 microM BPB and 10 microM AACOCF3 compared to the respective vehicle control. Likewise, IL-2 steady-state mRNA expression was inhibited by both PLA2 inhibitors in a concentration-dependent fashion with > 90% inhibition at 1 microM BPB and 20 microM AACOCF3. Taken together, these data demonstrated that PLA2 inhibitors BPB and AACOCF3 are robust inhibitors of IL-2 expression at both the mRNA and protein levels in murine splenocytes. Moreover, these findings suggest that drugs and chemicals which inhibit PLA2 may have marked effects on T-cell function.
[ "Phospholipase", "A2", "inhibitors", "p", "-", "bromophenacyl", "bromide", "and", "arachidonyl", "trifluoromethyl", "ketone", "suppressed", "interleukin-2", "(", "IL-2", ")", "expression", "in", "murine", "primary", "splenocytes", ".", "\n", "Phospholipase", "A2", "(", "PLA2", ")", "has", "been", "postulated", "to", "play", "a", "role", "in", "the", "regulation", "of", "cytokine", "expression", ".", "Therefore", ",", "the", "objective", "of", "the", "present", "study", "was", "to", "investigate", "the", "effects", "of", "PLA2", "inhibitors", "p", "-", "bromophenacyl", "bromide", "(", "BPB", ")", "and", "arachidonyl", "trifluoromethyl", "ketone", "(", "AACOCF3", ")", "on", "interleukin-2", "(", "IL-2", ")", "expression", "in", "murine", "primary", "splenocytes", ".", "Pretreatment", "of", "the", "splenocytes", "with", "both", "BPB", "and", "AACOCF3", "suppressed", "phorbol", "12-myristate", "13-acetate", "plus", "ionomycin", "-", "induced", "IL-2", "secretion", "in", "a", "concentration", "-", "dependent", "manner", ".", "Inhibition", ">", "90", "%", "of", "IL-2", "secretion", "was", "observed", "at", "1", "microM", "BPB", "and", "10", "microM", "AACOCF3", "compared", "to", "the", "respective", "vehicle", "control", ".", "Likewise", ",", "IL-2", "steady", "-", "state", "mRNA", "expression", "was", "inhibited", "by", "both", "PLA2", "inhibitors", "in", "a", "concentration", "-", "dependent", "fashion", "with", ">", "90", "%", "inhibition", "at", "1", "microM", "BPB", "and", "20", "microM", "AACOCF3", ".", "Taken", "together", ",", "these", "data", "demonstrated", "that", "PLA2", "inhibitors", "BPB", "and", "AACOCF3", "are", "robust", "inhibitors", "of", "IL-2", "expression", "at", "both", "the", "mRNA", "and", "protein", "levels", "in", "murine", "splenocytes", ".", "Moreover", ",", "these", "findings", "suggest", "that", "drugs", "and", "chemicals", "which", "inhibit", "PLA2", "may", "have", "marked", "effects", "on", "T", "-", "cell", "function", "." ]
[ "CHEMICAL", "GENE-Y", "GENE-N" ]
Phospholipase A2 is a GENE-Y, p - bromophenacyl bromide is a CHEMICAL, arachidonyl trifluoromethyl ketone is a CHEMICAL, interleukin-2 is a GENE-Y, IL-2 is a GENE-Y, Phospholipase A2 is a GENE-Y, PLA2 is a GENE-Y, cytokine is a GENE-N, PLA2 is a GENE-Y, p - bromophenacyl bromide is a CHEMICAL, BPB is a CHEMICAL, arachidonyl trifluoromethyl ketone is a CHEMICAL, AACOCF3 is a CHEMICAL, interleukin-2 is a GENE-Y, IL-2 is a GENE-Y, BPB is a CHEMICAL, AACOCF3 is a CHEMICAL, phorbol 12-myristate 13-acetate is a CHEMICAL, IL-2 is a GENE-Y, IL-2 is a GENE-Y, BPB is a CHEMICAL, AACOCF3 is a CHEMICAL, IL-2 is a GENE-Y, PLA2 is a GENE-Y, BPB is a CHEMICAL, AACOCF3 is a CHEMICAL, PLA2 is a GENE-Y, BPB is a CHEMICAL, AACOCF3 is a CHEMICAL, IL-2 is a GENE-Y, PLA2 is a GENE-Y
22715_task1
Sentence: Phospholipase A2 inhibitors p-bromophenacyl bromide and arachidonyl trifluoromethyl ketone suppressed interleukin-2 (IL-2) expression in murine primary splenocytes. Phospholipase A2 (PLA2) has been postulated to play a role in the regulation of cytokine expression. Therefore, the objective of the present study was to investigate the effects of PLA2 inhibitors p-bromophenacyl bromide (BPB) and arachidonyl trifluoromethyl ketone (AACOCF3) on interleukin-2 (IL-2) expression in murine primary splenocytes. Pretreatment of the splenocytes with both BPB and AACOCF3 suppressed phorbol 12-myristate 13-acetate plus ionomycin-induced IL-2 secretion in a concentration-dependent manner. Inhibition > 90% of IL-2 secretion was observed at 1 microM BPB and 10 microM AACOCF3 compared to the respective vehicle control. Likewise, IL-2 steady-state mRNA expression was inhibited by both PLA2 inhibitors in a concentration-dependent fashion with > 90% inhibition at 1 microM BPB and 20 microM AACOCF3. Taken together, these data demonstrated that PLA2 inhibitors BPB and AACOCF3 are robust inhibitors of IL-2 expression at both the mRNA and protein levels in murine splenocytes. Moreover, these findings suggest that drugs and chemicals which inhibit PLA2 may have marked effects on T-cell function. Instructions: please typing these entity words according to sentence: Phospholipase A2, p - bromophenacyl bromide, arachidonyl trifluoromethyl ketone, interleukin-2, IL-2, Phospholipase A2, PLA2, cytokine, PLA2, p - bromophenacyl bromide, BPB, arachidonyl trifluoromethyl ketone, AACOCF3, interleukin-2, IL-2, BPB, AACOCF3, phorbol 12-myristate 13-acetate, IL-2, IL-2, BPB, AACOCF3, IL-2, PLA2, BPB, AACOCF3, PLA2, BPB, AACOCF3, IL-2, PLA2 Options: GENE-N, GENE-Y, CHEMICAL
[ "B-GENE-Y", "I-GENE-Y", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Phospholipase A2 inhibitors p-bromophenacyl bromide and arachidonyl trifluoromethyl ketone suppressed interleukin-2 (IL-2) expression in murine primary splenocytes. Phospholipase A2 (PLA2) has been postulated to play a role in the regulation of cytokine expression. Therefore, the objective of the present study was to investigate the effects of PLA2 inhibitors p-bromophenacyl bromide (BPB) and arachidonyl trifluoromethyl ketone (AACOCF3) on interleukin-2 (IL-2) expression in murine primary splenocytes. Pretreatment of the splenocytes with both BPB and AACOCF3 suppressed phorbol 12-myristate 13-acetate plus ionomycin-induced IL-2 secretion in a concentration-dependent manner. Inhibition > 90% of IL-2 secretion was observed at 1 microM BPB and 10 microM AACOCF3 compared to the respective vehicle control. Likewise, IL-2 steady-state mRNA expression was inhibited by both PLA2 inhibitors in a concentration-dependent fashion with > 90% inhibition at 1 microM BPB and 20 microM AACOCF3. Taken together, these data demonstrated that PLA2 inhibitors BPB and AACOCF3 are robust inhibitors of IL-2 expression at both the mRNA and protein levels in murine splenocytes. Moreover, these findings suggest that drugs and chemicals which inhibit PLA2 may have marked effects on T-cell function.
[ "Phospholipase", "A2", "inhibitors", "p", "-", "bromophenacyl", "bromide", "and", "arachidonyl", "trifluoromethyl", "ketone", "suppressed", "interleukin-2", "(", "IL-2", ")", "expression", "in", "murine", "primary", "splenocytes", ".", "\n", "Phospholipase", "A2", "(", "PLA2", ")", "has", "been", "postulated", "to", "play", "a", "role", "in", "the", "regulation", "of", "cytokine", "expression", ".", "Therefore", ",", "the", "objective", "of", "the", "present", "study", "was", "to", "investigate", "the", "effects", "of", "PLA2", "inhibitors", "p", "-", "bromophenacyl", "bromide", "(", "BPB", ")", "and", "arachidonyl", "trifluoromethyl", "ketone", "(", "AACOCF3", ")", "on", "interleukin-2", "(", "IL-2", ")", "expression", "in", "murine", "primary", "splenocytes", ".", "Pretreatment", "of", "the", "splenocytes", "with", "both", "BPB", "and", "AACOCF3", "suppressed", "phorbol", "12-myristate", "13-acetate", "plus", "ionomycin", "-", "induced", "IL-2", "secretion", "in", "a", "concentration", "-", "dependent", "manner", ".", "Inhibition", ">", "90", "%", "of", "IL-2", "secretion", "was", "observed", "at", "1", "microM", "BPB", "and", "10", "microM", "AACOCF3", "compared", "to", "the", "respective", "vehicle", "control", ".", "Likewise", ",", "IL-2", "steady", "-", "state", "mRNA", "expression", "was", "inhibited", "by", "both", "PLA2", "inhibitors", "in", "a", "concentration", "-", "dependent", "fashion", "with", ">", "90", "%", "inhibition", "at", "1", "microM", "BPB", "and", "20", "microM", "AACOCF3", ".", "Taken", "together", ",", "these", "data", "demonstrated", "that", "PLA2", "inhibitors", "BPB", "and", "AACOCF3", "are", "robust", "inhibitors", "of", "IL-2", "expression", "at", "both", "the", "mRNA", "and", "protein", "levels", "in", "murine", "splenocytes", ".", "Moreover", ",", "these", "findings", "suggest", "that", "drugs", "and", "chemicals", "which", "inhibit", "PLA2", "may", "have", "marked", "effects", "on", "T", "-", "cell", "function", "." ]
[ "CHEMICAL", "GENE-Y", "GENE-N" ]
Phospholipase A2, p - bromophenacyl bromide, arachidonyl trifluoromethyl ketone, interleukin-2, IL-2, Phospholipase A2, PLA2, cytokine, PLA2, p - bromophenacyl bromide, BPB, arachidonyl trifluoromethyl ketone, AACOCF3, interleukin-2, IL-2, BPB, AACOCF3, phorbol 12-myristate 13-acetate, IL-2, IL-2, BPB, AACOCF3, IL-2, PLA2, BPB, AACOCF3, PLA2, BPB, AACOCF3, IL-2, PLA2
22715_task2
Sentence: Phospholipase A2 inhibitors p-bromophenacyl bromide and arachidonyl trifluoromethyl ketone suppressed interleukin-2 (IL-2) expression in murine primary splenocytes. Phospholipase A2 (PLA2) has been postulated to play a role in the regulation of cytokine expression. Therefore, the objective of the present study was to investigate the effects of PLA2 inhibitors p-bromophenacyl bromide (BPB) and arachidonyl trifluoromethyl ketone (AACOCF3) on interleukin-2 (IL-2) expression in murine primary splenocytes. Pretreatment of the splenocytes with both BPB and AACOCF3 suppressed phorbol 12-myristate 13-acetate plus ionomycin-induced IL-2 secretion in a concentration-dependent manner. Inhibition > 90% of IL-2 secretion was observed at 1 microM BPB and 10 microM AACOCF3 compared to the respective vehicle control. Likewise, IL-2 steady-state mRNA expression was inhibited by both PLA2 inhibitors in a concentration-dependent fashion with > 90% inhibition at 1 microM BPB and 20 microM AACOCF3. Taken together, these data demonstrated that PLA2 inhibitors BPB and AACOCF3 are robust inhibitors of IL-2 expression at both the mRNA and protein levels in murine splenocytes. Moreover, these findings suggest that drugs and chemicals which inhibit PLA2 may have marked effects on T-cell function. Instructions: please extract entity words from the input sentence
[ "B-GENE-Y", "I-GENE-Y", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Phospholipase A2 inhibitors p-bromophenacyl bromide and arachidonyl trifluoromethyl ketone suppressed interleukin-2 (IL-2) expression in murine primary splenocytes. Phospholipase A2 (PLA2) has been postulated to play a role in the regulation of cytokine expression. Therefore, the objective of the present study was to investigate the effects of PLA2 inhibitors p-bromophenacyl bromide (BPB) and arachidonyl trifluoromethyl ketone (AACOCF3) on interleukin-2 (IL-2) expression in murine primary splenocytes. Pretreatment of the splenocytes with both BPB and AACOCF3 suppressed phorbol 12-myristate 13-acetate plus ionomycin-induced IL-2 secretion in a concentration-dependent manner. Inhibition > 90% of IL-2 secretion was observed at 1 microM BPB and 10 microM AACOCF3 compared to the respective vehicle control. Likewise, IL-2 steady-state mRNA expression was inhibited by both PLA2 inhibitors in a concentration-dependent fashion with > 90% inhibition at 1 microM BPB and 20 microM AACOCF3. Taken together, these data demonstrated that PLA2 inhibitors BPB and AACOCF3 are robust inhibitors of IL-2 expression at both the mRNA and protein levels in murine splenocytes. Moreover, these findings suggest that drugs and chemicals which inhibit PLA2 may have marked effects on T-cell function.
[ "Phospholipase", "A2", "inhibitors", "p", "-", "bromophenacyl", "bromide", "and", "arachidonyl", "trifluoromethyl", "ketone", "suppressed", "interleukin-2", "(", "IL-2", ")", "expression", "in", "murine", "primary", "splenocytes", ".", "\n", "Phospholipase", "A2", "(", "PLA2", ")", "has", "been", "postulated", "to", "play", "a", "role", "in", "the", "regulation", "of", "cytokine", "expression", ".", "Therefore", ",", "the", "objective", "of", "the", "present", "study", "was", "to", "investigate", "the", "effects", "of", "PLA2", "inhibitors", "p", "-", "bromophenacyl", "bromide", "(", "BPB", ")", "and", "arachidonyl", "trifluoromethyl", "ketone", "(", "AACOCF3", ")", "on", "interleukin-2", "(", "IL-2", ")", "expression", "in", "murine", "primary", "splenocytes", ".", "Pretreatment", "of", "the", "splenocytes", "with", "both", "BPB", "and", "AACOCF3", "suppressed", "phorbol", "12-myristate", "13-acetate", "plus", "ionomycin", "-", "induced", "IL-2", "secretion", "in", "a", "concentration", "-", "dependent", "manner", ".", "Inhibition", ">", "90", "%", "of", "IL-2", "secretion", "was", "observed", "at", "1", "microM", "BPB", "and", "10", "microM", "AACOCF3", "compared", "to", "the", "respective", "vehicle", "control", ".", "Likewise", ",", "IL-2", "steady", "-", "state", "mRNA", "expression", "was", "inhibited", "by", "both", "PLA2", "inhibitors", "in", "a", "concentration", "-", "dependent", "fashion", "with", ">", "90", "%", "inhibition", "at", "1", "microM", "BPB", "and", "20", "microM", "AACOCF3", ".", "Taken", "together", ",", "these", "data", "demonstrated", "that", "PLA2", "inhibitors", "BPB", "and", "AACOCF3", "are", "robust", "inhibitors", "of", "IL-2", "expression", "at", "both", "the", "mRNA", "and", "protein", "levels", "in", "murine", "splenocytes", ".", "Moreover", ",", "these", "findings", "suggest", "that", "drugs", "and", "chemicals", "which", "inhibit", "PLA2", "may", "have", "marked", "effects", "on", "T", "-", "cell", "function", "." ]
[ "CHEMICAL", "GENE-Y", "GENE-N" ]
Losartan is a compound, TNF - alpha is a protein, IL-6 is a protein, IL-1beta is a protein
DS.d1407_task0
Sentence: Losartan treatment significantly attenuated TNF-alpha, IL-6, and IL-1beta 6 h after CLP. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein
[ "B-compound", "O", "O", "O", "B-protein", "I-protein", "I-protein", "O", "B-protein", "O", "O", "B-protein", "O", "O", "O", "O", "O" ]
Losartan treatment significantly attenuated TNF-alpha, IL-6, and IL-1beta 6 h after CLP.
[ "Losartan", "treatment", "significantly", "attenuated", "TNF", "-", "alpha", ",", "IL-6", ",", "and", "IL-1beta", "6", "h", "after", "CLP", "." ]
[ "protein", "compound" ]
Losartan is a compound, TNF - alpha is a protein, IL-6 is a protein, IL-1beta is a protein
DS.d1407_task1
Sentence: Losartan treatment significantly attenuated TNF-alpha, IL-6, and IL-1beta 6 h after CLP. Instructions: please typing these entity words according to sentence: Losartan, TNF - alpha, IL-6, IL-1beta Options: compound, protein
[ "B-compound", "O", "O", "O", "B-protein", "I-protein", "I-protein", "O", "B-protein", "O", "O", "B-protein", "O", "O", "O", "O", "O" ]
Losartan treatment significantly attenuated TNF-alpha, IL-6, and IL-1beta 6 h after CLP.
[ "Losartan", "treatment", "significantly", "attenuated", "TNF", "-", "alpha", ",", "IL-6", ",", "and", "IL-1beta", "6", "h", "after", "CLP", "." ]
[ "protein", "compound" ]
Losartan, TNF - alpha, IL-6, IL-1beta
DS.d1407_task2
Sentence: Losartan treatment significantly attenuated TNF-alpha, IL-6, and IL-1beta 6 h after CLP. Instructions: please extract entity words from the input sentence
[ "B-compound", "O", "O", "O", "B-protein", "I-protein", "I-protein", "O", "B-protein", "O", "O", "B-protein", "O", "O", "O", "O", "O" ]
Losartan treatment significantly attenuated TNF-alpha, IL-6, and IL-1beta 6 h after CLP.
[ "Losartan", "treatment", "significantly", "attenuated", "TNF", "-", "alpha", ",", "IL-6", ",", "and", "IL-1beta", "6", "h", "after", "CLP", "." ]
[ "protein", "compound" ]
Bupivacaine - CO2 is a Intervention_Pharmacological, bupivacaine - HCl is a Intervention_Pharmacological, peridural anesthesia is a Intervention_Pharmacological, onset times of sensory and motor blockade is a Outcome_Other, epidural anesthesia is a Intervention_Pharmacological, bupivacaine - CO2 is a Intervention_Pharmacological, 90 is a Participant_Sample-size, ASA class I - II urologic is a Participant_Condition, extracorporeal shock wave lithotripsy . is a Intervention_Physical, Epidural anesthesia is a Intervention_Pharmacological, 18-gauge Tuohy is a Intervention_Physical, bupivacaine with adrenaline is a Intervention_Pharmacological, Sensory blockade is a Outcome_Other, Spread of sensory blockade is a Outcome_Other
74728_task0
Sentence: [ Bupivacaine-CO2 and bupivacaine-HCl at various injection temperatures in peridural anesthesia for extracorporeal shock wave lithotripsy ] . INTRODUCTION The effect of different injection temperatures on carbonated anesthetics has been controversial since 1965 . The current study was undertaken to determine onset times of sensory and motor blockade after epidural anesthesia with 0.5 % bupivacaine-CO2 and 0.5 % bupivacaine-HCl at various injection temperatures . MATERIALS AND METHODS The study was performed on 90 ASA class I-II urologic patients during extracorporeal shock wave lithotripsy . The patients were randomized in six groups to receive either 0.5 % bupivacaine-CO2 or 0.5 % bupivacaine-HCl at temperatures of 4 degrees , 20 degrees , or 36 degrees C. The six groups were comparable in age , height , and weight . Epidural anesthesia was performed at the L2-3 interspace with an 18-gauge Tuohy needle using loss of resistance . A catheter was advanced 4 cm in the epidural space and 4 ml 0.5 % bupivacaine with adrenaline 1:200,000 was given as a test dose . After 4 min the full anesthetic dose , based on body size , was injected with the patient supine . Sensory blockade was determined by the pinprick method and motor blockade by the Bromage method at 2-min intervals for the first 20 min , at 5-min intervals for the next 10 min , and then every 15 min to a total of 240 min . Statistical analysis was done by the Mann-Whitney test , with P less than 0.05 considered significant . RESULTS Spread of sensory blockade was significantly faster with bupivacaine-CO2 and -HCl at a temperature of 36 degrees C as compared to 4 degrees or 20 degrees C ( P less than 0.05 ) ( Figs . 1 , 2 and Table 2 ) . ( ABSTRACT TRUNCATED AT 250 WORDS ) Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Intervention_Physical, Participant_Condition, Participant_Sample-size, Outcome_Other
[ "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
[ Bupivacaine-CO2 and bupivacaine-HCl at various injection temperatures in peridural anesthesia for extracorporeal shock wave lithotripsy ] . INTRODUCTION The effect of different injection temperatures on carbonated anesthetics has been controversial since 1965 . The current study was undertaken to determine onset times of sensory and motor blockade after epidural anesthesia with 0.5 % bupivacaine-CO2 and 0.5 % bupivacaine-HCl at various injection temperatures . MATERIALS AND METHODS The study was performed on 90 ASA class I-II urologic patients during extracorporeal shock wave lithotripsy . The patients were randomized in six groups to receive either 0.5 % bupivacaine-CO2 or 0.5 % bupivacaine-HCl at temperatures of 4 degrees , 20 degrees , or 36 degrees C. The six groups were comparable in age , height , and weight . Epidural anesthesia was performed at the L2-3 interspace with an 18-gauge Tuohy needle using loss of resistance . A catheter was advanced 4 cm in the epidural space and 4 ml 0.5 % bupivacaine with adrenaline 1:200,000 was given as a test dose . After 4 min the full anesthetic dose , based on body size , was injected with the patient supine . Sensory blockade was determined by the pinprick method and motor blockade by the Bromage method at 2-min intervals for the first 20 min , at 5-min intervals for the next 10 min , and then every 15 min to a total of 240 min . Statistical analysis was done by the Mann-Whitney test , with P less than 0.05 considered significant . RESULTS Spread of sensory blockade was significantly faster with bupivacaine-CO2 and -HCl at a temperature of 36 degrees C as compared to 4 degrees or 20 degrees C ( P less than 0.05 ) ( Figs . 1 , 2 and Table 2 ) . ( ABSTRACT TRUNCATED AT 250 WORDS )
[ "[", "Bupivacaine", "-", "CO2", "and", "bupivacaine", "-", "HCl", "at", "various", "injection", "temperatures", "in", "peridural", "anesthesia", "for", "extracorporeal", "shock", "wave", "lithotripsy", "]", ".", "INTRODUCTION", "The", "effect", "of", "different", "injection", "temperatures", "on", "carbonated", "anesthetics", "has", "been", "controversial", "since", "1965", ".", "The", "current", "study", "was", "undertaken", "to", "determine", "onset", "times", "of", "sensory", "and", "motor", "blockade", "after", "epidural", "anesthesia", "with", "0.5", "%", "bupivacaine", "-", "CO2", "and", "0.5", "%", "bupivacaine", "-", "HCl", "at", "various", "injection", "temperatures", ".", "MATERIALS", "AND", "METHODS", "The", "study", "was", "performed", "on", "90", "ASA", "class", "I", "-", "II", "urologic", "patients", "during", "extracorporeal", "shock", "wave", "lithotripsy", ".", "The", "patients", "were", "randomized", "in", "six", "groups", "to", "receive", "either", "0.5", "%", "bupivacaine", "-", "CO2", "or", "0.5", "%", "bupivacaine", "-", "HCl", "at", "temperatures", "of", "4", "degrees", ",", "20", "degrees", ",", "or", "36", "degrees", "C.", "The", "six", "groups", "were", "comparable", "in", "age", ",", "height", ",", "and", "weight", ".", "Epidural", "anesthesia", "was", "performed", "at", "the", "L2", "-", "3", "interspace", "with", "an", "18-gauge", "Tuohy", "needle", "using", "loss", "of", "resistance", ".", "A", "catheter", "was", "advanced", "4", "cm", "in", "the", "epidural", "space", "and", "4", "ml", "0.5", "%", "bupivacaine", "with", "adrenaline", "1:200,000", "was", "given", "as", "a", "test", "dose", ".", "After", "4", "min", "the", "full", "anesthetic", "dose", ",", "based", "on", "body", "size", ",", "was", "injected", "with", "the", "patient", "supine", ".", "Sensory", "blockade", "was", "determined", "by", "the", "pinprick", "method", "and", "motor", "blockade", "by", "the", "Bromage", "method", "at", "2-min", "intervals", "for", "the", "first", "20", "min", ",", "at", "5-min", "intervals", "for", "the", "next", "10", "min", ",", "and", "then", "every", "15", "min", "to", "a", "total", "of", "240", "min", ".", "Statistical", "analysis", "was", "done", "by", "the", "Mann", "-", "Whitney", "test", ",", "with", "P", "less", "than", "0.05", "considered", "significant", ".", "RESULTS", "Spread", "of", "sensory", "blockade", "was", "significantly", "faster", "with", "bupivacaine", "-", "CO2", "and", "-HCl", "at", "a", "temperature", "of", "36", "degrees", "C", "as", "compared", "to", "4", "degrees", "or", "20", "degrees", "C", "(", "P", "less", "than", "0.05", ")", "(", "Figs", ".", "1", ",", "2", "and", "Table", "2", ")", ".", "(", "ABSTRACT", "TRUNCATED", "AT", "250", "WORDS", ")" ]
[ "Outcome_Other", "Intervention_Physical", "Intervention_Pharmacological", "Participant_Condition", "Participant_Sample-size" ]
Bupivacaine - CO2 is a Intervention_Pharmacological, bupivacaine - HCl is a Intervention_Pharmacological, peridural anesthesia is a Intervention_Pharmacological, onset times of sensory and motor blockade is a Outcome_Other, epidural anesthesia is a Intervention_Pharmacological, bupivacaine - CO2 is a Intervention_Pharmacological, 90 is a Participant_Sample-size, ASA class I - II urologic is a Participant_Condition, extracorporeal shock wave lithotripsy . is a Intervention_Physical, Epidural anesthesia is a Intervention_Pharmacological, 18-gauge Tuohy is a Intervention_Physical, bupivacaine with adrenaline is a Intervention_Pharmacological, Sensory blockade is a Outcome_Other, Spread of sensory blockade is a Outcome_Other
74728_task1
Sentence: [ Bupivacaine-CO2 and bupivacaine-HCl at various injection temperatures in peridural anesthesia for extracorporeal shock wave lithotripsy ] . INTRODUCTION The effect of different injection temperatures on carbonated anesthetics has been controversial since 1965 . The current study was undertaken to determine onset times of sensory and motor blockade after epidural anesthesia with 0.5 % bupivacaine-CO2 and 0.5 % bupivacaine-HCl at various injection temperatures . MATERIALS AND METHODS The study was performed on 90 ASA class I-II urologic patients during extracorporeal shock wave lithotripsy . The patients were randomized in six groups to receive either 0.5 % bupivacaine-CO2 or 0.5 % bupivacaine-HCl at temperatures of 4 degrees , 20 degrees , or 36 degrees C. The six groups were comparable in age , height , and weight . Epidural anesthesia was performed at the L2-3 interspace with an 18-gauge Tuohy needle using loss of resistance . A catheter was advanced 4 cm in the epidural space and 4 ml 0.5 % bupivacaine with adrenaline 1:200,000 was given as a test dose . After 4 min the full anesthetic dose , based on body size , was injected with the patient supine . Sensory blockade was determined by the pinprick method and motor blockade by the Bromage method at 2-min intervals for the first 20 min , at 5-min intervals for the next 10 min , and then every 15 min to a total of 240 min . Statistical analysis was done by the Mann-Whitney test , with P less than 0.05 considered significant . RESULTS Spread of sensory blockade was significantly faster with bupivacaine-CO2 and -HCl at a temperature of 36 degrees C as compared to 4 degrees or 20 degrees C ( P less than 0.05 ) ( Figs . 1 , 2 and Table 2 ) . ( ABSTRACT TRUNCATED AT 250 WORDS ) Instructions: please typing these entity words according to sentence: Bupivacaine - CO2, bupivacaine - HCl, peridural anesthesia, onset times of sensory and motor blockade, epidural anesthesia, bupivacaine - CO2, 90, ASA class I - II urologic, extracorporeal shock wave lithotripsy ., Epidural anesthesia, 18-gauge Tuohy, bupivacaine with adrenaline, Sensory blockade, Spread of sensory blockade Options: Intervention_Pharmacological, Intervention_Physical, Participant_Condition, Participant_Sample-size, Outcome_Other
[ "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
[ Bupivacaine-CO2 and bupivacaine-HCl at various injection temperatures in peridural anesthesia for extracorporeal shock wave lithotripsy ] . INTRODUCTION The effect of different injection temperatures on carbonated anesthetics has been controversial since 1965 . The current study was undertaken to determine onset times of sensory and motor blockade after epidural anesthesia with 0.5 % bupivacaine-CO2 and 0.5 % bupivacaine-HCl at various injection temperatures . MATERIALS AND METHODS The study was performed on 90 ASA class I-II urologic patients during extracorporeal shock wave lithotripsy . The patients were randomized in six groups to receive either 0.5 % bupivacaine-CO2 or 0.5 % bupivacaine-HCl at temperatures of 4 degrees , 20 degrees , or 36 degrees C. The six groups were comparable in age , height , and weight . Epidural anesthesia was performed at the L2-3 interspace with an 18-gauge Tuohy needle using loss of resistance . A catheter was advanced 4 cm in the epidural space and 4 ml 0.5 % bupivacaine with adrenaline 1:200,000 was given as a test dose . After 4 min the full anesthetic dose , based on body size , was injected with the patient supine . Sensory blockade was determined by the pinprick method and motor blockade by the Bromage method at 2-min intervals for the first 20 min , at 5-min intervals for the next 10 min , and then every 15 min to a total of 240 min . Statistical analysis was done by the Mann-Whitney test , with P less than 0.05 considered significant . RESULTS Spread of sensory blockade was significantly faster with bupivacaine-CO2 and -HCl at a temperature of 36 degrees C as compared to 4 degrees or 20 degrees C ( P less than 0.05 ) ( Figs . 1 , 2 and Table 2 ) . ( ABSTRACT TRUNCATED AT 250 WORDS )
[ "[", "Bupivacaine", "-", "CO2", "and", "bupivacaine", "-", "HCl", "at", "various", "injection", "temperatures", "in", "peridural", "anesthesia", "for", "extracorporeal", "shock", "wave", "lithotripsy", "]", ".", "INTRODUCTION", "The", "effect", "of", "different", "injection", "temperatures", "on", "carbonated", "anesthetics", "has", "been", "controversial", "since", "1965", ".", "The", "current", "study", "was", "undertaken", "to", "determine", "onset", "times", "of", "sensory", "and", "motor", "blockade", "after", "epidural", "anesthesia", "with", "0.5", "%", "bupivacaine", "-", "CO2", "and", "0.5", "%", "bupivacaine", "-", "HCl", "at", "various", "injection", "temperatures", ".", "MATERIALS", "AND", "METHODS", "The", "study", "was", "performed", "on", "90", "ASA", "class", "I", "-", "II", "urologic", "patients", "during", "extracorporeal", "shock", "wave", "lithotripsy", ".", "The", "patients", "were", "randomized", "in", "six", "groups", "to", "receive", "either", "0.5", "%", "bupivacaine", "-", "CO2", "or", "0.5", "%", "bupivacaine", "-", "HCl", "at", "temperatures", "of", "4", "degrees", ",", "20", "degrees", ",", "or", "36", "degrees", "C.", "The", "six", "groups", "were", "comparable", "in", "age", ",", "height", ",", "and", "weight", ".", "Epidural", "anesthesia", "was", "performed", "at", "the", "L2", "-", "3", "interspace", "with", "an", "18-gauge", "Tuohy", "needle", "using", "loss", "of", "resistance", ".", "A", "catheter", "was", "advanced", "4", "cm", "in", "the", "epidural", "space", "and", "4", "ml", "0.5", "%", "bupivacaine", "with", "adrenaline", "1:200,000", "was", "given", "as", "a", "test", "dose", ".", "After", "4", "min", "the", "full", "anesthetic", "dose", ",", "based", "on", "body", "size", ",", "was", "injected", "with", "the", "patient", "supine", ".", "Sensory", "blockade", "was", "determined", "by", "the", "pinprick", "method", "and", "motor", "blockade", "by", "the", "Bromage", "method", "at", "2-min", "intervals", "for", "the", "first", "20", "min", ",", "at", "5-min", "intervals", "for", "the", "next", "10", "min", ",", "and", "then", "every", "15", "min", "to", "a", "total", "of", "240", "min", ".", "Statistical", "analysis", "was", "done", "by", "the", "Mann", "-", "Whitney", "test", ",", "with", "P", "less", "than", "0.05", "considered", "significant", ".", "RESULTS", "Spread", "of", "sensory", "blockade", "was", "significantly", "faster", "with", "bupivacaine", "-", "CO2", "and", "-HCl", "at", "a", "temperature", "of", "36", "degrees", "C", "as", "compared", "to", "4", "degrees", "or", "20", "degrees", "C", "(", "P", "less", "than", "0.05", ")", "(", "Figs", ".", "1", ",", "2", "and", "Table", "2", ")", ".", "(", "ABSTRACT", "TRUNCATED", "AT", "250", "WORDS", ")" ]
[ "Outcome_Other", "Intervention_Physical", "Intervention_Pharmacological", "Participant_Condition", "Participant_Sample-size" ]
Bupivacaine - CO2, bupivacaine - HCl, peridural anesthesia, onset times of sensory and motor blockade, epidural anesthesia, bupivacaine - CO2, 90, ASA class I - II urologic, extracorporeal shock wave lithotripsy ., Epidural anesthesia, 18-gauge Tuohy, bupivacaine with adrenaline, Sensory blockade, Spread of sensory blockade
74728_task2
Sentence: [ Bupivacaine-CO2 and bupivacaine-HCl at various injection temperatures in peridural anesthesia for extracorporeal shock wave lithotripsy ] . INTRODUCTION The effect of different injection temperatures on carbonated anesthetics has been controversial since 1965 . The current study was undertaken to determine onset times of sensory and motor blockade after epidural anesthesia with 0.5 % bupivacaine-CO2 and 0.5 % bupivacaine-HCl at various injection temperatures . MATERIALS AND METHODS The study was performed on 90 ASA class I-II urologic patients during extracorporeal shock wave lithotripsy . The patients were randomized in six groups to receive either 0.5 % bupivacaine-CO2 or 0.5 % bupivacaine-HCl at temperatures of 4 degrees , 20 degrees , or 36 degrees C. The six groups were comparable in age , height , and weight . Epidural anesthesia was performed at the L2-3 interspace with an 18-gauge Tuohy needle using loss of resistance . A catheter was advanced 4 cm in the epidural space and 4 ml 0.5 % bupivacaine with adrenaline 1:200,000 was given as a test dose . After 4 min the full anesthetic dose , based on body size , was injected with the patient supine . Sensory blockade was determined by the pinprick method and motor blockade by the Bromage method at 2-min intervals for the first 20 min , at 5-min intervals for the next 10 min , and then every 15 min to a total of 240 min . Statistical analysis was done by the Mann-Whitney test , with P less than 0.05 considered significant . RESULTS Spread of sensory blockade was significantly faster with bupivacaine-CO2 and -HCl at a temperature of 36 degrees C as compared to 4 degrees or 20 degrees C ( P less than 0.05 ) ( Figs . 1 , 2 and Table 2 ) . ( ABSTRACT TRUNCATED AT 250 WORDS ) Instructions: please extract entity words from the input sentence
[ "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
[ Bupivacaine-CO2 and bupivacaine-HCl at various injection temperatures in peridural anesthesia for extracorporeal shock wave lithotripsy ] . INTRODUCTION The effect of different injection temperatures on carbonated anesthetics has been controversial since 1965 . The current study was undertaken to determine onset times of sensory and motor blockade after epidural anesthesia with 0.5 % bupivacaine-CO2 and 0.5 % bupivacaine-HCl at various injection temperatures . MATERIALS AND METHODS The study was performed on 90 ASA class I-II urologic patients during extracorporeal shock wave lithotripsy . The patients were randomized in six groups to receive either 0.5 % bupivacaine-CO2 or 0.5 % bupivacaine-HCl at temperatures of 4 degrees , 20 degrees , or 36 degrees C. The six groups were comparable in age , height , and weight . Epidural anesthesia was performed at the L2-3 interspace with an 18-gauge Tuohy needle using loss of resistance . A catheter was advanced 4 cm in the epidural space and 4 ml 0.5 % bupivacaine with adrenaline 1:200,000 was given as a test dose . After 4 min the full anesthetic dose , based on body size , was injected with the patient supine . Sensory blockade was determined by the pinprick method and motor blockade by the Bromage method at 2-min intervals for the first 20 min , at 5-min intervals for the next 10 min , and then every 15 min to a total of 240 min . Statistical analysis was done by the Mann-Whitney test , with P less than 0.05 considered significant . RESULTS Spread of sensory blockade was significantly faster with bupivacaine-CO2 and -HCl at a temperature of 36 degrees C as compared to 4 degrees or 20 degrees C ( P less than 0.05 ) ( Figs . 1 , 2 and Table 2 ) . ( ABSTRACT TRUNCATED AT 250 WORDS )
[ "[", "Bupivacaine", "-", "CO2", "and", "bupivacaine", "-", "HCl", "at", "various", "injection", "temperatures", "in", "peridural", "anesthesia", "for", "extracorporeal", "shock", "wave", "lithotripsy", "]", ".", "INTRODUCTION", "The", "effect", "of", "different", "injection", "temperatures", "on", "carbonated", "anesthetics", "has", "been", "controversial", "since", "1965", ".", "The", "current", "study", "was", "undertaken", "to", "determine", "onset", "times", "of", "sensory", "and", "motor", "blockade", "after", "epidural", "anesthesia", "with", "0.5", "%", "bupivacaine", "-", "CO2", "and", "0.5", "%", "bupivacaine", "-", "HCl", "at", "various", "injection", "temperatures", ".", "MATERIALS", "AND", "METHODS", "The", "study", "was", "performed", "on", "90", "ASA", "class", "I", "-", "II", "urologic", "patients", "during", "extracorporeal", "shock", "wave", "lithotripsy", ".", "The", "patients", "were", "randomized", "in", "six", "groups", "to", "receive", "either", "0.5", "%", "bupivacaine", "-", "CO2", "or", "0.5", "%", "bupivacaine", "-", "HCl", "at", "temperatures", "of", "4", "degrees", ",", "20", "degrees", ",", "or", "36", "degrees", "C.", "The", "six", "groups", "were", "comparable", "in", "age", ",", "height", ",", "and", "weight", ".", "Epidural", "anesthesia", "was", "performed", "at", "the", "L2", "-", "3", "interspace", "with", "an", "18-gauge", "Tuohy", "needle", "using", "loss", "of", "resistance", ".", "A", "catheter", "was", "advanced", "4", "cm", "in", "the", "epidural", "space", "and", "4", "ml", "0.5", "%", "bupivacaine", "with", "adrenaline", "1:200,000", "was", "given", "as", "a", "test", "dose", ".", "After", "4", "min", "the", "full", "anesthetic", "dose", ",", "based", "on", "body", "size", ",", "was", "injected", "with", "the", "patient", "supine", ".", "Sensory", "blockade", "was", "determined", "by", "the", "pinprick", "method", "and", "motor", "blockade", "by", "the", "Bromage", "method", "at", "2-min", "intervals", "for", "the", "first", "20", "min", ",", "at", "5-min", "intervals", "for", "the", "next", "10", "min", ",", "and", "then", "every", "15", "min", "to", "a", "total", "of", "240", "min", ".", "Statistical", "analysis", "was", "done", "by", "the", "Mann", "-", "Whitney", "test", ",", "with", "P", "less", "than", "0.05", "considered", "significant", ".", "RESULTS", "Spread", "of", "sensory", "blockade", "was", "significantly", "faster", "with", "bupivacaine", "-", "CO2", "and", "-HCl", "at", "a", "temperature", "of", "36", "degrees", "C", "as", "compared", "to", "4", "degrees", "or", "20", "degrees", "C", "(", "P", "less", "than", "0.05", ")", "(", "Figs", ".", "1", ",", "2", "and", "Table", "2", ")", ".", "(", "ABSTRACT", "TRUNCATED", "AT", "250", "WORDS", ")" ]
[ "Outcome_Other", "Intervention_Physical", "Intervention_Pharmacological", "Participant_Condition", "Participant_Sample-size" ]
rifamycin SV is a CHEMICAL, rifampicin is a CHEMICAL
12085361_task0
Sentence: Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL
[ "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver.
[ "Interactions", "of", "rifamycin", "SV", "and", "rifampicin", "with", "organic", "anion", "uptake", "systems", "of", "human", "liver", "." ]
[ "GENE-Y", "GENE-N", "CHEMICAL" ]
rifamycin SV is a CHEMICAL, rifampicin is a CHEMICAL
12085361_task1
Sentence: Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Instructions: please typing these entity words according to sentence: rifamycin SV, rifampicin Options: CHEMICAL
[ "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver.
[ "Interactions", "of", "rifamycin", "SV", "and", "rifampicin", "with", "organic", "anion", "uptake", "systems", "of", "human", "liver", "." ]
[ "GENE-Y", "GENE-N", "CHEMICAL" ]
rifamycin SV, rifampicin
12085361_task2
Sentence: Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Instructions: please extract entity words from the input sentence
[ "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver.
[ "Interactions", "of", "rifamycin", "SV", "and", "rifampicin", "with", "organic", "anion", "uptake", "systems", "of", "human", "liver", "." ]
[ "GENE-Y", "GENE-N", "CHEMICAL" ]
TSA is a chemical, Sp1 is a protein, Sp1 consensus sequences is a DNA, Hep3B cells is a cell, TSA is a chemical, Sp1 is a protein, Sp1 is a protein, DNA is a DNA
1.0alpha7.train.204_task0
Sentence: Since TSA induced Sp1 binding to Sp1 consensus sequences in Hep3B cells, we investigated whether TSA affected Sp1 phosphorylation, a possible cause for the increase of Sp1 binding to its consensus DNA sequences. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: chemical, DNA, cell, protein
[ "O", "B-chemical", "O", "B-protein", "O", "O", "B-DNA", "I-DNA", "I-DNA", "O", "B-cell", "I-cell", "O", "O", "O", "O", "B-chemical", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "B-DNA", "O", "O" ]
Since TSA induced Sp1 binding to Sp1 consensus sequences in Hep3B cells, we investigated whether TSA affected Sp1 phosphorylation, a possible cause for the increase of Sp1 binding to its consensus DNA sequences.
[ "Since", "TSA", "induced", "Sp1", "binding", "to", "Sp1", "consensus", "sequences", "in", "Hep3B", "cells", ",", "we", "investigated", "whether", "TSA", "affected", "Sp1", "phosphorylation", ",", "a", "possible", "cause", "for", "the", "increase", "of", "Sp1", "binding", "to", "its", "consensus", "DNA", "sequences", "." ]
[ "DNA", "cell", "protein", "chemical" ]
TSA is a chemical, Sp1 is a protein, Sp1 consensus sequences is a DNA, Hep3B cells is a cell, TSA is a chemical, Sp1 is a protein, Sp1 is a protein, DNA is a DNA
1.0alpha7.train.204_task1
Sentence: Since TSA induced Sp1 binding to Sp1 consensus sequences in Hep3B cells, we investigated whether TSA affected Sp1 phosphorylation, a possible cause for the increase of Sp1 binding to its consensus DNA sequences. Instructions: please typing these entity words according to sentence: TSA, Sp1, Sp1 consensus sequences, Hep3B cells, TSA, Sp1, Sp1, DNA Options: chemical, DNA, cell, protein
[ "O", "B-chemical", "O", "B-protein", "O", "O", "B-DNA", "I-DNA", "I-DNA", "O", "B-cell", "I-cell", "O", "O", "O", "O", "B-chemical", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "B-DNA", "O", "O" ]
Since TSA induced Sp1 binding to Sp1 consensus sequences in Hep3B cells, we investigated whether TSA affected Sp1 phosphorylation, a possible cause for the increase of Sp1 binding to its consensus DNA sequences.
[ "Since", "TSA", "induced", "Sp1", "binding", "to", "Sp1", "consensus", "sequences", "in", "Hep3B", "cells", ",", "we", "investigated", "whether", "TSA", "affected", "Sp1", "phosphorylation", ",", "a", "possible", "cause", "for", "the", "increase", "of", "Sp1", "binding", "to", "its", "consensus", "DNA", "sequences", "." ]
[ "DNA", "cell", "protein", "chemical" ]
TSA, Sp1, Sp1 consensus sequences, Hep3B cells, TSA, Sp1, Sp1, DNA
1.0alpha7.train.204_task2
Sentence: Since TSA induced Sp1 binding to Sp1 consensus sequences in Hep3B cells, we investigated whether TSA affected Sp1 phosphorylation, a possible cause for the increase of Sp1 binding to its consensus DNA sequences. Instructions: please extract entity words from the input sentence
[ "O", "B-chemical", "O", "B-protein", "O", "O", "B-DNA", "I-DNA", "I-DNA", "O", "B-cell", "I-cell", "O", "O", "O", "O", "B-chemical", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "B-DNA", "O", "O" ]
Since TSA induced Sp1 binding to Sp1 consensus sequences in Hep3B cells, we investigated whether TSA affected Sp1 phosphorylation, a possible cause for the increase of Sp1 binding to its consensus DNA sequences.
[ "Since", "TSA", "induced", "Sp1", "binding", "to", "Sp1", "consensus", "sequences", "in", "Hep3B", "cells", ",", "we", "investigated", "whether", "TSA", "affected", "Sp1", "phosphorylation", ",", "a", "possible", "cause", "for", "the", "increase", "of", "Sp1", "binding", "to", "its", "consensus", "DNA", "sequences", "." ]
[ "DNA", "cell", "protein", "chemical" ]
chronic diseases is an umlsterm, osteoporosis is an umlsterm, cardiovascular diseases is an umlsterm, cancers is an umlsterm, breast is an umlsterm, prostate is an umlsterm, uterus is an umlsterm, direct is an umlsterm, cholesterol is an umlsterm, breast is an umlsterm, carcinoma is an umlsterm, cell lines is an umlsterm, osteoporosis is an umlsterm, menstrual cycle is an umlsterm, gonadotropins is an umlsterm, plasma is an umlsterm, human is an umlsterm, oestrogens is an umlsterm, concentrations is an umlsterm, endocrine system is an umlsterm, inhibition is an umlsterm, FSH is an umlsterm, secretion is an umlsterm, SHBG is an umlsterm, food is an umlsterm, risk of is an umlsterm, breast cancer is an umlsterm, elderly is an umlsterm, women is an umlsterm, osteoporosis is an umlsterm, inhibition is an umlsterm, osteoclast is an umlsterm, production is an umlsterm, osteoclasts is an umlsterm, osteoblasts is an umlsterm, bone is an umlsterm, prevention is an umlsterm, cardiovascular diseases is an umlsterm, secretion is an umlsterm, digestion is an umlsterm, fats is an umlsterm
DerGynaekologe.00330028.eng.abstr_task0
Sentence: It is known that phyto-oestrogens have an influence on chronic diseases such as osteoporosis , cardiovascular diseases , and hormone-dependent cancers ( breast , prostate , uterus ) . Phyto-oestrogens also have a direct effect on the following processes : antiangiogenesis , antioxidative effects , decrease in serums levels of cholesterol , antitumoral effects on breast carcinoma cell lines , protection against osteoporosis , lengthening of the menstrual cycle , suppression of gonadotropins in the middle of the cycle and reduction of free and active oestrogen in the plasma . The effect of phyto-oestrogenes is lower thanthat of human oestrogens but high concentrations of phyto-oestrogens can have an effect on the endocrine system by inhibition of FSH and LH secretion and stimulation of SHBG . It was shown that soy bean-rich food significantly decreased the risk of getting breast cancer . Phyto-oestrogens may protect elderly women against osteoporosis . The following mechanisms are discussed : inhibition of TNFa , stimulation of lymphopoiesis , suppression of the osteoclast activity , stimulation of TGFb production in osteoclasts , stimulation of the proliferation and differentiation of osteoblasts and increase in the mineralization in bone . A positive effect in the prevention of cardiovascular diseases by phyto-oestrogens is probably related to the secretion and digestion of fats . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]
It is known that phyto-oestrogens have an influence on chronic diseases such as osteoporosis , cardiovascular diseases , and hormone-dependent cancers ( breast , prostate , uterus ) . Phyto-oestrogens also have a direct effect on the following processes : antiangiogenesis , antioxidative effects , decrease in serums levels of cholesterol , antitumoral effects on breast carcinoma cell lines , protection against osteoporosis , lengthening of the menstrual cycle , suppression of gonadotropins in the middle of the cycle and reduction of free and active oestrogen in the plasma . The effect of phyto-oestrogenes is lower thanthat of human oestrogens but high concentrations of phyto-oestrogens can have an effect on the endocrine system by inhibition of FSH and LH secretion and stimulation of SHBG . It was shown that soy bean-rich food significantly decreased the risk of getting breast cancer . Phyto-oestrogens may protect elderly women against osteoporosis . The following mechanisms are discussed : inhibition of TNFa , stimulation of lymphopoiesis , suppression of the osteoclast activity , stimulation of TGFb production in osteoclasts , stimulation of the proliferation and differentiation of osteoblasts and increase in the mineralization in bone . A positive effect in the prevention of cardiovascular diseases by phyto-oestrogens is probably related to the secretion and digestion of fats .
[ "It", "is", "known", "that", "phyto", "-", "oestrogens", "have", "an", "influence", "on", "chronic", "diseases", "such", "as", "osteoporosis", ",", "cardiovascular", "diseases", ",", "and", "hormone", "-", "dependent", "cancers", "(", "breast", ",", "prostate", ",", "uterus", ")", ".", "Phyto", "-", "oestrogens", "also", "have", "a", "direct", "effect", "on", "the", "following", "processes", ":", "antiangiogenesis", ",", "antioxidative", "effects", ",", "decrease", "in", "serums", "levels", "of", "cholesterol", ",", "antitumoral", "effects", "on", "breast", "carcinoma", "cell", "lines", ",", "protection", "against", "osteoporosis", ",", "lengthening", "of", "the", "menstrual", "cycle", ",", "suppression", "of", "gonadotropins", "in", "the", "middle", "of", "the", "cycle", "and", "reduction", "of", "free", "and", "active", "oestrogen", "in", "the", "plasma", ".", "The", "effect", "of", "phyto", "-", "oestrogenes", "is", "lower", "thanthat", "of", "human", "oestrogens", "but", "high", "concentrations", "of", "phyto", "-", "oestrogens", "can", "have", "an", "effect", "on", "the", "endocrine", "system", "by", "inhibition", "of", "FSH", "and", "LH", "secretion", "and", "stimulation", "of", "SHBG", ".", "It", "was", "shown", "that", "soy", "bean", "-", "rich", "food", "significantly", "decreased", "the", "risk", "of", "getting", "breast", "cancer", ".", "Phyto", "-", "oestrogens", "may", "protect", "elderly", "women", "against", "osteoporosis", ".", "The", "following", "mechanisms", "are", "discussed", ":", "inhibition", "of", "TNFa", ",", "stimulation", "of", "lymphopoiesis", ",", "suppression", "of", "the", "osteoclast", "activity", ",", "stimulation", "of", "TGFb", "production", "in", "osteoclasts", ",", "stimulation", "of", "the", "proliferation", "and", "differentiation", "of", "osteoblasts", "and", "increase", "in", "the", "mineralization", "in", "bone", ".", "A", "positive", "effect", "in", "the", "prevention", "of", "cardiovascular", "diseases", "by", "phyto", "-", "oestrogens", "is", "probably", "related", "to", "the", "secretion", "and", "digestion", "of", "fats", "." ]
[ "umlsterm" ]
chronic diseases is an umlsterm, osteoporosis is an umlsterm, cardiovascular diseases is an umlsterm, cancers is an umlsterm, breast is an umlsterm, prostate is an umlsterm, uterus is an umlsterm, direct is an umlsterm, cholesterol is an umlsterm, breast is an umlsterm, carcinoma is an umlsterm, cell lines is an umlsterm, osteoporosis is an umlsterm, menstrual cycle is an umlsterm, gonadotropins is an umlsterm, plasma is an umlsterm, human is an umlsterm, oestrogens is an umlsterm, concentrations is an umlsterm, endocrine system is an umlsterm, inhibition is an umlsterm, FSH is an umlsterm, secretion is an umlsterm, SHBG is an umlsterm, food is an umlsterm, risk of is an umlsterm, breast cancer is an umlsterm, elderly is an umlsterm, women is an umlsterm, osteoporosis is an umlsterm, inhibition is an umlsterm, osteoclast is an umlsterm, production is an umlsterm, osteoclasts is an umlsterm, osteoblasts is an umlsterm, bone is an umlsterm, prevention is an umlsterm, cardiovascular diseases is an umlsterm, secretion is an umlsterm, digestion is an umlsterm, fats is an umlsterm
DerGynaekologe.00330028.eng.abstr_task1
Sentence: It is known that phyto-oestrogens have an influence on chronic diseases such as osteoporosis , cardiovascular diseases , and hormone-dependent cancers ( breast , prostate , uterus ) . Phyto-oestrogens also have a direct effect on the following processes : antiangiogenesis , antioxidative effects , decrease in serums levels of cholesterol , antitumoral effects on breast carcinoma cell lines , protection against osteoporosis , lengthening of the menstrual cycle , suppression of gonadotropins in the middle of the cycle and reduction of free and active oestrogen in the plasma . The effect of phyto-oestrogenes is lower thanthat of human oestrogens but high concentrations of phyto-oestrogens can have an effect on the endocrine system by inhibition of FSH and LH secretion and stimulation of SHBG . It was shown that soy bean-rich food significantly decreased the risk of getting breast cancer . Phyto-oestrogens may protect elderly women against osteoporosis . The following mechanisms are discussed : inhibition of TNFa , stimulation of lymphopoiesis , suppression of the osteoclast activity , stimulation of TGFb production in osteoclasts , stimulation of the proliferation and differentiation of osteoblasts and increase in the mineralization in bone . A positive effect in the prevention of cardiovascular diseases by phyto-oestrogens is probably related to the secretion and digestion of fats . Instructions: please typing these entity words according to sentence: chronic diseases, osteoporosis, cardiovascular diseases, cancers, breast, prostate, uterus, direct, cholesterol, breast, carcinoma, cell lines, osteoporosis, menstrual cycle, gonadotropins, plasma, human, oestrogens, concentrations, endocrine system, inhibition, FSH, secretion, SHBG, food, risk of, breast cancer, elderly, women, osteoporosis, inhibition, osteoclast, production, osteoclasts, osteoblasts, bone, prevention, cardiovascular diseases, secretion, digestion, fats Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]
It is known that phyto-oestrogens have an influence on chronic diseases such as osteoporosis , cardiovascular diseases , and hormone-dependent cancers ( breast , prostate , uterus ) . Phyto-oestrogens also have a direct effect on the following processes : antiangiogenesis , antioxidative effects , decrease in serums levels of cholesterol , antitumoral effects on breast carcinoma cell lines , protection against osteoporosis , lengthening of the menstrual cycle , suppression of gonadotropins in the middle of the cycle and reduction of free and active oestrogen in the plasma . The effect of phyto-oestrogenes is lower thanthat of human oestrogens but high concentrations of phyto-oestrogens can have an effect on the endocrine system by inhibition of FSH and LH secretion and stimulation of SHBG . It was shown that soy bean-rich food significantly decreased the risk of getting breast cancer . Phyto-oestrogens may protect elderly women against osteoporosis . The following mechanisms are discussed : inhibition of TNFa , stimulation of lymphopoiesis , suppression of the osteoclast activity , stimulation of TGFb production in osteoclasts , stimulation of the proliferation and differentiation of osteoblasts and increase in the mineralization in bone . A positive effect in the prevention of cardiovascular diseases by phyto-oestrogens is probably related to the secretion and digestion of fats .
[ "It", "is", "known", "that", "phyto", "-", "oestrogens", "have", "an", "influence", "on", "chronic", "diseases", "such", "as", "osteoporosis", ",", "cardiovascular", "diseases", ",", "and", "hormone", "-", "dependent", "cancers", "(", "breast", ",", "prostate", ",", "uterus", ")", ".", "Phyto", "-", "oestrogens", "also", "have", "a", "direct", "effect", "on", "the", "following", "processes", ":", "antiangiogenesis", ",", "antioxidative", "effects", ",", "decrease", "in", "serums", "levels", "of", "cholesterol", ",", "antitumoral", "effects", "on", "breast", "carcinoma", "cell", "lines", ",", "protection", "against", "osteoporosis", ",", "lengthening", "of", "the", "menstrual", "cycle", ",", "suppression", "of", "gonadotropins", "in", "the", "middle", "of", "the", "cycle", "and", "reduction", "of", "free", "and", "active", "oestrogen", "in", "the", "plasma", ".", "The", "effect", "of", "phyto", "-", "oestrogenes", "is", "lower", "thanthat", "of", "human", "oestrogens", "but", "high", "concentrations", "of", "phyto", "-", "oestrogens", "can", "have", "an", "effect", "on", "the", "endocrine", "system", "by", "inhibition", "of", "FSH", "and", "LH", "secretion", "and", "stimulation", "of", "SHBG", ".", "It", "was", "shown", "that", "soy", "bean", "-", "rich", "food", "significantly", "decreased", "the", "risk", "of", "getting", "breast", "cancer", ".", "Phyto", "-", "oestrogens", "may", "protect", "elderly", "women", "against", "osteoporosis", ".", "The", "following", "mechanisms", "are", "discussed", ":", "inhibition", "of", "TNFa", ",", "stimulation", "of", "lymphopoiesis", ",", "suppression", "of", "the", "osteoclast", "activity", ",", "stimulation", "of", "TGFb", "production", "in", "osteoclasts", ",", "stimulation", "of", "the", "proliferation", "and", "differentiation", "of", "osteoblasts", "and", "increase", "in", "the", "mineralization", "in", "bone", ".", "A", "positive", "effect", "in", "the", "prevention", "of", "cardiovascular", "diseases", "by", "phyto", "-", "oestrogens", "is", "probably", "related", "to", "the", "secretion", "and", "digestion", "of", "fats", "." ]
[ "umlsterm" ]
chronic diseases, osteoporosis, cardiovascular diseases, cancers, breast, prostate, uterus, direct, cholesterol, breast, carcinoma, cell lines, osteoporosis, menstrual cycle, gonadotropins, plasma, human, oestrogens, concentrations, endocrine system, inhibition, FSH, secretion, SHBG, food, risk of, breast cancer, elderly, women, osteoporosis, inhibition, osteoclast, production, osteoclasts, osteoblasts, bone, prevention, cardiovascular diseases, secretion, digestion, fats
DerGynaekologe.00330028.eng.abstr_task2
Sentence: It is known that phyto-oestrogens have an influence on chronic diseases such as osteoporosis , cardiovascular diseases , and hormone-dependent cancers ( breast , prostate , uterus ) . Phyto-oestrogens also have a direct effect on the following processes : antiangiogenesis , antioxidative effects , decrease in serums levels of cholesterol , antitumoral effects on breast carcinoma cell lines , protection against osteoporosis , lengthening of the menstrual cycle , suppression of gonadotropins in the middle of the cycle and reduction of free and active oestrogen in the plasma . The effect of phyto-oestrogenes is lower thanthat of human oestrogens but high concentrations of phyto-oestrogens can have an effect on the endocrine system by inhibition of FSH and LH secretion and stimulation of SHBG . It was shown that soy bean-rich food significantly decreased the risk of getting breast cancer . Phyto-oestrogens may protect elderly women against osteoporosis . The following mechanisms are discussed : inhibition of TNFa , stimulation of lymphopoiesis , suppression of the osteoclast activity , stimulation of TGFb production in osteoclasts , stimulation of the proliferation and differentiation of osteoblasts and increase in the mineralization in bone . A positive effect in the prevention of cardiovascular diseases by phyto-oestrogens is probably related to the secretion and digestion of fats . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]
It is known that phyto-oestrogens have an influence on chronic diseases such as osteoporosis , cardiovascular diseases , and hormone-dependent cancers ( breast , prostate , uterus ) . Phyto-oestrogens also have a direct effect on the following processes : antiangiogenesis , antioxidative effects , decrease in serums levels of cholesterol , antitumoral effects on breast carcinoma cell lines , protection against osteoporosis , lengthening of the menstrual cycle , suppression of gonadotropins in the middle of the cycle and reduction of free and active oestrogen in the plasma . The effect of phyto-oestrogenes is lower thanthat of human oestrogens but high concentrations of phyto-oestrogens can have an effect on the endocrine system by inhibition of FSH and LH secretion and stimulation of SHBG . It was shown that soy bean-rich food significantly decreased the risk of getting breast cancer . Phyto-oestrogens may protect elderly women against osteoporosis . The following mechanisms are discussed : inhibition of TNFa , stimulation of lymphopoiesis , suppression of the osteoclast activity , stimulation of TGFb production in osteoclasts , stimulation of the proliferation and differentiation of osteoblasts and increase in the mineralization in bone . A positive effect in the prevention of cardiovascular diseases by phyto-oestrogens is probably related to the secretion and digestion of fats .
[ "It", "is", "known", "that", "phyto", "-", "oestrogens", "have", "an", "influence", "on", "chronic", "diseases", "such", "as", "osteoporosis", ",", "cardiovascular", "diseases", ",", "and", "hormone", "-", "dependent", "cancers", "(", "breast", ",", "prostate", ",", "uterus", ")", ".", "Phyto", "-", "oestrogens", "also", "have", "a", "direct", "effect", "on", "the", "following", "processes", ":", "antiangiogenesis", ",", "antioxidative", "effects", ",", "decrease", "in", "serums", "levels", "of", "cholesterol", ",", "antitumoral", "effects", "on", "breast", "carcinoma", "cell", "lines", ",", "protection", "against", "osteoporosis", ",", "lengthening", "of", "the", "menstrual", "cycle", ",", "suppression", "of", "gonadotropins", "in", "the", "middle", "of", "the", "cycle", "and", "reduction", "of", "free", "and", "active", "oestrogen", "in", "the", "plasma", ".", "The", "effect", "of", "phyto", "-", "oestrogenes", "is", "lower", "thanthat", "of", "human", "oestrogens", "but", "high", "concentrations", "of", "phyto", "-", "oestrogens", "can", "have", "an", "effect", "on", "the", "endocrine", "system", "by", "inhibition", "of", "FSH", "and", "LH", "secretion", "and", "stimulation", "of", "SHBG", ".", "It", "was", "shown", "that", "soy", "bean", "-", "rich", "food", "significantly", "decreased", "the", "risk", "of", "getting", "breast", "cancer", ".", "Phyto", "-", "oestrogens", "may", "protect", "elderly", "women", "against", "osteoporosis", ".", "The", "following", "mechanisms", "are", "discussed", ":", "inhibition", "of", "TNFa", ",", "stimulation", "of", "lymphopoiesis", ",", "suppression", "of", "the", "osteoclast", "activity", ",", "stimulation", "of", "TGFb", "production", "in", "osteoclasts", ",", "stimulation", "of", "the", "proliferation", "and", "differentiation", "of", "osteoblasts", "and", "increase", "in", "the", "mineralization", "in", "bone", ".", "A", "positive", "effect", "in", "the", "prevention", "of", "cardiovascular", "diseases", "by", "phyto", "-", "oestrogens", "is", "probably", "related", "to", "the", "secretion", "and", "digestion", "of", "fats", "." ]
[ "umlsterm" ]
Mykobakteriendiagnostik is an umlsterm, Tuberkulosekultur is an umlsterm, Kulturergebnisses is an umlsterm, Nukleinsaeure - Amplifikationstechniken is an umlsterm, Zeit is an umlsterm, Tuberkulose is an umlsterm, Methoden is an umlsterm, Zeit is an umlsterm, Sensitivitaet und Spezifitaet is an umlsterm, Antibiotika is an umlsterm
Bundesgesundheitsblatt.90420713.ger.abstr_task0
Sentence: Die konventionelle Mykobakteriendiagnostik benoetigt z.Zt. durchschnittlich vier Wochen bis zum Vorliegen einer positiven Tuberkulosekultur und nachfolgender Empfindlichkeitspruefung . Bis zur Mitteilung eines negativen Kulturergebnisses vergehen sieben bis acht Wochen . Schnellere Resultate sind bei einzelnen diagnostischen Schritten durch neue Verfahren wie z.B. Nukleinsaeure-Amplifikationstechniken zu erzielen , diese haben zur Zeit aber noch nicht die gewuenschte hohe Sensitivitaet . Die weltweit beunruhigende epidemiologische Situation des Infektionsrisikos fuer Tuberkulose laesst keinen Zweifel aufkommen , dass die Weiterentwicklung von Methoden notwendig ist , die in moeglichst kurzer Zeit gestatten , Mykobakterien mit hoher Sensitivitaet und Spezifitaet nachzuweisen , zu differenzieren und auf ihre Empfindlichkeit gegenueber Antibiotika zu testen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]
Die konventionelle Mykobakteriendiagnostik benoetigt z.Zt. durchschnittlich vier Wochen bis zum Vorliegen einer positiven Tuberkulosekultur und nachfolgender Empfindlichkeitspruefung . Bis zur Mitteilung eines negativen Kulturergebnisses vergehen sieben bis acht Wochen . Schnellere Resultate sind bei einzelnen diagnostischen Schritten durch neue Verfahren wie z.B. Nukleinsaeure-Amplifikationstechniken zu erzielen , diese haben zur Zeit aber noch nicht die gewuenschte hohe Sensitivitaet . Die weltweit beunruhigende epidemiologische Situation des Infektionsrisikos fuer Tuberkulose laesst keinen Zweifel aufkommen , dass die Weiterentwicklung von Methoden notwendig ist , die in moeglichst kurzer Zeit gestatten , Mykobakterien mit hoher Sensitivitaet und Spezifitaet nachzuweisen , zu differenzieren und auf ihre Empfindlichkeit gegenueber Antibiotika zu testen .
[ "Die", "konventionelle", "Mykobakteriendiagnostik", "benoetigt", "z.", "Zt", ".", "durchschnittlich", "vier", "Wochen", "bis", "zum", "Vorliegen", "einer", "positiven", "Tuberkulosekultur", "und", "nachfolgender", "Empfindlichkeitspruefung", ".", "Bis", "zur", "Mitteilung", "eines", "negativen", "Kulturergebnisses", "vergehen", "sieben", "bis", "acht", "Wochen", ".", "Schnellere", "Resultate", "sind", "bei", "einzelnen", "diagnostischen", "Schritten", "durch", "neue", "Verfahren", "wie", "z.", "B.", "Nukleinsaeure", "-", "Amplifikationstechniken", "zu", "erzielen", ",", "diese", "haben", "zur", "Zeit", "aber", "noch", "nicht", "die", "gewuenschte", "hohe", "Sensitivitaet", ".", "Die", "weltweit", "beunruhigende", "epidemiologische", "Situation", "des", "Infektionsrisikos", "fuer", "Tuberkulose", "laesst", "keinen", "Zweifel", "aufkommen", ",", "dass", "die", "Weiterentwicklung", "von", "Methoden", "notwendig", "ist", ",", "die", "in", "moeglichst", "kurzer", "Zeit", "gestatten", ",", "Mykobakterien", "mit", "hoher", "Sensitivitaet", "und", "Spezifitaet", "nachzuweisen", ",", "zu", "differenzieren", "und", "auf", "ihre", "Empfindlichkeit", "gegenueber", "Antibiotika", "zu", "testen", "." ]
[ "umlsterm" ]
Mykobakteriendiagnostik is an umlsterm, Tuberkulosekultur is an umlsterm, Kulturergebnisses is an umlsterm, Nukleinsaeure - Amplifikationstechniken is an umlsterm, Zeit is an umlsterm, Tuberkulose is an umlsterm, Methoden is an umlsterm, Zeit is an umlsterm, Sensitivitaet und Spezifitaet is an umlsterm, Antibiotika is an umlsterm
Bundesgesundheitsblatt.90420713.ger.abstr_task1
Sentence: Die konventionelle Mykobakteriendiagnostik benoetigt z.Zt. durchschnittlich vier Wochen bis zum Vorliegen einer positiven Tuberkulosekultur und nachfolgender Empfindlichkeitspruefung . Bis zur Mitteilung eines negativen Kulturergebnisses vergehen sieben bis acht Wochen . Schnellere Resultate sind bei einzelnen diagnostischen Schritten durch neue Verfahren wie z.B. Nukleinsaeure-Amplifikationstechniken zu erzielen , diese haben zur Zeit aber noch nicht die gewuenschte hohe Sensitivitaet . Die weltweit beunruhigende epidemiologische Situation des Infektionsrisikos fuer Tuberkulose laesst keinen Zweifel aufkommen , dass die Weiterentwicklung von Methoden notwendig ist , die in moeglichst kurzer Zeit gestatten , Mykobakterien mit hoher Sensitivitaet und Spezifitaet nachzuweisen , zu differenzieren und auf ihre Empfindlichkeit gegenueber Antibiotika zu testen . Instructions: please typing these entity words according to sentence: Mykobakteriendiagnostik, Tuberkulosekultur, Kulturergebnisses, Nukleinsaeure - Amplifikationstechniken, Zeit, Tuberkulose, Methoden, Zeit, Sensitivitaet und Spezifitaet, Antibiotika Options: umlsterm
[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]
Die konventionelle Mykobakteriendiagnostik benoetigt z.Zt. durchschnittlich vier Wochen bis zum Vorliegen einer positiven Tuberkulosekultur und nachfolgender Empfindlichkeitspruefung . Bis zur Mitteilung eines negativen Kulturergebnisses vergehen sieben bis acht Wochen . Schnellere Resultate sind bei einzelnen diagnostischen Schritten durch neue Verfahren wie z.B. Nukleinsaeure-Amplifikationstechniken zu erzielen , diese haben zur Zeit aber noch nicht die gewuenschte hohe Sensitivitaet . Die weltweit beunruhigende epidemiologische Situation des Infektionsrisikos fuer Tuberkulose laesst keinen Zweifel aufkommen , dass die Weiterentwicklung von Methoden notwendig ist , die in moeglichst kurzer Zeit gestatten , Mykobakterien mit hoher Sensitivitaet und Spezifitaet nachzuweisen , zu differenzieren und auf ihre Empfindlichkeit gegenueber Antibiotika zu testen .
[ "Die", "konventionelle", "Mykobakteriendiagnostik", "benoetigt", "z.", "Zt", ".", "durchschnittlich", "vier", "Wochen", "bis", "zum", "Vorliegen", "einer", "positiven", "Tuberkulosekultur", "und", "nachfolgender", "Empfindlichkeitspruefung", ".", "Bis", "zur", "Mitteilung", "eines", "negativen", "Kulturergebnisses", "vergehen", "sieben", "bis", "acht", "Wochen", ".", "Schnellere", "Resultate", "sind", "bei", "einzelnen", "diagnostischen", "Schritten", "durch", "neue", "Verfahren", "wie", "z.", "B.", "Nukleinsaeure", "-", "Amplifikationstechniken", "zu", "erzielen", ",", "diese", "haben", "zur", "Zeit", "aber", "noch", "nicht", "die", "gewuenschte", "hohe", "Sensitivitaet", ".", "Die", "weltweit", "beunruhigende", "epidemiologische", "Situation", "des", "Infektionsrisikos", "fuer", "Tuberkulose", "laesst", "keinen", "Zweifel", "aufkommen", ",", "dass", "die", "Weiterentwicklung", "von", "Methoden", "notwendig", "ist", ",", "die", "in", "moeglichst", "kurzer", "Zeit", "gestatten", ",", "Mykobakterien", "mit", "hoher", "Sensitivitaet", "und", "Spezifitaet", "nachzuweisen", ",", "zu", "differenzieren", "und", "auf", "ihre", "Empfindlichkeit", "gegenueber", "Antibiotika", "zu", "testen", "." ]
[ "umlsterm" ]
Mykobakteriendiagnostik, Tuberkulosekultur, Kulturergebnisses, Nukleinsaeure - Amplifikationstechniken, Zeit, Tuberkulose, Methoden, Zeit, Sensitivitaet und Spezifitaet, Antibiotika
Bundesgesundheitsblatt.90420713.ger.abstr_task2
Sentence: Die konventionelle Mykobakteriendiagnostik benoetigt z.Zt. durchschnittlich vier Wochen bis zum Vorliegen einer positiven Tuberkulosekultur und nachfolgender Empfindlichkeitspruefung . Bis zur Mitteilung eines negativen Kulturergebnisses vergehen sieben bis acht Wochen . Schnellere Resultate sind bei einzelnen diagnostischen Schritten durch neue Verfahren wie z.B. Nukleinsaeure-Amplifikationstechniken zu erzielen , diese haben zur Zeit aber noch nicht die gewuenschte hohe Sensitivitaet . Die weltweit beunruhigende epidemiologische Situation des Infektionsrisikos fuer Tuberkulose laesst keinen Zweifel aufkommen , dass die Weiterentwicklung von Methoden notwendig ist , die in moeglichst kurzer Zeit gestatten , Mykobakterien mit hoher Sensitivitaet und Spezifitaet nachzuweisen , zu differenzieren und auf ihre Empfindlichkeit gegenueber Antibiotika zu testen . Instructions: please extract entity words from the input sentence
[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]
Die konventionelle Mykobakteriendiagnostik benoetigt z.Zt. durchschnittlich vier Wochen bis zum Vorliegen einer positiven Tuberkulosekultur und nachfolgender Empfindlichkeitspruefung . Bis zur Mitteilung eines negativen Kulturergebnisses vergehen sieben bis acht Wochen . Schnellere Resultate sind bei einzelnen diagnostischen Schritten durch neue Verfahren wie z.B. Nukleinsaeure-Amplifikationstechniken zu erzielen , diese haben zur Zeit aber noch nicht die gewuenschte hohe Sensitivitaet . Die weltweit beunruhigende epidemiologische Situation des Infektionsrisikos fuer Tuberkulose laesst keinen Zweifel aufkommen , dass die Weiterentwicklung von Methoden notwendig ist , die in moeglichst kurzer Zeit gestatten , Mykobakterien mit hoher Sensitivitaet und Spezifitaet nachzuweisen , zu differenzieren und auf ihre Empfindlichkeit gegenueber Antibiotika zu testen .
[ "Die", "konventionelle", "Mykobakteriendiagnostik", "benoetigt", "z.", "Zt", ".", "durchschnittlich", "vier", "Wochen", "bis", "zum", "Vorliegen", "einer", "positiven", "Tuberkulosekultur", "und", "nachfolgender", "Empfindlichkeitspruefung", ".", "Bis", "zur", "Mitteilung", "eines", "negativen", "Kulturergebnisses", "vergehen", "sieben", "bis", "acht", "Wochen", ".", "Schnellere", "Resultate", "sind", "bei", "einzelnen", "diagnostischen", "Schritten", "durch", "neue", "Verfahren", "wie", "z.", "B.", "Nukleinsaeure", "-", "Amplifikationstechniken", "zu", "erzielen", ",", "diese", "haben", "zur", "Zeit", "aber", "noch", "nicht", "die", "gewuenschte", "hohe", "Sensitivitaet", ".", "Die", "weltweit", "beunruhigende", "epidemiologische", "Situation", "des", "Infektionsrisikos", "fuer", "Tuberkulose", "laesst", "keinen", "Zweifel", "aufkommen", ",", "dass", "die", "Weiterentwicklung", "von", "Methoden", "notwendig", "ist", ",", "die", "in", "moeglichst", "kurzer", "Zeit", "gestatten", ",", "Mykobakterien", "mit", "hoher", "Sensitivitaet", "und", "Spezifitaet", "nachzuweisen", ",", "zu", "differenzieren", "und", "auf", "ihre", "Empfindlichkeit", "gegenueber", "Antibiotika", "zu", "testen", "." ]
[ "umlsterm" ]
Helicobacter pylori is a Microorganism, gastric is a Habitat, human immunodeficiency virus - infected outpatients is a Habitat, gastric is a Habitat, persons infected with human immunodeficiency virus is a Habitat, HIV is a Microorganism, asymptomatic subjects is a Habitat, Gastric is a Habitat, gastric is a Habitat, CD4 cell is a Habitat, Helicobacter pylori is a Microorganism, gastric is a Habitat, Subjects with hypoacidity is a Habitat, H. pylori is a Microorganism, subjects without hypoacidity is a Habitat, H. pylori is a Microorganism, gastric is a Habitat, HIV is a Microorganism, male is a Habitat, gastric is a Habitat, CD4 cell is a Habitat, gastric is a Habitat, H. pylori is a Microorganism, HIV - positive black is a Habitat, gastric is a Habitat
69_task0
Sentence: Previous infection with Helicobacter pylori is the primary determinant of spontaneous gastric hypoacidity in human immunodeficiency virus-infected outpatients. To investigate the incidence and demographics of gastric hypoacidity among persons infected with human immunodeficiency virus (HIV), 146 asymptomatic subjects were evaluated with use of a radiotelemetry device (Heidelberg capsule). Gastric hypoacidity (minimum gastric pH of > or = 3) occurred in 24 subjects (17%). Demographic characteristics, CD4 cell counts, and Helicobacter pylori serological status were evaluated for an association with gastric pH. Subjects with hypoacidity were more likely to have positive H. pylori serology than were subjects without hypoacidity (15 of 24 vs. 23 of 74, respectively; P = .004). Multivariate analysis indicated that a positive H. pylori serology was the most significant predictor of hypoacidity, accounting for an increase in gastric pH of 39%. A history of injection drug use, heterosexual transmission of HIV, and male gender were also associated with an elevated gastric pH. CD4 cell counts did not contribute to predictions of gastric pH. A history of H. pylori infection is relatively common in HIV-positive black and Hispanic populations and is a predictor of gastric pH. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Microorganism, Habitat
[ "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "B-Microorganism", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "B-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O" ]
Previous infection with Helicobacter pylori is the primary determinant of spontaneous gastric hypoacidity in human immunodeficiency virus-infected outpatients. To investigate the incidence and demographics of gastric hypoacidity among persons infected with human immunodeficiency virus (HIV), 146 asymptomatic subjects were evaluated with use of a radiotelemetry device (Heidelberg capsule). Gastric hypoacidity (minimum gastric pH of > or = 3) occurred in 24 subjects (17%). Demographic characteristics, CD4 cell counts, and Helicobacter pylori serological status were evaluated for an association with gastric pH. Subjects with hypoacidity were more likely to have positive H. pylori serology than were subjects without hypoacidity (15 of 24 vs. 23 of 74, respectively; P = .004). Multivariate analysis indicated that a positive H. pylori serology was the most significant predictor of hypoacidity, accounting for an increase in gastric pH of 39%. A history of injection drug use, heterosexual transmission of HIV, and male gender were also associated with an elevated gastric pH. CD4 cell counts did not contribute to predictions of gastric pH. A history of H. pylori infection is relatively common in HIV-positive black and Hispanic populations and is a predictor of gastric pH.
[ "Previous", "infection", "with", "Helicobacter", "pylori", "is", "the", "primary", "determinant", "of", "spontaneous", "gastric", "hypoacidity", "in", "human", "immunodeficiency", "virus", "-", "infected", "outpatients", ".", "To", "investigate", "the", "incidence", "and", "demographics", "of", "gastric", "hypoacidity", "among", "persons", "infected", "with", "human", "immunodeficiency", "virus", "(", "HIV", ")", ",", "146", "asymptomatic", "subjects", "were", "evaluated", "with", "use", "of", "a", "radiotelemetry", "device", "(", "Heidelberg", "capsule", ")", ".", "Gastric", "hypoacidity", "(", "minimum", "gastric", "pH", "of", ">", "or", "=", "3", ")", "occurred", "in", "24", "subjects", "(", "17", "%", ")", ".", "Demographic", "characteristics", ",", "CD4", "cell", "counts", ",", "and", "Helicobacter", "pylori", "serological", "status", "were", "evaluated", "for", "an", "association", "with", "gastric", "pH.", "Subjects", "with", "hypoacidity", "were", "more", "likely", "to", "have", "positive", "H.", "pylori", "serology", "than", "were", "subjects", "without", "hypoacidity", "(", "15", "of", "24", "vs", ".", "23", "of", "74", ",", "respectively", ";", "P", "=", ".004", ")", ".", "Multivariate", "analysis", "indicated", "that", "a", "positive", "H.", "pylori", "serology", "was", "the", "most", "significant", "predictor", "of", "hypoacidity", ",", "accounting", "for", "an", "increase", "in", "gastric", "pH", "of", "39", "%", ".", "A", "history", "of", "injection", "drug", "use", ",", "heterosexual", "transmission", "of", "HIV", ",", "and", "male", "gender", "were", "also", "associated", "with", "an", "elevated", "gastric", "pH.", "CD4", "cell", "counts", "did", "not", "contribute", "to", "predictions", "of", "gastric", "pH.", "A", "history", "of", "H.", "pylori", "infection", "is", "relatively", "common", "in", "HIV", "-", "positive", "black", "and", "Hispanic", "populations", "and", "is", "a", "predictor", "of", "gastric", "pH.", " " ]
[ "Habitat", "Microorganism" ]
Helicobacter pylori is a Microorganism, gastric is a Habitat, human immunodeficiency virus - infected outpatients is a Habitat, gastric is a Habitat, persons infected with human immunodeficiency virus is a Habitat, HIV is a Microorganism, asymptomatic subjects is a Habitat, Gastric is a Habitat, gastric is a Habitat, CD4 cell is a Habitat, Helicobacter pylori is a Microorganism, gastric is a Habitat, Subjects with hypoacidity is a Habitat, H. pylori is a Microorganism, subjects without hypoacidity is a Habitat, H. pylori is a Microorganism, gastric is a Habitat, HIV is a Microorganism, male is a Habitat, gastric is a Habitat, CD4 cell is a Habitat, gastric is a Habitat, H. pylori is a Microorganism, HIV - positive black is a Habitat, gastric is a Habitat
69_task1
Sentence: Previous infection with Helicobacter pylori is the primary determinant of spontaneous gastric hypoacidity in human immunodeficiency virus-infected outpatients. To investigate the incidence and demographics of gastric hypoacidity among persons infected with human immunodeficiency virus (HIV), 146 asymptomatic subjects were evaluated with use of a radiotelemetry device (Heidelberg capsule). Gastric hypoacidity (minimum gastric pH of > or = 3) occurred in 24 subjects (17%). Demographic characteristics, CD4 cell counts, and Helicobacter pylori serological status were evaluated for an association with gastric pH. Subjects with hypoacidity were more likely to have positive H. pylori serology than were subjects without hypoacidity (15 of 24 vs. 23 of 74, respectively; P = .004). Multivariate analysis indicated that a positive H. pylori serology was the most significant predictor of hypoacidity, accounting for an increase in gastric pH of 39%. A history of injection drug use, heterosexual transmission of HIV, and male gender were also associated with an elevated gastric pH. CD4 cell counts did not contribute to predictions of gastric pH. A history of H. pylori infection is relatively common in HIV-positive black and Hispanic populations and is a predictor of gastric pH. Instructions: please typing these entity words according to sentence: Helicobacter pylori, gastric, human immunodeficiency virus - infected outpatients, gastric, persons infected with human immunodeficiency virus, HIV, asymptomatic subjects, Gastric, gastric, CD4 cell, Helicobacter pylori, gastric, Subjects with hypoacidity, H. pylori, subjects without hypoacidity, H. pylori, gastric, HIV, male, gastric, CD4 cell, gastric, H. pylori, HIV - positive black, gastric Options: Microorganism, Habitat
[ "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "B-Microorganism", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "B-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O" ]
Previous infection with Helicobacter pylori is the primary determinant of spontaneous gastric hypoacidity in human immunodeficiency virus-infected outpatients. To investigate the incidence and demographics of gastric hypoacidity among persons infected with human immunodeficiency virus (HIV), 146 asymptomatic subjects were evaluated with use of a radiotelemetry device (Heidelberg capsule). Gastric hypoacidity (minimum gastric pH of > or = 3) occurred in 24 subjects (17%). Demographic characteristics, CD4 cell counts, and Helicobacter pylori serological status were evaluated for an association with gastric pH. Subjects with hypoacidity were more likely to have positive H. pylori serology than were subjects without hypoacidity (15 of 24 vs. 23 of 74, respectively; P = .004). Multivariate analysis indicated that a positive H. pylori serology was the most significant predictor of hypoacidity, accounting for an increase in gastric pH of 39%. A history of injection drug use, heterosexual transmission of HIV, and male gender were also associated with an elevated gastric pH. CD4 cell counts did not contribute to predictions of gastric pH. A history of H. pylori infection is relatively common in HIV-positive black and Hispanic populations and is a predictor of gastric pH.
[ "Previous", "infection", "with", "Helicobacter", "pylori", "is", "the", "primary", "determinant", "of", "spontaneous", "gastric", "hypoacidity", "in", "human", "immunodeficiency", "virus", "-", "infected", "outpatients", ".", "To", "investigate", "the", "incidence", "and", "demographics", "of", "gastric", "hypoacidity", "among", "persons", "infected", "with", "human", "immunodeficiency", "virus", "(", "HIV", ")", ",", "146", "asymptomatic", "subjects", "were", "evaluated", "with", "use", "of", "a", "radiotelemetry", "device", "(", "Heidelberg", "capsule", ")", ".", "Gastric", "hypoacidity", "(", "minimum", "gastric", "pH", "of", ">", "or", "=", "3", ")", "occurred", "in", "24", "subjects", "(", "17", "%", ")", ".", "Demographic", "characteristics", ",", "CD4", "cell", "counts", ",", "and", "Helicobacter", "pylori", "serological", "status", "were", "evaluated", "for", "an", "association", "with", "gastric", "pH.", "Subjects", "with", "hypoacidity", "were", "more", "likely", "to", "have", "positive", "H.", "pylori", "serology", "than", "were", "subjects", "without", "hypoacidity", "(", "15", "of", "24", "vs", ".", "23", "of", "74", ",", "respectively", ";", "P", "=", ".004", ")", ".", "Multivariate", "analysis", "indicated", "that", "a", "positive", "H.", "pylori", "serology", "was", "the", "most", "significant", "predictor", "of", "hypoacidity", ",", "accounting", "for", "an", "increase", "in", "gastric", "pH", "of", "39", "%", ".", "A", "history", "of", "injection", "drug", "use", ",", "heterosexual", "transmission", "of", "HIV", ",", "and", "male", "gender", "were", "also", "associated", "with", "an", "elevated", "gastric", "pH.", "CD4", "cell", "counts", "did", "not", "contribute", "to", "predictions", "of", "gastric", "pH.", "A", "history", "of", "H.", "pylori", "infection", "is", "relatively", "common", "in", "HIV", "-", "positive", "black", "and", "Hispanic", "populations", "and", "is", "a", "predictor", "of", "gastric", "pH.", " " ]
[ "Habitat", "Microorganism" ]
Helicobacter pylori, gastric, human immunodeficiency virus - infected outpatients, gastric, persons infected with human immunodeficiency virus, HIV, asymptomatic subjects, Gastric, gastric, CD4 cell, Helicobacter pylori, gastric, Subjects with hypoacidity, H. pylori, subjects without hypoacidity, H. pylori, gastric, HIV, male, gastric, CD4 cell, gastric, H. pylori, HIV - positive black, gastric
69_task2
Sentence: Previous infection with Helicobacter pylori is the primary determinant of spontaneous gastric hypoacidity in human immunodeficiency virus-infected outpatients. To investigate the incidence and demographics of gastric hypoacidity among persons infected with human immunodeficiency virus (HIV), 146 asymptomatic subjects were evaluated with use of a radiotelemetry device (Heidelberg capsule). Gastric hypoacidity (minimum gastric pH of > or = 3) occurred in 24 subjects (17%). Demographic characteristics, CD4 cell counts, and Helicobacter pylori serological status were evaluated for an association with gastric pH. Subjects with hypoacidity were more likely to have positive H. pylori serology than were subjects without hypoacidity (15 of 24 vs. 23 of 74, respectively; P = .004). Multivariate analysis indicated that a positive H. pylori serology was the most significant predictor of hypoacidity, accounting for an increase in gastric pH of 39%. A history of injection drug use, heterosexual transmission of HIV, and male gender were also associated with an elevated gastric pH. CD4 cell counts did not contribute to predictions of gastric pH. A history of H. pylori infection is relatively common in HIV-positive black and Hispanic populations and is a predictor of gastric pH. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "B-Microorganism", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "B-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O" ]
Previous infection with Helicobacter pylori is the primary determinant of spontaneous gastric hypoacidity in human immunodeficiency virus-infected outpatients. To investigate the incidence and demographics of gastric hypoacidity among persons infected with human immunodeficiency virus (HIV), 146 asymptomatic subjects were evaluated with use of a radiotelemetry device (Heidelberg capsule). Gastric hypoacidity (minimum gastric pH of > or = 3) occurred in 24 subjects (17%). Demographic characteristics, CD4 cell counts, and Helicobacter pylori serological status were evaluated for an association with gastric pH. Subjects with hypoacidity were more likely to have positive H. pylori serology than were subjects without hypoacidity (15 of 24 vs. 23 of 74, respectively; P = .004). Multivariate analysis indicated that a positive H. pylori serology was the most significant predictor of hypoacidity, accounting for an increase in gastric pH of 39%. A history of injection drug use, heterosexual transmission of HIV, and male gender were also associated with an elevated gastric pH. CD4 cell counts did not contribute to predictions of gastric pH. A history of H. pylori infection is relatively common in HIV-positive black and Hispanic populations and is a predictor of gastric pH.
[ "Previous", "infection", "with", "Helicobacter", "pylori", "is", "the", "primary", "determinant", "of", "spontaneous", "gastric", "hypoacidity", "in", "human", "immunodeficiency", "virus", "-", "infected", "outpatients", ".", "To", "investigate", "the", "incidence", "and", "demographics", "of", "gastric", "hypoacidity", "among", "persons", "infected", "with", "human", "immunodeficiency", "virus", "(", "HIV", ")", ",", "146", "asymptomatic", "subjects", "were", "evaluated", "with", "use", "of", "a", "radiotelemetry", "device", "(", "Heidelberg", "capsule", ")", ".", "Gastric", "hypoacidity", "(", "minimum", "gastric", "pH", "of", ">", "or", "=", "3", ")", "occurred", "in", "24", "subjects", "(", "17", "%", ")", ".", "Demographic", "characteristics", ",", "CD4", "cell", "counts", ",", "and", "Helicobacter", "pylori", "serological", "status", "were", "evaluated", "for", "an", "association", "with", "gastric", "pH.", "Subjects", "with", "hypoacidity", "were", "more", "likely", "to", "have", "positive", "H.", "pylori", "serology", "than", "were", "subjects", "without", "hypoacidity", "(", "15", "of", "24", "vs", ".", "23", "of", "74", ",", "respectively", ";", "P", "=", ".004", ")", ".", "Multivariate", "analysis", "indicated", "that", "a", "positive", "H.", "pylori", "serology", "was", "the", "most", "significant", "predictor", "of", "hypoacidity", ",", "accounting", "for", "an", "increase", "in", "gastric", "pH", "of", "39", "%", ".", "A", "history", "of", "injection", "drug", "use", ",", "heterosexual", "transmission", "of", "HIV", ",", "and", "male", "gender", "were", "also", "associated", "with", "an", "elevated", "gastric", "pH.", "CD4", "cell", "counts", "did", "not", "contribute", "to", "predictions", "of", "gastric", "pH.", "A", "history", "of", "H.", "pylori", "infection", "is", "relatively", "common", "in", "HIV", "-", "positive", "black", "and", "Hispanic", "populations", "and", "is", "a", "predictor", "of", "gastric", "pH.", " " ]
[ "Habitat", "Microorganism" ]
Stepwise hook extension technique is a Intervention_Physical, hepatocellular carcinoma is a Participant_Condition, stepwise hook extension technique for radiofrequency ablation ( RFA ) therapy is a Intervention_Physical, Twenty is a Participant_Sample-size, hepatocellular carcinoma measuring < 25 mm is a Participant_Condition, full extension method is a Intervention_Physical, 10-hook electrode of LeVeen needle is a Intervention_Other, Roll - off is a Outcome_Physical, median time to completion of treatment is a Outcome_Other, total power output is a Outcome_Other, diameters of RFA - induced lesions is a Outcome_Physical, same therapeutic effects is a Outcome_Other
10520_task0
Sentence: Stepwise hook extension technique for radiofrequency ablation therapy of hepatocellular carcinoma . OBJECTIVE Our study was designed to examine the efficacy of stepwise hook extension technique for radiofrequency ablation ( RFA ) therapy of hepatocellular carcinoma in a randomized controlled study . METHOD Twenty patients with hepatocellular carcinoma measuring < 25 mm were divided randomly into two equal groups . RFA was applied using our new stepwise hook extension technique in patients of group 1 , and the full extension method in group 2 . The 10-hook electrode of LeVeen needle was deployed in four steps to full extension during ablation in group 1 , and full extension at start of treatment in group 2 . RESULTS Roll-off was achieved in all 10 patients of group 1 , indicative of sufficient tumor coagulation , but only in 3 of 10 patients of group 2 . The median time to completion of treatment was 6 min and 55 s ( range 3 min to 14 min and 3 s ) and 15 min ( 6-15 min ) , respectively . The total power output used for RF was lower in group 1 than in group 2 ( median 271 vs. 1,045 W.m ) . The diameters of RFA-induced lesions were not significantly different between the groups ( group 1 : 27 , range 23-37 mm ; group 2 : 23 , 0-42 mm ) . CONCLUSIONS Application of RFA using stepwise hook extension technique is superior to the full extension method since it produces the same therapeutic effects within a short period using a lower energy . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Physical, Participant_Condition, Intervention_Other, Outcome_Physical, Participant_Sample-size, Outcome_Other
[ "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Stepwise hook extension technique for radiofrequency ablation therapy of hepatocellular carcinoma . OBJECTIVE Our study was designed to examine the efficacy of stepwise hook extension technique for radiofrequency ablation ( RFA ) therapy of hepatocellular carcinoma in a randomized controlled study . METHOD Twenty patients with hepatocellular carcinoma measuring < 25 mm were divided randomly into two equal groups . RFA was applied using our new stepwise hook extension technique in patients of group 1 , and the full extension method in group 2 . The 10-hook electrode of LeVeen needle was deployed in four steps to full extension during ablation in group 1 , and full extension at start of treatment in group 2 . RESULTS Roll-off was achieved in all 10 patients of group 1 , indicative of sufficient tumor coagulation , but only in 3 of 10 patients of group 2 . The median time to completion of treatment was 6 min and 55 s ( range 3 min to 14 min and 3 s ) and 15 min ( 6-15 min ) , respectively . The total power output used for RF was lower in group 1 than in group 2 ( median 271 vs. 1,045 W.m ) . The diameters of RFA-induced lesions were not significantly different between the groups ( group 1 : 27 , range 23-37 mm ; group 2 : 23 , 0-42 mm ) . CONCLUSIONS Application of RFA using stepwise hook extension technique is superior to the full extension method since it produces the same therapeutic effects within a short period using a lower energy .
[ "Stepwise", "hook", "extension", "technique", "for", "radiofrequency", "ablation", "therapy", "of", "hepatocellular", "carcinoma", ".", "OBJECTIVE", "Our", "study", "was", "designed", "to", "examine", "the", "efficacy", "of", "stepwise", "hook", "extension", "technique", "for", "radiofrequency", "ablation", "(", "RFA", ")", "therapy", "of", "hepatocellular", "carcinoma", "in", "a", "randomized", "controlled", "study", ".", "METHOD", "Twenty", "patients", "with", "hepatocellular", "carcinoma", "measuring", "<", "25", "mm", "were", "divided", "randomly", "into", "two", "equal", "groups", ".", "RFA", "was", "applied", "using", "our", "new", "stepwise", "hook", "extension", "technique", "in", "patients", "of", "group", "1", ",", "and", "the", "full", "extension", "method", "in", "group", "2", ".", "The", "10-hook", "electrode", "of", "LeVeen", "needle", "was", "deployed", "in", "four", "steps", "to", "full", "extension", "during", "ablation", "in", "group", "1", ",", "and", "full", "extension", "at", "start", "of", "treatment", "in", "group", "2", ".", "RESULTS", "Roll", "-", "off", "was", "achieved", "in", "all", "10", "patients", "of", "group", "1", ",", "indicative", "of", "sufficient", "tumor", "coagulation", ",", "but", "only", "in", "3", "of", "10", "patients", "of", "group", "2", ".", "The", "median", "time", "to", "completion", "of", "treatment", "was", "6", "min", "and", "55", "s", "(", "range", "3", "min", "to", "14", "min", "and", "3", "s", ")", "and", "15", "min", "(", "6", "-", "15", "min", ")", ",", "respectively", ".", "The", "total", "power", "output", "used", "for", "RF", "was", "lower", "in", "group", "1", "than", "in", "group", "2", "(", "median", "271", "vs", ".", "1,045", "W.m", ")", ".", "The", "diameters", "of", "RFA", "-", "induced", "lesions", "were", "not", "significantly", "different", "between", "the", "groups", "(", "group", "1", ":", "27", ",", "range", "23", "-", "37", "mm", ";", "group", "2", ":", "23", ",", "0", "-", "42", "mm", ")", ".", "CONCLUSIONS", "Application", "of", "RFA", "using", "stepwise", "hook", "extension", "technique", "is", "superior", "to", "the", "full", "extension", "method", "since", "it", "produces", "the", "same", "therapeutic", "effects", "within", "a", "short", "period", "using", "a", "lower", "energy", "." ]
[ "Intervention_Physical", "Participant_Condition", "Outcome_Other", "Intervention_Other", "Outcome_Physical", "Participant_Sample-size" ]
Stepwise hook extension technique is a Intervention_Physical, hepatocellular carcinoma is a Participant_Condition, stepwise hook extension technique for radiofrequency ablation ( RFA ) therapy is a Intervention_Physical, Twenty is a Participant_Sample-size, hepatocellular carcinoma measuring < 25 mm is a Participant_Condition, full extension method is a Intervention_Physical, 10-hook electrode of LeVeen needle is a Intervention_Other, Roll - off is a Outcome_Physical, median time to completion of treatment is a Outcome_Other, total power output is a Outcome_Other, diameters of RFA - induced lesions is a Outcome_Physical, same therapeutic effects is a Outcome_Other
10520_task1
Sentence: Stepwise hook extension technique for radiofrequency ablation therapy of hepatocellular carcinoma . OBJECTIVE Our study was designed to examine the efficacy of stepwise hook extension technique for radiofrequency ablation ( RFA ) therapy of hepatocellular carcinoma in a randomized controlled study . METHOD Twenty patients with hepatocellular carcinoma measuring < 25 mm were divided randomly into two equal groups . RFA was applied using our new stepwise hook extension technique in patients of group 1 , and the full extension method in group 2 . The 10-hook electrode of LeVeen needle was deployed in four steps to full extension during ablation in group 1 , and full extension at start of treatment in group 2 . RESULTS Roll-off was achieved in all 10 patients of group 1 , indicative of sufficient tumor coagulation , but only in 3 of 10 patients of group 2 . The median time to completion of treatment was 6 min and 55 s ( range 3 min to 14 min and 3 s ) and 15 min ( 6-15 min ) , respectively . The total power output used for RF was lower in group 1 than in group 2 ( median 271 vs. 1,045 W.m ) . The diameters of RFA-induced lesions were not significantly different between the groups ( group 1 : 27 , range 23-37 mm ; group 2 : 23 , 0-42 mm ) . CONCLUSIONS Application of RFA using stepwise hook extension technique is superior to the full extension method since it produces the same therapeutic effects within a short period using a lower energy . Instructions: please typing these entity words according to sentence: Stepwise hook extension technique, hepatocellular carcinoma, stepwise hook extension technique for radiofrequency ablation ( RFA ) therapy, Twenty, hepatocellular carcinoma measuring < 25 mm, full extension method, 10-hook electrode of LeVeen needle, Roll - off, median time to completion of treatment, total power output, diameters of RFA - induced lesions, same therapeutic effects Options: Intervention_Physical, Participant_Condition, Intervention_Other, Outcome_Physical, Participant_Sample-size, Outcome_Other
[ "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Stepwise hook extension technique for radiofrequency ablation therapy of hepatocellular carcinoma . OBJECTIVE Our study was designed to examine the efficacy of stepwise hook extension technique for radiofrequency ablation ( RFA ) therapy of hepatocellular carcinoma in a randomized controlled study . METHOD Twenty patients with hepatocellular carcinoma measuring < 25 mm were divided randomly into two equal groups . RFA was applied using our new stepwise hook extension technique in patients of group 1 , and the full extension method in group 2 . The 10-hook electrode of LeVeen needle was deployed in four steps to full extension during ablation in group 1 , and full extension at start of treatment in group 2 . RESULTS Roll-off was achieved in all 10 patients of group 1 , indicative of sufficient tumor coagulation , but only in 3 of 10 patients of group 2 . The median time to completion of treatment was 6 min and 55 s ( range 3 min to 14 min and 3 s ) and 15 min ( 6-15 min ) , respectively . The total power output used for RF was lower in group 1 than in group 2 ( median 271 vs. 1,045 W.m ) . The diameters of RFA-induced lesions were not significantly different between the groups ( group 1 : 27 , range 23-37 mm ; group 2 : 23 , 0-42 mm ) . CONCLUSIONS Application of RFA using stepwise hook extension technique is superior to the full extension method since it produces the same therapeutic effects within a short period using a lower energy .
[ "Stepwise", "hook", "extension", "technique", "for", "radiofrequency", "ablation", "therapy", "of", "hepatocellular", "carcinoma", ".", "OBJECTIVE", "Our", "study", "was", "designed", "to", "examine", "the", "efficacy", "of", "stepwise", "hook", "extension", "technique", "for", "radiofrequency", "ablation", "(", "RFA", ")", "therapy", "of", "hepatocellular", "carcinoma", "in", "a", "randomized", "controlled", "study", ".", "METHOD", "Twenty", "patients", "with", "hepatocellular", "carcinoma", "measuring", "<", "25", "mm", "were", "divided", "randomly", "into", "two", "equal", "groups", ".", "RFA", "was", "applied", "using", "our", "new", "stepwise", "hook", "extension", "technique", "in", "patients", "of", "group", "1", ",", "and", "the", "full", "extension", "method", "in", "group", "2", ".", "The", "10-hook", "electrode", "of", "LeVeen", "needle", "was", "deployed", "in", "four", "steps", "to", "full", "extension", "during", "ablation", "in", "group", "1", ",", "and", "full", "extension", "at", "start", "of", "treatment", "in", "group", "2", ".", "RESULTS", "Roll", "-", "off", "was", "achieved", "in", "all", "10", "patients", "of", "group", "1", ",", "indicative", "of", "sufficient", "tumor", "coagulation", ",", "but", "only", "in", "3", "of", "10", "patients", "of", "group", "2", ".", "The", "median", "time", "to", "completion", "of", "treatment", "was", "6", "min", "and", "55", "s", "(", "range", "3", "min", "to", "14", "min", "and", "3", "s", ")", "and", "15", "min", "(", "6", "-", "15", "min", ")", ",", "respectively", ".", "The", "total", "power", "output", "used", "for", "RF", "was", "lower", "in", "group", "1", "than", "in", "group", "2", "(", "median", "271", "vs", ".", "1,045", "W.m", ")", ".", "The", "diameters", "of", "RFA", "-", "induced", "lesions", "were", "not", "significantly", "different", "between", "the", "groups", "(", "group", "1", ":", "27", ",", "range", "23", "-", "37", "mm", ";", "group", "2", ":", "23", ",", "0", "-", "42", "mm", ")", ".", "CONCLUSIONS", "Application", "of", "RFA", "using", "stepwise", "hook", "extension", "technique", "is", "superior", "to", "the", "full", "extension", "method", "since", "it", "produces", "the", "same", "therapeutic", "effects", "within", "a", "short", "period", "using", "a", "lower", "energy", "." ]
[ "Intervention_Physical", "Participant_Condition", "Outcome_Other", "Intervention_Other", "Outcome_Physical", "Participant_Sample-size" ]
Stepwise hook extension technique, hepatocellular carcinoma, stepwise hook extension technique for radiofrequency ablation ( RFA ) therapy, Twenty, hepatocellular carcinoma measuring < 25 mm, full extension method, 10-hook electrode of LeVeen needle, Roll - off, median time to completion of treatment, total power output, diameters of RFA - induced lesions, same therapeutic effects
10520_task2
Sentence: Stepwise hook extension technique for radiofrequency ablation therapy of hepatocellular carcinoma . OBJECTIVE Our study was designed to examine the efficacy of stepwise hook extension technique for radiofrequency ablation ( RFA ) therapy of hepatocellular carcinoma in a randomized controlled study . METHOD Twenty patients with hepatocellular carcinoma measuring < 25 mm were divided randomly into two equal groups . RFA was applied using our new stepwise hook extension technique in patients of group 1 , and the full extension method in group 2 . The 10-hook electrode of LeVeen needle was deployed in four steps to full extension during ablation in group 1 , and full extension at start of treatment in group 2 . RESULTS Roll-off was achieved in all 10 patients of group 1 , indicative of sufficient tumor coagulation , but only in 3 of 10 patients of group 2 . The median time to completion of treatment was 6 min and 55 s ( range 3 min to 14 min and 3 s ) and 15 min ( 6-15 min ) , respectively . The total power output used for RF was lower in group 1 than in group 2 ( median 271 vs. 1,045 W.m ) . The diameters of RFA-induced lesions were not significantly different between the groups ( group 1 : 27 , range 23-37 mm ; group 2 : 23 , 0-42 mm ) . CONCLUSIONS Application of RFA using stepwise hook extension technique is superior to the full extension method since it produces the same therapeutic effects within a short period using a lower energy . Instructions: please extract entity words from the input sentence
[ "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Stepwise hook extension technique for radiofrequency ablation therapy of hepatocellular carcinoma . OBJECTIVE Our study was designed to examine the efficacy of stepwise hook extension technique for radiofrequency ablation ( RFA ) therapy of hepatocellular carcinoma in a randomized controlled study . METHOD Twenty patients with hepatocellular carcinoma measuring < 25 mm were divided randomly into two equal groups . RFA was applied using our new stepwise hook extension technique in patients of group 1 , and the full extension method in group 2 . The 10-hook electrode of LeVeen needle was deployed in four steps to full extension during ablation in group 1 , and full extension at start of treatment in group 2 . RESULTS Roll-off was achieved in all 10 patients of group 1 , indicative of sufficient tumor coagulation , but only in 3 of 10 patients of group 2 . The median time to completion of treatment was 6 min and 55 s ( range 3 min to 14 min and 3 s ) and 15 min ( 6-15 min ) , respectively . The total power output used for RF was lower in group 1 than in group 2 ( median 271 vs. 1,045 W.m ) . The diameters of RFA-induced lesions were not significantly different between the groups ( group 1 : 27 , range 23-37 mm ; group 2 : 23 , 0-42 mm ) . CONCLUSIONS Application of RFA using stepwise hook extension technique is superior to the full extension method since it produces the same therapeutic effects within a short period using a lower energy .
[ "Stepwise", "hook", "extension", "technique", "for", "radiofrequency", "ablation", "therapy", "of", "hepatocellular", "carcinoma", ".", "OBJECTIVE", "Our", "study", "was", "designed", "to", "examine", "the", "efficacy", "of", "stepwise", "hook", "extension", "technique", "for", "radiofrequency", "ablation", "(", "RFA", ")", "therapy", "of", "hepatocellular", "carcinoma", "in", "a", "randomized", "controlled", "study", ".", "METHOD", "Twenty", "patients", "with", "hepatocellular", "carcinoma", "measuring", "<", "25", "mm", "were", "divided", "randomly", "into", "two", "equal", "groups", ".", "RFA", "was", "applied", "using", "our", "new", "stepwise", "hook", "extension", "technique", "in", "patients", "of", "group", "1", ",", "and", "the", "full", "extension", "method", "in", "group", "2", ".", "The", "10-hook", "electrode", "of", "LeVeen", "needle", "was", "deployed", "in", "four", "steps", "to", "full", "extension", "during", "ablation", "in", "group", "1", ",", "and", "full", "extension", "at", "start", "of", "treatment", "in", "group", "2", ".", "RESULTS", "Roll", "-", "off", "was", "achieved", "in", "all", "10", "patients", "of", "group", "1", ",", "indicative", "of", "sufficient", "tumor", "coagulation", ",", "but", "only", "in", "3", "of", "10", "patients", "of", "group", "2", ".", "The", "median", "time", "to", "completion", "of", "treatment", "was", "6", "min", "and", "55", "s", "(", "range", "3", "min", "to", "14", "min", "and", "3", "s", ")", "and", "15", "min", "(", "6", "-", "15", "min", ")", ",", "respectively", ".", "The", "total", "power", "output", "used", "for", "RF", "was", "lower", "in", "group", "1", "than", "in", "group", "2", "(", "median", "271", "vs", ".", "1,045", "W.m", ")", ".", "The", "diameters", "of", "RFA", "-", "induced", "lesions", "were", "not", "significantly", "different", "between", "the", "groups", "(", "group", "1", ":", "27", ",", "range", "23", "-", "37", "mm", ";", "group", "2", ":", "23", ",", "0", "-", "42", "mm", ")", ".", "CONCLUSIONS", "Application", "of", "RFA", "using", "stepwise", "hook", "extension", "technique", "is", "superior", "to", "the", "full", "extension", "method", "since", "it", "produces", "the", "same", "therapeutic", "effects", "within", "a", "short", "period", "using", "a", "lower", "energy", "." ]
[ "Intervention_Physical", "Participant_Condition", "Outcome_Other", "Intervention_Other", "Outcome_Physical", "Participant_Sample-size" ]
UV - induced CYP1A1 gene expression is an other_name, tryptophan is an amino_acid_monomer
39215_task0
Sentence: UV-induced CYP1A1 gene expression in human cells is mediated by tryptophan. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: amino_acid_monomer, other_name
[ "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "O", "O", "O", "O", "O", "B-amino_acid_monomer", "O" ]
UV-induced CYP1A1 gene expression in human cells is mediated by tryptophan.
[ "UV", "-", "induced", "CYP1A1", "gene", "expression", "in", "human", "cells", "is", "mediated", "by", "tryptophan", "." ]
[ "other_name", "(AND cell_line cell_line)", "cell_type", "other_organic_compound", "cell_line", "", "protein_molecule", "RNA_molecule", "amino_acid_monomer" ]
UV - induced CYP1A1 gene expression is an other_name, tryptophan is an amino_acid_monomer
39215_task1
Sentence: UV-induced CYP1A1 gene expression in human cells is mediated by tryptophan. Instructions: please typing these entity words according to sentence: UV - induced CYP1A1 gene expression, tryptophan Options: amino_acid_monomer, other_name
[ "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "O", "O", "O", "O", "O", "B-amino_acid_monomer", "O" ]
UV-induced CYP1A1 gene expression in human cells is mediated by tryptophan.
[ "UV", "-", "induced", "CYP1A1", "gene", "expression", "in", "human", "cells", "is", "mediated", "by", "tryptophan", "." ]
[ "other_name", "(AND cell_line cell_line)", "cell_type", "other_organic_compound", "cell_line", "", "protein_molecule", "RNA_molecule", "amino_acid_monomer" ]
UV - induced CYP1A1 gene expression, tryptophan
39215_task2
Sentence: UV-induced CYP1A1 gene expression in human cells is mediated by tryptophan. Instructions: please extract entity words from the input sentence
[ "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "O", "O", "O", "O", "O", "B-amino_acid_monomer", "O" ]
UV-induced CYP1A1 gene expression in human cells is mediated by tryptophan.
[ "UV", "-", "induced", "CYP1A1", "gene", "expression", "in", "human", "cells", "is", "mediated", "by", "tryptophan", "." ]
[ "other_name", "(AND cell_line cell_line)", "cell_type", "other_organic_compound", "cell_line", "", "protein_molecule", "RNA_molecule", "amino_acid_monomer" ]
epanolol is a Intervention_Pharmacological, atenolol is a Intervention_Pharmacological, blood pressure is a Outcome_Physical, hypertension is a Participant_Condition, Epanolol is a Intervention_Pharmacological, intraarterial pressure is a Outcome_Physical, 12 patients with essential hypertension . is a Participant_Condition, Heart rate , stroke index , and cardiac index is a Outcome_Physical, total peripheral resistance index is a Outcome_Physical, Cardiac index and heart rate is a Outcome_Physical, Twenty - four hour ambulatory blood pressure is a Outcome_Physical, heart rate and cardiac output is a Outcome_Physical, cardiovascular disorders is a Participant_Condition, cardiac arrhythmia is a Participant_Condition
83956_task0
Sentence: Modest antihypertensive effect of epanolol , a beta 1-selective receptor blocker with beta 1 agonist activity : an acute and long-term hemodynamic study at rest and during exercise and double crossover comparison with atenolol on ambulatory blood pressure . Beta-blockers with less cardiodepressive effect than traditional nonselective beta ( 1+2 ) -blocking agents could be useful in the treatment of hypertension , provided the reduction in blood pressure was satisfactory . Epanolol , a selective beta 1-receptor blocker with intrinsic sympathomimetic activity , induced a fall in intraarterial pressure of 8 % at rest sitting and 11 % during 100 W bicycle exercise after the first dose of 200 mg in 12 patients with essential hypertension . Heart rate , stroke index , and cardiac index initially fell by 14 % , 11 % , and 23 % , respectively . The total peripheral resistance index increased by 21 % after 2 hours , and then reverted towards the pretreatment level . After 10 months of epanolol treatment ( mean 300 mg/day ) , the reduction in arterial pressure was 5 % at rest and 10 % during exercise . Cardiac index and heart rate were still reduced 14-21 % , while total peripheral resistance was unchanged or slightly increased ( 2-10 % ) . Twenty-four hour ambulatory blood pressure was higher on epanolol ( 300 mg/day ) than on atenolol ( 150 mg/day ) treatment ( 137/97 vs. 128/91 mmHg ) . Thus , the achieved blood pressure reduction induced by epanolol was moderate , while other characteristics of beta-receptor blockade , in particular , the reduction of heart rate and cardiac output , were maintained . This suggests that the compound may be useful for other cardiovascular disorders , e.g. , angina pectoris in patients without hypertension or cardiac arrhythmia . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Outcome_Physical, Participant_Condition
[ "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O" ]
Modest antihypertensive effect of epanolol , a beta 1-selective receptor blocker with beta 1 agonist activity : an acute and long-term hemodynamic study at rest and during exercise and double crossover comparison with atenolol on ambulatory blood pressure . Beta-blockers with less cardiodepressive effect than traditional nonselective beta ( 1+2 ) -blocking agents could be useful in the treatment of hypertension , provided the reduction in blood pressure was satisfactory . Epanolol , a selective beta 1-receptor blocker with intrinsic sympathomimetic activity , induced a fall in intraarterial pressure of 8 % at rest sitting and 11 % during 100 W bicycle exercise after the first dose of 200 mg in 12 patients with essential hypertension . Heart rate , stroke index , and cardiac index initially fell by 14 % , 11 % , and 23 % , respectively . The total peripheral resistance index increased by 21 % after 2 hours , and then reverted towards the pretreatment level . After 10 months of epanolol treatment ( mean 300 mg/day ) , the reduction in arterial pressure was 5 % at rest and 10 % during exercise . Cardiac index and heart rate were still reduced 14-21 % , while total peripheral resistance was unchanged or slightly increased ( 2-10 % ) . Twenty-four hour ambulatory blood pressure was higher on epanolol ( 300 mg/day ) than on atenolol ( 150 mg/day ) treatment ( 137/97 vs. 128/91 mmHg ) . Thus , the achieved blood pressure reduction induced by epanolol was moderate , while other characteristics of beta-receptor blockade , in particular , the reduction of heart rate and cardiac output , were maintained . This suggests that the compound may be useful for other cardiovascular disorders , e.g. , angina pectoris in patients without hypertension or cardiac arrhythmia .
[ "Modest", "antihypertensive", "effect", "of", "epanolol", ",", "a", "beta", "1-selective", "receptor", "blocker", "with", "beta", "1", "agonist", "activity", ":", "an", "acute", "and", "long", "-", "term", "hemodynamic", "study", "at", "rest", "and", "during", "exercise", "and", "double", "crossover", "comparison", "with", "atenolol", "on", "ambulatory", "blood", "pressure", ".", "Beta", "-", "blockers", "with", "less", "cardiodepressive", "effect", "than", "traditional", "nonselective", "beta", "(", "1", "+", "2", ")", "-blocking", "agents", "could", "be", "useful", "in", "the", "treatment", "of", "hypertension", ",", "provided", "the", "reduction", "in", "blood", "pressure", "was", "satisfactory", ".", "Epanolol", ",", "a", "selective", "beta", "1-receptor", "blocker", "with", "intrinsic", "sympathomimetic", "activity", ",", "induced", "a", "fall", "in", "intraarterial", "pressure", "of", "8", "%", "at", "rest", "sitting", "and", "11", "%", "during", "100", "W", "bicycle", "exercise", "after", "the", "first", "dose", "of", "200", "mg", "in", "12", "patients", "with", "essential", "hypertension", ".", "Heart", "rate", ",", "stroke", "index", ",", "and", "cardiac", "index", "initially", "fell", "by", "14", "%", ",", "11", "%", ",", "and", "23", "%", ",", "respectively", ".", "The", "total", "peripheral", "resistance", "index", "increased", "by", "21", "%", "after", "2", "hours", ",", "and", "then", "reverted", "towards", "the", "pretreatment", "level", ".", "After", "10", "months", "of", "epanolol", "treatment", "(", "mean", "300", "mg", "/", "day", ")", ",", "the", "reduction", "in", "arterial", "pressure", "was", "5", "%", "at", "rest", "and", "10", "%", "during", "exercise", ".", "Cardiac", "index", "and", "heart", "rate", "were", "still", "reduced", "14", "-", "21", "%", ",", "while", "total", "peripheral", "resistance", "was", "unchanged", "or", "slightly", "increased", "(", "2", "-", "10", "%", ")", ".", "Twenty", "-", "four", "hour", "ambulatory", "blood", "pressure", "was", "higher", "on", "epanolol", "(", "300", "mg", "/", "day", ")", "than", "on", "atenolol", "(", "150", "mg", "/", "day", ")", "treatment", "(", "137/97", "vs", ".", "128/91", "mmHg", ")", ".", "Thus", ",", "the", "achieved", "blood", "pressure", "reduction", "induced", "by", "epanolol", "was", "moderate", ",", "while", "other", "characteristics", "of", "beta", "-", "receptor", "blockade", ",", "in", "particular", ",", "the", "reduction", "of", "heart", "rate", "and", "cardiac", "output", ",", "were", "maintained", ".", "This", "suggests", "that", "the", "compound", "may", "be", "useful", "for", "other", "cardiovascular", "disorders", ",", "e.g", ".", ",", "angina", "pectoris", "in", "patients", "without", "hypertension", "or", "cardiac", "arrhythmia", "." ]
[ "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological" ]
epanolol is a Intervention_Pharmacological, atenolol is a Intervention_Pharmacological, blood pressure is a Outcome_Physical, hypertension is a Participant_Condition, Epanolol is a Intervention_Pharmacological, intraarterial pressure is a Outcome_Physical, 12 patients with essential hypertension . is a Participant_Condition, Heart rate , stroke index , and cardiac index is a Outcome_Physical, total peripheral resistance index is a Outcome_Physical, Cardiac index and heart rate is a Outcome_Physical, Twenty - four hour ambulatory blood pressure is a Outcome_Physical, heart rate and cardiac output is a Outcome_Physical, cardiovascular disorders is a Participant_Condition, cardiac arrhythmia is a Participant_Condition
83956_task1
Sentence: Modest antihypertensive effect of epanolol , a beta 1-selective receptor blocker with beta 1 agonist activity : an acute and long-term hemodynamic study at rest and during exercise and double crossover comparison with atenolol on ambulatory blood pressure . Beta-blockers with less cardiodepressive effect than traditional nonselective beta ( 1+2 ) -blocking agents could be useful in the treatment of hypertension , provided the reduction in blood pressure was satisfactory . Epanolol , a selective beta 1-receptor blocker with intrinsic sympathomimetic activity , induced a fall in intraarterial pressure of 8 % at rest sitting and 11 % during 100 W bicycle exercise after the first dose of 200 mg in 12 patients with essential hypertension . Heart rate , stroke index , and cardiac index initially fell by 14 % , 11 % , and 23 % , respectively . The total peripheral resistance index increased by 21 % after 2 hours , and then reverted towards the pretreatment level . After 10 months of epanolol treatment ( mean 300 mg/day ) , the reduction in arterial pressure was 5 % at rest and 10 % during exercise . Cardiac index and heart rate were still reduced 14-21 % , while total peripheral resistance was unchanged or slightly increased ( 2-10 % ) . Twenty-four hour ambulatory blood pressure was higher on epanolol ( 300 mg/day ) than on atenolol ( 150 mg/day ) treatment ( 137/97 vs. 128/91 mmHg ) . Thus , the achieved blood pressure reduction induced by epanolol was moderate , while other characteristics of beta-receptor blockade , in particular , the reduction of heart rate and cardiac output , were maintained . This suggests that the compound may be useful for other cardiovascular disorders , e.g. , angina pectoris in patients without hypertension or cardiac arrhythmia . Instructions: please typing these entity words according to sentence: epanolol, atenolol, blood pressure, hypertension, Epanolol, intraarterial pressure, 12 patients with essential hypertension ., Heart rate , stroke index , and cardiac index, total peripheral resistance index, Cardiac index and heart rate, Twenty - four hour ambulatory blood pressure, heart rate and cardiac output, cardiovascular disorders, cardiac arrhythmia Options: Intervention_Pharmacological, Outcome_Physical, Participant_Condition
[ "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O" ]
Modest antihypertensive effect of epanolol , a beta 1-selective receptor blocker with beta 1 agonist activity : an acute and long-term hemodynamic study at rest and during exercise and double crossover comparison with atenolol on ambulatory blood pressure . Beta-blockers with less cardiodepressive effect than traditional nonselective beta ( 1+2 ) -blocking agents could be useful in the treatment of hypertension , provided the reduction in blood pressure was satisfactory . Epanolol , a selective beta 1-receptor blocker with intrinsic sympathomimetic activity , induced a fall in intraarterial pressure of 8 % at rest sitting and 11 % during 100 W bicycle exercise after the first dose of 200 mg in 12 patients with essential hypertension . Heart rate , stroke index , and cardiac index initially fell by 14 % , 11 % , and 23 % , respectively . The total peripheral resistance index increased by 21 % after 2 hours , and then reverted towards the pretreatment level . After 10 months of epanolol treatment ( mean 300 mg/day ) , the reduction in arterial pressure was 5 % at rest and 10 % during exercise . Cardiac index and heart rate were still reduced 14-21 % , while total peripheral resistance was unchanged or slightly increased ( 2-10 % ) . Twenty-four hour ambulatory blood pressure was higher on epanolol ( 300 mg/day ) than on atenolol ( 150 mg/day ) treatment ( 137/97 vs. 128/91 mmHg ) . Thus , the achieved blood pressure reduction induced by epanolol was moderate , while other characteristics of beta-receptor blockade , in particular , the reduction of heart rate and cardiac output , were maintained . This suggests that the compound may be useful for other cardiovascular disorders , e.g. , angina pectoris in patients without hypertension or cardiac arrhythmia .
[ "Modest", "antihypertensive", "effect", "of", "epanolol", ",", "a", "beta", "1-selective", "receptor", "blocker", "with", "beta", "1", "agonist", "activity", ":", "an", "acute", "and", "long", "-", "term", "hemodynamic", "study", "at", "rest", "and", "during", "exercise", "and", "double", "crossover", "comparison", "with", "atenolol", "on", "ambulatory", "blood", "pressure", ".", "Beta", "-", "blockers", "with", "less", "cardiodepressive", "effect", "than", "traditional", "nonselective", "beta", "(", "1", "+", "2", ")", "-blocking", "agents", "could", "be", "useful", "in", "the", "treatment", "of", "hypertension", ",", "provided", "the", "reduction", "in", "blood", "pressure", "was", "satisfactory", ".", "Epanolol", ",", "a", "selective", "beta", "1-receptor", "blocker", "with", "intrinsic", "sympathomimetic", "activity", ",", "induced", "a", "fall", "in", "intraarterial", "pressure", "of", "8", "%", "at", "rest", "sitting", "and", "11", "%", "during", "100", "W", "bicycle", "exercise", "after", "the", "first", "dose", "of", "200", "mg", "in", "12", "patients", "with", "essential", "hypertension", ".", "Heart", "rate", ",", "stroke", "index", ",", "and", "cardiac", "index", "initially", "fell", "by", "14", "%", ",", "11", "%", ",", "and", "23", "%", ",", "respectively", ".", "The", "total", "peripheral", "resistance", "index", "increased", "by", "21", "%", "after", "2", "hours", ",", "and", "then", "reverted", "towards", "the", "pretreatment", "level", ".", "After", "10", "months", "of", "epanolol", "treatment", "(", "mean", "300", "mg", "/", "day", ")", ",", "the", "reduction", "in", "arterial", "pressure", "was", "5", "%", "at", "rest", "and", "10", "%", "during", "exercise", ".", "Cardiac", "index", "and", "heart", "rate", "were", "still", "reduced", "14", "-", "21", "%", ",", "while", "total", "peripheral", "resistance", "was", "unchanged", "or", "slightly", "increased", "(", "2", "-", "10", "%", ")", ".", "Twenty", "-", "four", "hour", "ambulatory", "blood", "pressure", "was", "higher", "on", "epanolol", "(", "300", "mg", "/", "day", ")", "than", "on", "atenolol", "(", "150", "mg", "/", "day", ")", "treatment", "(", "137/97", "vs", ".", "128/91", "mmHg", ")", ".", "Thus", ",", "the", "achieved", "blood", "pressure", "reduction", "induced", "by", "epanolol", "was", "moderate", ",", "while", "other", "characteristics", "of", "beta", "-", "receptor", "blockade", ",", "in", "particular", ",", "the", "reduction", "of", "heart", "rate", "and", "cardiac", "output", ",", "were", "maintained", ".", "This", "suggests", "that", "the", "compound", "may", "be", "useful", "for", "other", "cardiovascular", "disorders", ",", "e.g", ".", ",", "angina", "pectoris", "in", "patients", "without", "hypertension", "or", "cardiac", "arrhythmia", "." ]
[ "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological" ]
epanolol, atenolol, blood pressure, hypertension, Epanolol, intraarterial pressure, 12 patients with essential hypertension ., Heart rate , stroke index , and cardiac index, total peripheral resistance index, Cardiac index and heart rate, Twenty - four hour ambulatory blood pressure, heart rate and cardiac output, cardiovascular disorders, cardiac arrhythmia
83956_task2
Sentence: Modest antihypertensive effect of epanolol , a beta 1-selective receptor blocker with beta 1 agonist activity : an acute and long-term hemodynamic study at rest and during exercise and double crossover comparison with atenolol on ambulatory blood pressure . Beta-blockers with less cardiodepressive effect than traditional nonselective beta ( 1+2 ) -blocking agents could be useful in the treatment of hypertension , provided the reduction in blood pressure was satisfactory . Epanolol , a selective beta 1-receptor blocker with intrinsic sympathomimetic activity , induced a fall in intraarterial pressure of 8 % at rest sitting and 11 % during 100 W bicycle exercise after the first dose of 200 mg in 12 patients with essential hypertension . Heart rate , stroke index , and cardiac index initially fell by 14 % , 11 % , and 23 % , respectively . The total peripheral resistance index increased by 21 % after 2 hours , and then reverted towards the pretreatment level . After 10 months of epanolol treatment ( mean 300 mg/day ) , the reduction in arterial pressure was 5 % at rest and 10 % during exercise . Cardiac index and heart rate were still reduced 14-21 % , while total peripheral resistance was unchanged or slightly increased ( 2-10 % ) . Twenty-four hour ambulatory blood pressure was higher on epanolol ( 300 mg/day ) than on atenolol ( 150 mg/day ) treatment ( 137/97 vs. 128/91 mmHg ) . Thus , the achieved blood pressure reduction induced by epanolol was moderate , while other characteristics of beta-receptor blockade , in particular , the reduction of heart rate and cardiac output , were maintained . This suggests that the compound may be useful for other cardiovascular disorders , e.g. , angina pectoris in patients without hypertension or cardiac arrhythmia . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O" ]
Modest antihypertensive effect of epanolol , a beta 1-selective receptor blocker with beta 1 agonist activity : an acute and long-term hemodynamic study at rest and during exercise and double crossover comparison with atenolol on ambulatory blood pressure . Beta-blockers with less cardiodepressive effect than traditional nonselective beta ( 1+2 ) -blocking agents could be useful in the treatment of hypertension , provided the reduction in blood pressure was satisfactory . Epanolol , a selective beta 1-receptor blocker with intrinsic sympathomimetic activity , induced a fall in intraarterial pressure of 8 % at rest sitting and 11 % during 100 W bicycle exercise after the first dose of 200 mg in 12 patients with essential hypertension . Heart rate , stroke index , and cardiac index initially fell by 14 % , 11 % , and 23 % , respectively . The total peripheral resistance index increased by 21 % after 2 hours , and then reverted towards the pretreatment level . After 10 months of epanolol treatment ( mean 300 mg/day ) , the reduction in arterial pressure was 5 % at rest and 10 % during exercise . Cardiac index and heart rate were still reduced 14-21 % , while total peripheral resistance was unchanged or slightly increased ( 2-10 % ) . Twenty-four hour ambulatory blood pressure was higher on epanolol ( 300 mg/day ) than on atenolol ( 150 mg/day ) treatment ( 137/97 vs. 128/91 mmHg ) . Thus , the achieved blood pressure reduction induced by epanolol was moderate , while other characteristics of beta-receptor blockade , in particular , the reduction of heart rate and cardiac output , were maintained . This suggests that the compound may be useful for other cardiovascular disorders , e.g. , angina pectoris in patients without hypertension or cardiac arrhythmia .
[ "Modest", "antihypertensive", "effect", "of", "epanolol", ",", "a", "beta", "1-selective", "receptor", "blocker", "with", "beta", "1", "agonist", "activity", ":", "an", "acute", "and", "long", "-", "term", "hemodynamic", "study", "at", "rest", "and", "during", "exercise", "and", "double", "crossover", "comparison", "with", "atenolol", "on", "ambulatory", "blood", "pressure", ".", "Beta", "-", "blockers", "with", "less", "cardiodepressive", "effect", "than", "traditional", "nonselective", "beta", "(", "1", "+", "2", ")", "-blocking", "agents", "could", "be", "useful", "in", "the", "treatment", "of", "hypertension", ",", "provided", "the", "reduction", "in", "blood", "pressure", "was", "satisfactory", ".", "Epanolol", ",", "a", "selective", "beta", "1-receptor", "blocker", "with", "intrinsic", "sympathomimetic", "activity", ",", "induced", "a", "fall", "in", "intraarterial", "pressure", "of", "8", "%", "at", "rest", "sitting", "and", "11", "%", "during", "100", "W", "bicycle", "exercise", "after", "the", "first", "dose", "of", "200", "mg", "in", "12", "patients", "with", "essential", "hypertension", ".", "Heart", "rate", ",", "stroke", "index", ",", "and", "cardiac", "index", "initially", "fell", "by", "14", "%", ",", "11", "%", ",", "and", "23", "%", ",", "respectively", ".", "The", "total", "peripheral", "resistance", "index", "increased", "by", "21", "%", "after", "2", "hours", ",", "and", "then", "reverted", "towards", "the", "pretreatment", "level", ".", "After", "10", "months", "of", "epanolol", "treatment", "(", "mean", "300", "mg", "/", "day", ")", ",", "the", "reduction", "in", "arterial", "pressure", "was", "5", "%", "at", "rest", "and", "10", "%", "during", "exercise", ".", "Cardiac", "index", "and", "heart", "rate", "were", "still", "reduced", "14", "-", "21", "%", ",", "while", "total", "peripheral", "resistance", "was", "unchanged", "or", "slightly", "increased", "(", "2", "-", "10", "%", ")", ".", "Twenty", "-", "four", "hour", "ambulatory", "blood", "pressure", "was", "higher", "on", "epanolol", "(", "300", "mg", "/", "day", ")", "than", "on", "atenolol", "(", "150", "mg", "/", "day", ")", "treatment", "(", "137/97", "vs", ".", "128/91", "mmHg", ")", ".", "Thus", ",", "the", "achieved", "blood", "pressure", "reduction", "induced", "by", "epanolol", "was", "moderate", ",", "while", "other", "characteristics", "of", "beta", "-", "receptor", "blockade", ",", "in", "particular", ",", "the", "reduction", "of", "heart", "rate", "and", "cardiac", "output", ",", "were", "maintained", ".", "This", "suggests", "that", "the", "compound", "may", "be", "useful", "for", "other", "cardiovascular", "disorders", ",", "e.g", ".", ",", "angina", "pectoris", "in", "patients", "without", "hypertension", "or", "cardiac", "arrhythmia", "." ]
[ "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological" ]
goal is an umlsterm, evaluation study is an umlsterm, outpatient service is an umlsterm, day - hospital is an umlsterm, elderly is an umlsterm, mental disorders is an umlsterm, treatment is an umlsterm, government is an umlsterm, time is an umlsterm, longitudinal studies is an umlsterm, city is an umlsterm, control is an umlsterm, treatment is an umlsterm, elderly is an umlsterm, care is an umlsterm, patients is an umlsterm, diagnosis is an umlsterm, mental disorders is an umlsterm, treatment facilities is an umlsterm, outpatient treatment is an umlsterm, elderly is an umlsterm, disorder is an umlsterm, patients is an umlsterm, symptoms is an umlsterm, self - care is an umlsterm, health services is an umlsterm, general hospitals is an umlsterm, hospitals is an umlsterm, patients is an umlsterm, mental disorder is an umlsterm, diagnosis is an umlsterm, direct is an umlsterm, transfers of patients is an umlsterm, elderly is an umlsterm
ZfuerGerontologie+Geriatrie.00330059.eng.abstr_task0
Sentence: The goal of this evaluation study is to analyze the effects of a new gerontopsychiatric institution , the gerontopsychiatric center ( GC : a combination of a home-based outpatient service , a day-hospital and a consulting office for elderly with mental disorders ) on the reorganization process of the treatment system from intramural toward extramural structures , as experts of the government of the FRG have been demanding for a long time . Based on data of cross-sectional and longitudinal studies two regional catchment areas - the city of Bielefeld ( without GC , control region ) and the district of Guetersloh ( with GC ) - are compared and analyzed , whether changes within the gerontopsychiatric system ( subsystem A ) , the system of general medical treatment ( subsystem B ) , or within the elderly care system ( subsystem C ) occurred . Concerning subsystem A the results are that the GC has a strong impact on the intended shift from intra- to extramural structures , without selecting patients by diagnosis nor by severity degrees of their mental disorders in extramural treatment facilities . The home-based outpatient treatment is especially successful for elderly with a functional psychic disorder . These patients had the highest scores in improvement of psychiatric symptoms as well as in reduction of their self-care deficits within one year Effects of the GC on subsystem B were evident soon after its establishment , for example , by the increasing cooperation between the gerontopsychiatric health services and general hospitals in the region with GC , in which ( hospitals ) two fifths of all clinical gerontopsychiatric patients with a mental disorder as the main diagnosis ( ICD-9) are treated . An effect of the GC on subsystem C is possibly the fact that in its region the rate of direct transfers of patients from the clinical gerontopsychiatric department into homes for the elderly is significantly lower than in the region without GC . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
The goal of this evaluation study is to analyze the effects of a new gerontopsychiatric institution , the gerontopsychiatric center ( GC : a combination of a home-based outpatient service , a day-hospital and a consulting office for elderly with mental disorders ) on the reorganization process of the treatment system from intramural toward extramural structures , as experts of the government of the FRG have been demanding for a long time . Based on data of cross-sectional and longitudinal studies two regional catchment areas - the city of Bielefeld ( without GC , control region ) and the district of Guetersloh ( with GC ) - are compared and analyzed , whether changes within the gerontopsychiatric system ( subsystem A ) , the system of general medical treatment ( subsystem B ) , or within the elderly care system ( subsystem C ) occurred . Concerning subsystem A the results are that the GC has a strong impact on the intended shift from intra- to extramural structures , without selecting patients by diagnosis nor by severity degrees of their mental disorders in extramural treatment facilities . The home-based outpatient treatment is especially successful for elderly with a functional psychic disorder . These patients had the highest scores in improvement of psychiatric symptoms as well as in reduction of their self-care deficits within one year Effects of the GC on subsystem B were evident soon after its establishment , for example , by the increasing cooperation between the gerontopsychiatric health services and general hospitals in the region with GC , in which ( hospitals ) two fifths of all clinical gerontopsychiatric patients with a mental disorder as the main diagnosis ( ICD-9) are treated . An effect of the GC on subsystem C is possibly the fact that in its region the rate of direct transfers of patients from the clinical gerontopsychiatric department into homes for the elderly is significantly lower than in the region without GC .
[ "The", "goal", "of", "this", "evaluation", "study", "is", "to", "analyze", "the", "effects", "of", "a", "new", "gerontopsychiatric", "institution", ",", "the", "gerontopsychiatric", "center", "(", "GC", ":", "a", "combination", "of", "a", "home", "-", "based", "outpatient", "service", ",", "a", "day", "-", "hospital", "and", "a", "consulting", "office", "for", "elderly", "with", "mental", "disorders", ")", "on", "the", "reorganization", "process", "of", "the", "treatment", "system", "from", "intramural", "toward", "extramural", "structures", ",", "as", "experts", "of", "the", "government", "of", "the", "FRG", "have", "been", "demanding", "for", "a", "long", "time", ".", "Based", "on", "data", "of", "cross", "-", "sectional", "and", "longitudinal", "studies", "two", "regional", "catchment", "areas", "-", "the", "city", "of", "Bielefeld", "(", "without", "GC", ",", "control", "region", ")", "and", "the", "district", "of", "Guetersloh", "(", "with", "GC", ")", "-", "are", "compared", "and", "analyzed", ",", "whether", "changes", "within", "the", "gerontopsychiatric", "system", "(", "subsystem", "A", ")", ",", "the", "system", "of", "general", "medical", "treatment", "(", "subsystem", "B", ")", ",", "or", "within", "the", "elderly", "care", "system", "(", "subsystem", "C", ")", "occurred", ".", "Concerning", "subsystem", "A", "the", "results", "are", "that", "the", "GC", "has", "a", "strong", "impact", "on", "the", "intended", "shift", "from", "intra-", "to", "extramural", "structures", ",", "without", "selecting", "patients", "by", "diagnosis", "nor", "by", "severity", "degrees", "of", "their", "mental", "disorders", "in", "extramural", "treatment", "facilities", ".", "The", "home", "-", "based", "outpatient", "treatment", "is", "especially", "successful", "for", "elderly", "with", "a", "functional", "psychic", "disorder", ".", "These", "patients", "had", "the", "highest", "scores", "in", "improvement", "of", "psychiatric", "symptoms", "as", "well", "as", "in", "reduction", "of", "their", "self", "-", "care", "deficits", "within", "one", "year", "Effects", "of", "the", "GC", "on", "subsystem", "B", "were", "evident", "soon", "after", "its", "establishment", ",", "for", "example", ",", "by", "the", "increasing", "cooperation", "between", "the", "gerontopsychiatric", "health", "services", "and", "general", "hospitals", "in", "the", "region", "with", "GC", ",", "in", "which", "(", "hospitals", ")", "two", "fifths", "of", "all", "clinical", "gerontopsychiatric", "patients", "with", "a", "mental", "disorder", "as", "the", "main", "diagnosis", "(", "ICD-9", ")", "are", "treated", ".", "An", "effect", "of", "the", "GC", "on", "subsystem", "C", "is", "possibly", "the", "fact", "that", "in", "its", "region", "the", "rate", "of", "direct", "transfers", "of", "patients", "from", "the", "clinical", "gerontopsychiatric", "department", "into", "homes", "for", "the", "elderly", "is", "significantly", "lower", "than", "in", "the", "region", "without", "GC", "." ]
[ "umlsterm" ]
goal is an umlsterm, evaluation study is an umlsterm, outpatient service is an umlsterm, day - hospital is an umlsterm, elderly is an umlsterm, mental disorders is an umlsterm, treatment is an umlsterm, government is an umlsterm, time is an umlsterm, longitudinal studies is an umlsterm, city is an umlsterm, control is an umlsterm, treatment is an umlsterm, elderly is an umlsterm, care is an umlsterm, patients is an umlsterm, diagnosis is an umlsterm, mental disorders is an umlsterm, treatment facilities is an umlsterm, outpatient treatment is an umlsterm, elderly is an umlsterm, disorder is an umlsterm, patients is an umlsterm, symptoms is an umlsterm, self - care is an umlsterm, health services is an umlsterm, general hospitals is an umlsterm, hospitals is an umlsterm, patients is an umlsterm, mental disorder is an umlsterm, diagnosis is an umlsterm, direct is an umlsterm, transfers of patients is an umlsterm, elderly is an umlsterm
ZfuerGerontologie+Geriatrie.00330059.eng.abstr_task1
Sentence: The goal of this evaluation study is to analyze the effects of a new gerontopsychiatric institution , the gerontopsychiatric center ( GC : a combination of a home-based outpatient service , a day-hospital and a consulting office for elderly with mental disorders ) on the reorganization process of the treatment system from intramural toward extramural structures , as experts of the government of the FRG have been demanding for a long time . Based on data of cross-sectional and longitudinal studies two regional catchment areas - the city of Bielefeld ( without GC , control region ) and the district of Guetersloh ( with GC ) - are compared and analyzed , whether changes within the gerontopsychiatric system ( subsystem A ) , the system of general medical treatment ( subsystem B ) , or within the elderly care system ( subsystem C ) occurred . Concerning subsystem A the results are that the GC has a strong impact on the intended shift from intra- to extramural structures , without selecting patients by diagnosis nor by severity degrees of their mental disorders in extramural treatment facilities . The home-based outpatient treatment is especially successful for elderly with a functional psychic disorder . These patients had the highest scores in improvement of psychiatric symptoms as well as in reduction of their self-care deficits within one year Effects of the GC on subsystem B were evident soon after its establishment , for example , by the increasing cooperation between the gerontopsychiatric health services and general hospitals in the region with GC , in which ( hospitals ) two fifths of all clinical gerontopsychiatric patients with a mental disorder as the main diagnosis ( ICD-9) are treated . An effect of the GC on subsystem C is possibly the fact that in its region the rate of direct transfers of patients from the clinical gerontopsychiatric department into homes for the elderly is significantly lower than in the region without GC . Instructions: please typing these entity words according to sentence: goal, evaluation study, outpatient service, day - hospital, elderly, mental disorders, treatment, government, time, longitudinal studies, city, control, treatment, elderly, care, patients, diagnosis, mental disorders, treatment facilities, outpatient treatment, elderly, disorder, patients, symptoms, self - care, health services, general hospitals, hospitals, patients, mental disorder, diagnosis, direct, transfers of patients, elderly Options: umlsterm
[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
The goal of this evaluation study is to analyze the effects of a new gerontopsychiatric institution , the gerontopsychiatric center ( GC : a combination of a home-based outpatient service , a day-hospital and a consulting office for elderly with mental disorders ) on the reorganization process of the treatment system from intramural toward extramural structures , as experts of the government of the FRG have been demanding for a long time . Based on data of cross-sectional and longitudinal studies two regional catchment areas - the city of Bielefeld ( without GC , control region ) and the district of Guetersloh ( with GC ) - are compared and analyzed , whether changes within the gerontopsychiatric system ( subsystem A ) , the system of general medical treatment ( subsystem B ) , or within the elderly care system ( subsystem C ) occurred . Concerning subsystem A the results are that the GC has a strong impact on the intended shift from intra- to extramural structures , without selecting patients by diagnosis nor by severity degrees of their mental disorders in extramural treatment facilities . The home-based outpatient treatment is especially successful for elderly with a functional psychic disorder . These patients had the highest scores in improvement of psychiatric symptoms as well as in reduction of their self-care deficits within one year Effects of the GC on subsystem B were evident soon after its establishment , for example , by the increasing cooperation between the gerontopsychiatric health services and general hospitals in the region with GC , in which ( hospitals ) two fifths of all clinical gerontopsychiatric patients with a mental disorder as the main diagnosis ( ICD-9) are treated . An effect of the GC on subsystem C is possibly the fact that in its region the rate of direct transfers of patients from the clinical gerontopsychiatric department into homes for the elderly is significantly lower than in the region without GC .
[ "The", "goal", "of", "this", "evaluation", "study", "is", "to", "analyze", "the", "effects", "of", "a", "new", "gerontopsychiatric", "institution", ",", "the", "gerontopsychiatric", "center", "(", "GC", ":", "a", "combination", "of", "a", "home", "-", "based", "outpatient", "service", ",", "a", "day", "-", "hospital", "and", "a", "consulting", "office", "for", "elderly", "with", "mental", "disorders", ")", "on", "the", "reorganization", "process", "of", "the", "treatment", "system", "from", "intramural", "toward", "extramural", "structures", ",", "as", "experts", "of", "the", "government", "of", "the", "FRG", "have", "been", "demanding", "for", "a", "long", "time", ".", "Based", "on", "data", "of", "cross", "-", "sectional", "and", "longitudinal", "studies", "two", "regional", "catchment", "areas", "-", "the", "city", "of", "Bielefeld", "(", "without", "GC", ",", "control", "region", ")", "and", "the", "district", "of", "Guetersloh", "(", "with", "GC", ")", "-", "are", "compared", "and", "analyzed", ",", "whether", "changes", "within", "the", "gerontopsychiatric", "system", "(", "subsystem", "A", ")", ",", "the", "system", "of", "general", "medical", "treatment", "(", "subsystem", "B", ")", ",", "or", "within", "the", "elderly", "care", "system", "(", "subsystem", "C", ")", "occurred", ".", "Concerning", "subsystem", "A", "the", "results", "are", "that", "the", "GC", "has", "a", "strong", "impact", "on", "the", "intended", "shift", "from", "intra-", "to", "extramural", "structures", ",", "without", "selecting", "patients", "by", "diagnosis", "nor", "by", "severity", "degrees", "of", "their", "mental", "disorders", "in", "extramural", "treatment", "facilities", ".", "The", "home", "-", "based", "outpatient", "treatment", "is", "especially", "successful", "for", "elderly", "with", "a", "functional", "psychic", "disorder", ".", "These", "patients", "had", "the", "highest", "scores", "in", "improvement", "of", "psychiatric", "symptoms", "as", "well", "as", "in", "reduction", "of", "their", "self", "-", "care", "deficits", "within", "one", "year", "Effects", "of", "the", "GC", "on", "subsystem", "B", "were", "evident", "soon", "after", "its", "establishment", ",", "for", "example", ",", "by", "the", "increasing", "cooperation", "between", "the", "gerontopsychiatric", "health", "services", "and", "general", "hospitals", "in", "the", "region", "with", "GC", ",", "in", "which", "(", "hospitals", ")", "two", "fifths", "of", "all", "clinical", "gerontopsychiatric", "patients", "with", "a", "mental", "disorder", "as", "the", "main", "diagnosis", "(", "ICD-9", ")", "are", "treated", ".", "An", "effect", "of", "the", "GC", "on", "subsystem", "C", "is", "possibly", "the", "fact", "that", "in", "its", "region", "the", "rate", "of", "direct", "transfers", "of", "patients", "from", "the", "clinical", "gerontopsychiatric", "department", "into", "homes", "for", "the", "elderly", "is", "significantly", "lower", "than", "in", "the", "region", "without", "GC", "." ]
[ "umlsterm" ]
goal, evaluation study, outpatient service, day - hospital, elderly, mental disorders, treatment, government, time, longitudinal studies, city, control, treatment, elderly, care, patients, diagnosis, mental disorders, treatment facilities, outpatient treatment, elderly, disorder, patients, symptoms, self - care, health services, general hospitals, hospitals, patients, mental disorder, diagnosis, direct, transfers of patients, elderly
ZfuerGerontologie+Geriatrie.00330059.eng.abstr_task2
Sentence: The goal of this evaluation study is to analyze the effects of a new gerontopsychiatric institution , the gerontopsychiatric center ( GC : a combination of a home-based outpatient service , a day-hospital and a consulting office for elderly with mental disorders ) on the reorganization process of the treatment system from intramural toward extramural structures , as experts of the government of the FRG have been demanding for a long time . Based on data of cross-sectional and longitudinal studies two regional catchment areas - the city of Bielefeld ( without GC , control region ) and the district of Guetersloh ( with GC ) - are compared and analyzed , whether changes within the gerontopsychiatric system ( subsystem A ) , the system of general medical treatment ( subsystem B ) , or within the elderly care system ( subsystem C ) occurred . Concerning subsystem A the results are that the GC has a strong impact on the intended shift from intra- to extramural structures , without selecting patients by diagnosis nor by severity degrees of their mental disorders in extramural treatment facilities . The home-based outpatient treatment is especially successful for elderly with a functional psychic disorder . These patients had the highest scores in improvement of psychiatric symptoms as well as in reduction of their self-care deficits within one year Effects of the GC on subsystem B were evident soon after its establishment , for example , by the increasing cooperation between the gerontopsychiatric health services and general hospitals in the region with GC , in which ( hospitals ) two fifths of all clinical gerontopsychiatric patients with a mental disorder as the main diagnosis ( ICD-9) are treated . An effect of the GC on subsystem C is possibly the fact that in its region the rate of direct transfers of patients from the clinical gerontopsychiatric department into homes for the elderly is significantly lower than in the region without GC . Instructions: please extract entity words from the input sentence
[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
The goal of this evaluation study is to analyze the effects of a new gerontopsychiatric institution , the gerontopsychiatric center ( GC : a combination of a home-based outpatient service , a day-hospital and a consulting office for elderly with mental disorders ) on the reorganization process of the treatment system from intramural toward extramural structures , as experts of the government of the FRG have been demanding for a long time . Based on data of cross-sectional and longitudinal studies two regional catchment areas - the city of Bielefeld ( without GC , control region ) and the district of Guetersloh ( with GC ) - are compared and analyzed , whether changes within the gerontopsychiatric system ( subsystem A ) , the system of general medical treatment ( subsystem B ) , or within the elderly care system ( subsystem C ) occurred . Concerning subsystem A the results are that the GC has a strong impact on the intended shift from intra- to extramural structures , without selecting patients by diagnosis nor by severity degrees of their mental disorders in extramural treatment facilities . The home-based outpatient treatment is especially successful for elderly with a functional psychic disorder . These patients had the highest scores in improvement of psychiatric symptoms as well as in reduction of their self-care deficits within one year Effects of the GC on subsystem B were evident soon after its establishment , for example , by the increasing cooperation between the gerontopsychiatric health services and general hospitals in the region with GC , in which ( hospitals ) two fifths of all clinical gerontopsychiatric patients with a mental disorder as the main diagnosis ( ICD-9) are treated . An effect of the GC on subsystem C is possibly the fact that in its region the rate of direct transfers of patients from the clinical gerontopsychiatric department into homes for the elderly is significantly lower than in the region without GC .
[ "The", "goal", "of", "this", "evaluation", "study", "is", "to", "analyze", "the", "effects", "of", "a", "new", "gerontopsychiatric", "institution", ",", "the", "gerontopsychiatric", "center", "(", "GC", ":", "a", "combination", "of", "a", "home", "-", "based", "outpatient", "service", ",", "a", "day", "-", "hospital", "and", "a", "consulting", "office", "for", "elderly", "with", "mental", "disorders", ")", "on", "the", "reorganization", "process", "of", "the", "treatment", "system", "from", "intramural", "toward", "extramural", "structures", ",", "as", "experts", "of", "the", "government", "of", "the", "FRG", "have", "been", "demanding", "for", "a", "long", "time", ".", "Based", "on", "data", "of", "cross", "-", "sectional", "and", "longitudinal", "studies", "two", "regional", "catchment", "areas", "-", "the", "city", "of", "Bielefeld", "(", "without", "GC", ",", "control", "region", ")", "and", "the", "district", "of", "Guetersloh", "(", "with", "GC", ")", "-", "are", "compared", "and", "analyzed", ",", "whether", "changes", "within", "the", "gerontopsychiatric", "system", "(", "subsystem", "A", ")", ",", "the", "system", "of", "general", "medical", "treatment", "(", "subsystem", "B", ")", ",", "or", "within", "the", "elderly", "care", "system", "(", "subsystem", "C", ")", "occurred", ".", "Concerning", "subsystem", "A", "the", "results", "are", "that", "the", "GC", "has", "a", "strong", "impact", "on", "the", "intended", "shift", "from", "intra-", "to", "extramural", "structures", ",", "without", "selecting", "patients", "by", "diagnosis", "nor", "by", "severity", "degrees", "of", "their", "mental", "disorders", "in", "extramural", "treatment", "facilities", ".", "The", "home", "-", "based", "outpatient", "treatment", "is", "especially", "successful", "for", "elderly", "with", "a", "functional", "psychic", "disorder", ".", "These", "patients", "had", "the", "highest", "scores", "in", "improvement", "of", "psychiatric", "symptoms", "as", "well", "as", "in", "reduction", "of", "their", "self", "-", "care", "deficits", "within", "one", "year", "Effects", "of", "the", "GC", "on", "subsystem", "B", "were", "evident", "soon", "after", "its", "establishment", ",", "for", "example", ",", "by", "the", "increasing", "cooperation", "between", "the", "gerontopsychiatric", "health", "services", "and", "general", "hospitals", "in", "the", "region", "with", "GC", ",", "in", "which", "(", "hospitals", ")", "two", "fifths", "of", "all", "clinical", "gerontopsychiatric", "patients", "with", "a", "mental", "disorder", "as", "the", "main", "diagnosis", "(", "ICD-9", ")", "are", "treated", ".", "An", "effect", "of", "the", "GC", "on", "subsystem", "C", "is", "possibly", "the", "fact", "that", "in", "its", "region", "the", "rate", "of", "direct", "transfers", "of", "patients", "from", "the", "clinical", "gerontopsychiatric", "department", "into", "homes", "for", "the", "elderly", "is", "significantly", "lower", "than", "in", "the", "region", "without", "GC", "." ]
[ "umlsterm" ]
PGC-1α is a GENE-Y, glucose is a CHEMICAL
23086035_task0
Sentence: PGC-1α improves glucose homeostasis in skeletal muscle in an activity-dependent manner. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL
[ "B-GENE-Y", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
PGC-1α improves glucose homeostasis in skeletal muscle in an activity-dependent manner.
[ "PGC-1α", "improves", "glucose", "homeostasis", "in", "skeletal", "muscle", "in", "an", "activity", "-", "dependent", "manner", "." ]
[ "GENE-Y", "CHEMICAL" ]
PGC-1α is a GENE-Y, glucose is a CHEMICAL
23086035_task1
Sentence: PGC-1α improves glucose homeostasis in skeletal muscle in an activity-dependent manner. Instructions: please typing these entity words according to sentence: PGC-1α, glucose Options: GENE-Y, CHEMICAL
[ "B-GENE-Y", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
PGC-1α improves glucose homeostasis in skeletal muscle in an activity-dependent manner.
[ "PGC-1α", "improves", "glucose", "homeostasis", "in", "skeletal", "muscle", "in", "an", "activity", "-", "dependent", "manner", "." ]
[ "GENE-Y", "CHEMICAL" ]
PGC-1α, glucose
23086035_task2
Sentence: PGC-1α improves glucose homeostasis in skeletal muscle in an activity-dependent manner. Instructions: please extract entity words from the input sentence
[ "B-GENE-Y", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
PGC-1α improves glucose homeostasis in skeletal muscle in an activity-dependent manner.
[ "PGC-1α", "improves", "glucose", "homeostasis", "in", "skeletal", "muscle", "in", "an", "activity", "-", "dependent", "manner", "." ]
[ "GENE-Y", "CHEMICAL" ]
Arthrobacter is a Microorganism, cheese is a Habitat, Arthrobacter is a Microorganism, soil is a Habitat, ubiquitous is a Phenotype, cheese is a Habitat, cheese habitat is a Habitat, catabolism of D - galactonate is a Phenotype, Arthrobacter arilaitensis Re117 is a Microorganism
114_task0
Sentence: In a first example, we compared the genomic sequences of the four Arthrobacter strains isolated from cheese to that of 15 environmental isolates. Most bacteria of the genus Arthrobacter are isolated from environments such as soil, where they are considered to be ubiquitous [41]. Interestingly, the four cheese strains share several properties that may be linked to adaptation to the cheese habitat, such as a cluster of five genes involved in the catabolism of D-galactonate, as already described in Arthrobacter arilaitensis Re117 [20]. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Microorganism, Phenotype, Habitat
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "B-Phenotype", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Phenotype", "I-Phenotype", "I-Phenotype", "I-Phenotype", "I-Phenotype", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "I-Microorganism", "O", "O", "O", "O" ]
In a first example, we compared the genomic sequences of the four Arthrobacter strains isolated from cheese to that of 15 environmental isolates. Most bacteria of the genus Arthrobacter are isolated from environments such as soil, where they are considered to be ubiquitous [41]. Interestingly, the four cheese strains share several properties that may be linked to adaptation to the cheese habitat, such as a cluster of five genes involved in the catabolism of D-galactonate, as already described in Arthrobacter arilaitensis Re117 [20].
[ "In", "a", "first", " ", "example", ",", "we", "compared", "the", "genomic", "sequences", "of", "the", "four", "Arthrobacter", "strains", "isolated", "from", "cheese", "to", "that", "of", "15", "environmental", "isolates", ".", "Most", "bacteria", "of", "the", "genus", "Arthrobacter", "are", "isolated", "from", "environments", "such", "as", "soil", ",", "where", "they", "are", "considered", "to", "be", "ubiquitous", "[", "41", "]", ".", " ", "Interestingly", ",", "the", "four", "cheese", "strains", "share", "several", "properties", "that", " ", "may", "be", "linked", "to", "adaptation", "to", "the", "cheese", "habitat", ",", "such", "as", "a", "cluster", "of", " ", "five", "genes", "involved", "in", "the", "catabolism", "of", "D", "-", "galactonate", ",", "as", "already", " ", "described", "in", "Arthrobacter", "arilaitensis", "Re117", "[", "20", "]", "." ]
[ "Microorganism", "Phenotype", "Habitat" ]
Arthrobacter is a Microorganism, cheese is a Habitat, Arthrobacter is a Microorganism, soil is a Habitat, ubiquitous is a Phenotype, cheese is a Habitat, cheese habitat is a Habitat, catabolism of D - galactonate is a Phenotype, Arthrobacter arilaitensis Re117 is a Microorganism
114_task1
Sentence: In a first example, we compared the genomic sequences of the four Arthrobacter strains isolated from cheese to that of 15 environmental isolates. Most bacteria of the genus Arthrobacter are isolated from environments such as soil, where they are considered to be ubiquitous [41]. Interestingly, the four cheese strains share several properties that may be linked to adaptation to the cheese habitat, such as a cluster of five genes involved in the catabolism of D-galactonate, as already described in Arthrobacter arilaitensis Re117 [20]. Instructions: please typing these entity words according to sentence: Arthrobacter, cheese, Arthrobacter, soil, ubiquitous, cheese, cheese habitat, catabolism of D - galactonate, Arthrobacter arilaitensis Re117 Options: Microorganism, Phenotype, Habitat
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "B-Phenotype", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Phenotype", "I-Phenotype", "I-Phenotype", "I-Phenotype", "I-Phenotype", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "I-Microorganism", "O", "O", "O", "O" ]
In a first example, we compared the genomic sequences of the four Arthrobacter strains isolated from cheese to that of 15 environmental isolates. Most bacteria of the genus Arthrobacter are isolated from environments such as soil, where they are considered to be ubiquitous [41]. Interestingly, the four cheese strains share several properties that may be linked to adaptation to the cheese habitat, such as a cluster of five genes involved in the catabolism of D-galactonate, as already described in Arthrobacter arilaitensis Re117 [20].
[ "In", "a", "first", " ", "example", ",", "we", "compared", "the", "genomic", "sequences", "of", "the", "four", "Arthrobacter", "strains", "isolated", "from", "cheese", "to", "that", "of", "15", "environmental", "isolates", ".", "Most", "bacteria", "of", "the", "genus", "Arthrobacter", "are", "isolated", "from", "environments", "such", "as", "soil", ",", "where", "they", "are", "considered", "to", "be", "ubiquitous", "[", "41", "]", ".", " ", "Interestingly", ",", "the", "four", "cheese", "strains", "share", "several", "properties", "that", " ", "may", "be", "linked", "to", "adaptation", "to", "the", "cheese", "habitat", ",", "such", "as", "a", "cluster", "of", " ", "five", "genes", "involved", "in", "the", "catabolism", "of", "D", "-", "galactonate", ",", "as", "already", " ", "described", "in", "Arthrobacter", "arilaitensis", "Re117", "[", "20", "]", "." ]
[ "Microorganism", "Phenotype", "Habitat" ]
Arthrobacter, cheese, Arthrobacter, soil, ubiquitous, cheese, cheese habitat, catabolism of D - galactonate, Arthrobacter arilaitensis Re117
114_task2
Sentence: In a first example, we compared the genomic sequences of the four Arthrobacter strains isolated from cheese to that of 15 environmental isolates. Most bacteria of the genus Arthrobacter are isolated from environments such as soil, where they are considered to be ubiquitous [41]. Interestingly, the four cheese strains share several properties that may be linked to adaptation to the cheese habitat, such as a cluster of five genes involved in the catabolism of D-galactonate, as already described in Arthrobacter arilaitensis Re117 [20]. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "B-Phenotype", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Phenotype", "I-Phenotype", "I-Phenotype", "I-Phenotype", "I-Phenotype", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "I-Microorganism", "O", "O", "O", "O" ]
In a first example, we compared the genomic sequences of the four Arthrobacter strains isolated from cheese to that of 15 environmental isolates. Most bacteria of the genus Arthrobacter are isolated from environments such as soil, where they are considered to be ubiquitous [41]. Interestingly, the four cheese strains share several properties that may be linked to adaptation to the cheese habitat, such as a cluster of five genes involved in the catabolism of D-galactonate, as already described in Arthrobacter arilaitensis Re117 [20].
[ "In", "a", "first", " ", "example", ",", "we", "compared", "the", "genomic", "sequences", "of", "the", "four", "Arthrobacter", "strains", "isolated", "from", "cheese", "to", "that", "of", "15", "environmental", "isolates", ".", "Most", "bacteria", "of", "the", "genus", "Arthrobacter", "are", "isolated", "from", "environments", "such", "as", "soil", ",", "where", "they", "are", "considered", "to", "be", "ubiquitous", "[", "41", "]", ".", " ", "Interestingly", ",", "the", "four", "cheese", "strains", "share", "several", "properties", "that", " ", "may", "be", "linked", "to", "adaptation", "to", "the", "cheese", "habitat", ",", "such", "as", "a", "cluster", "of", " ", "five", "genes", "involved", "in", "the", "catabolism", "of", "D", "-", "galactonate", ",", "as", "already", " ", "described", "in", "Arthrobacter", "arilaitensis", "Re117", "[", "20", "]", "." ]
[ "Microorganism", "Phenotype", "Habitat" ]
Oberschenkelfraktur is an umlsterm, Kniegelenks is an umlsterm, Methode is an umlsterm, Frakturen is an umlsterm
DerUnfallchirurg.91020811.ger.abstr_task0
Sentence: Die unterschiedlichen Behandlungsverfahren bei periprothetischer Oberschenkelfraktur nach endoprothetischem Ersatz des Kniegelenks werden diskutiert . Eine neue Methode der Versorgung solcher periprothetischen Frakturen mit dem LIS-Sytem ( LISS Synthes ) , wird beschrieben und erste klinische Ergebnisse werden vorgestellt . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Die unterschiedlichen Behandlungsverfahren bei periprothetischer Oberschenkelfraktur nach endoprothetischem Ersatz des Kniegelenks werden diskutiert . Eine neue Methode der Versorgung solcher periprothetischen Frakturen mit dem LIS-Sytem ( LISS Synthes ) , wird beschrieben und erste klinische Ergebnisse werden vorgestellt .
[ "Die", "unterschiedlichen", "Behandlungsverfahren", "bei", "periprothetischer", "Oberschenkelfraktur", "nach", "endoprothetischem", "Ersatz", "des", "Kniegelenks", "werden", "diskutiert", ".", "Eine", "neue", "Methode", "der", "Versorgung", "solcher", "periprothetischen", "Frakturen", "mit", "dem", "LIS", "-", "Sytem", "(", "LISS", "Synthes", ")", ",", "wird", "beschrieben", "und", "erste", "klinische", "Ergebnisse", "werden", "vorgestellt", "." ]
[ "umlsterm" ]
Oberschenkelfraktur is an umlsterm, Kniegelenks is an umlsterm, Methode is an umlsterm, Frakturen is an umlsterm
DerUnfallchirurg.91020811.ger.abstr_task1
Sentence: Die unterschiedlichen Behandlungsverfahren bei periprothetischer Oberschenkelfraktur nach endoprothetischem Ersatz des Kniegelenks werden diskutiert . Eine neue Methode der Versorgung solcher periprothetischen Frakturen mit dem LIS-Sytem ( LISS Synthes ) , wird beschrieben und erste klinische Ergebnisse werden vorgestellt . Instructions: please typing these entity words according to sentence: Oberschenkelfraktur, Kniegelenks, Methode, Frakturen Options: umlsterm
[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Die unterschiedlichen Behandlungsverfahren bei periprothetischer Oberschenkelfraktur nach endoprothetischem Ersatz des Kniegelenks werden diskutiert . Eine neue Methode der Versorgung solcher periprothetischen Frakturen mit dem LIS-Sytem ( LISS Synthes ) , wird beschrieben und erste klinische Ergebnisse werden vorgestellt .
[ "Die", "unterschiedlichen", "Behandlungsverfahren", "bei", "periprothetischer", "Oberschenkelfraktur", "nach", "endoprothetischem", "Ersatz", "des", "Kniegelenks", "werden", "diskutiert", ".", "Eine", "neue", "Methode", "der", "Versorgung", "solcher", "periprothetischen", "Frakturen", "mit", "dem", "LIS", "-", "Sytem", "(", "LISS", "Synthes", ")", ",", "wird", "beschrieben", "und", "erste", "klinische", "Ergebnisse", "werden", "vorgestellt", "." ]
[ "umlsterm" ]
Oberschenkelfraktur, Kniegelenks, Methode, Frakturen
DerUnfallchirurg.91020811.ger.abstr_task2
Sentence: Die unterschiedlichen Behandlungsverfahren bei periprothetischer Oberschenkelfraktur nach endoprothetischem Ersatz des Kniegelenks werden diskutiert . Eine neue Methode der Versorgung solcher periprothetischen Frakturen mit dem LIS-Sytem ( LISS Synthes ) , wird beschrieben und erste klinische Ergebnisse werden vorgestellt . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Die unterschiedlichen Behandlungsverfahren bei periprothetischer Oberschenkelfraktur nach endoprothetischem Ersatz des Kniegelenks werden diskutiert . Eine neue Methode der Versorgung solcher periprothetischen Frakturen mit dem LIS-Sytem ( LISS Synthes ) , wird beschrieben und erste klinische Ergebnisse werden vorgestellt .
[ "Die", "unterschiedlichen", "Behandlungsverfahren", "bei", "periprothetischer", "Oberschenkelfraktur", "nach", "endoprothetischem", "Ersatz", "des", "Kniegelenks", "werden", "diskutiert", ".", "Eine", "neue", "Methode", "der", "Versorgung", "solcher", "periprothetischen", "Frakturen", "mit", "dem", "LIS", "-", "Sytem", "(", "LISS", "Synthes", ")", ",", "wird", "beschrieben", "und", "erste", "klinische", "Ergebnisse", "werden", "vorgestellt", "." ]
[ "umlsterm" ]
Gabriel is a NOMBRE_SUJETO_ASISTENCIA, Fernandez Otegui is a NOMBRE_SUJETO_ASISTENCIA, 7316503 is a ID_SUJETO_ASISTENCIA, Calle Carabias , 12 , 3 , 2 is a CALLE, Madrid is a TERRITORIO, 28005 is a TERRITORIO, 20/05/2011 is a FECHAS, España is a PAIS, 3 años is a EDAD_SUJETO_ASISTENCIA, 07/07/2014 is a FECHAS, Andrés Meana Meana is a NOMBRE_PERSONAL_SANITARIO, 28 28 68532 is a ID_TITULACION_PERSONAL_SANITARIO, Varón is a SEXO_SUJETO_ASISTENCIA, tres años y medio is a EDAD_SUJETO_ASISTENCIA, madre is a FAMILIARES_SUJETO_ASISTENCIA, niño is a SEXO_SUJETO_ASISTENCIA, niño is a SEXO_SUJETO_ASISTENCIA, hijo único is a ID_SUJETO_ASISTENCIA, padres is a FAMILIARES_SUJETO_ASISTENCIA, padre is a FAMILIARES_SUJETO_ASISTENCIA, niño is a SEXO_SUJETO_ASISTENCIA, niño is a SEXO_SUJETO_ASISTENCIA, padre is a FAMILIARES_SUJETO_ASISTENCIA, paterna is a FAMILIARES_SUJETO_ASISTENCIA, niño is a SEXO_SUJETO_ASISTENCIA, Andrés Meana Meana is a NOMBRE_PERSONAL_SANITARIO, andres.meana@sespa.es is a CORREO_ELECTRONICO
457_task0
Sentence: Datos del paciente. Nombre: Gabriel. Apellidos: Fernandez Otegui. NHC: 7316503. Domicilio: Calle Carabias, 12, 3, 2. Localidad/ Provincia: Madrid. CP: 28005. Datos asistenciales. Fecha de nacimiento: 20/05/2011. País: España. Edad: 3 años Sexo: H. Fecha de Ingreso: 07/07/2014. Médico: Andrés Meana Meana NºCol: 28 28 68532. Informe clínico del paciente: Varón de tres años y medio afecto de daño neurológico grave secundario a accidente cerebrovascular agudo (ACV) isquémico perinatal. Acude a consulta con su madre, que nos relata un llanto inusual desde hace unas semanas y la sospecha de que el niño tiene dolor en las manos. Asimismo nos comenta que el niño recibe desde hace unas semanas tratamiento con esteroides orales, pues en el seguimiento de su daño neurológico, al consultar por los síntomas del aparato locomotor, se sospechó artritis crónica idiopática con radiografía normal de manos y muñecas. Es hijo único de padres no consanguíneos. El padre tiende un problema óseo en las muñecas desde la infancia; recuerda haber padecido dolores en las muñecas cuando era niño y nos refiere que no tiene los huesos de las muñecas, que conserva movilidad normal y que no le supone problemas en su profesión de conductor de coches. La exploración física del niño está condicionada por su daño neurológico (emite gritos, sin lenguaje de otro tipo y escucha y atiende cuando se le habla, sonriendo con las caricias); no es capaz de deambulación sin ayuda; una hemiplejia izquierda derivada de su ACV perinatal y los datos propios de espasticidad. La somatometría recoge un perímetro craneal de 46 cm (< P3), una longitud de 104 cm (P25-50) y un peso de 16,5 Kg (P50). Los valores de presión arterial son normales (111/66 mmHg). No se aprecian rasgos dismórficos. Llama la atención el intento repetido del niño de morderse su muñeca derecha. No hay signos inflamatorios y se expresa con gemidos ante la movilización repetida de esa muñeca derecha. No apreciamos afectación de otras articulaciones. El padre tiene una talla de 180 cm, pero su envergadura está reducida a 164 cm. Su mano mide 18,7 cm de longitud (resulta acortada 4 cm para su estatura) con un tercer dedo de 8,3 cm (normal). La radiografía paterna muestra ausencia bilateral del carpo. La radiografía del niño muestra lesiones carpales compatibles con osteólisis carpiana y lesiones en el escafoides tarsiano unilaterales. Solicitamos consulta al servicio de genética donde se estudia y se confirma el diagnóstico de osteólisis multicéntrica carpotarsal de transmisión autosómica dominante sin nefropatía. Remitido por: Dr. Andrés Meana Meana. Email: andres.meana@sespa.es Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, FAMILIARES_SUJETO_ASISTENCIA, CALLE, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO
[ "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "I-ID_SUJETO_ASISTENCIA", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]
Datos del paciente. Nombre: Gabriel. Apellidos: Fernandez Otegui. NHC: 7316503. Domicilio: Calle Carabias, 12, 3, 2. Localidad/ Provincia: Madrid. CP: 28005. Datos asistenciales. Fecha de nacimiento: 20/05/2011. País: España. Edad: 3 años Sexo: H. Fecha de Ingreso: 07/07/2014. Médico: Andrés Meana Meana NºCol: 28 28 68532. Informe clínico del paciente: Varón de tres años y medio afecto de daño neurológico grave secundario a accidente cerebrovascular agudo (ACV) isquémico perinatal. Acude a consulta con su madre, que nos relata un llanto inusual desde hace unas semanas y la sospecha de que el niño tiene dolor en las manos. Asimismo nos comenta que el niño recibe desde hace unas semanas tratamiento con esteroides orales, pues en el seguimiento de su daño neurológico, al consultar por los síntomas del aparato locomotor, se sospechó artritis crónica idiopática con radiografía normal de manos y muñecas. Es hijo único de padres no consanguíneos. El padre tiende un problema óseo en las muñecas desde la infancia; recuerda haber padecido dolores en las muñecas cuando era niño y nos refiere que no tiene los huesos de las muñecas, que conserva movilidad normal y que no le supone problemas en su profesión de conductor de coches. La exploración física del niño está condicionada por su daño neurológico (emite gritos, sin lenguaje de otro tipo y escucha y atiende cuando se le habla, sonriendo con las caricias); no es capaz de deambulación sin ayuda; una hemiplejia izquierda derivada de su ACV perinatal y los datos propios de espasticidad. La somatometría recoge un perímetro craneal de 46 cm (< P3), una longitud de 104 cm (P25-50) y un peso de 16,5 Kg (P50). Los valores de presión arterial son normales (111/66 mmHg). No se aprecian rasgos dismórficos. Llama la atención el intento repetido del niño de morderse su muñeca derecha. No hay signos inflamatorios y se expresa con gemidos ante la movilización repetida de esa muñeca derecha. No apreciamos afectación de otras articulaciones. El padre tiene una talla de 180 cm, pero su envergadura está reducida a 164 cm. Su mano mide 18,7 cm de longitud (resulta acortada 4 cm para su estatura) con un tercer dedo de 8,3 cm (normal). La radiografía paterna muestra ausencia bilateral del carpo. La radiografía del niño muestra lesiones carpales compatibles con osteólisis carpiana y lesiones en el escafoides tarsiano unilaterales. Solicitamos consulta al servicio de genética donde se estudia y se confirma el diagnóstico de osteólisis multicéntrica carpotarsal de transmisión autosómica dominante sin nefropatía. Remitido por: Dr. Andrés Meana Meana. Email: andres.meana@sespa.es
[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", " ", "Gabriel", ".", "\n", "Apellidos", ":", "Fernandez", "Otegui", ".", "\n", "NHC", ":", "7316503", ".", "\n", "Domicilio", ":", "Calle", "Carabias", ",", "12", ",", "3", ",", "2", ".", "\n", "Localidad/", "Provincia", ":", "Madrid", ".", "\n", "CP", ":", "28005", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "20/05/2011", ".", "\n", "País", ":", "España", ".", "\n", "Edad", ":", "3", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "07/07/2014", ".", "\n", "Médico", ":", "Andrés", "Meana", "Meana", "NºCol", ":", "28", "28", "68532", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Varón", "de", "tres", "años", "y", "medio", "afecto", "de", "daño", "neurológico", "grave", "secundario", "a", "accidente", "cerebrovascular", "agudo", "(", "ACV", ")", "isquémico", "perinatal", ".", "Acude", "a", "consulta", "con", "su", "madre", ",", "que", "nos", "relata", "un", "llanto", "inusual", "desde", "hace", "unas", "semanas", "y", "la", "sospecha", "de", "que", "el", "niño", "tiene", "dolor", "en", "las", "manos", ".", "Asimismo", "nos", "comenta", "que", "el", "niño", "recibe", "desde", "hace", "unas", "semanas", "tratamiento", "con", "esteroides", "orales", ",", "pues", "en", "el", "seguimiento", "de", "su", "daño", "neurológico", ",", "al", "consultar", "por", "los", "síntomas", "del", "aparato", "locomotor", ",", "se", "sospechó", "artritis", "crónica", "idiopática", "con", "radiografía", "normal", "de", "manos", "y", "muñecas", ".", "\n", "Es", "hijo", "único", "de", "padres", "no", "consanguíneos", ".", "El", "padre", "tiende", "un", "problema", "óseo", "en", "las", "muñecas", "desde", "la", "infancia", ";", "recuerda", "haber", "padecido", "dolores", "en", "las", "muñecas", "cuando", "era", "niño", "y", "nos", "refiere", "que", "no", "tiene", "los", "huesos", "de", "las", "muñecas", ",", "que", "conserva", "movilidad", "normal", "y", "que", "no", "le", "supone", "problemas", "en", "su", "profesión", "de", "conductor", "de", "coches", ".", "\n", "La", "exploración", "física", "del", "niño", "está", "condicionada", "por", "su", "daño", "neurológico", "(", "emite", "gritos", ",", "sin", "lenguaje", "de", "otro", "tipo", "y", "escucha", "y", "atiende", "cuando", "se", "le", "habla", ",", "sonriendo", "con", "las", "caricias", ")", ";", "no", "es", "capaz", "de", "deambulación", "sin", "ayuda", ";", "una", "hemiplejia", "izquierda", "derivada", "de", "su", "ACV", "perinatal", "y", "los", "datos", "propios", "de", "espasticidad", ".", "La", "somatometría", "recoge", "un", "perímetro", "craneal", "de", "46", "cm", "(", "<", "P3", ")", ",", "una", "longitud", "de", "104", "cm", "(", "P25", "-", "50", ")", "y", "un", "peso", "de", "16,5", "Kg", "(", "P50", ")", ".", "Los", "valores", "de", "presión", "arterial", "son", "normales", "(", "111/66", "mmHg", ")", ".", "No", "se", "aprecian", "rasgos", "dismórficos", ".", "Llama", "la", "atención", "el", "intento", "repetido", "del", "niño", "de", "morderse", "su", "muñeca", "derecha", ".", "No", "hay", "signos", "inflamatorios", "y", "se", "expresa", "con", "gemidos", "ante", "la", "movilización", "repetida", "de", "esa", "muñeca", "derecha", ".", "No", "apreciamos", "afectación", "de", "otras", "articulaciones", ".", "\n", "El", "padre", "tiene", "una", "talla", "de", "180", "cm", ",", "pero", "su", "envergadura", "está", "reducida", "a", "164", "cm", ".", "Su", "mano", "mide", "18,7", "cm", "de", "longitud", "(", "resulta", "acortada", "4", "cm", "para", "su", "estatura", ")", "con", "un", "tercer", "dedo", "de", "8,3", "cm", "(", "normal", ")", ".", "La", "radiografía", "paterna", "muestra", "ausencia", "bilateral", "del", "carpo", ".", "\n", "La", "radiografía", "del", "niño", "muestra", "lesiones", "carpales", "compatibles", "con", "osteólisis", "carpiana", "y", "lesiones", "en", "el", "escafoides", "tarsiano", "unilaterales", ".", "\n", "Solicitamos", "consulta", "al", "servicio", "de", "genética", "donde", "se", "estudia", "y", "se", "confirma", "el", "diagnóstico", "de", "osteólisis", "multicéntrica", "carpotarsal", "de", "transmisión", "autosómica", "dominante", "sin", "nefropatía", ".", "\n", "Remitido", "por", ":", "Dr", ".", "Andrés", "Meana", "Meana", ".", "Email", ":", "andres.meana@sespa.es", "\n" ]
[ "CALLE", "CORREO_ELECTRONICO", "NOMBRE_PERSONAL_SANITARIO", "EDAD_SUJETO_ASISTENCIA", "NOMBRE_SUJETO_ASISTENCIA", "ID_TITULACION_PERSONAL_SANITARIO", "ID_SUJETO_ASISTENCIA", "FECHAS", "FAMILIARES_SUJETO_ASISTENCIA", "PAIS", "TERRITORIO", "SEXO_SUJETO_ASISTENCIA" ]
Gabriel is a NOMBRE_SUJETO_ASISTENCIA, Fernandez Otegui is a NOMBRE_SUJETO_ASISTENCIA, 7316503 is a ID_SUJETO_ASISTENCIA, Calle Carabias , 12 , 3 , 2 is a CALLE, Madrid is a TERRITORIO, 28005 is a TERRITORIO, 20/05/2011 is a FECHAS, España is a PAIS, 3 años is a EDAD_SUJETO_ASISTENCIA, 07/07/2014 is a FECHAS, Andrés Meana Meana is a NOMBRE_PERSONAL_SANITARIO, 28 28 68532 is a ID_TITULACION_PERSONAL_SANITARIO, Varón is a SEXO_SUJETO_ASISTENCIA, tres años y medio is a EDAD_SUJETO_ASISTENCIA, madre is a FAMILIARES_SUJETO_ASISTENCIA, niño is a SEXO_SUJETO_ASISTENCIA, niño is a SEXO_SUJETO_ASISTENCIA, hijo único is a ID_SUJETO_ASISTENCIA, padres is a FAMILIARES_SUJETO_ASISTENCIA, padre is a FAMILIARES_SUJETO_ASISTENCIA, niño is a SEXO_SUJETO_ASISTENCIA, niño is a SEXO_SUJETO_ASISTENCIA, padre is a FAMILIARES_SUJETO_ASISTENCIA, paterna is a FAMILIARES_SUJETO_ASISTENCIA, niño is a SEXO_SUJETO_ASISTENCIA, Andrés Meana Meana is a NOMBRE_PERSONAL_SANITARIO, andres.meana@sespa.es is a CORREO_ELECTRONICO
457_task1
Sentence: Datos del paciente. Nombre: Gabriel. Apellidos: Fernandez Otegui. NHC: 7316503. Domicilio: Calle Carabias, 12, 3, 2. Localidad/ Provincia: Madrid. CP: 28005. Datos asistenciales. Fecha de nacimiento: 20/05/2011. País: España. Edad: 3 años Sexo: H. Fecha de Ingreso: 07/07/2014. Médico: Andrés Meana Meana NºCol: 28 28 68532. Informe clínico del paciente: Varón de tres años y medio afecto de daño neurológico grave secundario a accidente cerebrovascular agudo (ACV) isquémico perinatal. Acude a consulta con su madre, que nos relata un llanto inusual desde hace unas semanas y la sospecha de que el niño tiene dolor en las manos. Asimismo nos comenta que el niño recibe desde hace unas semanas tratamiento con esteroides orales, pues en el seguimiento de su daño neurológico, al consultar por los síntomas del aparato locomotor, se sospechó artritis crónica idiopática con radiografía normal de manos y muñecas. Es hijo único de padres no consanguíneos. El padre tiende un problema óseo en las muñecas desde la infancia; recuerda haber padecido dolores en las muñecas cuando era niño y nos refiere que no tiene los huesos de las muñecas, que conserva movilidad normal y que no le supone problemas en su profesión de conductor de coches. La exploración física del niño está condicionada por su daño neurológico (emite gritos, sin lenguaje de otro tipo y escucha y atiende cuando se le habla, sonriendo con las caricias); no es capaz de deambulación sin ayuda; una hemiplejia izquierda derivada de su ACV perinatal y los datos propios de espasticidad. La somatometría recoge un perímetro craneal de 46 cm (< P3), una longitud de 104 cm (P25-50) y un peso de 16,5 Kg (P50). Los valores de presión arterial son normales (111/66 mmHg). No se aprecian rasgos dismórficos. Llama la atención el intento repetido del niño de morderse su muñeca derecha. No hay signos inflamatorios y se expresa con gemidos ante la movilización repetida de esa muñeca derecha. No apreciamos afectación de otras articulaciones. El padre tiene una talla de 180 cm, pero su envergadura está reducida a 164 cm. Su mano mide 18,7 cm de longitud (resulta acortada 4 cm para su estatura) con un tercer dedo de 8,3 cm (normal). La radiografía paterna muestra ausencia bilateral del carpo. La radiografía del niño muestra lesiones carpales compatibles con osteólisis carpiana y lesiones en el escafoides tarsiano unilaterales. Solicitamos consulta al servicio de genética donde se estudia y se confirma el diagnóstico de osteólisis multicéntrica carpotarsal de transmisión autosómica dominante sin nefropatía. Remitido por: Dr. Andrés Meana Meana. Email: andres.meana@sespa.es Instructions: please typing these entity words according to sentence: Gabriel, Fernandez Otegui, 7316503, Calle Carabias , 12 , 3 , 2, Madrid, 28005, 20/05/2011, España, 3 años, 07/07/2014, Andrés Meana Meana, 28 28 68532, Varón, tres años y medio, madre, niño, niño, hijo único, padres, padre, niño, niño, padre, paterna, niño, Andrés Meana Meana, andres.meana@sespa.es Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, FAMILIARES_SUJETO_ASISTENCIA, CALLE, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO
[ "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "I-ID_SUJETO_ASISTENCIA", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]
Datos del paciente. Nombre: Gabriel. Apellidos: Fernandez Otegui. NHC: 7316503. Domicilio: Calle Carabias, 12, 3, 2. Localidad/ Provincia: Madrid. CP: 28005. Datos asistenciales. Fecha de nacimiento: 20/05/2011. País: España. Edad: 3 años Sexo: H. Fecha de Ingreso: 07/07/2014. Médico: Andrés Meana Meana NºCol: 28 28 68532. Informe clínico del paciente: Varón de tres años y medio afecto de daño neurológico grave secundario a accidente cerebrovascular agudo (ACV) isquémico perinatal. Acude a consulta con su madre, que nos relata un llanto inusual desde hace unas semanas y la sospecha de que el niño tiene dolor en las manos. Asimismo nos comenta que el niño recibe desde hace unas semanas tratamiento con esteroides orales, pues en el seguimiento de su daño neurológico, al consultar por los síntomas del aparato locomotor, se sospechó artritis crónica idiopática con radiografía normal de manos y muñecas. Es hijo único de padres no consanguíneos. El padre tiende un problema óseo en las muñecas desde la infancia; recuerda haber padecido dolores en las muñecas cuando era niño y nos refiere que no tiene los huesos de las muñecas, que conserva movilidad normal y que no le supone problemas en su profesión de conductor de coches. La exploración física del niño está condicionada por su daño neurológico (emite gritos, sin lenguaje de otro tipo y escucha y atiende cuando se le habla, sonriendo con las caricias); no es capaz de deambulación sin ayuda; una hemiplejia izquierda derivada de su ACV perinatal y los datos propios de espasticidad. La somatometría recoge un perímetro craneal de 46 cm (< P3), una longitud de 104 cm (P25-50) y un peso de 16,5 Kg (P50). Los valores de presión arterial son normales (111/66 mmHg). No se aprecian rasgos dismórficos. Llama la atención el intento repetido del niño de morderse su muñeca derecha. No hay signos inflamatorios y se expresa con gemidos ante la movilización repetida de esa muñeca derecha. No apreciamos afectación de otras articulaciones. El padre tiene una talla de 180 cm, pero su envergadura está reducida a 164 cm. Su mano mide 18,7 cm de longitud (resulta acortada 4 cm para su estatura) con un tercer dedo de 8,3 cm (normal). La radiografía paterna muestra ausencia bilateral del carpo. La radiografía del niño muestra lesiones carpales compatibles con osteólisis carpiana y lesiones en el escafoides tarsiano unilaterales. Solicitamos consulta al servicio de genética donde se estudia y se confirma el diagnóstico de osteólisis multicéntrica carpotarsal de transmisión autosómica dominante sin nefropatía. Remitido por: Dr. Andrés Meana Meana. Email: andres.meana@sespa.es
[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", " ", "Gabriel", ".", "\n", "Apellidos", ":", "Fernandez", "Otegui", ".", "\n", "NHC", ":", "7316503", ".", "\n", "Domicilio", ":", "Calle", "Carabias", ",", "12", ",", "3", ",", "2", ".", "\n", "Localidad/", "Provincia", ":", "Madrid", ".", "\n", "CP", ":", "28005", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "20/05/2011", ".", "\n", "País", ":", "España", ".", "\n", "Edad", ":", "3", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "07/07/2014", ".", "\n", "Médico", ":", "Andrés", "Meana", "Meana", "NºCol", ":", "28", "28", "68532", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Varón", "de", "tres", "años", "y", "medio", "afecto", "de", "daño", "neurológico", "grave", "secundario", "a", "accidente", "cerebrovascular", "agudo", "(", "ACV", ")", "isquémico", "perinatal", ".", "Acude", "a", "consulta", "con", "su", "madre", ",", "que", "nos", "relata", "un", "llanto", "inusual", "desde", "hace", "unas", "semanas", "y", "la", "sospecha", "de", "que", "el", "niño", "tiene", "dolor", "en", "las", "manos", ".", "Asimismo", "nos", "comenta", "que", "el", "niño", "recibe", "desde", "hace", "unas", "semanas", "tratamiento", "con", "esteroides", "orales", ",", "pues", "en", "el", "seguimiento", "de", "su", "daño", "neurológico", ",", "al", "consultar", "por", "los", "síntomas", "del", "aparato", "locomotor", ",", "se", "sospechó", "artritis", "crónica", "idiopática", "con", "radiografía", "normal", "de", "manos", "y", "muñecas", ".", "\n", "Es", "hijo", "único", "de", "padres", "no", "consanguíneos", ".", "El", "padre", "tiende", "un", "problema", "óseo", "en", "las", "muñecas", "desde", "la", "infancia", ";", "recuerda", "haber", "padecido", "dolores", "en", "las", "muñecas", "cuando", "era", "niño", "y", "nos", "refiere", "que", "no", "tiene", "los", "huesos", "de", "las", "muñecas", ",", "que", "conserva", "movilidad", "normal", "y", "que", "no", "le", "supone", "problemas", "en", "su", "profesión", "de", "conductor", "de", "coches", ".", "\n", "La", "exploración", "física", "del", "niño", "está", "condicionada", "por", "su", "daño", "neurológico", "(", "emite", "gritos", ",", "sin", "lenguaje", "de", "otro", "tipo", "y", "escucha", "y", "atiende", "cuando", "se", "le", "habla", ",", "sonriendo", "con", "las", "caricias", ")", ";", "no", "es", "capaz", "de", "deambulación", "sin", "ayuda", ";", "una", "hemiplejia", "izquierda", "derivada", "de", "su", "ACV", "perinatal", "y", "los", "datos", "propios", "de", "espasticidad", ".", "La", "somatometría", "recoge", "un", "perímetro", "craneal", "de", "46", "cm", "(", "<", "P3", ")", ",", "una", "longitud", "de", "104", "cm", "(", "P25", "-", "50", ")", "y", "un", "peso", "de", "16,5", "Kg", "(", "P50", ")", ".", "Los", "valores", "de", "presión", "arterial", "son", "normales", "(", "111/66", "mmHg", ")", ".", "No", "se", "aprecian", "rasgos", "dismórficos", ".", "Llama", "la", "atención", "el", "intento", "repetido", "del", "niño", "de", "morderse", "su", "muñeca", "derecha", ".", "No", "hay", "signos", "inflamatorios", "y", "se", "expresa", "con", "gemidos", "ante", "la", "movilización", "repetida", "de", "esa", "muñeca", "derecha", ".", "No", "apreciamos", "afectación", "de", "otras", "articulaciones", ".", "\n", "El", "padre", "tiene", "una", "talla", "de", "180", "cm", ",", "pero", "su", "envergadura", "está", "reducida", "a", "164", "cm", ".", "Su", "mano", "mide", "18,7", "cm", "de", "longitud", "(", "resulta", "acortada", "4", "cm", "para", "su", "estatura", ")", "con", "un", "tercer", "dedo", "de", "8,3", "cm", "(", "normal", ")", ".", "La", "radiografía", "paterna", "muestra", "ausencia", "bilateral", "del", "carpo", ".", "\n", "La", "radiografía", "del", "niño", "muestra", "lesiones", "carpales", "compatibles", "con", "osteólisis", "carpiana", "y", "lesiones", "en", "el", "escafoides", "tarsiano", "unilaterales", ".", "\n", "Solicitamos", "consulta", "al", "servicio", "de", "genética", "donde", "se", "estudia", "y", "se", "confirma", "el", "diagnóstico", "de", "osteólisis", "multicéntrica", "carpotarsal", "de", "transmisión", "autosómica", "dominante", "sin", "nefropatía", ".", "\n", "Remitido", "por", ":", "Dr", ".", "Andrés", "Meana", "Meana", ".", "Email", ":", "andres.meana@sespa.es", "\n" ]
[ "CALLE", "CORREO_ELECTRONICO", "NOMBRE_PERSONAL_SANITARIO", "EDAD_SUJETO_ASISTENCIA", "NOMBRE_SUJETO_ASISTENCIA", "ID_TITULACION_PERSONAL_SANITARIO", "ID_SUJETO_ASISTENCIA", "FECHAS", "FAMILIARES_SUJETO_ASISTENCIA", "PAIS", "TERRITORIO", "SEXO_SUJETO_ASISTENCIA" ]
Gabriel, Fernandez Otegui, 7316503, Calle Carabias , 12 , 3 , 2, Madrid, 28005, 20/05/2011, España, 3 años, 07/07/2014, Andrés Meana Meana, 28 28 68532, Varón, tres años y medio, madre, niño, niño, hijo único, padres, padre, niño, niño, padre, paterna, niño, Andrés Meana Meana, andres.meana@sespa.es
457_task2
Sentence: Datos del paciente. Nombre: Gabriel. Apellidos: Fernandez Otegui. NHC: 7316503. Domicilio: Calle Carabias, 12, 3, 2. Localidad/ Provincia: Madrid. CP: 28005. Datos asistenciales. Fecha de nacimiento: 20/05/2011. País: España. Edad: 3 años Sexo: H. Fecha de Ingreso: 07/07/2014. Médico: Andrés Meana Meana NºCol: 28 28 68532. Informe clínico del paciente: Varón de tres años y medio afecto de daño neurológico grave secundario a accidente cerebrovascular agudo (ACV) isquémico perinatal. Acude a consulta con su madre, que nos relata un llanto inusual desde hace unas semanas y la sospecha de que el niño tiene dolor en las manos. Asimismo nos comenta que el niño recibe desde hace unas semanas tratamiento con esteroides orales, pues en el seguimiento de su daño neurológico, al consultar por los síntomas del aparato locomotor, se sospechó artritis crónica idiopática con radiografía normal de manos y muñecas. Es hijo único de padres no consanguíneos. El padre tiende un problema óseo en las muñecas desde la infancia; recuerda haber padecido dolores en las muñecas cuando era niño y nos refiere que no tiene los huesos de las muñecas, que conserva movilidad normal y que no le supone problemas en su profesión de conductor de coches. La exploración física del niño está condicionada por su daño neurológico (emite gritos, sin lenguaje de otro tipo y escucha y atiende cuando se le habla, sonriendo con las caricias); no es capaz de deambulación sin ayuda; una hemiplejia izquierda derivada de su ACV perinatal y los datos propios de espasticidad. La somatometría recoge un perímetro craneal de 46 cm (< P3), una longitud de 104 cm (P25-50) y un peso de 16,5 Kg (P50). Los valores de presión arterial son normales (111/66 mmHg). No se aprecian rasgos dismórficos. Llama la atención el intento repetido del niño de morderse su muñeca derecha. No hay signos inflamatorios y se expresa con gemidos ante la movilización repetida de esa muñeca derecha. No apreciamos afectación de otras articulaciones. El padre tiene una talla de 180 cm, pero su envergadura está reducida a 164 cm. Su mano mide 18,7 cm de longitud (resulta acortada 4 cm para su estatura) con un tercer dedo de 8,3 cm (normal). La radiografía paterna muestra ausencia bilateral del carpo. La radiografía del niño muestra lesiones carpales compatibles con osteólisis carpiana y lesiones en el escafoides tarsiano unilaterales. Solicitamos consulta al servicio de genética donde se estudia y se confirma el diagnóstico de osteólisis multicéntrica carpotarsal de transmisión autosómica dominante sin nefropatía. Remitido por: Dr. Andrés Meana Meana. Email: andres.meana@sespa.es Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "I-ID_SUJETO_ASISTENCIA", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]
Datos del paciente. Nombre: Gabriel. Apellidos: Fernandez Otegui. NHC: 7316503. Domicilio: Calle Carabias, 12, 3, 2. Localidad/ Provincia: Madrid. CP: 28005. Datos asistenciales. Fecha de nacimiento: 20/05/2011. País: España. Edad: 3 años Sexo: H. Fecha de Ingreso: 07/07/2014. Médico: Andrés Meana Meana NºCol: 28 28 68532. Informe clínico del paciente: Varón de tres años y medio afecto de daño neurológico grave secundario a accidente cerebrovascular agudo (ACV) isquémico perinatal. Acude a consulta con su madre, que nos relata un llanto inusual desde hace unas semanas y la sospecha de que el niño tiene dolor en las manos. Asimismo nos comenta que el niño recibe desde hace unas semanas tratamiento con esteroides orales, pues en el seguimiento de su daño neurológico, al consultar por los síntomas del aparato locomotor, se sospechó artritis crónica idiopática con radiografía normal de manos y muñecas. Es hijo único de padres no consanguíneos. El padre tiende un problema óseo en las muñecas desde la infancia; recuerda haber padecido dolores en las muñecas cuando era niño y nos refiere que no tiene los huesos de las muñecas, que conserva movilidad normal y que no le supone problemas en su profesión de conductor de coches. La exploración física del niño está condicionada por su daño neurológico (emite gritos, sin lenguaje de otro tipo y escucha y atiende cuando se le habla, sonriendo con las caricias); no es capaz de deambulación sin ayuda; una hemiplejia izquierda derivada de su ACV perinatal y los datos propios de espasticidad. La somatometría recoge un perímetro craneal de 46 cm (< P3), una longitud de 104 cm (P25-50) y un peso de 16,5 Kg (P50). Los valores de presión arterial son normales (111/66 mmHg). No se aprecian rasgos dismórficos. Llama la atención el intento repetido del niño de morderse su muñeca derecha. No hay signos inflamatorios y se expresa con gemidos ante la movilización repetida de esa muñeca derecha. No apreciamos afectación de otras articulaciones. El padre tiene una talla de 180 cm, pero su envergadura está reducida a 164 cm. Su mano mide 18,7 cm de longitud (resulta acortada 4 cm para su estatura) con un tercer dedo de 8,3 cm (normal). La radiografía paterna muestra ausencia bilateral del carpo. La radiografía del niño muestra lesiones carpales compatibles con osteólisis carpiana y lesiones en el escafoides tarsiano unilaterales. Solicitamos consulta al servicio de genética donde se estudia y se confirma el diagnóstico de osteólisis multicéntrica carpotarsal de transmisión autosómica dominante sin nefropatía. Remitido por: Dr. Andrés Meana Meana. Email: andres.meana@sespa.es
[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", " ", "Gabriel", ".", "\n", "Apellidos", ":", "Fernandez", "Otegui", ".", "\n", "NHC", ":", "7316503", ".", "\n", "Domicilio", ":", "Calle", "Carabias", ",", "12", ",", "3", ",", "2", ".", "\n", "Localidad/", "Provincia", ":", "Madrid", ".", "\n", "CP", ":", "28005", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "20/05/2011", ".", "\n", "País", ":", "España", ".", "\n", "Edad", ":", "3", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "07/07/2014", ".", "\n", "Médico", ":", "Andrés", "Meana", "Meana", "NºCol", ":", "28", "28", "68532", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Varón", "de", "tres", "años", "y", "medio", "afecto", "de", "daño", "neurológico", "grave", "secundario", "a", "accidente", "cerebrovascular", "agudo", "(", "ACV", ")", "isquémico", "perinatal", ".", "Acude", "a", "consulta", "con", "su", "madre", ",", "que", "nos", "relata", "un", "llanto", "inusual", "desde", "hace", "unas", "semanas", "y", "la", "sospecha", "de", "que", "el", "niño", "tiene", "dolor", "en", "las", "manos", ".", "Asimismo", "nos", "comenta", "que", "el", "niño", "recibe", "desde", "hace", "unas", "semanas", "tratamiento", "con", "esteroides", "orales", ",", "pues", "en", "el", "seguimiento", "de", "su", "daño", "neurológico", ",", "al", "consultar", "por", "los", "síntomas", "del", "aparato", "locomotor", ",", "se", "sospechó", "artritis", "crónica", "idiopática", "con", "radiografía", "normal", "de", "manos", "y", "muñecas", ".", "\n", "Es", "hijo", "único", "de", "padres", "no", "consanguíneos", ".", "El", "padre", "tiende", "un", "problema", "óseo", "en", "las", "muñecas", "desde", "la", "infancia", ";", "recuerda", "haber", "padecido", "dolores", "en", "las", "muñecas", "cuando", "era", "niño", "y", "nos", "refiere", "que", "no", "tiene", "los", "huesos", "de", "las", "muñecas", ",", "que", "conserva", "movilidad", "normal", "y", "que", "no", "le", "supone", "problemas", "en", "su", "profesión", "de", "conductor", "de", "coches", ".", "\n", "La", "exploración", "física", "del", "niño", "está", "condicionada", "por", "su", "daño", "neurológico", "(", "emite", "gritos", ",", "sin", "lenguaje", "de", "otro", "tipo", "y", "escucha", "y", "atiende", "cuando", "se", "le", "habla", ",", "sonriendo", "con", "las", "caricias", ")", ";", "no", "es", "capaz", "de", "deambulación", "sin", "ayuda", ";", "una", "hemiplejia", "izquierda", "derivada", "de", "su", "ACV", "perinatal", "y", "los", "datos", "propios", "de", "espasticidad", ".", "La", "somatometría", "recoge", "un", "perímetro", "craneal", "de", "46", "cm", "(", "<", "P3", ")", ",", "una", "longitud", "de", "104", "cm", "(", "P25", "-", "50", ")", "y", "un", "peso", "de", "16,5", "Kg", "(", "P50", ")", ".", "Los", "valores", "de", "presión", "arterial", "son", "normales", "(", "111/66", "mmHg", ")", ".", "No", "se", "aprecian", "rasgos", "dismórficos", ".", "Llama", "la", "atención", "el", "intento", "repetido", "del", "niño", "de", "morderse", "su", "muñeca", "derecha", ".", "No", "hay", "signos", "inflamatorios", "y", "se", "expresa", "con", "gemidos", "ante", "la", "movilización", "repetida", "de", "esa", "muñeca", "derecha", ".", "No", "apreciamos", "afectación", "de", "otras", "articulaciones", ".", "\n", "El", "padre", "tiene", "una", "talla", "de", "180", "cm", ",", "pero", "su", "envergadura", "está", "reducida", "a", "164", "cm", ".", "Su", "mano", "mide", "18,7", "cm", "de", "longitud", "(", "resulta", "acortada", "4", "cm", "para", "su", "estatura", ")", "con", "un", "tercer", "dedo", "de", "8,3", "cm", "(", "normal", ")", ".", "La", "radiografía", "paterna", "muestra", "ausencia", "bilateral", "del", "carpo", ".", "\n", "La", "radiografía", "del", "niño", "muestra", "lesiones", "carpales", "compatibles", "con", "osteólisis", "carpiana", "y", "lesiones", "en", "el", "escafoides", "tarsiano", "unilaterales", ".", "\n", "Solicitamos", "consulta", "al", "servicio", "de", "genética", "donde", "se", "estudia", "y", "se", "confirma", "el", "diagnóstico", "de", "osteólisis", "multicéntrica", "carpotarsal", "de", "transmisión", "autosómica", "dominante", "sin", "nefropatía", ".", "\n", "Remitido", "por", ":", "Dr", ".", "Andrés", "Meana", "Meana", ".", "Email", ":", "andres.meana@sespa.es", "\n" ]
[ "CALLE", "CORREO_ELECTRONICO", "NOMBRE_PERSONAL_SANITARIO", "EDAD_SUJETO_ASISTENCIA", "NOMBRE_SUJETO_ASISTENCIA", "ID_TITULACION_PERSONAL_SANITARIO", "ID_SUJETO_ASISTENCIA", "FECHAS", "FAMILIARES_SUJETO_ASISTENCIA", "PAIS", "TERRITORIO", "SEXO_SUJETO_ASISTENCIA" ]
blood pressure is a Outcome_Physical, home blood pressure is a Outcome_Physical, HBP is a Outcome_Physical, ABP is a Outcome_Physical, WCE is a Outcome_Physical, Hypertensive is a Participant_Condition, Clinic blood pressure ( CBP ) is a Outcome_Physical, clinic reactors is a Outcome_Physical, 189 is a Participant_Sample-size, 79 is a Participant_Sample-size, systolic BP : is a Outcome_Physical, diastolic BP : is a Outcome_Physical
92329_task0
Sentence: White coat effect detected using self-monitoring of blood pressure at home : comparison with ambulatory blood pressure . The objective of the study was to investigate whether home blood pressure ( HBP ) is a reliable alternative to ambulatory blood pressure ( ABP ) for the detection of the white coat effect ( WCE ) . Hypertensive patients were randomized to measure HBP for 2 weeks or ABP for 24 h. The alternative measurement was then performed . Clinic blood pressure ( CBP ) was measured in the beginning and end of the study . Subjects with a difference of > or = 20 mm Hg systolic or > or = 10 mm Hg diastolic BP between CBP and awake ABP or CBP and HBP , were classified as clinic reactors . A total of 189 patients completed the study ( 79 on stable antihypertensive treatment ) . There was no difference in the magnitude of WCE assessed using the ABP or the HBP method ( mean discrepancy , systolic BP : -1.5 +/- 11.7 mm Hg , 95 % CI -3.2 , 0.2 ; diastolic BP : 0.9 +/- 7.0 , 95 % CI -0.1 , 1.9 ) . A strong association existed between WCE calculated using the HBP or the ABP method ( r = 0.64/0.59 systolic/diastolic , P < .001 ) . The proportion of patients classified as clinic reactors was identical using the HBP or the ABP method ( 25.9 % ) . Agreement between methods in the classification of clinic reactors was found in 147 patients ( 78 % ) . The sensitivity and specificity of the HBP method to classify correctly clinic reactors ( ABP method used as the standard ) were 57 % and 85 % , respectively , whereas its positive and negative predictive value were 57 % and 85 % . These results indicate that HBP is not appropriate as an alternative to ABP diagnostic testing in the detection of WCE . Nevertheless , HBP appears useful as a screening test for the detection of this phenomenon . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Outcome_Physical, Participant_Condition, Participant_Sample-size
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
White coat effect detected using self-monitoring of blood pressure at home : comparison with ambulatory blood pressure . The objective of the study was to investigate whether home blood pressure ( HBP ) is a reliable alternative to ambulatory blood pressure ( ABP ) for the detection of the white coat effect ( WCE ) . Hypertensive patients were randomized to measure HBP for 2 weeks or ABP for 24 h. The alternative measurement was then performed . Clinic blood pressure ( CBP ) was measured in the beginning and end of the study . Subjects with a difference of > or = 20 mm Hg systolic or > or = 10 mm Hg diastolic BP between CBP and awake ABP or CBP and HBP , were classified as clinic reactors . A total of 189 patients completed the study ( 79 on stable antihypertensive treatment ) . There was no difference in the magnitude of WCE assessed using the ABP or the HBP method ( mean discrepancy , systolic BP : -1.5 +/- 11.7 mm Hg , 95 % CI -3.2 , 0.2 ; diastolic BP : 0.9 +/- 7.0 , 95 % CI -0.1 , 1.9 ) . A strong association existed between WCE calculated using the HBP or the ABP method ( r = 0.64/0.59 systolic/diastolic , P < .001 ) . The proportion of patients classified as clinic reactors was identical using the HBP or the ABP method ( 25.9 % ) . Agreement between methods in the classification of clinic reactors was found in 147 patients ( 78 % ) . The sensitivity and specificity of the HBP method to classify correctly clinic reactors ( ABP method used as the standard ) were 57 % and 85 % , respectively , whereas its positive and negative predictive value were 57 % and 85 % . These results indicate that HBP is not appropriate as an alternative to ABP diagnostic testing in the detection of WCE . Nevertheless , HBP appears useful as a screening test for the detection of this phenomenon .
[ "White", "coat", "effect", "detected", "using", "self", "-", "monitoring", "of", "blood", "pressure", "at", "home", ":", "comparison", "with", "ambulatory", "blood", "pressure", ".", "The", "objective", "of", "the", "study", "was", "to", "investigate", "whether", "home", "blood", "pressure", "(", "HBP", ")", "is", "a", "reliable", "alternative", "to", "ambulatory", "blood", "pressure", "(", "ABP", ")", "for", "the", "detection", "of", "the", "white", "coat", "effect", "(", "WCE", ")", ".", "Hypertensive", "patients", "were", "randomized", "to", "measure", "HBP", "for", "2", "weeks", "or", "ABP", "for", "24", "h.", "The", "alternative", "measurement", "was", "then", "performed", ".", "Clinic", "blood", "pressure", "(", "CBP", ")", "was", "measured", "in", "the", "beginning", "and", "end", "of", "the", "study", ".", "Subjects", "with", "a", "difference", "of", ">", "or", "=", "20", "mm", "Hg", "systolic", "or", ">", "or", "=", "10", "mm", "Hg", "diastolic", "BP", "between", "CBP", "and", "awake", "ABP", "or", "CBP", "and", "HBP", ",", "were", "classified", "as", "clinic", "reactors", ".", "A", "total", "of", "189", "patients", "completed", "the", "study", "(", "79", "on", "stable", "antihypertensive", "treatment", ")", ".", "There", "was", "no", "difference", "in", "the", "magnitude", "of", "WCE", "assessed", "using", "the", "ABP", "or", "the", "HBP", "method", "(", "mean", "discrepancy", ",", "systolic", "BP", ":", "-1.5", "+", "/-", "11.7", "mm", "Hg", ",", "95", "%", "CI", "-3.2", ",", "0.2", ";", "diastolic", "BP", ":", "0.9", "+", "/-", "7.0", ",", "95", "%", "CI", "-0.1", ",", "1.9", ")", ".", "A", "strong", "association", "existed", "between", "WCE", "calculated", "using", "the", "HBP", "or", "the", "ABP", "method", "(", "r", "=", "0.64/0.59", "systolic", "/", "diastolic", ",", "P", "<", ".001", ")", ".", "The", "proportion", "of", "patients", "classified", "as", "clinic", "reactors", "was", "identical", "using", "the", "HBP", "or", "the", "ABP", "method", "(", "25.9", "%", ")", ".", "Agreement", "between", "methods", "in", "the", "classification", "of", "clinic", "reactors", "was", "found", "in", "147", "patients", "(", "78", "%", ")", ".", "The", "sensitivity", "and", "specificity", "of", "the", "HBP", "method", "to", "classify", "correctly", "clinic", "reactors", "(", "ABP", "method", "used", "as", "the", "standard", ")", "were", "57", "%", "and", "85", "%", ",", "respectively", ",", "whereas", "its", "positive", "and", "negative", "predictive", "value", "were", "57", "%", "and", "85", "%", ".", "These", "results", "indicate", "that", "HBP", "is", "not", "appropriate", "as", "an", "alternative", "to", "ABP", "diagnostic", "testing", "in", "the", "detection", "of", "WCE", ".", "Nevertheless", ",", "HBP", "appears", "useful", "as", "a", "screening", "test", "for", "the", "detection", "of", "this", "phenomenon", "." ]
[ "Outcome_Physical", "Participant_Condition", "Participant_Sample-size" ]
blood pressure is a Outcome_Physical, home blood pressure is a Outcome_Physical, HBP is a Outcome_Physical, ABP is a Outcome_Physical, WCE is a Outcome_Physical, Hypertensive is a Participant_Condition, Clinic blood pressure ( CBP ) is a Outcome_Physical, clinic reactors is a Outcome_Physical, 189 is a Participant_Sample-size, 79 is a Participant_Sample-size, systolic BP : is a Outcome_Physical, diastolic BP : is a Outcome_Physical
92329_task1
Sentence: White coat effect detected using self-monitoring of blood pressure at home : comparison with ambulatory blood pressure . The objective of the study was to investigate whether home blood pressure ( HBP ) is a reliable alternative to ambulatory blood pressure ( ABP ) for the detection of the white coat effect ( WCE ) . Hypertensive patients were randomized to measure HBP for 2 weeks or ABP for 24 h. The alternative measurement was then performed . Clinic blood pressure ( CBP ) was measured in the beginning and end of the study . Subjects with a difference of > or = 20 mm Hg systolic or > or = 10 mm Hg diastolic BP between CBP and awake ABP or CBP and HBP , were classified as clinic reactors . A total of 189 patients completed the study ( 79 on stable antihypertensive treatment ) . There was no difference in the magnitude of WCE assessed using the ABP or the HBP method ( mean discrepancy , systolic BP : -1.5 +/- 11.7 mm Hg , 95 % CI -3.2 , 0.2 ; diastolic BP : 0.9 +/- 7.0 , 95 % CI -0.1 , 1.9 ) . A strong association existed between WCE calculated using the HBP or the ABP method ( r = 0.64/0.59 systolic/diastolic , P < .001 ) . The proportion of patients classified as clinic reactors was identical using the HBP or the ABP method ( 25.9 % ) . Agreement between methods in the classification of clinic reactors was found in 147 patients ( 78 % ) . The sensitivity and specificity of the HBP method to classify correctly clinic reactors ( ABP method used as the standard ) were 57 % and 85 % , respectively , whereas its positive and negative predictive value were 57 % and 85 % . These results indicate that HBP is not appropriate as an alternative to ABP diagnostic testing in the detection of WCE . Nevertheless , HBP appears useful as a screening test for the detection of this phenomenon . Instructions: please typing these entity words according to sentence: blood pressure, home blood pressure, HBP, ABP, WCE, Hypertensive, Clinic blood pressure ( CBP ), clinic reactors, 189, 79, systolic BP :, diastolic BP : Options: Outcome_Physical, Participant_Condition, Participant_Sample-size
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
White coat effect detected using self-monitoring of blood pressure at home : comparison with ambulatory blood pressure . The objective of the study was to investigate whether home blood pressure ( HBP ) is a reliable alternative to ambulatory blood pressure ( ABP ) for the detection of the white coat effect ( WCE ) . Hypertensive patients were randomized to measure HBP for 2 weeks or ABP for 24 h. The alternative measurement was then performed . Clinic blood pressure ( CBP ) was measured in the beginning and end of the study . Subjects with a difference of > or = 20 mm Hg systolic or > or = 10 mm Hg diastolic BP between CBP and awake ABP or CBP and HBP , were classified as clinic reactors . A total of 189 patients completed the study ( 79 on stable antihypertensive treatment ) . There was no difference in the magnitude of WCE assessed using the ABP or the HBP method ( mean discrepancy , systolic BP : -1.5 +/- 11.7 mm Hg , 95 % CI -3.2 , 0.2 ; diastolic BP : 0.9 +/- 7.0 , 95 % CI -0.1 , 1.9 ) . A strong association existed between WCE calculated using the HBP or the ABP method ( r = 0.64/0.59 systolic/diastolic , P < .001 ) . The proportion of patients classified as clinic reactors was identical using the HBP or the ABP method ( 25.9 % ) . Agreement between methods in the classification of clinic reactors was found in 147 patients ( 78 % ) . The sensitivity and specificity of the HBP method to classify correctly clinic reactors ( ABP method used as the standard ) were 57 % and 85 % , respectively , whereas its positive and negative predictive value were 57 % and 85 % . These results indicate that HBP is not appropriate as an alternative to ABP diagnostic testing in the detection of WCE . Nevertheless , HBP appears useful as a screening test for the detection of this phenomenon .
[ "White", "coat", "effect", "detected", "using", "self", "-", "monitoring", "of", "blood", "pressure", "at", "home", ":", "comparison", "with", "ambulatory", "blood", "pressure", ".", "The", "objective", "of", "the", "study", "was", "to", "investigate", "whether", "home", "blood", "pressure", "(", "HBP", ")", "is", "a", "reliable", "alternative", "to", "ambulatory", "blood", "pressure", "(", "ABP", ")", "for", "the", "detection", "of", "the", "white", "coat", "effect", "(", "WCE", ")", ".", "Hypertensive", "patients", "were", "randomized", "to", "measure", "HBP", "for", "2", "weeks", "or", "ABP", "for", "24", "h.", "The", "alternative", "measurement", "was", "then", "performed", ".", "Clinic", "blood", "pressure", "(", "CBP", ")", "was", "measured", "in", "the", "beginning", "and", "end", "of", "the", "study", ".", "Subjects", "with", "a", "difference", "of", ">", "or", "=", "20", "mm", "Hg", "systolic", "or", ">", "or", "=", "10", "mm", "Hg", "diastolic", "BP", "between", "CBP", "and", "awake", "ABP", "or", "CBP", "and", "HBP", ",", "were", "classified", "as", "clinic", "reactors", ".", "A", "total", "of", "189", "patients", "completed", "the", "study", "(", "79", "on", "stable", "antihypertensive", "treatment", ")", ".", "There", "was", "no", "difference", "in", "the", "magnitude", "of", "WCE", "assessed", "using", "the", "ABP", "or", "the", "HBP", "method", "(", "mean", "discrepancy", ",", "systolic", "BP", ":", "-1.5", "+", "/-", "11.7", "mm", "Hg", ",", "95", "%", "CI", "-3.2", ",", "0.2", ";", "diastolic", "BP", ":", "0.9", "+", "/-", "7.0", ",", "95", "%", "CI", "-0.1", ",", "1.9", ")", ".", "A", "strong", "association", "existed", "between", "WCE", "calculated", "using", "the", "HBP", "or", "the", "ABP", "method", "(", "r", "=", "0.64/0.59", "systolic", "/", "diastolic", ",", "P", "<", ".001", ")", ".", "The", "proportion", "of", "patients", "classified", "as", "clinic", "reactors", "was", "identical", "using", "the", "HBP", "or", "the", "ABP", "method", "(", "25.9", "%", ")", ".", "Agreement", "between", "methods", "in", "the", "classification", "of", "clinic", "reactors", "was", "found", "in", "147", "patients", "(", "78", "%", ")", ".", "The", "sensitivity", "and", "specificity", "of", "the", "HBP", "method", "to", "classify", "correctly", "clinic", "reactors", "(", "ABP", "method", "used", "as", "the", "standard", ")", "were", "57", "%", "and", "85", "%", ",", "respectively", ",", "whereas", "its", "positive", "and", "negative", "predictive", "value", "were", "57", "%", "and", "85", "%", ".", "These", "results", "indicate", "that", "HBP", "is", "not", "appropriate", "as", "an", "alternative", "to", "ABP", "diagnostic", "testing", "in", "the", "detection", "of", "WCE", ".", "Nevertheless", ",", "HBP", "appears", "useful", "as", "a", "screening", "test", "for", "the", "detection", "of", "this", "phenomenon", "." ]
[ "Outcome_Physical", "Participant_Condition", "Participant_Sample-size" ]
blood pressure, home blood pressure, HBP, ABP, WCE, Hypertensive, Clinic blood pressure ( CBP ), clinic reactors, 189, 79, systolic BP :, diastolic BP :
92329_task2
Sentence: White coat effect detected using self-monitoring of blood pressure at home : comparison with ambulatory blood pressure . The objective of the study was to investigate whether home blood pressure ( HBP ) is a reliable alternative to ambulatory blood pressure ( ABP ) for the detection of the white coat effect ( WCE ) . Hypertensive patients were randomized to measure HBP for 2 weeks or ABP for 24 h. The alternative measurement was then performed . Clinic blood pressure ( CBP ) was measured in the beginning and end of the study . Subjects with a difference of > or = 20 mm Hg systolic or > or = 10 mm Hg diastolic BP between CBP and awake ABP or CBP and HBP , were classified as clinic reactors . A total of 189 patients completed the study ( 79 on stable antihypertensive treatment ) . There was no difference in the magnitude of WCE assessed using the ABP or the HBP method ( mean discrepancy , systolic BP : -1.5 +/- 11.7 mm Hg , 95 % CI -3.2 , 0.2 ; diastolic BP : 0.9 +/- 7.0 , 95 % CI -0.1 , 1.9 ) . A strong association existed between WCE calculated using the HBP or the ABP method ( r = 0.64/0.59 systolic/diastolic , P < .001 ) . The proportion of patients classified as clinic reactors was identical using the HBP or the ABP method ( 25.9 % ) . Agreement between methods in the classification of clinic reactors was found in 147 patients ( 78 % ) . The sensitivity and specificity of the HBP method to classify correctly clinic reactors ( ABP method used as the standard ) were 57 % and 85 % , respectively , whereas its positive and negative predictive value were 57 % and 85 % . These results indicate that HBP is not appropriate as an alternative to ABP diagnostic testing in the detection of WCE . Nevertheless , HBP appears useful as a screening test for the detection of this phenomenon . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
White coat effect detected using self-monitoring of blood pressure at home : comparison with ambulatory blood pressure . The objective of the study was to investigate whether home blood pressure ( HBP ) is a reliable alternative to ambulatory blood pressure ( ABP ) for the detection of the white coat effect ( WCE ) . Hypertensive patients were randomized to measure HBP for 2 weeks or ABP for 24 h. The alternative measurement was then performed . Clinic blood pressure ( CBP ) was measured in the beginning and end of the study . Subjects with a difference of > or = 20 mm Hg systolic or > or = 10 mm Hg diastolic BP between CBP and awake ABP or CBP and HBP , were classified as clinic reactors . A total of 189 patients completed the study ( 79 on stable antihypertensive treatment ) . There was no difference in the magnitude of WCE assessed using the ABP or the HBP method ( mean discrepancy , systolic BP : -1.5 +/- 11.7 mm Hg , 95 % CI -3.2 , 0.2 ; diastolic BP : 0.9 +/- 7.0 , 95 % CI -0.1 , 1.9 ) . A strong association existed between WCE calculated using the HBP or the ABP method ( r = 0.64/0.59 systolic/diastolic , P < .001 ) . The proportion of patients classified as clinic reactors was identical using the HBP or the ABP method ( 25.9 % ) . Agreement between methods in the classification of clinic reactors was found in 147 patients ( 78 % ) . The sensitivity and specificity of the HBP method to classify correctly clinic reactors ( ABP method used as the standard ) were 57 % and 85 % , respectively , whereas its positive and negative predictive value were 57 % and 85 % . These results indicate that HBP is not appropriate as an alternative to ABP diagnostic testing in the detection of WCE . Nevertheless , HBP appears useful as a screening test for the detection of this phenomenon .
[ "White", "coat", "effect", "detected", "using", "self", "-", "monitoring", "of", "blood", "pressure", "at", "home", ":", "comparison", "with", "ambulatory", "blood", "pressure", ".", "The", "objective", "of", "the", "study", "was", "to", "investigate", "whether", "home", "blood", "pressure", "(", "HBP", ")", "is", "a", "reliable", "alternative", "to", "ambulatory", "blood", "pressure", "(", "ABP", ")", "for", "the", "detection", "of", "the", "white", "coat", "effect", "(", "WCE", ")", ".", "Hypertensive", "patients", "were", "randomized", "to", "measure", "HBP", "for", "2", "weeks", "or", "ABP", "for", "24", "h.", "The", "alternative", "measurement", "was", "then", "performed", ".", "Clinic", "blood", "pressure", "(", "CBP", ")", "was", "measured", "in", "the", "beginning", "and", "end", "of", "the", "study", ".", "Subjects", "with", "a", "difference", "of", ">", "or", "=", "20", "mm", "Hg", "systolic", "or", ">", "or", "=", "10", "mm", "Hg", "diastolic", "BP", "between", "CBP", "and", "awake", "ABP", "or", "CBP", "and", "HBP", ",", "were", "classified", "as", "clinic", "reactors", ".", "A", "total", "of", "189", "patients", "completed", "the", "study", "(", "79", "on", "stable", "antihypertensive", "treatment", ")", ".", "There", "was", "no", "difference", "in", "the", "magnitude", "of", "WCE", "assessed", "using", "the", "ABP", "or", "the", "HBP", "method", "(", "mean", "discrepancy", ",", "systolic", "BP", ":", "-1.5", "+", "/-", "11.7", "mm", "Hg", ",", "95", "%", "CI", "-3.2", ",", "0.2", ";", "diastolic", "BP", ":", "0.9", "+", "/-", "7.0", ",", "95", "%", "CI", "-0.1", ",", "1.9", ")", ".", "A", "strong", "association", "existed", "between", "WCE", "calculated", "using", "the", "HBP", "or", "the", "ABP", "method", "(", "r", "=", "0.64/0.59", "systolic", "/", "diastolic", ",", "P", "<", ".001", ")", ".", "The", "proportion", "of", "patients", "classified", "as", "clinic", "reactors", "was", "identical", "using", "the", "HBP", "or", "the", "ABP", "method", "(", "25.9", "%", ")", ".", "Agreement", "between", "methods", "in", "the", "classification", "of", "clinic", "reactors", "was", "found", "in", "147", "patients", "(", "78", "%", ")", ".", "The", "sensitivity", "and", "specificity", "of", "the", "HBP", "method", "to", "classify", "correctly", "clinic", "reactors", "(", "ABP", "method", "used", "as", "the", "standard", ")", "were", "57", "%", "and", "85", "%", ",", "respectively", ",", "whereas", "its", "positive", "and", "negative", "predictive", "value", "were", "57", "%", "and", "85", "%", ".", "These", "results", "indicate", "that", "HBP", "is", "not", "appropriate", "as", "an", "alternative", "to", "ABP", "diagnostic", "testing", "in", "the", "detection", "of", "WCE", ".", "Nevertheless", ",", "HBP", "appears", "useful", "as", "a", "screening", "test", "for", "the", "detection", "of", "this", "phenomenon", "." ]
[ "Outcome_Physical", "Participant_Condition", "Participant_Sample-size" ]
profilin is a Individual_protein, DNase I is a Individual_protein, actin is a Individual_protein
234_task0
Sentence: These data indicated a negative co-operativity between the profilin and DNase I binding sites on actin. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Individual_protein
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "I-Individual_protein", "O", "O", "O", "B-Individual_protein", "O" ]
These data indicated a negative co-operativity between the profilin and DNase I binding sites on actin.
[ "These", "data", "indicated", "a", "negative", "co", "-", "operativity", "between", "the", "profilin", "and", "DNase", "I", "binding", "sites", "on", "actin", "." ]
[ "Individual_protein" ]
profilin is a Individual_protein, DNase I is a Individual_protein, actin is a Individual_protein
234_task1
Sentence: These data indicated a negative co-operativity between the profilin and DNase I binding sites on actin. Instructions: please typing these entity words according to sentence: profilin, DNase I, actin Options: Individual_protein
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "I-Individual_protein", "O", "O", "O", "B-Individual_protein", "O" ]
These data indicated a negative co-operativity between the profilin and DNase I binding sites on actin.
[ "These", "data", "indicated", "a", "negative", "co", "-", "operativity", "between", "the", "profilin", "and", "DNase", "I", "binding", "sites", "on", "actin", "." ]
[ "Individual_protein" ]
profilin, DNase I, actin
234_task2
Sentence: These data indicated a negative co-operativity between the profilin and DNase I binding sites on actin. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "I-Individual_protein", "O", "O", "O", "B-Individual_protein", "O" ]
These data indicated a negative co-operativity between the profilin and DNase I binding sites on actin.
[ "These", "data", "indicated", "a", "negative", "co", "-", "operativity", "between", "the", "profilin", "and", "DNase", "I", "binding", "sites", "on", "actin", "." ]
[ "Individual_protein" ]
opioid physical dependence is a Participant_Condition, heroin addicts is a Participant_Condition, opioid withdrawal syndrome is a Outcome_Physical, naloxone is a Intervention_Pharmacological, placebo is a Intervention_Control, subjective symptoms is a Outcome_Mental, objective signs of opioid withdrawal is a Outcome_Physical, 18 is a Participant_Sample-size, 58 is a Participant_Sample-size
37519_task0
Sentence: Levels of opioid physical dependence in heroin addicts . The levels of opioid physical dependence in a group of long-term heroin addicts were ascertained by measuring the severity of the opioid withdrawal syndrome before and after pharmacological challenge with either 0.4 mg naloxone or placebo . Prior to challenge , patients manifested some subjective symptoms but few objective signs of opioid withdrawal . Patients who received placebo ( n = 18 ) showed a significant increase in the mean score on one of three rating scales used to assess opioid withdrawal . Patients who received naloxone ( n = 58 ) showed significant increases in mean scores on all three rating scales , but this was due primarily to increases observed in a minority of patients . Sixty-one percent of patients failed to manifest clinically significant changes in subjective symptoms , and 74 % of patients failed to manifest clinically significant changes in objective signs of opioid withdrawal following naloxone administration . The results suggest that a substantial subgroup of heroin addicts are able to use opioids regularly while maintaining relatively low levels of physical dependence . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Intervention_Control, Participant_Condition, Outcome_Physical, Participant_Sample-size, Outcome_Mental
[ "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Levels of opioid physical dependence in heroin addicts . The levels of opioid physical dependence in a group of long-term heroin addicts were ascertained by measuring the severity of the opioid withdrawal syndrome before and after pharmacological challenge with either 0.4 mg naloxone or placebo . Prior to challenge , patients manifested some subjective symptoms but few objective signs of opioid withdrawal . Patients who received placebo ( n = 18 ) showed a significant increase in the mean score on one of three rating scales used to assess opioid withdrawal . Patients who received naloxone ( n = 58 ) showed significant increases in mean scores on all three rating scales , but this was due primarily to increases observed in a minority of patients . Sixty-one percent of patients failed to manifest clinically significant changes in subjective symptoms , and 74 % of patients failed to manifest clinically significant changes in objective signs of opioid withdrawal following naloxone administration . The results suggest that a substantial subgroup of heroin addicts are able to use opioids regularly while maintaining relatively low levels of physical dependence .
[ "Levels", "of", "opioid", "physical", "dependence", "in", "heroin", "addicts", ".", "The", "levels", "of", "opioid", "physical", "dependence", "in", "a", "group", "of", "long", "-", "term", "heroin", "addicts", "were", "ascertained", "by", "measuring", "the", "severity", "of", "the", "opioid", "withdrawal", "syndrome", "before", "and", "after", "pharmacological", "challenge", "with", "either", "0.4", "mg", "naloxone", "or", "placebo", ".", "Prior", "to", "challenge", ",", "patients", "manifested", "some", "subjective", "symptoms", "but", "few", "objective", "signs", "of", "opioid", "withdrawal", ".", "Patients", "who", "received", "placebo", "(", "n", "=", "18", ")", "showed", "a", "significant", "increase", "in", "the", "mean", "score", "on", "one", "of", "three", "rating", "scales", "used", "to", "assess", "opioid", "withdrawal", ".", "Patients", "who", "received", "naloxone", "(", "n", "=", "58", ")", "showed", "significant", "increases", "in", "mean", "scores", "on", "all", "three", "rating", "scales", ",", "but", "this", "was", "due", "primarily", "to", "increases", "observed", "in", "a", "minority", "of", "patients", ".", "Sixty", "-", "one", "percent", "of", "patients", "failed", "to", "manifest", "clinically", "significant", "changes", "in", "subjective", "symptoms", ",", "and", "74", "%", "of", "patients", "failed", "to", "manifest", "clinically", "significant", "changes", "in", "objective", "signs", "of", "opioid", "withdrawal", "following", "naloxone", "administration", ".", "The", "results", "suggest", "that", "a", "substantial", "subgroup", "of", "heroin", "addicts", "are", "able", "to", "use", "opioids", "regularly", "while", "maintaining", "relatively", "low", "levels", "of", "physical", "dependence", "." ]
[ "Outcome_Physical", "Participant_Condition", "Outcome_Mental", "Intervention_Pharmacological", "Intervention_Control", "Participant_Sample-size" ]
opioid physical dependence is a Participant_Condition, heroin addicts is a Participant_Condition, opioid withdrawal syndrome is a Outcome_Physical, naloxone is a Intervention_Pharmacological, placebo is a Intervention_Control, subjective symptoms is a Outcome_Mental, objective signs of opioid withdrawal is a Outcome_Physical, 18 is a Participant_Sample-size, 58 is a Participant_Sample-size
37519_task1
Sentence: Levels of opioid physical dependence in heroin addicts . The levels of opioid physical dependence in a group of long-term heroin addicts were ascertained by measuring the severity of the opioid withdrawal syndrome before and after pharmacological challenge with either 0.4 mg naloxone or placebo . Prior to challenge , patients manifested some subjective symptoms but few objective signs of opioid withdrawal . Patients who received placebo ( n = 18 ) showed a significant increase in the mean score on one of three rating scales used to assess opioid withdrawal . Patients who received naloxone ( n = 58 ) showed significant increases in mean scores on all three rating scales , but this was due primarily to increases observed in a minority of patients . Sixty-one percent of patients failed to manifest clinically significant changes in subjective symptoms , and 74 % of patients failed to manifest clinically significant changes in objective signs of opioid withdrawal following naloxone administration . The results suggest that a substantial subgroup of heroin addicts are able to use opioids regularly while maintaining relatively low levels of physical dependence . Instructions: please typing these entity words according to sentence: opioid physical dependence, heroin addicts, opioid withdrawal syndrome, naloxone, placebo, subjective symptoms, objective signs of opioid withdrawal, 18, 58 Options: Intervention_Pharmacological, Intervention_Control, Participant_Condition, Outcome_Physical, Participant_Sample-size, Outcome_Mental
[ "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Levels of opioid physical dependence in heroin addicts . The levels of opioid physical dependence in a group of long-term heroin addicts were ascertained by measuring the severity of the opioid withdrawal syndrome before and after pharmacological challenge with either 0.4 mg naloxone or placebo . Prior to challenge , patients manifested some subjective symptoms but few objective signs of opioid withdrawal . Patients who received placebo ( n = 18 ) showed a significant increase in the mean score on one of three rating scales used to assess opioid withdrawal . Patients who received naloxone ( n = 58 ) showed significant increases in mean scores on all three rating scales , but this was due primarily to increases observed in a minority of patients . Sixty-one percent of patients failed to manifest clinically significant changes in subjective symptoms , and 74 % of patients failed to manifest clinically significant changes in objective signs of opioid withdrawal following naloxone administration . The results suggest that a substantial subgroup of heroin addicts are able to use opioids regularly while maintaining relatively low levels of physical dependence .
[ "Levels", "of", "opioid", "physical", "dependence", "in", "heroin", "addicts", ".", "The", "levels", "of", "opioid", "physical", "dependence", "in", "a", "group", "of", "long", "-", "term", "heroin", "addicts", "were", "ascertained", "by", "measuring", "the", "severity", "of", "the", "opioid", "withdrawal", "syndrome", "before", "and", "after", "pharmacological", "challenge", "with", "either", "0.4", "mg", "naloxone", "or", "placebo", ".", "Prior", "to", "challenge", ",", "patients", "manifested", "some", "subjective", "symptoms", "but", "few", "objective", "signs", "of", "opioid", "withdrawal", ".", "Patients", "who", "received", "placebo", "(", "n", "=", "18", ")", "showed", "a", "significant", "increase", "in", "the", "mean", "score", "on", "one", "of", "three", "rating", "scales", "used", "to", "assess", "opioid", "withdrawal", ".", "Patients", "who", "received", "naloxone", "(", "n", "=", "58", ")", "showed", "significant", "increases", "in", "mean", "scores", "on", "all", "three", "rating", "scales", ",", "but", "this", "was", "due", "primarily", "to", "increases", "observed", "in", "a", "minority", "of", "patients", ".", "Sixty", "-", "one", "percent", "of", "patients", "failed", "to", "manifest", "clinically", "significant", "changes", "in", "subjective", "symptoms", ",", "and", "74", "%", "of", "patients", "failed", "to", "manifest", "clinically", "significant", "changes", "in", "objective", "signs", "of", "opioid", "withdrawal", "following", "naloxone", "administration", ".", "The", "results", "suggest", "that", "a", "substantial", "subgroup", "of", "heroin", "addicts", "are", "able", "to", "use", "opioids", "regularly", "while", "maintaining", "relatively", "low", "levels", "of", "physical", "dependence", "." ]
[ "Outcome_Physical", "Participant_Condition", "Outcome_Mental", "Intervention_Pharmacological", "Intervention_Control", "Participant_Sample-size" ]
opioid physical dependence, heroin addicts, opioid withdrawal syndrome, naloxone, placebo, subjective symptoms, objective signs of opioid withdrawal, 18, 58
37519_task2
Sentence: Levels of opioid physical dependence in heroin addicts . The levels of opioid physical dependence in a group of long-term heroin addicts were ascertained by measuring the severity of the opioid withdrawal syndrome before and after pharmacological challenge with either 0.4 mg naloxone or placebo . Prior to challenge , patients manifested some subjective symptoms but few objective signs of opioid withdrawal . Patients who received placebo ( n = 18 ) showed a significant increase in the mean score on one of three rating scales used to assess opioid withdrawal . Patients who received naloxone ( n = 58 ) showed significant increases in mean scores on all three rating scales , but this was due primarily to increases observed in a minority of patients . Sixty-one percent of patients failed to manifest clinically significant changes in subjective symptoms , and 74 % of patients failed to manifest clinically significant changes in objective signs of opioid withdrawal following naloxone administration . The results suggest that a substantial subgroup of heroin addicts are able to use opioids regularly while maintaining relatively low levels of physical dependence . Instructions: please extract entity words from the input sentence
[ "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Levels of opioid physical dependence in heroin addicts . The levels of opioid physical dependence in a group of long-term heroin addicts were ascertained by measuring the severity of the opioid withdrawal syndrome before and after pharmacological challenge with either 0.4 mg naloxone or placebo . Prior to challenge , patients manifested some subjective symptoms but few objective signs of opioid withdrawal . Patients who received placebo ( n = 18 ) showed a significant increase in the mean score on one of three rating scales used to assess opioid withdrawal . Patients who received naloxone ( n = 58 ) showed significant increases in mean scores on all three rating scales , but this was due primarily to increases observed in a minority of patients . Sixty-one percent of patients failed to manifest clinically significant changes in subjective symptoms , and 74 % of patients failed to manifest clinically significant changes in objective signs of opioid withdrawal following naloxone administration . The results suggest that a substantial subgroup of heroin addicts are able to use opioids regularly while maintaining relatively low levels of physical dependence .
[ "Levels", "of", "opioid", "physical", "dependence", "in", "heroin", "addicts", ".", "The", "levels", "of", "opioid", "physical", "dependence", "in", "a", "group", "of", "long", "-", "term", "heroin", "addicts", "were", "ascertained", "by", "measuring", "the", "severity", "of", "the", "opioid", "withdrawal", "syndrome", "before", "and", "after", "pharmacological", "challenge", "with", "either", "0.4", "mg", "naloxone", "or", "placebo", ".", "Prior", "to", "challenge", ",", "patients", "manifested", "some", "subjective", "symptoms", "but", "few", "objective", "signs", "of", "opioid", "withdrawal", ".", "Patients", "who", "received", "placebo", "(", "n", "=", "18", ")", "showed", "a", "significant", "increase", "in", "the", "mean", "score", "on", "one", "of", "three", "rating", "scales", "used", "to", "assess", "opioid", "withdrawal", ".", "Patients", "who", "received", "naloxone", "(", "n", "=", "58", ")", "showed", "significant", "increases", "in", "mean", "scores", "on", "all", "three", "rating", "scales", ",", "but", "this", "was", "due", "primarily", "to", "increases", "observed", "in", "a", "minority", "of", "patients", ".", "Sixty", "-", "one", "percent", "of", "patients", "failed", "to", "manifest", "clinically", "significant", "changes", "in", "subjective", "symptoms", ",", "and", "74", "%", "of", "patients", "failed", "to", "manifest", "clinically", "significant", "changes", "in", "objective", "signs", "of", "opioid", "withdrawal", "following", "naloxone", "administration", ".", "The", "results", "suggest", "that", "a", "substantial", "subgroup", "of", "heroin", "addicts", "are", "able", "to", "use", "opioids", "regularly", "while", "maintaining", "relatively", "low", "levels", "of", "physical", "dependence", "." ]
[ "Outcome_Physical", "Participant_Condition", "Outcome_Mental", "Intervention_Pharmacological", "Intervention_Control", "Participant_Sample-size" ]
E - cadherin is a Protein, CpG is a Entity, E - cadherin is a Protein, CpG is a Entity, CpG is a Entity, E - cadherin is a Protein, E - cadherin is a Protein, CpG is a Entity, E - cadherin is a Protein, CpG is a Entity, E - cadherin is a Protein
573_task0
Sentence: The E-cadherin gene is silenced by CpG methylation in human hepatocellular carcinomas. Our study was designed to clarify the significance of silencing the E-cadherin gene, which is located on 16q22.1, due to CpG methylation during hepatocarcinogenesis. The CpG methylation status of primary hepatocellular carcinomas (HCCs) and corresponding liver tissues showing chronic hepatitis or cirrhosis, which are widely considered to be precancerous conditions, were assessed by digesting DNA with methylation-sensitive and non-sensitive restriction enzymes. CpG methylation around the promoter region of the E-cadherin gene was detected in 46% of liver tissues showing chronic hepatitis or cirrhosis and 67% of HCCs examined. Immunohistochemical examination revealed reduced E-cadherin expression in 59% of HCCs examined. CpG methylation around the promoter region correlated significantly with reduced E-cadherin expression in HCCs (p < 0.05). CpG methylation around the promoter region, which increases during the progression from a precancerous condition to HCC, may participate in hepatocarcinogenesis through reduction of E-cadherin expression, resulting in loss of intercellular adhesiveness and destruction of tissue morphology. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein
[ "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
The E-cadherin gene is silenced by CpG methylation in human hepatocellular carcinomas. Our study was designed to clarify the significance of silencing the E-cadherin gene, which is located on 16q22.1, due to CpG methylation during hepatocarcinogenesis. The CpG methylation status of primary hepatocellular carcinomas (HCCs) and corresponding liver tissues showing chronic hepatitis or cirrhosis, which are widely considered to be precancerous conditions, were assessed by digesting DNA with methylation-sensitive and non-sensitive restriction enzymes. CpG methylation around the promoter region of the E-cadherin gene was detected in 46% of liver tissues showing chronic hepatitis or cirrhosis and 67% of HCCs examined. Immunohistochemical examination revealed reduced E-cadherin expression in 59% of HCCs examined. CpG methylation around the promoter region correlated significantly with reduced E-cadherin expression in HCCs (p < 0.05). CpG methylation around the promoter region, which increases during the progression from a precancerous condition to HCC, may participate in hepatocarcinogenesis through reduction of E-cadherin expression, resulting in loss of intercellular adhesiveness and destruction of tissue morphology.
[ "The", "E", "-", "cadherin", "gene", "is", "silenced", "by", "CpG", "methylation", "in", "human", "hepatocellular", "carcinomas", ".", "\n", "Our", "study", "was", "designed", "to", "clarify", "the", "significance", "of", "silencing", "the", "E", "-", "cadherin", "gene", ",", "which", "is", "located", "on", "16q22.1", ",", "due", "to", "CpG", "methylation", "during", "hepatocarcinogenesis", ".", "The", "CpG", "methylation", "status", "of", "primary", "hepatocellular", "carcinomas", "(", "HCCs", ")", "and", "corresponding", "liver", "tissues", "showing", "chronic", "hepatitis", "or", "cirrhosis", ",", "which", "are", "widely", "considered", "to", "be", "precancerous", "conditions", ",", "were", "assessed", "by", "digesting", "DNA", "with", "methylation", "-", "sensitive", "and", "non", "-", "sensitive", "restriction", "enzymes", ".", "CpG", "methylation", "around", "the", "promoter", "region", "of", "the", "E", "-", "cadherin", "gene", "was", "detected", "in", "46", "%", "of", "liver", "tissues", "showing", "chronic", "hepatitis", "or", "cirrhosis", "and", "67", "%", "of", "HCCs", "examined", ".", "Immunohistochemical", "examination", "revealed", "reduced", "E", "-", "cadherin", "expression", "in", "59", "%", "of", "HCCs", "examined", ".", "CpG", "methylation", "around", "the", "promoter", "region", "correlated", "significantly", "with", "reduced", "E", "-", "cadherin", "expression", "in", "HCCs", "(", "p", "<", "0.05", ")", ".", "CpG", "methylation", "around", "the", "promoter", "region", ",", "which", "increases", "during", "the", "progression", "from", "a", "precancerous", "condition", "to", "HCC", ",", "may", "participate", "in", "hepatocarcinogenesis", "through", "reduction", "of", "E", "-", "cadherin", "expression", ",", "resulting", "in", "loss", "of", "intercellular", "adhesiveness", "and", "destruction", "of", "tissue", "morphology", ".", "\n" ]
[ "Protein", "Entity" ]
E - cadherin is a Protein, CpG is a Entity, E - cadherin is a Protein, CpG is a Entity, CpG is a Entity, E - cadherin is a Protein, E - cadherin is a Protein, CpG is a Entity, E - cadherin is a Protein, CpG is a Entity, E - cadherin is a Protein
573_task1
Sentence: The E-cadherin gene is silenced by CpG methylation in human hepatocellular carcinomas. Our study was designed to clarify the significance of silencing the E-cadherin gene, which is located on 16q22.1, due to CpG methylation during hepatocarcinogenesis. The CpG methylation status of primary hepatocellular carcinomas (HCCs) and corresponding liver tissues showing chronic hepatitis or cirrhosis, which are widely considered to be precancerous conditions, were assessed by digesting DNA with methylation-sensitive and non-sensitive restriction enzymes. CpG methylation around the promoter region of the E-cadherin gene was detected in 46% of liver tissues showing chronic hepatitis or cirrhosis and 67% of HCCs examined. Immunohistochemical examination revealed reduced E-cadherin expression in 59% of HCCs examined. CpG methylation around the promoter region correlated significantly with reduced E-cadherin expression in HCCs (p < 0.05). CpG methylation around the promoter region, which increases during the progression from a precancerous condition to HCC, may participate in hepatocarcinogenesis through reduction of E-cadherin expression, resulting in loss of intercellular adhesiveness and destruction of tissue morphology. Instructions: please typing these entity words according to sentence: E - cadherin, CpG, E - cadherin, CpG, CpG, E - cadherin, E - cadherin, CpG, E - cadherin, CpG, E - cadherin Options: Entity, Protein
[ "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
The E-cadherin gene is silenced by CpG methylation in human hepatocellular carcinomas. Our study was designed to clarify the significance of silencing the E-cadherin gene, which is located on 16q22.1, due to CpG methylation during hepatocarcinogenesis. The CpG methylation status of primary hepatocellular carcinomas (HCCs) and corresponding liver tissues showing chronic hepatitis or cirrhosis, which are widely considered to be precancerous conditions, were assessed by digesting DNA with methylation-sensitive and non-sensitive restriction enzymes. CpG methylation around the promoter region of the E-cadherin gene was detected in 46% of liver tissues showing chronic hepatitis or cirrhosis and 67% of HCCs examined. Immunohistochemical examination revealed reduced E-cadherin expression in 59% of HCCs examined. CpG methylation around the promoter region correlated significantly with reduced E-cadherin expression in HCCs (p < 0.05). CpG methylation around the promoter region, which increases during the progression from a precancerous condition to HCC, may participate in hepatocarcinogenesis through reduction of E-cadherin expression, resulting in loss of intercellular adhesiveness and destruction of tissue morphology.
[ "The", "E", "-", "cadherin", "gene", "is", "silenced", "by", "CpG", "methylation", "in", "human", "hepatocellular", "carcinomas", ".", "\n", "Our", "study", "was", "designed", "to", "clarify", "the", "significance", "of", "silencing", "the", "E", "-", "cadherin", "gene", ",", "which", "is", "located", "on", "16q22.1", ",", "due", "to", "CpG", "methylation", "during", "hepatocarcinogenesis", ".", "The", "CpG", "methylation", "status", "of", "primary", "hepatocellular", "carcinomas", "(", "HCCs", ")", "and", "corresponding", "liver", "tissues", "showing", "chronic", "hepatitis", "or", "cirrhosis", ",", "which", "are", "widely", "considered", "to", "be", "precancerous", "conditions", ",", "were", "assessed", "by", "digesting", "DNA", "with", "methylation", "-", "sensitive", "and", "non", "-", "sensitive", "restriction", "enzymes", ".", "CpG", "methylation", "around", "the", "promoter", "region", "of", "the", "E", "-", "cadherin", "gene", "was", "detected", "in", "46", "%", "of", "liver", "tissues", "showing", "chronic", "hepatitis", "or", "cirrhosis", "and", "67", "%", "of", "HCCs", "examined", ".", "Immunohistochemical", "examination", "revealed", "reduced", "E", "-", "cadherin", "expression", "in", "59", "%", "of", "HCCs", "examined", ".", "CpG", "methylation", "around", "the", "promoter", "region", "correlated", "significantly", "with", "reduced", "E", "-", "cadherin", "expression", "in", "HCCs", "(", "p", "<", "0.05", ")", ".", "CpG", "methylation", "around", "the", "promoter", "region", ",", "which", "increases", "during", "the", "progression", "from", "a", "precancerous", "condition", "to", "HCC", ",", "may", "participate", "in", "hepatocarcinogenesis", "through", "reduction", "of", "E", "-", "cadherin", "expression", ",", "resulting", "in", "loss", "of", "intercellular", "adhesiveness", "and", "destruction", "of", "tissue", "morphology", ".", "\n" ]
[ "Protein", "Entity" ]
E - cadherin, CpG, E - cadherin, CpG, CpG, E - cadherin, E - cadherin, CpG, E - cadherin, CpG, E - cadherin
573_task2
Sentence: The E-cadherin gene is silenced by CpG methylation in human hepatocellular carcinomas. Our study was designed to clarify the significance of silencing the E-cadherin gene, which is located on 16q22.1, due to CpG methylation during hepatocarcinogenesis. The CpG methylation status of primary hepatocellular carcinomas (HCCs) and corresponding liver tissues showing chronic hepatitis or cirrhosis, which are widely considered to be precancerous conditions, were assessed by digesting DNA with methylation-sensitive and non-sensitive restriction enzymes. CpG methylation around the promoter region of the E-cadherin gene was detected in 46% of liver tissues showing chronic hepatitis or cirrhosis and 67% of HCCs examined. Immunohistochemical examination revealed reduced E-cadherin expression in 59% of HCCs examined. CpG methylation around the promoter region correlated significantly with reduced E-cadherin expression in HCCs (p < 0.05). CpG methylation around the promoter region, which increases during the progression from a precancerous condition to HCC, may participate in hepatocarcinogenesis through reduction of E-cadherin expression, resulting in loss of intercellular adhesiveness and destruction of tissue morphology. Instructions: please extract entity words from the input sentence
[ "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
The E-cadherin gene is silenced by CpG methylation in human hepatocellular carcinomas. Our study was designed to clarify the significance of silencing the E-cadherin gene, which is located on 16q22.1, due to CpG methylation during hepatocarcinogenesis. The CpG methylation status of primary hepatocellular carcinomas (HCCs) and corresponding liver tissues showing chronic hepatitis or cirrhosis, which are widely considered to be precancerous conditions, were assessed by digesting DNA with methylation-sensitive and non-sensitive restriction enzymes. CpG methylation around the promoter region of the E-cadherin gene was detected in 46% of liver tissues showing chronic hepatitis or cirrhosis and 67% of HCCs examined. Immunohistochemical examination revealed reduced E-cadherin expression in 59% of HCCs examined. CpG methylation around the promoter region correlated significantly with reduced E-cadherin expression in HCCs (p < 0.05). CpG methylation around the promoter region, which increases during the progression from a precancerous condition to HCC, may participate in hepatocarcinogenesis through reduction of E-cadherin expression, resulting in loss of intercellular adhesiveness and destruction of tissue morphology.
[ "The", "E", "-", "cadherin", "gene", "is", "silenced", "by", "CpG", "methylation", "in", "human", "hepatocellular", "carcinomas", ".", "\n", "Our", "study", "was", "designed", "to", "clarify", "the", "significance", "of", "silencing", "the", "E", "-", "cadherin", "gene", ",", "which", "is", "located", "on", "16q22.1", ",", "due", "to", "CpG", "methylation", "during", "hepatocarcinogenesis", ".", "The", "CpG", "methylation", "status", "of", "primary", "hepatocellular", "carcinomas", "(", "HCCs", ")", "and", "corresponding", "liver", "tissues", "showing", "chronic", "hepatitis", "or", "cirrhosis", ",", "which", "are", "widely", "considered", "to", "be", "precancerous", "conditions", ",", "were", "assessed", "by", "digesting", "DNA", "with", "methylation", "-", "sensitive", "and", "non", "-", "sensitive", "restriction", "enzymes", ".", "CpG", "methylation", "around", "the", "promoter", "region", "of", "the", "E", "-", "cadherin", "gene", "was", "detected", "in", "46", "%", "of", "liver", "tissues", "showing", "chronic", "hepatitis", "or", "cirrhosis", "and", "67", "%", "of", "HCCs", "examined", ".", "Immunohistochemical", "examination", "revealed", "reduced", "E", "-", "cadherin", "expression", "in", "59", "%", "of", "HCCs", "examined", ".", "CpG", "methylation", "around", "the", "promoter", "region", "correlated", "significantly", "with", "reduced", "E", "-", "cadherin", "expression", "in", "HCCs", "(", "p", "<", "0.05", ")", ".", "CpG", "methylation", "around", "the", "promoter", "region", ",", "which", "increases", "during", "the", "progression", "from", "a", "precancerous", "condition", "to", "HCC", ",", "may", "participate", "in", "hepatocarcinogenesis", "through", "reduction", "of", "E", "-", "cadherin", "expression", ",", "resulting", "in", "loss", "of", "intercellular", "adhesiveness", "and", "destruction", "of", "tissue", "morphology", ".", "\n" ]
[ "Protein", "Entity" ]
Thrombin is a Protein, CD69 is a Protein, interleukin 2 is a Protein, Thrombin is a Protein, thrombin is a Protein, thrombin III is a Protein, thrombin is a Protein, thrombin is a Protein, Thrombin is a Protein, thrombin is a Protein, Thrombin is a Protein, thrombin is a Protein, thrombin is a Protein, thrombin is a Protein, thrombin is a Protein, thrombin receptor is a Protein, phytohemagglutinin is a Protein, thrombin receptor is a Protein, thrombin is a Protein, thrombin is a Protein, CD69 is a Protein, interleukin 2 is a Protein, thrombin is a Protein
7510689_task0
Sentence: Thrombin and thrombin receptor agonist peptide induce early events of T cell activation and synergize with TCR cross-linking for CD69 expression and interleukin 2 production. Thrombin stimulation of the T leukemic cell line Jurkat induced a transient increase in [Ca2+]i. Proteolytic activity of the enzyme was required for this effect since diisopropyl fluorophosphate-thrombin failed to increase [Ca2+]i. Furthermore, hirudin and anti-thrombin III inhibited the thrombin-induced [Ca2+]i rise in Jurkat T cells. A synthetic thrombin receptor agonist peptide (TRP) of 7 residues (SFLLRNP) was found to be as effective as thrombin for [Ca2+]i mobilization, and both agonists induced Ca2+ release exclusively from internal stores. Thrombin stimulated tyrosine phosphorylation of several proteins of molecular mass 40, 42, 70, 120, and 130 kDa. There was a good correlation between thrombin-induced tyrosine phosphorylation of the latter three proteins and Ca2+ mobilization. Thrombin and TRP also caused translocation of protein kinase C from the cytosol to the plasma membrane. As a likely consequence of these events, thrombin activated the nuclear factor NF-kB. Several cell lines of hematopoietic origin including the leukemic T cell line HPB.ALL and the erythroleukemic cell line K562 were responsive to thrombin, whereas others such as THP1, a myelomonocytic cell line, and BL2, a Burkitt lymphoma were refractory to thrombin or TRP stimulation. The magnitude of the thrombin response in the different cell types paralleled the expression of the thrombin receptor mRNA. We found that activation of Jurkat T cells by a combination of phytohemagglutinin and phorbol 12-myristate 13-acetate led to a dramatic inhibition of thrombin receptor mRNA expression and to a concomitant loss of the thrombin response. Finally, we demonstrate that thrombin and TRP enhanced CD69 expression and interleukin 2 production induced by T cell receptor cross-linking in both Jurkat T cells and peripheral blood lymphocytes. These findings highlight the role of thrombin as a potential regulator of T lymphocyte activation. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein
[ "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Thrombin and thrombin receptor agonist peptide induce early events of T cell activation and synergize with TCR cross-linking for CD69 expression and interleukin 2 production. Thrombin stimulation of the T leukemic cell line Jurkat induced a transient increase in [Ca2+]i. Proteolytic activity of the enzyme was required for this effect since diisopropyl fluorophosphate-thrombin failed to increase [Ca2+]i. Furthermore, hirudin and anti-thrombin III inhibited the thrombin-induced [Ca2+]i rise in Jurkat T cells. A synthetic thrombin receptor agonist peptide (TRP) of 7 residues (SFLLRNP) was found to be as effective as thrombin for [Ca2+]i mobilization, and both agonists induced Ca2+ release exclusively from internal stores. Thrombin stimulated tyrosine phosphorylation of several proteins of molecular mass 40, 42, 70, 120, and 130 kDa. There was a good correlation between thrombin-induced tyrosine phosphorylation of the latter three proteins and Ca2+ mobilization. Thrombin and TRP also caused translocation of protein kinase C from the cytosol to the plasma membrane. As a likely consequence of these events, thrombin activated the nuclear factor NF-kB. Several cell lines of hematopoietic origin including the leukemic T cell line HPB.ALL and the erythroleukemic cell line K562 were responsive to thrombin, whereas others such as THP1, a myelomonocytic cell line, and BL2, a Burkitt lymphoma were refractory to thrombin or TRP stimulation. The magnitude of the thrombin response in the different cell types paralleled the expression of the thrombin receptor mRNA. We found that activation of Jurkat T cells by a combination of phytohemagglutinin and phorbol 12-myristate 13-acetate led to a dramatic inhibition of thrombin receptor mRNA expression and to a concomitant loss of the thrombin response. Finally, we demonstrate that thrombin and TRP enhanced CD69 expression and interleukin 2 production induced by T cell receptor cross-linking in both Jurkat T cells and peripheral blood lymphocytes. These findings highlight the role of thrombin as a potential regulator of T lymphocyte activation.
[ "Thrombin", "and", "thrombin", "receptor", "agonist", "peptide", "induce", "early", "events", "of", "T", "cell", "activation", "and", "synergize", "with", "TCR", "cross", "-", "linking", "for", "CD69", "expression", "and", "interleukin", "2", "production", ".", "\n", "Thrombin", "stimulation", "of", "the", "T", "leukemic", "cell", "line", "Jurkat", "induced", "a", "transient", "increase", "in", "[", "Ca2+]i", ".", "Proteolytic", "activity", "of", "the", "enzyme", "was", "required", "for", "this", "effect", "since", "diisopropyl", "fluorophosphate", "-", "thrombin", "failed", "to", "increase", "[", "Ca2+]i", ".", "Furthermore", ",", "hirudin", "and", "anti", "-", "thrombin", "III", "inhibited", "the", "thrombin", "-", "induced", "[", "Ca2+]i", "rise", "in", "Jurkat", "T", "cells", ".", "A", "synthetic", "thrombin", "receptor", "agonist", "peptide", "(", "TRP", ")", "of", "7", "residues", "(", "SFLLRNP", ")", "was", "found", "to", "be", "as", "effective", "as", "thrombin", "for", "[", "Ca2+]i", "mobilization", ",", "and", "both", "agonists", "induced", "Ca2", "+", "release", "exclusively", "from", "internal", "stores", ".", "Thrombin", "stimulated", "tyrosine", "phosphorylation", "of", "several", "proteins", "of", "molecular", "mass", "40", ",", "42", ",", "70", ",", "120", ",", "and", "130", "kDa", ".", "There", "was", "a", "good", "correlation", "between", "thrombin", "-", "induced", "tyrosine", "phosphorylation", "of", "the", "latter", "three", "proteins", "and", "Ca2", "+", "mobilization", ".", "Thrombin", "and", "TRP", "also", "caused", "translocation", "of", "protein", "kinase", "C", "from", "the", "cytosol", "to", "the", "plasma", "membrane", ".", "As", "a", "likely", "consequence", "of", "these", "events", ",", "thrombin", "activated", "the", "nuclear", "factor", "NF", "-", "kB.", "Several", "cell", "lines", "of", "hematopoietic", "origin", "including", "the", "leukemic", "T", "cell", "line", "HPB.ALL", "and", "the", "erythroleukemic", "cell", "line", "K562", "were", "responsive", "to", "thrombin", ",", "whereas", "others", "such", "as", "THP1", ",", "a", "myelomonocytic", "cell", "line", ",", "and", "BL2", ",", "a", "Burkitt", "lymphoma", "were", "refractory", "to", "thrombin", "or", "TRP", "stimulation", ".", "The", "magnitude", "of", "the", "thrombin", "response", "in", "the", "different", "cell", "types", "paralleled", "the", "expression", "of", "the", "thrombin", "receptor", "mRNA", ".", "We", "found", "that", "activation", "of", "Jurkat", "T", "cells", "by", "a", "combination", "of", "phytohemagglutinin", "and", "phorbol", "12-myristate", "13-acetate", "led", "to", "a", "dramatic", "inhibition", "of", "thrombin", "receptor", "mRNA", "expression", "and", "to", "a", "concomitant", "loss", "of", "the", "thrombin", "response", ".", "Finally", ",", "we", "demonstrate", "that", "thrombin", "and", "TRP", "enhanced", "CD69", "expression", "and", "interleukin", "2", "production", "induced", "by", "T", "cell", "receptor", "cross", "-", "linking", "in", "both", "Jurkat", "T", "cells", "and", "peripheral", "blood", "lymphocytes", ".", "These", "findings", "highlight", "the", "role", "of", "thrombin", "as", "a", "potential", "regulator", "of", "T", "lymphocyte", "activation", "." ]
[ "Protein" ]
Thrombin is a Protein, CD69 is a Protein, interleukin 2 is a Protein, Thrombin is a Protein, thrombin is a Protein, thrombin III is a Protein, thrombin is a Protein, thrombin is a Protein, Thrombin is a Protein, thrombin is a Protein, Thrombin is a Protein, thrombin is a Protein, thrombin is a Protein, thrombin is a Protein, thrombin is a Protein, thrombin receptor is a Protein, phytohemagglutinin is a Protein, thrombin receptor is a Protein, thrombin is a Protein, thrombin is a Protein, CD69 is a Protein, interleukin 2 is a Protein, thrombin is a Protein
7510689_task1
Sentence: Thrombin and thrombin receptor agonist peptide induce early events of T cell activation and synergize with TCR cross-linking for CD69 expression and interleukin 2 production. Thrombin stimulation of the T leukemic cell line Jurkat induced a transient increase in [Ca2+]i. Proteolytic activity of the enzyme was required for this effect since diisopropyl fluorophosphate-thrombin failed to increase [Ca2+]i. Furthermore, hirudin and anti-thrombin III inhibited the thrombin-induced [Ca2+]i rise in Jurkat T cells. A synthetic thrombin receptor agonist peptide (TRP) of 7 residues (SFLLRNP) was found to be as effective as thrombin for [Ca2+]i mobilization, and both agonists induced Ca2+ release exclusively from internal stores. Thrombin stimulated tyrosine phosphorylation of several proteins of molecular mass 40, 42, 70, 120, and 130 kDa. There was a good correlation between thrombin-induced tyrosine phosphorylation of the latter three proteins and Ca2+ mobilization. Thrombin and TRP also caused translocation of protein kinase C from the cytosol to the plasma membrane. As a likely consequence of these events, thrombin activated the nuclear factor NF-kB. Several cell lines of hematopoietic origin including the leukemic T cell line HPB.ALL and the erythroleukemic cell line K562 were responsive to thrombin, whereas others such as THP1, a myelomonocytic cell line, and BL2, a Burkitt lymphoma were refractory to thrombin or TRP stimulation. The magnitude of the thrombin response in the different cell types paralleled the expression of the thrombin receptor mRNA. We found that activation of Jurkat T cells by a combination of phytohemagglutinin and phorbol 12-myristate 13-acetate led to a dramatic inhibition of thrombin receptor mRNA expression and to a concomitant loss of the thrombin response. Finally, we demonstrate that thrombin and TRP enhanced CD69 expression and interleukin 2 production induced by T cell receptor cross-linking in both Jurkat T cells and peripheral blood lymphocytes. These findings highlight the role of thrombin as a potential regulator of T lymphocyte activation. Instructions: please typing these entity words according to sentence: Thrombin, CD69, interleukin 2, Thrombin, thrombin, thrombin III, thrombin, thrombin, Thrombin, thrombin, Thrombin, thrombin, thrombin, thrombin, thrombin, thrombin receptor, phytohemagglutinin, thrombin receptor, thrombin, thrombin, CD69, interleukin 2, thrombin Options: Protein
[ "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Thrombin and thrombin receptor agonist peptide induce early events of T cell activation and synergize with TCR cross-linking for CD69 expression and interleukin 2 production. Thrombin stimulation of the T leukemic cell line Jurkat induced a transient increase in [Ca2+]i. Proteolytic activity of the enzyme was required for this effect since diisopropyl fluorophosphate-thrombin failed to increase [Ca2+]i. Furthermore, hirudin and anti-thrombin III inhibited the thrombin-induced [Ca2+]i rise in Jurkat T cells. A synthetic thrombin receptor agonist peptide (TRP) of 7 residues (SFLLRNP) was found to be as effective as thrombin for [Ca2+]i mobilization, and both agonists induced Ca2+ release exclusively from internal stores. Thrombin stimulated tyrosine phosphorylation of several proteins of molecular mass 40, 42, 70, 120, and 130 kDa. There was a good correlation between thrombin-induced tyrosine phosphorylation of the latter three proteins and Ca2+ mobilization. Thrombin and TRP also caused translocation of protein kinase C from the cytosol to the plasma membrane. As a likely consequence of these events, thrombin activated the nuclear factor NF-kB. Several cell lines of hematopoietic origin including the leukemic T cell line HPB.ALL and the erythroleukemic cell line K562 were responsive to thrombin, whereas others such as THP1, a myelomonocytic cell line, and BL2, a Burkitt lymphoma were refractory to thrombin or TRP stimulation. The magnitude of the thrombin response in the different cell types paralleled the expression of the thrombin receptor mRNA. We found that activation of Jurkat T cells by a combination of phytohemagglutinin and phorbol 12-myristate 13-acetate led to a dramatic inhibition of thrombin receptor mRNA expression and to a concomitant loss of the thrombin response. Finally, we demonstrate that thrombin and TRP enhanced CD69 expression and interleukin 2 production induced by T cell receptor cross-linking in both Jurkat T cells and peripheral blood lymphocytes. These findings highlight the role of thrombin as a potential regulator of T lymphocyte activation.
[ "Thrombin", "and", "thrombin", "receptor", "agonist", "peptide", "induce", "early", "events", "of", "T", "cell", "activation", "and", "synergize", "with", "TCR", "cross", "-", "linking", "for", "CD69", "expression", "and", "interleukin", "2", "production", ".", "\n", "Thrombin", "stimulation", "of", "the", "T", "leukemic", "cell", "line", "Jurkat", "induced", "a", "transient", "increase", "in", "[", "Ca2+]i", ".", "Proteolytic", "activity", "of", "the", "enzyme", "was", "required", "for", "this", "effect", "since", "diisopropyl", "fluorophosphate", "-", "thrombin", "failed", "to", "increase", "[", "Ca2+]i", ".", "Furthermore", ",", "hirudin", "and", "anti", "-", "thrombin", "III", "inhibited", "the", "thrombin", "-", "induced", "[", "Ca2+]i", "rise", "in", "Jurkat", "T", "cells", ".", "A", "synthetic", "thrombin", "receptor", "agonist", "peptide", "(", "TRP", ")", "of", "7", "residues", "(", "SFLLRNP", ")", "was", "found", "to", "be", "as", "effective", "as", "thrombin", "for", "[", "Ca2+]i", "mobilization", ",", "and", "both", "agonists", "induced", "Ca2", "+", "release", "exclusively", "from", "internal", "stores", ".", "Thrombin", "stimulated", "tyrosine", "phosphorylation", "of", "several", "proteins", "of", "molecular", "mass", "40", ",", "42", ",", "70", ",", "120", ",", "and", "130", "kDa", ".", "There", "was", "a", "good", "correlation", "between", "thrombin", "-", "induced", "tyrosine", "phosphorylation", "of", "the", "latter", "three", "proteins", "and", "Ca2", "+", "mobilization", ".", "Thrombin", "and", "TRP", "also", "caused", "translocation", "of", "protein", "kinase", "C", "from", "the", "cytosol", "to", "the", "plasma", "membrane", ".", "As", "a", "likely", "consequence", "of", "these", "events", ",", "thrombin", "activated", "the", "nuclear", "factor", "NF", "-", "kB.", "Several", "cell", "lines", "of", "hematopoietic", "origin", "including", "the", "leukemic", "T", "cell", "line", "HPB.ALL", "and", "the", "erythroleukemic", "cell", "line", "K562", "were", "responsive", "to", "thrombin", ",", "whereas", "others", "such", "as", "THP1", ",", "a", "myelomonocytic", "cell", "line", ",", "and", "BL2", ",", "a", "Burkitt", "lymphoma", "were", "refractory", "to", "thrombin", "or", "TRP", "stimulation", ".", "The", "magnitude", "of", "the", "thrombin", "response", "in", "the", "different", "cell", "types", "paralleled", "the", "expression", "of", "the", "thrombin", "receptor", "mRNA", ".", "We", "found", "that", "activation", "of", "Jurkat", "T", "cells", "by", "a", "combination", "of", "phytohemagglutinin", "and", "phorbol", "12-myristate", "13-acetate", "led", "to", "a", "dramatic", "inhibition", "of", "thrombin", "receptor", "mRNA", "expression", "and", "to", "a", "concomitant", "loss", "of", "the", "thrombin", "response", ".", "Finally", ",", "we", "demonstrate", "that", "thrombin", "and", "TRP", "enhanced", "CD69", "expression", "and", "interleukin", "2", "production", "induced", "by", "T", "cell", "receptor", "cross", "-", "linking", "in", "both", "Jurkat", "T", "cells", "and", "peripheral", "blood", "lymphocytes", ".", "These", "findings", "highlight", "the", "role", "of", "thrombin", "as", "a", "potential", "regulator", "of", "T", "lymphocyte", "activation", "." ]
[ "Protein" ]
Thrombin, CD69, interleukin 2, Thrombin, thrombin, thrombin III, thrombin, thrombin, Thrombin, thrombin, Thrombin, thrombin, thrombin, thrombin, thrombin, thrombin receptor, phytohemagglutinin, thrombin receptor, thrombin, thrombin, CD69, interleukin 2, thrombin
7510689_task2
Sentence: Thrombin and thrombin receptor agonist peptide induce early events of T cell activation and synergize with TCR cross-linking for CD69 expression and interleukin 2 production. Thrombin stimulation of the T leukemic cell line Jurkat induced a transient increase in [Ca2+]i. Proteolytic activity of the enzyme was required for this effect since diisopropyl fluorophosphate-thrombin failed to increase [Ca2+]i. Furthermore, hirudin and anti-thrombin III inhibited the thrombin-induced [Ca2+]i rise in Jurkat T cells. A synthetic thrombin receptor agonist peptide (TRP) of 7 residues (SFLLRNP) was found to be as effective as thrombin for [Ca2+]i mobilization, and both agonists induced Ca2+ release exclusively from internal stores. Thrombin stimulated tyrosine phosphorylation of several proteins of molecular mass 40, 42, 70, 120, and 130 kDa. There was a good correlation between thrombin-induced tyrosine phosphorylation of the latter three proteins and Ca2+ mobilization. Thrombin and TRP also caused translocation of protein kinase C from the cytosol to the plasma membrane. As a likely consequence of these events, thrombin activated the nuclear factor NF-kB. Several cell lines of hematopoietic origin including the leukemic T cell line HPB.ALL and the erythroleukemic cell line K562 were responsive to thrombin, whereas others such as THP1, a myelomonocytic cell line, and BL2, a Burkitt lymphoma were refractory to thrombin or TRP stimulation. The magnitude of the thrombin response in the different cell types paralleled the expression of the thrombin receptor mRNA. We found that activation of Jurkat T cells by a combination of phytohemagglutinin and phorbol 12-myristate 13-acetate led to a dramatic inhibition of thrombin receptor mRNA expression and to a concomitant loss of the thrombin response. Finally, we demonstrate that thrombin and TRP enhanced CD69 expression and interleukin 2 production induced by T cell receptor cross-linking in both Jurkat T cells and peripheral blood lymphocytes. These findings highlight the role of thrombin as a potential regulator of T lymphocyte activation. Instructions: please extract entity words from the input sentence
[ "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Thrombin and thrombin receptor agonist peptide induce early events of T cell activation and synergize with TCR cross-linking for CD69 expression and interleukin 2 production. Thrombin stimulation of the T leukemic cell line Jurkat induced a transient increase in [Ca2+]i. Proteolytic activity of the enzyme was required for this effect since diisopropyl fluorophosphate-thrombin failed to increase [Ca2+]i. Furthermore, hirudin and anti-thrombin III inhibited the thrombin-induced [Ca2+]i rise in Jurkat T cells. A synthetic thrombin receptor agonist peptide (TRP) of 7 residues (SFLLRNP) was found to be as effective as thrombin for [Ca2+]i mobilization, and both agonists induced Ca2+ release exclusively from internal stores. Thrombin stimulated tyrosine phosphorylation of several proteins of molecular mass 40, 42, 70, 120, and 130 kDa. There was a good correlation between thrombin-induced tyrosine phosphorylation of the latter three proteins and Ca2+ mobilization. Thrombin and TRP also caused translocation of protein kinase C from the cytosol to the plasma membrane. As a likely consequence of these events, thrombin activated the nuclear factor NF-kB. Several cell lines of hematopoietic origin including the leukemic T cell line HPB.ALL and the erythroleukemic cell line K562 were responsive to thrombin, whereas others such as THP1, a myelomonocytic cell line, and BL2, a Burkitt lymphoma were refractory to thrombin or TRP stimulation. The magnitude of the thrombin response in the different cell types paralleled the expression of the thrombin receptor mRNA. We found that activation of Jurkat T cells by a combination of phytohemagglutinin and phorbol 12-myristate 13-acetate led to a dramatic inhibition of thrombin receptor mRNA expression and to a concomitant loss of the thrombin response. Finally, we demonstrate that thrombin and TRP enhanced CD69 expression and interleukin 2 production induced by T cell receptor cross-linking in both Jurkat T cells and peripheral blood lymphocytes. These findings highlight the role of thrombin as a potential regulator of T lymphocyte activation.
[ "Thrombin", "and", "thrombin", "receptor", "agonist", "peptide", "induce", "early", "events", "of", "T", "cell", "activation", "and", "synergize", "with", "TCR", "cross", "-", "linking", "for", "CD69", "expression", "and", "interleukin", "2", "production", ".", "\n", "Thrombin", "stimulation", "of", "the", "T", "leukemic", "cell", "line", "Jurkat", "induced", "a", "transient", "increase", "in", "[", "Ca2+]i", ".", "Proteolytic", "activity", "of", "the", "enzyme", "was", "required", "for", "this", "effect", "since", "diisopropyl", "fluorophosphate", "-", "thrombin", "failed", "to", "increase", "[", "Ca2+]i", ".", "Furthermore", ",", "hirudin", "and", "anti", "-", "thrombin", "III", "inhibited", "the", "thrombin", "-", "induced", "[", "Ca2+]i", "rise", "in", "Jurkat", "T", "cells", ".", "A", "synthetic", "thrombin", "receptor", "agonist", "peptide", "(", "TRP", ")", "of", "7", "residues", "(", "SFLLRNP", ")", "was", "found", "to", "be", "as", "effective", "as", "thrombin", "for", "[", "Ca2+]i", "mobilization", ",", "and", "both", "agonists", "induced", "Ca2", "+", "release", "exclusively", "from", "internal", "stores", ".", "Thrombin", "stimulated", "tyrosine", "phosphorylation", "of", "several", "proteins", "of", "molecular", "mass", "40", ",", "42", ",", "70", ",", "120", ",", "and", "130", "kDa", ".", "There", "was", "a", "good", "correlation", "between", "thrombin", "-", "induced", "tyrosine", "phosphorylation", "of", "the", "latter", "three", "proteins", "and", "Ca2", "+", "mobilization", ".", "Thrombin", "and", "TRP", "also", "caused", "translocation", "of", "protein", "kinase", "C", "from", "the", "cytosol", "to", "the", "plasma", "membrane", ".", "As", "a", "likely", "consequence", "of", "these", "events", ",", "thrombin", "activated", "the", "nuclear", "factor", "NF", "-", "kB.", "Several", "cell", "lines", "of", "hematopoietic", "origin", "including", "the", "leukemic", "T", "cell", "line", "HPB.ALL", "and", "the", "erythroleukemic", "cell", "line", "K562", "were", "responsive", "to", "thrombin", ",", "whereas", "others", "such", "as", "THP1", ",", "a", "myelomonocytic", "cell", "line", ",", "and", "BL2", ",", "a", "Burkitt", "lymphoma", "were", "refractory", "to", "thrombin", "or", "TRP", "stimulation", ".", "The", "magnitude", "of", "the", "thrombin", "response", "in", "the", "different", "cell", "types", "paralleled", "the", "expression", "of", "the", "thrombin", "receptor", "mRNA", ".", "We", "found", "that", "activation", "of", "Jurkat", "T", "cells", "by", "a", "combination", "of", "phytohemagglutinin", "and", "phorbol", "12-myristate", "13-acetate", "led", "to", "a", "dramatic", "inhibition", "of", "thrombin", "receptor", "mRNA", "expression", "and", "to", "a", "concomitant", "loss", "of", "the", "thrombin", "response", ".", "Finally", ",", "we", "demonstrate", "that", "thrombin", "and", "TRP", "enhanced", "CD69", "expression", "and", "interleukin", "2", "production", "induced", "by", "T", "cell", "receptor", "cross", "-", "linking", "in", "both", "Jurkat", "T", "cells", "and", "peripheral", "blood", "lymphocytes", ".", "These", "findings", "highlight", "the", "role", "of", "thrombin", "as", "a", "potential", "regulator", "of", "T", "lymphocyte", "activation", "." ]
[ "Protein" ]
stent is an umlsterm, implantation is an umlsterm, procedures is an umlsterm, stents is an umlsterm, architecture is an umlsterm, surface - morphology is an umlsterm, stent is an umlsterm, objective is an umlsterm, instent is an umlsterm, stent is an umlsterm, thrombosis is an umlsterm, electron microscopy is an umlsterm, stents is an umlsterm, stents is an umlsterm, Stent is an umlsterm, stent is an umlsterm, stent is an umlsterm, balloon dilation is an umlsterm, lead is an umlsterm, stent is an umlsterm, margaine is an umlsterm, stents is an umlsterm, stent is an umlsterm, implantation is an umlsterm, hearts is an umlsterm
ZfuerKardiologie.70860990.eng.abstr_task0
Sentence: Parallel with the increasing number of coronary stent implantation procedures , new or more elaborate coronary stents were introduced into clinical use almost every month in 1996. We have studied the architecture , surface-morphology , and shape-conversion of 16 different coronary stent systems . The objective of our study was to detect possible specific design and surface features which might influence the healing process , instent restenosis , and stent thrombosis . Using electron microscopy we found ultrasmooth surfaces on 5 stents . All other coronary stents revealed individually varying and partly sharp-edged surface irregularities . Video-based morphometry showed covering between 8.3% and 26.4% . Stent shortening after in-vitro expansion ranged from 0% up to 10.5% of the initial stent length . In some stent systems balloon dilation lead to over-expansion of the stent margaine . This over-expansion mounted up to 20% of the balloon diameter and the stents revealed a rather biconcave than homogenous expansion pattern . This phenomenon was also found after postmortal stent implantation in 20 autopsied hearts . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O" ]
Parallel with the increasing number of coronary stent implantation procedures , new or more elaborate coronary stents were introduced into clinical use almost every month in 1996. We have studied the architecture , surface-morphology , and shape-conversion of 16 different coronary stent systems . The objective of our study was to detect possible specific design and surface features which might influence the healing process , instent restenosis , and stent thrombosis . Using electron microscopy we found ultrasmooth surfaces on 5 stents . All other coronary stents revealed individually varying and partly sharp-edged surface irregularities . Video-based morphometry showed covering between 8.3% and 26.4% . Stent shortening after in-vitro expansion ranged from 0% up to 10.5% of the initial stent length . In some stent systems balloon dilation lead to over-expansion of the stent margaine . This over-expansion mounted up to 20% of the balloon diameter and the stents revealed a rather biconcave than homogenous expansion pattern . This phenomenon was also found after postmortal stent implantation in 20 autopsied hearts .
[ "Parallel", "with", "the", "increasing", "number", "of", "coronary", "stent", "implantation", "procedures", ",", "new", "or", "more", "elaborate", "coronary", "stents", "were", "introduced", "into", "clinical", "use", "almost", "every", "month", "in", "1996", ".", "We", "have", "studied", "the", "architecture", ",", "surface", "-", "morphology", ",", "and", "shape", "-", "conversion", "of", "16", "different", "coronary", "stent", "systems", ".", "The", "objective", "of", "our", "study", "was", "to", "detect", "possible", "specific", "design", "and", "surface", "features", "which", "might", "influence", "the", "healing", "process", ",", "instent", "restenosis", ",", "and", "stent", "thrombosis", ".", "Using", "electron", "microscopy", "we", "found", "ultrasmooth", "surfaces", "on", "5", "stents", ".", "All", "other", "coronary", "stents", "revealed", "individually", "varying", "and", "partly", "sharp", "-", "edged", "surface", "irregularities", ".", "Video", "-", "based", "morphometry", "showed", "covering", "between", "8.3", "%", "and", "26.4", "%", ".", "Stent", "shortening", "after", "in", "-", "vitro", "expansion", "ranged", "from", "0", "%", "up", "to", "10.5", "%", "of", "the", "initial", "stent", "length", ".", "In", "some", "stent", "systems", "balloon", "dilation", "lead", "to", "over", "-", "expansion", "of", "the", "stent", "margaine", ".", "This", "over", "-", "expansion", "mounted", "up", "to", "20", "%", "of", "the", "balloon", "diameter", "and", "the", "stents", "revealed", "a", "rather", "biconcave", "than", "homogenous", "expansion", "pattern", ".", "This", "phenomenon", "was", "also", "found", "after", "postmortal", "stent", "implantation", "in", "20", "autopsied", "hearts", "." ]
[ "umlsterm" ]
stent is an umlsterm, implantation is an umlsterm, procedures is an umlsterm, stents is an umlsterm, architecture is an umlsterm, surface - morphology is an umlsterm, stent is an umlsterm, objective is an umlsterm, instent is an umlsterm, stent is an umlsterm, thrombosis is an umlsterm, electron microscopy is an umlsterm, stents is an umlsterm, stents is an umlsterm, Stent is an umlsterm, stent is an umlsterm, stent is an umlsterm, balloon dilation is an umlsterm, lead is an umlsterm, stent is an umlsterm, margaine is an umlsterm, stents is an umlsterm, stent is an umlsterm, implantation is an umlsterm, hearts is an umlsterm
ZfuerKardiologie.70860990.eng.abstr_task1
Sentence: Parallel with the increasing number of coronary stent implantation procedures , new or more elaborate coronary stents were introduced into clinical use almost every month in 1996. We have studied the architecture , surface-morphology , and shape-conversion of 16 different coronary stent systems . The objective of our study was to detect possible specific design and surface features which might influence the healing process , instent restenosis , and stent thrombosis . Using electron microscopy we found ultrasmooth surfaces on 5 stents . All other coronary stents revealed individually varying and partly sharp-edged surface irregularities . Video-based morphometry showed covering between 8.3% and 26.4% . Stent shortening after in-vitro expansion ranged from 0% up to 10.5% of the initial stent length . In some stent systems balloon dilation lead to over-expansion of the stent margaine . This over-expansion mounted up to 20% of the balloon diameter and the stents revealed a rather biconcave than homogenous expansion pattern . This phenomenon was also found after postmortal stent implantation in 20 autopsied hearts . Instructions: please typing these entity words according to sentence: stent, implantation, procedures, stents, architecture, surface - morphology, stent, objective, instent, stent, thrombosis, electron microscopy, stents, stents, Stent, stent, stent, balloon dilation, lead, stent, margaine, stents, stent, implantation, hearts Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O" ]
Parallel with the increasing number of coronary stent implantation procedures , new or more elaborate coronary stents were introduced into clinical use almost every month in 1996. We have studied the architecture , surface-morphology , and shape-conversion of 16 different coronary stent systems . The objective of our study was to detect possible specific design and surface features which might influence the healing process , instent restenosis , and stent thrombosis . Using electron microscopy we found ultrasmooth surfaces on 5 stents . All other coronary stents revealed individually varying and partly sharp-edged surface irregularities . Video-based morphometry showed covering between 8.3% and 26.4% . Stent shortening after in-vitro expansion ranged from 0% up to 10.5% of the initial stent length . In some stent systems balloon dilation lead to over-expansion of the stent margaine . This over-expansion mounted up to 20% of the balloon diameter and the stents revealed a rather biconcave than homogenous expansion pattern . This phenomenon was also found after postmortal stent implantation in 20 autopsied hearts .
[ "Parallel", "with", "the", "increasing", "number", "of", "coronary", "stent", "implantation", "procedures", ",", "new", "or", "more", "elaborate", "coronary", "stents", "were", "introduced", "into", "clinical", "use", "almost", "every", "month", "in", "1996", ".", "We", "have", "studied", "the", "architecture", ",", "surface", "-", "morphology", ",", "and", "shape", "-", "conversion", "of", "16", "different", "coronary", "stent", "systems", ".", "The", "objective", "of", "our", "study", "was", "to", "detect", "possible", "specific", "design", "and", "surface", "features", "which", "might", "influence", "the", "healing", "process", ",", "instent", "restenosis", ",", "and", "stent", "thrombosis", ".", "Using", "electron", "microscopy", "we", "found", "ultrasmooth", "surfaces", "on", "5", "stents", ".", "All", "other", "coronary", "stents", "revealed", "individually", "varying", "and", "partly", "sharp", "-", "edged", "surface", "irregularities", ".", "Video", "-", "based", "morphometry", "showed", "covering", "between", "8.3", "%", "and", "26.4", "%", ".", "Stent", "shortening", "after", "in", "-", "vitro", "expansion", "ranged", "from", "0", "%", "up", "to", "10.5", "%", "of", "the", "initial", "stent", "length", ".", "In", "some", "stent", "systems", "balloon", "dilation", "lead", "to", "over", "-", "expansion", "of", "the", "stent", "margaine", ".", "This", "over", "-", "expansion", "mounted", "up", "to", "20", "%", "of", "the", "balloon", "diameter", "and", "the", "stents", "revealed", "a", "rather", "biconcave", "than", "homogenous", "expansion", "pattern", ".", "This", "phenomenon", "was", "also", "found", "after", "postmortal", "stent", "implantation", "in", "20", "autopsied", "hearts", "." ]
[ "umlsterm" ]
stent, implantation, procedures, stents, architecture, surface - morphology, stent, objective, instent, stent, thrombosis, electron microscopy, stents, stents, Stent, stent, stent, balloon dilation, lead, stent, margaine, stents, stent, implantation, hearts
ZfuerKardiologie.70860990.eng.abstr_task2
Sentence: Parallel with the increasing number of coronary stent implantation procedures , new or more elaborate coronary stents were introduced into clinical use almost every month in 1996. We have studied the architecture , surface-morphology , and shape-conversion of 16 different coronary stent systems . The objective of our study was to detect possible specific design and surface features which might influence the healing process , instent restenosis , and stent thrombosis . Using electron microscopy we found ultrasmooth surfaces on 5 stents . All other coronary stents revealed individually varying and partly sharp-edged surface irregularities . Video-based morphometry showed covering between 8.3% and 26.4% . Stent shortening after in-vitro expansion ranged from 0% up to 10.5% of the initial stent length . In some stent systems balloon dilation lead to over-expansion of the stent margaine . This over-expansion mounted up to 20% of the balloon diameter and the stents revealed a rather biconcave than homogenous expansion pattern . This phenomenon was also found after postmortal stent implantation in 20 autopsied hearts . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O" ]
Parallel with the increasing number of coronary stent implantation procedures , new or more elaborate coronary stents were introduced into clinical use almost every month in 1996. We have studied the architecture , surface-morphology , and shape-conversion of 16 different coronary stent systems . The objective of our study was to detect possible specific design and surface features which might influence the healing process , instent restenosis , and stent thrombosis . Using electron microscopy we found ultrasmooth surfaces on 5 stents . All other coronary stents revealed individually varying and partly sharp-edged surface irregularities . Video-based morphometry showed covering between 8.3% and 26.4% . Stent shortening after in-vitro expansion ranged from 0% up to 10.5% of the initial stent length . In some stent systems balloon dilation lead to over-expansion of the stent margaine . This over-expansion mounted up to 20% of the balloon diameter and the stents revealed a rather biconcave than homogenous expansion pattern . This phenomenon was also found after postmortal stent implantation in 20 autopsied hearts .
[ "Parallel", "with", "the", "increasing", "number", "of", "coronary", "stent", "implantation", "procedures", ",", "new", "or", "more", "elaborate", "coronary", "stents", "were", "introduced", "into", "clinical", "use", "almost", "every", "month", "in", "1996", ".", "We", "have", "studied", "the", "architecture", ",", "surface", "-", "morphology", ",", "and", "shape", "-", "conversion", "of", "16", "different", "coronary", "stent", "systems", ".", "The", "objective", "of", "our", "study", "was", "to", "detect", "possible", "specific", "design", "and", "surface", "features", "which", "might", "influence", "the", "healing", "process", ",", "instent", "restenosis", ",", "and", "stent", "thrombosis", ".", "Using", "electron", "microscopy", "we", "found", "ultrasmooth", "surfaces", "on", "5", "stents", ".", "All", "other", "coronary", "stents", "revealed", "individually", "varying", "and", "partly", "sharp", "-", "edged", "surface", "irregularities", ".", "Video", "-", "based", "morphometry", "showed", "covering", "between", "8.3", "%", "and", "26.4", "%", ".", "Stent", "shortening", "after", "in", "-", "vitro", "expansion", "ranged", "from", "0", "%", "up", "to", "10.5", "%", "of", "the", "initial", "stent", "length", ".", "In", "some", "stent", "systems", "balloon", "dilation", "lead", "to", "over", "-", "expansion", "of", "the", "stent", "margaine", ".", "This", "over", "-", "expansion", "mounted", "up", "to", "20", "%", "of", "the", "balloon", "diameter", "and", "the", "stents", "revealed", "a", "rather", "biconcave", "than", "homogenous", "expansion", "pattern", ".", "This", "phenomenon", "was", "also", "found", "after", "postmortal", "stent", "implantation", "in", "20", "autopsied", "hearts", "." ]
[ "umlsterm" ]
Neutropenie is an umlsterm, Aetiologie is an umlsterm, Leukopenie is an umlsterm, Neutropenie is an umlsterm, Lymphozytose is an umlsterm, Fieber is an umlsterm, Komplikationen is an umlsterm, Schleimhautnekrosen is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Neutropenie is an umlsterm, Mundschleimhaut is an umlsterm
DerHautarzt.90500503.ger.abstr_task0
Sentence: Die zyklische Neutropenie ist eine seltene , familiaer gehaeufte haematologische Erkrankung unklarer Aetiologie . Sie ist durch periodisches Auftreten einer Leukopenie mit relativer Neutropenie und Lymphozytose gekennzeichnet , die 3-7 Tage anhaelt und mit Leistungsminderung , Fieber , septischen Komplikationen und Schleimhautnekrosen einhergeht . Zwischen den Schueben , die bei einem Patienten in streng regelmaessigen Abstaenden von 15-35 Tagen auftreten , tritt eine komplette klinische und laborchemische Remission ein . Wir berichten ueber einen 34jaehrigen Patienten mit zyklischer Neutropenie , die mit ulzeroesen Laesionen der Mundschleimhaut einhergeht . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]
Die zyklische Neutropenie ist eine seltene , familiaer gehaeufte haematologische Erkrankung unklarer Aetiologie . Sie ist durch periodisches Auftreten einer Leukopenie mit relativer Neutropenie und Lymphozytose gekennzeichnet , die 3-7 Tage anhaelt und mit Leistungsminderung , Fieber , septischen Komplikationen und Schleimhautnekrosen einhergeht . Zwischen den Schueben , die bei einem Patienten in streng regelmaessigen Abstaenden von 15-35 Tagen auftreten , tritt eine komplette klinische und laborchemische Remission ein . Wir berichten ueber einen 34jaehrigen Patienten mit zyklischer Neutropenie , die mit ulzeroesen Laesionen der Mundschleimhaut einhergeht .
[ "Die", "zyklische", "Neutropenie", "ist", "eine", "seltene", ",", "familiaer", "gehaeufte", "haematologische", "Erkrankung", "unklarer", "Aetiologie", ".", "Sie", "ist", "durch", "periodisches", "Auftreten", "einer", "Leukopenie", "mit", "relativer", "Neutropenie", "und", "Lymphozytose", "gekennzeichnet", ",", "die", "3", "-", "7", "Tage", "anhaelt", "und", "mit", "Leistungsminderung", ",", "Fieber", ",", "septischen", "Komplikationen", "und", "Schleimhautnekrosen", "einhergeht", ".", "Zwischen", "den", "Schueben", ",", "die", "bei", "einem", "Patienten", "in", "streng", "regelmaessigen", "Abstaenden", "von", "15", "-", "35", "Tagen", "auftreten", ",", "tritt", "eine", "komplette", "klinische", "und", "laborchemische", "Remission", "ein", ".", "Wir", "berichten", "ueber", "einen", "34jaehrigen", "Patienten", "mit", "zyklischer", "Neutropenie", ",", "die", "mit", "ulzeroesen", "Laesionen", "der", "Mundschleimhaut", "einhergeht", "." ]
[ "umlsterm" ]
Neutropenie is an umlsterm, Aetiologie is an umlsterm, Leukopenie is an umlsterm, Neutropenie is an umlsterm, Lymphozytose is an umlsterm, Fieber is an umlsterm, Komplikationen is an umlsterm, Schleimhautnekrosen is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Neutropenie is an umlsterm, Mundschleimhaut is an umlsterm
DerHautarzt.90500503.ger.abstr_task1
Sentence: Die zyklische Neutropenie ist eine seltene , familiaer gehaeufte haematologische Erkrankung unklarer Aetiologie . Sie ist durch periodisches Auftreten einer Leukopenie mit relativer Neutropenie und Lymphozytose gekennzeichnet , die 3-7 Tage anhaelt und mit Leistungsminderung , Fieber , septischen Komplikationen und Schleimhautnekrosen einhergeht . Zwischen den Schueben , die bei einem Patienten in streng regelmaessigen Abstaenden von 15-35 Tagen auftreten , tritt eine komplette klinische und laborchemische Remission ein . Wir berichten ueber einen 34jaehrigen Patienten mit zyklischer Neutropenie , die mit ulzeroesen Laesionen der Mundschleimhaut einhergeht . Instructions: please typing these entity words according to sentence: Neutropenie, Aetiologie, Leukopenie, Neutropenie, Lymphozytose, Fieber, Komplikationen, Schleimhautnekrosen, Patienten, Patienten, Neutropenie, Mundschleimhaut Options: umlsterm
[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]
Die zyklische Neutropenie ist eine seltene , familiaer gehaeufte haematologische Erkrankung unklarer Aetiologie . Sie ist durch periodisches Auftreten einer Leukopenie mit relativer Neutropenie und Lymphozytose gekennzeichnet , die 3-7 Tage anhaelt und mit Leistungsminderung , Fieber , septischen Komplikationen und Schleimhautnekrosen einhergeht . Zwischen den Schueben , die bei einem Patienten in streng regelmaessigen Abstaenden von 15-35 Tagen auftreten , tritt eine komplette klinische und laborchemische Remission ein . Wir berichten ueber einen 34jaehrigen Patienten mit zyklischer Neutropenie , die mit ulzeroesen Laesionen der Mundschleimhaut einhergeht .
[ "Die", "zyklische", "Neutropenie", "ist", "eine", "seltene", ",", "familiaer", "gehaeufte", "haematologische", "Erkrankung", "unklarer", "Aetiologie", ".", "Sie", "ist", "durch", "periodisches", "Auftreten", "einer", "Leukopenie", "mit", "relativer", "Neutropenie", "und", "Lymphozytose", "gekennzeichnet", ",", "die", "3", "-", "7", "Tage", "anhaelt", "und", "mit", "Leistungsminderung", ",", "Fieber", ",", "septischen", "Komplikationen", "und", "Schleimhautnekrosen", "einhergeht", ".", "Zwischen", "den", "Schueben", ",", "die", "bei", "einem", "Patienten", "in", "streng", "regelmaessigen", "Abstaenden", "von", "15", "-", "35", "Tagen", "auftreten", ",", "tritt", "eine", "komplette", "klinische", "und", "laborchemische", "Remission", "ein", ".", "Wir", "berichten", "ueber", "einen", "34jaehrigen", "Patienten", "mit", "zyklischer", "Neutropenie", ",", "die", "mit", "ulzeroesen", "Laesionen", "der", "Mundschleimhaut", "einhergeht", "." ]
[ "umlsterm" ]
Neutropenie, Aetiologie, Leukopenie, Neutropenie, Lymphozytose, Fieber, Komplikationen, Schleimhautnekrosen, Patienten, Patienten, Neutropenie, Mundschleimhaut
DerHautarzt.90500503.ger.abstr_task2
Sentence: Die zyklische Neutropenie ist eine seltene , familiaer gehaeufte haematologische Erkrankung unklarer Aetiologie . Sie ist durch periodisches Auftreten einer Leukopenie mit relativer Neutropenie und Lymphozytose gekennzeichnet , die 3-7 Tage anhaelt und mit Leistungsminderung , Fieber , septischen Komplikationen und Schleimhautnekrosen einhergeht . Zwischen den Schueben , die bei einem Patienten in streng regelmaessigen Abstaenden von 15-35 Tagen auftreten , tritt eine komplette klinische und laborchemische Remission ein . Wir berichten ueber einen 34jaehrigen Patienten mit zyklischer Neutropenie , die mit ulzeroesen Laesionen der Mundschleimhaut einhergeht . Instructions: please extract entity words from the input sentence
[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]
Die zyklische Neutropenie ist eine seltene , familiaer gehaeufte haematologische Erkrankung unklarer Aetiologie . Sie ist durch periodisches Auftreten einer Leukopenie mit relativer Neutropenie und Lymphozytose gekennzeichnet , die 3-7 Tage anhaelt und mit Leistungsminderung , Fieber , septischen Komplikationen und Schleimhautnekrosen einhergeht . Zwischen den Schueben , die bei einem Patienten in streng regelmaessigen Abstaenden von 15-35 Tagen auftreten , tritt eine komplette klinische und laborchemische Remission ein . Wir berichten ueber einen 34jaehrigen Patienten mit zyklischer Neutropenie , die mit ulzeroesen Laesionen der Mundschleimhaut einhergeht .
[ "Die", "zyklische", "Neutropenie", "ist", "eine", "seltene", ",", "familiaer", "gehaeufte", "haematologische", "Erkrankung", "unklarer", "Aetiologie", ".", "Sie", "ist", "durch", "periodisches", "Auftreten", "einer", "Leukopenie", "mit", "relativer", "Neutropenie", "und", "Lymphozytose", "gekennzeichnet", ",", "die", "3", "-", "7", "Tage", "anhaelt", "und", "mit", "Leistungsminderung", ",", "Fieber", ",", "septischen", "Komplikationen", "und", "Schleimhautnekrosen", "einhergeht", ".", "Zwischen", "den", "Schueben", ",", "die", "bei", "einem", "Patienten", "in", "streng", "regelmaessigen", "Abstaenden", "von", "15", "-", "35", "Tagen", "auftreten", ",", "tritt", "eine", "komplette", "klinische", "und", "laborchemische", "Remission", "ein", ".", "Wir", "berichten", "ueber", "einen", "34jaehrigen", "Patienten", "mit", "zyklischer", "Neutropenie", ",", "die", "mit", "ulzeroesen", "Laesionen", "der", "Mundschleimhaut", "einhergeht", "." ]
[ "umlsterm" ]
vascular is a Multi-tissue_structure, blood is a Organism_substance, vascular is a Multi-tissue_structure, blood is a Organism_substance, coronary is a Multi-tissue_structure, heart is a Organ, oral is a Organism_subdivision, oral is a Organism_subdivision, proteinuria is a Organism_substance, oral is a Organism_subdivision, oral is a Organism_subdivision
PMC-2903584-sec-40_task0
Sentence: Treatment for patients with diabetes It is notable that treatment of diabetes has not been directly monitored by OECD indicators, largely due to complexity in data collection. Treatment is tailored for individuals depending on the patient's disease status, and plays a crucial role in diabetes management. Clinical trials have found that a one percentage point reduction in HbA1c levels would reduce micro-vascular complications by 25% to 30% [49,50] and a 10 mmHg reduction in blood pressure would decrease macro- and micro-vascular complications and death rates by 32% [51]. Improved control of blood lipids can reduce risk of coronary heart disease by 39% and risk of death by 43% [52]. RAND's Quality Assessment Tools System offers indicators relating to diabetes treatment [53], and application of these indicators in a national study in the US has provided insight into adherence to recommended treatment regimens. For people with newly diagnosed diabetes 56% received dietary and exercise counselling. In type 2 diabetes patients, use of oral hypoglycaemic agents for those inadequately controlled on dietary therapy was 38% and use of insulin for those inadequately controlled on oral hypoglycaemics was 39%. Fifty-five percent of diabetics were offered an ACE inhibitor within 3 months of the notation of proteinuria unless contraindicated. The AusDiab study reported the treatment pattern among Australian adults with type 2 diabetes [37]. While 32% of diabetes patients were on diet regimen only, 58% used oral hypoglycaemic agents and diet only, and another 10% took insulin. Bailie and colleagues reported pharmaceutical interventions for diabetes patients in remote Aboriginal communities in the Northern Territory [54]. During the 3-years study period, 75-79% of Aboriginal patients took oral hypoglycaemic agents, and 4-7% used insulin. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Organism_subdivision, Organ, Multi-tissue_structure, Organism_substance
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "B-Organ", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_subdivision", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_subdivision", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_subdivision", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_subdivision", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Treatment for patients with diabetes It is notable that treatment of diabetes has not been directly monitored by OECD indicators, largely due to complexity in data collection. Treatment is tailored for individuals depending on the patient's disease status, and plays a crucial role in diabetes management. Clinical trials have found that a one percentage point reduction in HbA1c levels would reduce micro-vascular complications by 25% to 30% [49,50] and a 10 mmHg reduction in blood pressure would decrease macro- and micro-vascular complications and death rates by 32% [51]. Improved control of blood lipids can reduce risk of coronary heart disease by 39% and risk of death by 43% [52]. RAND's Quality Assessment Tools System offers indicators relating to diabetes treatment [53], and application of these indicators in a national study in the US has provided insight into adherence to recommended treatment regimens. For people with newly diagnosed diabetes 56% received dietary and exercise counselling. In type 2 diabetes patients, use of oral hypoglycaemic agents for those inadequately controlled on dietary therapy was 38% and use of insulin for those inadequately controlled on oral hypoglycaemics was 39%. Fifty-five percent of diabetics were offered an ACE inhibitor within 3 months of the notation of proteinuria unless contraindicated. The AusDiab study reported the treatment pattern among Australian adults with type 2 diabetes [37]. While 32% of diabetes patients were on diet regimen only, 58% used oral hypoglycaemic agents and diet only, and another 10% took insulin. Bailie and colleagues reported pharmaceutical interventions for diabetes patients in remote Aboriginal communities in the Northern Territory [54]. During the 3-years study period, 75-79% of Aboriginal patients took oral hypoglycaemic agents, and 4-7% used insulin.
[ "Treatment", "for", "patients", "with", "diabetes", "\n", "It", "is", "notable", "that", "treatment", "of", "diabetes", "has", "not", "been", "directly", "monitored", "by", "OECD", "indicators", ",", "largely", "due", "to", "complexity", "in", "data", "collection", ".", "Treatment", "is", "tailored", "for", "individuals", "depending", "on", "the", "patient", "'s", "disease", "status", ",", "and", "plays", "a", "crucial", "role", "in", "diabetes", "management", ".", "Clinical", "trials", "have", "found", "that", "a", "one", "percentage", "point", "reduction", "in", "HbA1c", "levels", "would", "reduce", "micro", "-", "vascular", "complications", "by", "25", "%", "to", "30", "%", "[", "49,50", "]", "and", "a", "10", "mmHg", "reduction", "in", "blood", "pressure", "would", "decrease", "macro-", "and", "micro", "-", "vascular", "complications", "and", "death", "rates", "by", "32", "%", "[", "51", "]", ".", "Improved", "control", "of", "blood", "lipids", "can", "reduce", "risk", "of", "coronary", "heart", "disease", "by", "39", "%", "and", "risk", "of", "death", "by", "43", "%", "[", "52", "]", ".", "\n", "RAND", "'s", "Quality", "Assessment", "Tools", "System", "offers", "indicators", "relating", "to", "diabetes", "treatment", "[", "53", "]", ",", "and", "application", "of", "these", "indicators", "in", "a", "national", "study", "in", "the", "US", "has", "provided", "insight", "into", "adherence", "to", "recommended", "treatment", "regimens", ".", "For", "people", "with", "newly", "diagnosed", "diabetes", "56", "%", "received", "dietary", "and", "exercise", "counselling", ".", "In", "type", "2", "diabetes", "patients", ",", "use", "of", "oral", "hypoglycaemic", "agents", "for", "those", "inadequately", "controlled", "on", "dietary", "therapy", "was", "38", "%", "and", "use", "of", "insulin", "for", "those", "inadequately", "controlled", "on", "oral", "hypoglycaemics", "was", "39", "%", ".", "Fifty", "-", "five", "percent", "of", "diabetics", "were", "offered", "an", "ACE", "inhibitor", "within", "3", "months", "of", "the", "notation", "of", "proteinuria", "unless", "contraindicated", ".", "\n", "The", "AusDiab", "study", "reported", "the", "treatment", "pattern", "among", "Australian", "adults", "with", "type", "2", "diabetes", "[", "37", "]", ".", "While", "32", "%", "of", "diabetes", "patients", "were", "on", "diet", "regimen", "only", ",", "58", "%", "used", "oral", "hypoglycaemic", "agents", "and", "diet", "only", ",", "and", "another", "10", "%", "took", "insulin", ".", "Bailie", "and", "colleagues", "reported", "pharmaceutical", "interventions", "for", "diabetes", "patients", "in", "remote", "Aboriginal", "communities", "in", "the", "Northern", "Territory", "[", "54", "]", ".", "During", "the", "3-years", "study", "period", ",", "75", "-", "79", "%", "of", "Aboriginal", "patients", "took", "oral", "hypoglycaemic", "agents", ",", "and", "4", "-", "7", "%", "used", "insulin", ".", "\n" ]
[ "Organism_substance", "Multi-tissue_structure", "Organ", "Organism_subdivision" ]
vascular is a Multi-tissue_structure, blood is a Organism_substance, vascular is a Multi-tissue_structure, blood is a Organism_substance, coronary is a Multi-tissue_structure, heart is a Organ, oral is a Organism_subdivision, oral is a Organism_subdivision, proteinuria is a Organism_substance, oral is a Organism_subdivision, oral is a Organism_subdivision
PMC-2903584-sec-40_task1
Sentence: Treatment for patients with diabetes It is notable that treatment of diabetes has not been directly monitored by OECD indicators, largely due to complexity in data collection. Treatment is tailored for individuals depending on the patient's disease status, and plays a crucial role in diabetes management. Clinical trials have found that a one percentage point reduction in HbA1c levels would reduce micro-vascular complications by 25% to 30% [49,50] and a 10 mmHg reduction in blood pressure would decrease macro- and micro-vascular complications and death rates by 32% [51]. Improved control of blood lipids can reduce risk of coronary heart disease by 39% and risk of death by 43% [52]. RAND's Quality Assessment Tools System offers indicators relating to diabetes treatment [53], and application of these indicators in a national study in the US has provided insight into adherence to recommended treatment regimens. For people with newly diagnosed diabetes 56% received dietary and exercise counselling. In type 2 diabetes patients, use of oral hypoglycaemic agents for those inadequately controlled on dietary therapy was 38% and use of insulin for those inadequately controlled on oral hypoglycaemics was 39%. Fifty-five percent of diabetics were offered an ACE inhibitor within 3 months of the notation of proteinuria unless contraindicated. The AusDiab study reported the treatment pattern among Australian adults with type 2 diabetes [37]. While 32% of diabetes patients were on diet regimen only, 58% used oral hypoglycaemic agents and diet only, and another 10% took insulin. Bailie and colleagues reported pharmaceutical interventions for diabetes patients in remote Aboriginal communities in the Northern Territory [54]. During the 3-years study period, 75-79% of Aboriginal patients took oral hypoglycaemic agents, and 4-7% used insulin. Instructions: please typing these entity words according to sentence: vascular, blood, vascular, blood, coronary, heart, oral, oral, proteinuria, oral, oral Options: Organism_subdivision, Organ, Multi-tissue_structure, Organism_substance
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "B-Organ", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_subdivision", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_subdivision", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_subdivision", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_subdivision", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Treatment for patients with diabetes It is notable that treatment of diabetes has not been directly monitored by OECD indicators, largely due to complexity in data collection. Treatment is tailored for individuals depending on the patient's disease status, and plays a crucial role in diabetes management. Clinical trials have found that a one percentage point reduction in HbA1c levels would reduce micro-vascular complications by 25% to 30% [49,50] and a 10 mmHg reduction in blood pressure would decrease macro- and micro-vascular complications and death rates by 32% [51]. Improved control of blood lipids can reduce risk of coronary heart disease by 39% and risk of death by 43% [52]. RAND's Quality Assessment Tools System offers indicators relating to diabetes treatment [53], and application of these indicators in a national study in the US has provided insight into adherence to recommended treatment regimens. For people with newly diagnosed diabetes 56% received dietary and exercise counselling. In type 2 diabetes patients, use of oral hypoglycaemic agents for those inadequately controlled on dietary therapy was 38% and use of insulin for those inadequately controlled on oral hypoglycaemics was 39%. Fifty-five percent of diabetics were offered an ACE inhibitor within 3 months of the notation of proteinuria unless contraindicated. The AusDiab study reported the treatment pattern among Australian adults with type 2 diabetes [37]. While 32% of diabetes patients were on diet regimen only, 58% used oral hypoglycaemic agents and diet only, and another 10% took insulin. Bailie and colleagues reported pharmaceutical interventions for diabetes patients in remote Aboriginal communities in the Northern Territory [54]. During the 3-years study period, 75-79% of Aboriginal patients took oral hypoglycaemic agents, and 4-7% used insulin.
[ "Treatment", "for", "patients", "with", "diabetes", "\n", "It", "is", "notable", "that", "treatment", "of", "diabetes", "has", "not", "been", "directly", "monitored", "by", "OECD", "indicators", ",", "largely", "due", "to", "complexity", "in", "data", "collection", ".", "Treatment", "is", "tailored", "for", "individuals", "depending", "on", "the", "patient", "'s", "disease", "status", ",", "and", "plays", "a", "crucial", "role", "in", "diabetes", "management", ".", "Clinical", "trials", "have", "found", "that", "a", "one", "percentage", "point", "reduction", "in", "HbA1c", "levels", "would", "reduce", "micro", "-", "vascular", "complications", "by", "25", "%", "to", "30", "%", "[", "49,50", "]", "and", "a", "10", "mmHg", "reduction", "in", "blood", "pressure", "would", "decrease", "macro-", "and", "micro", "-", "vascular", "complications", "and", "death", "rates", "by", "32", "%", "[", "51", "]", ".", "Improved", "control", "of", "blood", "lipids", "can", "reduce", "risk", "of", "coronary", "heart", "disease", "by", "39", "%", "and", "risk", "of", "death", "by", "43", "%", "[", "52", "]", ".", "\n", "RAND", "'s", "Quality", "Assessment", "Tools", "System", "offers", "indicators", "relating", "to", "diabetes", "treatment", "[", "53", "]", ",", "and", "application", "of", "these", "indicators", "in", "a", "national", "study", "in", "the", "US", "has", "provided", "insight", "into", "adherence", "to", "recommended", "treatment", "regimens", ".", "For", "people", "with", "newly", "diagnosed", "diabetes", "56", "%", "received", "dietary", "and", "exercise", "counselling", ".", "In", "type", "2", "diabetes", "patients", ",", "use", "of", "oral", "hypoglycaemic", "agents", "for", "those", "inadequately", "controlled", "on", "dietary", "therapy", "was", "38", "%", "and", "use", "of", "insulin", "for", "those", "inadequately", "controlled", "on", "oral", "hypoglycaemics", "was", "39", "%", ".", "Fifty", "-", "five", "percent", "of", "diabetics", "were", "offered", "an", "ACE", "inhibitor", "within", "3", "months", "of", "the", "notation", "of", "proteinuria", "unless", "contraindicated", ".", "\n", "The", "AusDiab", "study", "reported", "the", "treatment", "pattern", "among", "Australian", "adults", "with", "type", "2", "diabetes", "[", "37", "]", ".", "While", "32", "%", "of", "diabetes", "patients", "were", "on", "diet", "regimen", "only", ",", "58", "%", "used", "oral", "hypoglycaemic", "agents", "and", "diet", "only", ",", "and", "another", "10", "%", "took", "insulin", ".", "Bailie", "and", "colleagues", "reported", "pharmaceutical", "interventions", "for", "diabetes", "patients", "in", "remote", "Aboriginal", "communities", "in", "the", "Northern", "Territory", "[", "54", "]", ".", "During", "the", "3-years", "study", "period", ",", "75", "-", "79", "%", "of", "Aboriginal", "patients", "took", "oral", "hypoglycaemic", "agents", ",", "and", "4", "-", "7", "%", "used", "insulin", ".", "\n" ]
[ "Organism_substance", "Multi-tissue_structure", "Organ", "Organism_subdivision" ]
vascular, blood, vascular, blood, coronary, heart, oral, oral, proteinuria, oral, oral
PMC-2903584-sec-40_task2
Sentence: Treatment for patients with diabetes It is notable that treatment of diabetes has not been directly monitored by OECD indicators, largely due to complexity in data collection. Treatment is tailored for individuals depending on the patient's disease status, and plays a crucial role in diabetes management. Clinical trials have found that a one percentage point reduction in HbA1c levels would reduce micro-vascular complications by 25% to 30% [49,50] and a 10 mmHg reduction in blood pressure would decrease macro- and micro-vascular complications and death rates by 32% [51]. Improved control of blood lipids can reduce risk of coronary heart disease by 39% and risk of death by 43% [52]. RAND's Quality Assessment Tools System offers indicators relating to diabetes treatment [53], and application of these indicators in a national study in the US has provided insight into adherence to recommended treatment regimens. For people with newly diagnosed diabetes 56% received dietary and exercise counselling. In type 2 diabetes patients, use of oral hypoglycaemic agents for those inadequately controlled on dietary therapy was 38% and use of insulin for those inadequately controlled on oral hypoglycaemics was 39%. Fifty-five percent of diabetics were offered an ACE inhibitor within 3 months of the notation of proteinuria unless contraindicated. The AusDiab study reported the treatment pattern among Australian adults with type 2 diabetes [37]. While 32% of diabetes patients were on diet regimen only, 58% used oral hypoglycaemic agents and diet only, and another 10% took insulin. Bailie and colleagues reported pharmaceutical interventions for diabetes patients in remote Aboriginal communities in the Northern Territory [54]. During the 3-years study period, 75-79% of Aboriginal patients took oral hypoglycaemic agents, and 4-7% used insulin. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "B-Organ", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_subdivision", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_subdivision", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_subdivision", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_subdivision", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Treatment for patients with diabetes It is notable that treatment of diabetes has not been directly monitored by OECD indicators, largely due to complexity in data collection. Treatment is tailored for individuals depending on the patient's disease status, and plays a crucial role in diabetes management. Clinical trials have found that a one percentage point reduction in HbA1c levels would reduce micro-vascular complications by 25% to 30% [49,50] and a 10 mmHg reduction in blood pressure would decrease macro- and micro-vascular complications and death rates by 32% [51]. Improved control of blood lipids can reduce risk of coronary heart disease by 39% and risk of death by 43% [52]. RAND's Quality Assessment Tools System offers indicators relating to diabetes treatment [53], and application of these indicators in a national study in the US has provided insight into adherence to recommended treatment regimens. For people with newly diagnosed diabetes 56% received dietary and exercise counselling. In type 2 diabetes patients, use of oral hypoglycaemic agents for those inadequately controlled on dietary therapy was 38% and use of insulin for those inadequately controlled on oral hypoglycaemics was 39%. Fifty-five percent of diabetics were offered an ACE inhibitor within 3 months of the notation of proteinuria unless contraindicated. The AusDiab study reported the treatment pattern among Australian adults with type 2 diabetes [37]. While 32% of diabetes patients were on diet regimen only, 58% used oral hypoglycaemic agents and diet only, and another 10% took insulin. Bailie and colleagues reported pharmaceutical interventions for diabetes patients in remote Aboriginal communities in the Northern Territory [54]. During the 3-years study period, 75-79% of Aboriginal patients took oral hypoglycaemic agents, and 4-7% used insulin.
[ "Treatment", "for", "patients", "with", "diabetes", "\n", "It", "is", "notable", "that", "treatment", "of", "diabetes", "has", "not", "been", "directly", "monitored", "by", "OECD", "indicators", ",", "largely", "due", "to", "complexity", "in", "data", "collection", ".", "Treatment", "is", "tailored", "for", "individuals", "depending", "on", "the", "patient", "'s", "disease", "status", ",", "and", "plays", "a", "crucial", "role", "in", "diabetes", "management", ".", "Clinical", "trials", "have", "found", "that", "a", "one", "percentage", "point", "reduction", "in", "HbA1c", "levels", "would", "reduce", "micro", "-", "vascular", "complications", "by", "25", "%", "to", "30", "%", "[", "49,50", "]", "and", "a", "10", "mmHg", "reduction", "in", "blood", "pressure", "would", "decrease", "macro-", "and", "micro", "-", "vascular", "complications", "and", "death", "rates", "by", "32", "%", "[", "51", "]", ".", "Improved", "control", "of", "blood", "lipids", "can", "reduce", "risk", "of", "coronary", "heart", "disease", "by", "39", "%", "and", "risk", "of", "death", "by", "43", "%", "[", "52", "]", ".", "\n", "RAND", "'s", "Quality", "Assessment", "Tools", "System", "offers", "indicators", "relating", "to", "diabetes", "treatment", "[", "53", "]", ",", "and", "application", "of", "these", "indicators", "in", "a", "national", "study", "in", "the", "US", "has", "provided", "insight", "into", "adherence", "to", "recommended", "treatment", "regimens", ".", "For", "people", "with", "newly", "diagnosed", "diabetes", "56", "%", "received", "dietary", "and", "exercise", "counselling", ".", "In", "type", "2", "diabetes", "patients", ",", "use", "of", "oral", "hypoglycaemic", "agents", "for", "those", "inadequately", "controlled", "on", "dietary", "therapy", "was", "38", "%", "and", "use", "of", "insulin", "for", "those", "inadequately", "controlled", "on", "oral", "hypoglycaemics", "was", "39", "%", ".", "Fifty", "-", "five", "percent", "of", "diabetics", "were", "offered", "an", "ACE", "inhibitor", "within", "3", "months", "of", "the", "notation", "of", "proteinuria", "unless", "contraindicated", ".", "\n", "The", "AusDiab", "study", "reported", "the", "treatment", "pattern", "among", "Australian", "adults", "with", "type", "2", "diabetes", "[", "37", "]", ".", "While", "32", "%", "of", "diabetes", "patients", "were", "on", "diet", "regimen", "only", ",", "58", "%", "used", "oral", "hypoglycaemic", "agents", "and", "diet", "only", ",", "and", "another", "10", "%", "took", "insulin", ".", "Bailie", "and", "colleagues", "reported", "pharmaceutical", "interventions", "for", "diabetes", "patients", "in", "remote", "Aboriginal", "communities", "in", "the", "Northern", "Territory", "[", "54", "]", ".", "During", "the", "3-years", "study", "period", ",", "75", "-", "79", "%", "of", "Aboriginal", "patients", "took", "oral", "hypoglycaemic", "agents", ",", "and", "4", "-", "7", "%", "used", "insulin", ".", "\n" ]
[ "Organism_substance", "Multi-tissue_structure", "Organ", "Organism_subdivision" ]
PTCA is an umlsterm, Stenose is an umlsterm, Ballonangioplastie is an umlsterm, PTCA is an umlsterm, PTCA is an umlsterm, Blutfluss is an umlsterm, Belastung is an umlsterm, PTCA is an umlsterm, Kontrollkoronarangiographie is an umlsterm
ZfuerKardiologie.90880955.ger.abstr_task0
Sentence: Wir berichten ueber die PTCA einer hochgradigen Stenose des Ramus interventricularis anterior ( RIVA ) distal der Anastomose eines Arteria-thoracica-interna-Bypasses , wobei die Intervention via des Bypassgefaesses erfolgte . Vor und nach der perkutanen transluminalen Ballonangioplastie ( PTCA ) wurde eine nichtinvasive transkutane Ultraschall-Duplex-Untersuchung des Bypassgefaesses in Ruhe und unter Handgrip-Belastung mit Aufzeichnung der verschiedenen Geschwindigkeitsprofile durchgefuehrt . Es zeigt sich , dass nach der erfolgreichen PTCA die mittlere diastolische Flussgeschwindigkeit , welche ein Mass fuer den koronaren Blutfluss in diesem Bypassgefaess darstellt , sowohl in Ruhe als auch unter Belastung groesser ist als vor der PTCA . Nach sechs Monaten konnte das Gefaess vor der Kontrollkoronarangiographie richtig als offen klassifiziert werden . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]
Wir berichten ueber die PTCA einer hochgradigen Stenose des Ramus interventricularis anterior ( RIVA ) distal der Anastomose eines Arteria-thoracica-interna-Bypasses , wobei die Intervention via des Bypassgefaesses erfolgte . Vor und nach der perkutanen transluminalen Ballonangioplastie ( PTCA ) wurde eine nichtinvasive transkutane Ultraschall-Duplex-Untersuchung des Bypassgefaesses in Ruhe und unter Handgrip-Belastung mit Aufzeichnung der verschiedenen Geschwindigkeitsprofile durchgefuehrt . Es zeigt sich , dass nach der erfolgreichen PTCA die mittlere diastolische Flussgeschwindigkeit , welche ein Mass fuer den koronaren Blutfluss in diesem Bypassgefaess darstellt , sowohl in Ruhe als auch unter Belastung groesser ist als vor der PTCA . Nach sechs Monaten konnte das Gefaess vor der Kontrollkoronarangiographie richtig als offen klassifiziert werden .
[ "Wir", "berichten", "ueber", "die", "PTCA", "einer", "hochgradigen", "Stenose", "des", "Ramus", "interventricularis", "anterior", "(", "RIVA", ")", "distal", "der", "Anastomose", "eines", "Arteria", "-", "thoracica", "-", "interna", "-", "Bypasses", ",", "wobei", "die", "Intervention", "via", "des", "Bypassgefaesses", "erfolgte", ".", "Vor", "und", "nach", "der", "perkutanen", "transluminalen", "Ballonangioplastie", "(", "PTCA", ")", "wurde", "eine", "nichtinvasive", "transkutane", "Ultraschall", "-", "Duplex", "-", "Untersuchung", "des", "Bypassgefaesses", "in", "Ruhe", "und", "unter", "Handgrip", "-", "Belastung", "mit", "Aufzeichnung", "der", "verschiedenen", "Geschwindigkeitsprofile", "durchgefuehrt", ".", "Es", "zeigt", "sich", ",", "dass", "nach", "der", "erfolgreichen", "PTCA", "die", "mittlere", "diastolische", "Flussgeschwindigkeit", ",", "welche", "ein", "Mass", "fuer", "den", "koronaren", "Blutfluss", "in", "diesem", "Bypassgefaess", "darstellt", ",", "sowohl", "in", "Ruhe", "als", "auch", "unter", "Belastung", "groesser", "ist", "als", "vor", "der", "PTCA", ".", "Nach", "sechs", "Monaten", "konnte", "das", "Gefaess", "vor", "der", "Kontrollkoronarangiographie", "richtig", "als", "offen", "klassifiziert", "werden", "." ]
[ "umlsterm" ]
PTCA is an umlsterm, Stenose is an umlsterm, Ballonangioplastie is an umlsterm, PTCA is an umlsterm, PTCA is an umlsterm, Blutfluss is an umlsterm, Belastung is an umlsterm, PTCA is an umlsterm, Kontrollkoronarangiographie is an umlsterm
ZfuerKardiologie.90880955.ger.abstr_task1
Sentence: Wir berichten ueber die PTCA einer hochgradigen Stenose des Ramus interventricularis anterior ( RIVA ) distal der Anastomose eines Arteria-thoracica-interna-Bypasses , wobei die Intervention via des Bypassgefaesses erfolgte . Vor und nach der perkutanen transluminalen Ballonangioplastie ( PTCA ) wurde eine nichtinvasive transkutane Ultraschall-Duplex-Untersuchung des Bypassgefaesses in Ruhe und unter Handgrip-Belastung mit Aufzeichnung der verschiedenen Geschwindigkeitsprofile durchgefuehrt . Es zeigt sich , dass nach der erfolgreichen PTCA die mittlere diastolische Flussgeschwindigkeit , welche ein Mass fuer den koronaren Blutfluss in diesem Bypassgefaess darstellt , sowohl in Ruhe als auch unter Belastung groesser ist als vor der PTCA . Nach sechs Monaten konnte das Gefaess vor der Kontrollkoronarangiographie richtig als offen klassifiziert werden . Instructions: please typing these entity words according to sentence: PTCA, Stenose, Ballonangioplastie, PTCA, PTCA, Blutfluss, Belastung, PTCA, Kontrollkoronarangiographie Options: umlsterm
[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]
Wir berichten ueber die PTCA einer hochgradigen Stenose des Ramus interventricularis anterior ( RIVA ) distal der Anastomose eines Arteria-thoracica-interna-Bypasses , wobei die Intervention via des Bypassgefaesses erfolgte . Vor und nach der perkutanen transluminalen Ballonangioplastie ( PTCA ) wurde eine nichtinvasive transkutane Ultraschall-Duplex-Untersuchung des Bypassgefaesses in Ruhe und unter Handgrip-Belastung mit Aufzeichnung der verschiedenen Geschwindigkeitsprofile durchgefuehrt . Es zeigt sich , dass nach der erfolgreichen PTCA die mittlere diastolische Flussgeschwindigkeit , welche ein Mass fuer den koronaren Blutfluss in diesem Bypassgefaess darstellt , sowohl in Ruhe als auch unter Belastung groesser ist als vor der PTCA . Nach sechs Monaten konnte das Gefaess vor der Kontrollkoronarangiographie richtig als offen klassifiziert werden .
[ "Wir", "berichten", "ueber", "die", "PTCA", "einer", "hochgradigen", "Stenose", "des", "Ramus", "interventricularis", "anterior", "(", "RIVA", ")", "distal", "der", "Anastomose", "eines", "Arteria", "-", "thoracica", "-", "interna", "-", "Bypasses", ",", "wobei", "die", "Intervention", "via", "des", "Bypassgefaesses", "erfolgte", ".", "Vor", "und", "nach", "der", "perkutanen", "transluminalen", "Ballonangioplastie", "(", "PTCA", ")", "wurde", "eine", "nichtinvasive", "transkutane", "Ultraschall", "-", "Duplex", "-", "Untersuchung", "des", "Bypassgefaesses", "in", "Ruhe", "und", "unter", "Handgrip", "-", "Belastung", "mit", "Aufzeichnung", "der", "verschiedenen", "Geschwindigkeitsprofile", "durchgefuehrt", ".", "Es", "zeigt", "sich", ",", "dass", "nach", "der", "erfolgreichen", "PTCA", "die", "mittlere", "diastolische", "Flussgeschwindigkeit", ",", "welche", "ein", "Mass", "fuer", "den", "koronaren", "Blutfluss", "in", "diesem", "Bypassgefaess", "darstellt", ",", "sowohl", "in", "Ruhe", "als", "auch", "unter", "Belastung", "groesser", "ist", "als", "vor", "der", "PTCA", ".", "Nach", "sechs", "Monaten", "konnte", "das", "Gefaess", "vor", "der", "Kontrollkoronarangiographie", "richtig", "als", "offen", "klassifiziert", "werden", "." ]
[ "umlsterm" ]
PTCA, Stenose, Ballonangioplastie, PTCA, PTCA, Blutfluss, Belastung, PTCA, Kontrollkoronarangiographie
ZfuerKardiologie.90880955.ger.abstr_task2
Sentence: Wir berichten ueber die PTCA einer hochgradigen Stenose des Ramus interventricularis anterior ( RIVA ) distal der Anastomose eines Arteria-thoracica-interna-Bypasses , wobei die Intervention via des Bypassgefaesses erfolgte . Vor und nach der perkutanen transluminalen Ballonangioplastie ( PTCA ) wurde eine nichtinvasive transkutane Ultraschall-Duplex-Untersuchung des Bypassgefaesses in Ruhe und unter Handgrip-Belastung mit Aufzeichnung der verschiedenen Geschwindigkeitsprofile durchgefuehrt . Es zeigt sich , dass nach der erfolgreichen PTCA die mittlere diastolische Flussgeschwindigkeit , welche ein Mass fuer den koronaren Blutfluss in diesem Bypassgefaess darstellt , sowohl in Ruhe als auch unter Belastung groesser ist als vor der PTCA . Nach sechs Monaten konnte das Gefaess vor der Kontrollkoronarangiographie richtig als offen klassifiziert werden . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]
Wir berichten ueber die PTCA einer hochgradigen Stenose des Ramus interventricularis anterior ( RIVA ) distal der Anastomose eines Arteria-thoracica-interna-Bypasses , wobei die Intervention via des Bypassgefaesses erfolgte . Vor und nach der perkutanen transluminalen Ballonangioplastie ( PTCA ) wurde eine nichtinvasive transkutane Ultraschall-Duplex-Untersuchung des Bypassgefaesses in Ruhe und unter Handgrip-Belastung mit Aufzeichnung der verschiedenen Geschwindigkeitsprofile durchgefuehrt . Es zeigt sich , dass nach der erfolgreichen PTCA die mittlere diastolische Flussgeschwindigkeit , welche ein Mass fuer den koronaren Blutfluss in diesem Bypassgefaess darstellt , sowohl in Ruhe als auch unter Belastung groesser ist als vor der PTCA . Nach sechs Monaten konnte das Gefaess vor der Kontrollkoronarangiographie richtig als offen klassifiziert werden .
[ "Wir", "berichten", "ueber", "die", "PTCA", "einer", "hochgradigen", "Stenose", "des", "Ramus", "interventricularis", "anterior", "(", "RIVA", ")", "distal", "der", "Anastomose", "eines", "Arteria", "-", "thoracica", "-", "interna", "-", "Bypasses", ",", "wobei", "die", "Intervention", "via", "des", "Bypassgefaesses", "erfolgte", ".", "Vor", "und", "nach", "der", "perkutanen", "transluminalen", "Ballonangioplastie", "(", "PTCA", ")", "wurde", "eine", "nichtinvasive", "transkutane", "Ultraschall", "-", "Duplex", "-", "Untersuchung", "des", "Bypassgefaesses", "in", "Ruhe", "und", "unter", "Handgrip", "-", "Belastung", "mit", "Aufzeichnung", "der", "verschiedenen", "Geschwindigkeitsprofile", "durchgefuehrt", ".", "Es", "zeigt", "sich", ",", "dass", "nach", "der", "erfolgreichen", "PTCA", "die", "mittlere", "diastolische", "Flussgeschwindigkeit", ",", "welche", "ein", "Mass", "fuer", "den", "koronaren", "Blutfluss", "in", "diesem", "Bypassgefaess", "darstellt", ",", "sowohl", "in", "Ruhe", "als", "auch", "unter", "Belastung", "groesser", "ist", "als", "vor", "der", "PTCA", ".", "Nach", "sechs", "Monaten", "konnte", "das", "Gefaess", "vor", "der", "Kontrollkoronarangiographie", "richtig", "als", "offen", "klassifiziert", "werden", "." ]
[ "umlsterm" ]
CMV is an umlsterm, transmission is an umlsterm, blood is an umlsterm, infants is an umlsterm, CMV infections is an umlsterm, infants is an umlsterm, CMV infection is an umlsterm, breast milk is an umlsterm, Methods is an umlsterm, PCR is an umlsterm, viral is an umlsterm, cultures is an umlsterm, Criteria is an umlsterm, transmission is an umlsterm, CMV is an umlsterm, breast milk is an umlsterm, infants is an umlsterm, congenital is an umlsterm, infection is an umlsterm, donor 's is an umlsterm, breast milk is an umlsterm, CMV is an umlsterm, blood transfusions is an umlsterm, infants is an umlsterm, symptoms is an umlsterm, CMV infection is an umlsterm, sepsis - like is an umlsterm, symptoms is an umlsterm, apnoea is an umlsterm, bradycardia is an umlsterm, thrombocytopenia is an umlsterm, neutropenia is an umlsterm, Infection is an umlsterm, age is an umlsterm, infants is an umlsterm, incidence is an umlsterm, CMV infections is an umlsterm, infants is an umlsterm, breast milk is an umlsterm, transmission is an umlsterm, CMV infection is an umlsterm
MonatsschriftKinderheilkunde.71450619.eng.abstr_task0
Sentence: Background : After elimination of CMV transmission by blood products we have still observed preterm infants with postnatally acquired CMV infections . 16 preterm infants with CMV infection by breast milk were identified . Methods : CMV-DNA PCR and viral cultures . Criteria of transmission : CMV in breast milk ; viruria in preterm infants ; exclusions of congenital infection , of donor's breast milk and of CMV seropositive blood transfusions . Results : 8 infants ( 50 % ) had marked symptoms of an acute CMV infection : sepsis-like symptoms with apnoea and bradycardia ( 4 ) , cholestasis/hepatitis ( 4/2 ) , thrombocytopenia ( 6 ) , neutropenia ( 5 ) . Infection in the latter group occurred at an median postnatal age of 46 vs. 62 days in asymptomatic infected infants ( p 0.01 ) . Conclusion : There is a high incidence of symptomatic CMV infections in preterm infants due to breast milk transmission . An early postnatal CMV infection seems to be associated with a symptomatic clinical course . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Background : After elimination of CMV transmission by blood products we have still observed preterm infants with postnatally acquired CMV infections . 16 preterm infants with CMV infection by breast milk were identified . Methods : CMV-DNA PCR and viral cultures . Criteria of transmission : CMV in breast milk ; viruria in preterm infants ; exclusions of congenital infection , of donor's breast milk and of CMV seropositive blood transfusions . Results : 8 infants ( 50 % ) had marked symptoms of an acute CMV infection : sepsis-like symptoms with apnoea and bradycardia ( 4 ) , cholestasis/hepatitis ( 4/2 ) , thrombocytopenia ( 6 ) , neutropenia ( 5 ) . Infection in the latter group occurred at an median postnatal age of 46 vs. 62 days in asymptomatic infected infants ( p 0.01 ) . Conclusion : There is a high incidence of symptomatic CMV infections in preterm infants due to breast milk transmission . An early postnatal CMV infection seems to be associated with a symptomatic clinical course .
[ "Background", ":", "After", "elimination", "of", "CMV", "transmission", "by", "blood", "products", "we", "have", "still", "observed", "preterm", "infants", "with", "postnatally", "acquired", "CMV", "infections", ".", "16", "preterm", "infants", "with", "CMV", "infection", "by", "breast", "milk", "were", "identified", ".", "Methods", ":", "CMV", "-", "DNA", "PCR", "and", "viral", "cultures", ".", "Criteria", "of", "transmission", ":", "CMV", "in", "breast", "milk", ";", "viruria", "in", "preterm", "infants", ";", "exclusions", "of", "congenital", "infection", ",", "of", "donor", "'s", "breast", "milk", "and", "of", "CMV", "seropositive", "blood", "transfusions", ".", "Results", ":", "8", "infants", "(", "50", "%", ")", "had", "marked", "symptoms", "of", "an", "acute", "CMV", "infection", ":", "sepsis", "-", "like", "symptoms", "with", "apnoea", "and", "bradycardia", "(", "4", ")", ",", "cholestasis", "/", "hepatitis", "(", "4/2", ")", ",", "thrombocytopenia", "(", "6", ")", ",", "neutropenia", "(", "5", ")", ".", "Infection", "in", "the", "latter", "group", "occurred", "at", "an", "median", "postnatal", "age", "of", "46", "vs", ".", "62", "days", "in", "asymptomatic", "infected", "infants", "(", "p", "0.01", ")", ".", "Conclusion", ":", "There", "is", "a", "high", "incidence", "of", "symptomatic", "CMV", "infections", "in", "preterm", "infants", "due", "to", "breast", "milk", "transmission", ".", "An", "early", "postnatal", "CMV", "infection", "seems", "to", "be", "associated", "with", "a", "symptomatic", "clinical", "course", "." ]
[ "umlsterm" ]
CMV is an umlsterm, transmission is an umlsterm, blood is an umlsterm, infants is an umlsterm, CMV infections is an umlsterm, infants is an umlsterm, CMV infection is an umlsterm, breast milk is an umlsterm, Methods is an umlsterm, PCR is an umlsterm, viral is an umlsterm, cultures is an umlsterm, Criteria is an umlsterm, transmission is an umlsterm, CMV is an umlsterm, breast milk is an umlsterm, infants is an umlsterm, congenital is an umlsterm, infection is an umlsterm, donor 's is an umlsterm, breast milk is an umlsterm, CMV is an umlsterm, blood transfusions is an umlsterm, infants is an umlsterm, symptoms is an umlsterm, CMV infection is an umlsterm, sepsis - like is an umlsterm, symptoms is an umlsterm, apnoea is an umlsterm, bradycardia is an umlsterm, thrombocytopenia is an umlsterm, neutropenia is an umlsterm, Infection is an umlsterm, age is an umlsterm, infants is an umlsterm, incidence is an umlsterm, CMV infections is an umlsterm, infants is an umlsterm, breast milk is an umlsterm, transmission is an umlsterm, CMV infection is an umlsterm
MonatsschriftKinderheilkunde.71450619.eng.abstr_task1
Sentence: Background : After elimination of CMV transmission by blood products we have still observed preterm infants with postnatally acquired CMV infections . 16 preterm infants with CMV infection by breast milk were identified . Methods : CMV-DNA PCR and viral cultures . Criteria of transmission : CMV in breast milk ; viruria in preterm infants ; exclusions of congenital infection , of donor's breast milk and of CMV seropositive blood transfusions . Results : 8 infants ( 50 % ) had marked symptoms of an acute CMV infection : sepsis-like symptoms with apnoea and bradycardia ( 4 ) , cholestasis/hepatitis ( 4/2 ) , thrombocytopenia ( 6 ) , neutropenia ( 5 ) . Infection in the latter group occurred at an median postnatal age of 46 vs. 62 days in asymptomatic infected infants ( p 0.01 ) . Conclusion : There is a high incidence of symptomatic CMV infections in preterm infants due to breast milk transmission . An early postnatal CMV infection seems to be associated with a symptomatic clinical course . Instructions: please typing these entity words according to sentence: CMV, transmission, blood, infants, CMV infections, infants, CMV infection, breast milk, Methods, PCR, viral, cultures, Criteria, transmission, CMV, breast milk, infants, congenital, infection, donor 's, breast milk, CMV, blood transfusions, infants, symptoms, CMV infection, sepsis - like, symptoms, apnoea, bradycardia, thrombocytopenia, neutropenia, Infection, age, infants, incidence, CMV infections, infants, breast milk, transmission, CMV infection Options: umlsterm
[ "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Background : After elimination of CMV transmission by blood products we have still observed preterm infants with postnatally acquired CMV infections . 16 preterm infants with CMV infection by breast milk were identified . Methods : CMV-DNA PCR and viral cultures . Criteria of transmission : CMV in breast milk ; viruria in preterm infants ; exclusions of congenital infection , of donor's breast milk and of CMV seropositive blood transfusions . Results : 8 infants ( 50 % ) had marked symptoms of an acute CMV infection : sepsis-like symptoms with apnoea and bradycardia ( 4 ) , cholestasis/hepatitis ( 4/2 ) , thrombocytopenia ( 6 ) , neutropenia ( 5 ) . Infection in the latter group occurred at an median postnatal age of 46 vs. 62 days in asymptomatic infected infants ( p 0.01 ) . Conclusion : There is a high incidence of symptomatic CMV infections in preterm infants due to breast milk transmission . An early postnatal CMV infection seems to be associated with a symptomatic clinical course .
[ "Background", ":", "After", "elimination", "of", "CMV", "transmission", "by", "blood", "products", "we", "have", "still", "observed", "preterm", "infants", "with", "postnatally", "acquired", "CMV", "infections", ".", "16", "preterm", "infants", "with", "CMV", "infection", "by", "breast", "milk", "were", "identified", ".", "Methods", ":", "CMV", "-", "DNA", "PCR", "and", "viral", "cultures", ".", "Criteria", "of", "transmission", ":", "CMV", "in", "breast", "milk", ";", "viruria", "in", "preterm", "infants", ";", "exclusions", "of", "congenital", "infection", ",", "of", "donor", "'s", "breast", "milk", "and", "of", "CMV", "seropositive", "blood", "transfusions", ".", "Results", ":", "8", "infants", "(", "50", "%", ")", "had", "marked", "symptoms", "of", "an", "acute", "CMV", "infection", ":", "sepsis", "-", "like", "symptoms", "with", "apnoea", "and", "bradycardia", "(", "4", ")", ",", "cholestasis", "/", "hepatitis", "(", "4/2", ")", ",", "thrombocytopenia", "(", "6", ")", ",", "neutropenia", "(", "5", ")", ".", "Infection", "in", "the", "latter", "group", "occurred", "at", "an", "median", "postnatal", "age", "of", "46", "vs", ".", "62", "days", "in", "asymptomatic", "infected", "infants", "(", "p", "0.01", ")", ".", "Conclusion", ":", "There", "is", "a", "high", "incidence", "of", "symptomatic", "CMV", "infections", "in", "preterm", "infants", "due", "to", "breast", "milk", "transmission", ".", "An", "early", "postnatal", "CMV", "infection", "seems", "to", "be", "associated", "with", "a", "symptomatic", "clinical", "course", "." ]
[ "umlsterm" ]
CMV, transmission, blood, infants, CMV infections, infants, CMV infection, breast milk, Methods, PCR, viral, cultures, Criteria, transmission, CMV, breast milk, infants, congenital, infection, donor 's, breast milk, CMV, blood transfusions, infants, symptoms, CMV infection, sepsis - like, symptoms, apnoea, bradycardia, thrombocytopenia, neutropenia, Infection, age, infants, incidence, CMV infections, infants, breast milk, transmission, CMV infection
MonatsschriftKinderheilkunde.71450619.eng.abstr_task2
Sentence: Background : After elimination of CMV transmission by blood products we have still observed preterm infants with postnatally acquired CMV infections . 16 preterm infants with CMV infection by breast milk were identified . Methods : CMV-DNA PCR and viral cultures . Criteria of transmission : CMV in breast milk ; viruria in preterm infants ; exclusions of congenital infection , of donor's breast milk and of CMV seropositive blood transfusions . Results : 8 infants ( 50 % ) had marked symptoms of an acute CMV infection : sepsis-like symptoms with apnoea and bradycardia ( 4 ) , cholestasis/hepatitis ( 4/2 ) , thrombocytopenia ( 6 ) , neutropenia ( 5 ) . Infection in the latter group occurred at an median postnatal age of 46 vs. 62 days in asymptomatic infected infants ( p 0.01 ) . Conclusion : There is a high incidence of symptomatic CMV infections in preterm infants due to breast milk transmission . An early postnatal CMV infection seems to be associated with a symptomatic clinical course . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Background : After elimination of CMV transmission by blood products we have still observed preterm infants with postnatally acquired CMV infections . 16 preterm infants with CMV infection by breast milk were identified . Methods : CMV-DNA PCR and viral cultures . Criteria of transmission : CMV in breast milk ; viruria in preterm infants ; exclusions of congenital infection , of donor's breast milk and of CMV seropositive blood transfusions . Results : 8 infants ( 50 % ) had marked symptoms of an acute CMV infection : sepsis-like symptoms with apnoea and bradycardia ( 4 ) , cholestasis/hepatitis ( 4/2 ) , thrombocytopenia ( 6 ) , neutropenia ( 5 ) . Infection in the latter group occurred at an median postnatal age of 46 vs. 62 days in asymptomatic infected infants ( p 0.01 ) . Conclusion : There is a high incidence of symptomatic CMV infections in preterm infants due to breast milk transmission . An early postnatal CMV infection seems to be associated with a symptomatic clinical course .
[ "Background", ":", "After", "elimination", "of", "CMV", "transmission", "by", "blood", "products", "we", "have", "still", "observed", "preterm", "infants", "with", "postnatally", "acquired", "CMV", "infections", ".", "16", "preterm", "infants", "with", "CMV", "infection", "by", "breast", "milk", "were", "identified", ".", "Methods", ":", "CMV", "-", "DNA", "PCR", "and", "viral", "cultures", ".", "Criteria", "of", "transmission", ":", "CMV", "in", "breast", "milk", ";", "viruria", "in", "preterm", "infants", ";", "exclusions", "of", "congenital", "infection", ",", "of", "donor", "'s", "breast", "milk", "and", "of", "CMV", "seropositive", "blood", "transfusions", ".", "Results", ":", "8", "infants", "(", "50", "%", ")", "had", "marked", "symptoms", "of", "an", "acute", "CMV", "infection", ":", "sepsis", "-", "like", "symptoms", "with", "apnoea", "and", "bradycardia", "(", "4", ")", ",", "cholestasis", "/", "hepatitis", "(", "4/2", ")", ",", "thrombocytopenia", "(", "6", ")", ",", "neutropenia", "(", "5", ")", ".", "Infection", "in", "the", "latter", "group", "occurred", "at", "an", "median", "postnatal", "age", "of", "46", "vs", ".", "62", "days", "in", "asymptomatic", "infected", "infants", "(", "p", "0.01", ")", ".", "Conclusion", ":", "There", "is", "a", "high", "incidence", "of", "symptomatic", "CMV", "infections", "in", "preterm", "infants", "due", "to", "breast", "milk", "transmission", ".", "An", "early", "postnatal", "CMV", "infection", "seems", "to", "be", "associated", "with", "a", "symptomatic", "clinical", "course", "." ]
[ "umlsterm" ]
Aricept is a BRAND
Donepezil_ddi_task0
Sentence: Drugs that inhibit or Induce CYP 2D6 and CYP 3A4 may affect the concentration on Aricept. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: BRAND
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O" ]
Drugs that inhibit or Induce CYP 2D6 and CYP 3A4 may affect the concentration on Aricept.
[ "Drugs", "that", "inhibit", "or", "Induce", "CYP", "2D6", "and", "CYP", "3A4", "may", "affect", "the", "concentration", "on", "Aricept", "." ]
[ "BRAND" ]
Aricept is a BRAND
Donepezil_ddi_task1
Sentence: Drugs that inhibit or Induce CYP 2D6 and CYP 3A4 may affect the concentration on Aricept. Instructions: please typing these entity words according to sentence: Aricept Options: BRAND
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O" ]
Drugs that inhibit or Induce CYP 2D6 and CYP 3A4 may affect the concentration on Aricept.
[ "Drugs", "that", "inhibit", "or", "Induce", "CYP", "2D6", "and", "CYP", "3A4", "may", "affect", "the", "concentration", "on", "Aricept", "." ]
[ "BRAND" ]
Aricept
Donepezil_ddi_task2
Sentence: Drugs that inhibit or Induce CYP 2D6 and CYP 3A4 may affect the concentration on Aricept. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O" ]
Drugs that inhibit or Induce CYP 2D6 and CYP 3A4 may affect the concentration on Aricept.
[ "Drugs", "that", "inhibit", "or", "Induce", "CYP", "2D6", "and", "CYP", "3A4", "may", "affect", "the", "concentration", "on", "Aricept", "." ]
[ "BRAND" ]
Arbeit is an umlsterm, Chirurgie is an umlsterm, Anaesthesie is an umlsterm, engen is an umlsterm, Diagnostik is an umlsterm, Therapie is an umlsterm, Aufwachraum is an umlsterm, Chirurgiepersonals is an umlsterm, Schmerztherapie is an umlsterm, Medizin is an umlsterm, Selbstbestimmung is an umlsterm
DerChirurg.90700010.ger.abstr_task0
Sentence: Zusammenfassung . In der Kooperationsvielfalt der taeglichen Arbeit stellt die Zusammenarbeit zwischen Chirurgie und Anaesthesie wegen der engen Verflechtung beider Disziplinen eine Besonderheit dar . Sie kann durch Beachtung folgender Punkte rationalisiert und erleichtert werden : Klare Zuordnung von Kompetenzen , Beachtung des Vertrauensgrundsatzes , Einbeziehung des Anaesthesisten in Aufnahmeuntersuchung , Vorgabe zur bedarfsorientierten praeoperativen Diagnostik , Absprache ueber notwendige praeoperative Therapie , gemeinsame Indikationssprechstunde fuer ambulante Operationen , Aufwachraum fuer 24 Std , Unterweisung des Chirurgiepersonals in spezieller Schmerztherapie , Verfuegbarkeit kompetenter und kooperationsfaehiger Partner , Teilhabe des Chirurgen an der perioperativen Medizin und kein Verzicht auf organisatorische und strukturelle Selbstbestimmung . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]
Zusammenfassung . In der Kooperationsvielfalt der taeglichen Arbeit stellt die Zusammenarbeit zwischen Chirurgie und Anaesthesie wegen der engen Verflechtung beider Disziplinen eine Besonderheit dar . Sie kann durch Beachtung folgender Punkte rationalisiert und erleichtert werden : Klare Zuordnung von Kompetenzen , Beachtung des Vertrauensgrundsatzes , Einbeziehung des Anaesthesisten in Aufnahmeuntersuchung , Vorgabe zur bedarfsorientierten praeoperativen Diagnostik , Absprache ueber notwendige praeoperative Therapie , gemeinsame Indikationssprechstunde fuer ambulante Operationen , Aufwachraum fuer 24 Std , Unterweisung des Chirurgiepersonals in spezieller Schmerztherapie , Verfuegbarkeit kompetenter und kooperationsfaehiger Partner , Teilhabe des Chirurgen an der perioperativen Medizin und kein Verzicht auf organisatorische und strukturelle Selbstbestimmung .
[ "Zusammenfassung", ".", "In", "der", "Kooperationsvielfalt", "der", "taeglichen", "Arbeit", "stellt", "die", "Zusammenarbeit", "zwischen", "Chirurgie", "und", "Anaesthesie", "wegen", "der", "engen", "Verflechtung", "beider", "Disziplinen", "eine", "Besonderheit", "dar", ".", "Sie", "kann", "durch", "Beachtung", "folgender", "Punkte", "rationalisiert", "und", "erleichtert", "werden", ":", "Klare", "Zuordnung", "von", "Kompetenzen", ",", "Beachtung", "des", "Vertrauensgrundsatzes", ",", "Einbeziehung", "des", "Anaesthesisten", "in", "Aufnahmeuntersuchung", ",", "Vorgabe", "zur", "bedarfsorientierten", "praeoperativen", "Diagnostik", ",", "Absprache", "ueber", "notwendige", "praeoperative", "Therapie", ",", "gemeinsame", "Indikationssprechstunde", "fuer", "ambulante", "Operationen", ",", "Aufwachraum", "fuer", "24", "Std", ",", "Unterweisung", "des", "Chirurgiepersonals", "in", "spezieller", "Schmerztherapie", ",", "Verfuegbarkeit", "kompetenter", "und", "kooperationsfaehiger", "Partner", ",", "Teilhabe", "des", "Chirurgen", "an", "der", "perioperativen", "Medizin", "und", "kein", "Verzicht", "auf", "organisatorische", "und", "strukturelle", "Selbstbestimmung", "." ]
[ "umlsterm" ]
Arbeit is an umlsterm, Chirurgie is an umlsterm, Anaesthesie is an umlsterm, engen is an umlsterm, Diagnostik is an umlsterm, Therapie is an umlsterm, Aufwachraum is an umlsterm, Chirurgiepersonals is an umlsterm, Schmerztherapie is an umlsterm, Medizin is an umlsterm, Selbstbestimmung is an umlsterm
DerChirurg.90700010.ger.abstr_task1
Sentence: Zusammenfassung . In der Kooperationsvielfalt der taeglichen Arbeit stellt die Zusammenarbeit zwischen Chirurgie und Anaesthesie wegen der engen Verflechtung beider Disziplinen eine Besonderheit dar . Sie kann durch Beachtung folgender Punkte rationalisiert und erleichtert werden : Klare Zuordnung von Kompetenzen , Beachtung des Vertrauensgrundsatzes , Einbeziehung des Anaesthesisten in Aufnahmeuntersuchung , Vorgabe zur bedarfsorientierten praeoperativen Diagnostik , Absprache ueber notwendige praeoperative Therapie , gemeinsame Indikationssprechstunde fuer ambulante Operationen , Aufwachraum fuer 24 Std , Unterweisung des Chirurgiepersonals in spezieller Schmerztherapie , Verfuegbarkeit kompetenter und kooperationsfaehiger Partner , Teilhabe des Chirurgen an der perioperativen Medizin und kein Verzicht auf organisatorische und strukturelle Selbstbestimmung . Instructions: please typing these entity words according to sentence: Arbeit, Chirurgie, Anaesthesie, engen, Diagnostik, Therapie, Aufwachraum, Chirurgiepersonals, Schmerztherapie, Medizin, Selbstbestimmung Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]
Zusammenfassung . In der Kooperationsvielfalt der taeglichen Arbeit stellt die Zusammenarbeit zwischen Chirurgie und Anaesthesie wegen der engen Verflechtung beider Disziplinen eine Besonderheit dar . Sie kann durch Beachtung folgender Punkte rationalisiert und erleichtert werden : Klare Zuordnung von Kompetenzen , Beachtung des Vertrauensgrundsatzes , Einbeziehung des Anaesthesisten in Aufnahmeuntersuchung , Vorgabe zur bedarfsorientierten praeoperativen Diagnostik , Absprache ueber notwendige praeoperative Therapie , gemeinsame Indikationssprechstunde fuer ambulante Operationen , Aufwachraum fuer 24 Std , Unterweisung des Chirurgiepersonals in spezieller Schmerztherapie , Verfuegbarkeit kompetenter und kooperationsfaehiger Partner , Teilhabe des Chirurgen an der perioperativen Medizin und kein Verzicht auf organisatorische und strukturelle Selbstbestimmung .
[ "Zusammenfassung", ".", "In", "der", "Kooperationsvielfalt", "der", "taeglichen", "Arbeit", "stellt", "die", "Zusammenarbeit", "zwischen", "Chirurgie", "und", "Anaesthesie", "wegen", "der", "engen", "Verflechtung", "beider", "Disziplinen", "eine", "Besonderheit", "dar", ".", "Sie", "kann", "durch", "Beachtung", "folgender", "Punkte", "rationalisiert", "und", "erleichtert", "werden", ":", "Klare", "Zuordnung", "von", "Kompetenzen", ",", "Beachtung", "des", "Vertrauensgrundsatzes", ",", "Einbeziehung", "des", "Anaesthesisten", "in", "Aufnahmeuntersuchung", ",", "Vorgabe", "zur", "bedarfsorientierten", "praeoperativen", "Diagnostik", ",", "Absprache", "ueber", "notwendige", "praeoperative", "Therapie", ",", "gemeinsame", "Indikationssprechstunde", "fuer", "ambulante", "Operationen", ",", "Aufwachraum", "fuer", "24", "Std", ",", "Unterweisung", "des", "Chirurgiepersonals", "in", "spezieller", "Schmerztherapie", ",", "Verfuegbarkeit", "kompetenter", "und", "kooperationsfaehiger", "Partner", ",", "Teilhabe", "des", "Chirurgen", "an", "der", "perioperativen", "Medizin", "und", "kein", "Verzicht", "auf", "organisatorische", "und", "strukturelle", "Selbstbestimmung", "." ]
[ "umlsterm" ]
Arbeit, Chirurgie, Anaesthesie, engen, Diagnostik, Therapie, Aufwachraum, Chirurgiepersonals, Schmerztherapie, Medizin, Selbstbestimmung
DerChirurg.90700010.ger.abstr_task2
Sentence: Zusammenfassung . In der Kooperationsvielfalt der taeglichen Arbeit stellt die Zusammenarbeit zwischen Chirurgie und Anaesthesie wegen der engen Verflechtung beider Disziplinen eine Besonderheit dar . Sie kann durch Beachtung folgender Punkte rationalisiert und erleichtert werden : Klare Zuordnung von Kompetenzen , Beachtung des Vertrauensgrundsatzes , Einbeziehung des Anaesthesisten in Aufnahmeuntersuchung , Vorgabe zur bedarfsorientierten praeoperativen Diagnostik , Absprache ueber notwendige praeoperative Therapie , gemeinsame Indikationssprechstunde fuer ambulante Operationen , Aufwachraum fuer 24 Std , Unterweisung des Chirurgiepersonals in spezieller Schmerztherapie , Verfuegbarkeit kompetenter und kooperationsfaehiger Partner , Teilhabe des Chirurgen an der perioperativen Medizin und kein Verzicht auf organisatorische und strukturelle Selbstbestimmung . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]
Zusammenfassung . In der Kooperationsvielfalt der taeglichen Arbeit stellt die Zusammenarbeit zwischen Chirurgie und Anaesthesie wegen der engen Verflechtung beider Disziplinen eine Besonderheit dar . Sie kann durch Beachtung folgender Punkte rationalisiert und erleichtert werden : Klare Zuordnung von Kompetenzen , Beachtung des Vertrauensgrundsatzes , Einbeziehung des Anaesthesisten in Aufnahmeuntersuchung , Vorgabe zur bedarfsorientierten praeoperativen Diagnostik , Absprache ueber notwendige praeoperative Therapie , gemeinsame Indikationssprechstunde fuer ambulante Operationen , Aufwachraum fuer 24 Std , Unterweisung des Chirurgiepersonals in spezieller Schmerztherapie , Verfuegbarkeit kompetenter und kooperationsfaehiger Partner , Teilhabe des Chirurgen an der perioperativen Medizin und kein Verzicht auf organisatorische und strukturelle Selbstbestimmung .
[ "Zusammenfassung", ".", "In", "der", "Kooperationsvielfalt", "der", "taeglichen", "Arbeit", "stellt", "die", "Zusammenarbeit", "zwischen", "Chirurgie", "und", "Anaesthesie", "wegen", "der", "engen", "Verflechtung", "beider", "Disziplinen", "eine", "Besonderheit", "dar", ".", "Sie", "kann", "durch", "Beachtung", "folgender", "Punkte", "rationalisiert", "und", "erleichtert", "werden", ":", "Klare", "Zuordnung", "von", "Kompetenzen", ",", "Beachtung", "des", "Vertrauensgrundsatzes", ",", "Einbeziehung", "des", "Anaesthesisten", "in", "Aufnahmeuntersuchung", ",", "Vorgabe", "zur", "bedarfsorientierten", "praeoperativen", "Diagnostik", ",", "Absprache", "ueber", "notwendige", "praeoperative", "Therapie", ",", "gemeinsame", "Indikationssprechstunde", "fuer", "ambulante", "Operationen", ",", "Aufwachraum", "fuer", "24", "Std", ",", "Unterweisung", "des", "Chirurgiepersonals", "in", "spezieller", "Schmerztherapie", ",", "Verfuegbarkeit", "kompetenter", "und", "kooperationsfaehiger", "Partner", ",", "Teilhabe", "des", "Chirurgen", "an", "der", "perioperativen", "Medizin", "und", "kein", "Verzicht", "auf", "organisatorische", "und", "strukturelle", "Selbstbestimmung", "." ]
[ "umlsterm" ]
cáncer is a MORFOLOGIA_NEOPLASIA, neoplasia is a MORFOLOGIA_NEOPLASIA, cáncer is a MORFOLOGIA_NEOPLASIA, tumoración is a MORFOLOGIA_NEOPLASIA, GIST is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, fibromatosis mesentérica de tipo desmoide is a MORFOLOGIA_NEOPLASIA, tumores desmoides is a MORFOLOGIA_NEOPLASIA, poliposis adenomatosa familiar is a MORFOLOGIA_NEOPLASIA, PAF is a MORFOLOGIA_NEOPLASIA, implantes peritoneales is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, PAF is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, implantes peritoneales is a MORFOLOGIA_NEOPLASIA, linfoma B difuso de células grandes , inmunofenotipo germinal is a MORFOLOGIA_NEOPLASIA, afectación a nivel abdominal is a MORFOLOGIA_NEOPLASIA, masas intraperitoneales is a MORFOLOGIA_NEOPLASIA, metastásicos is a MORFOLOGIA_NEOPLASIA, masas a nivel abdominal is a MORFOLOGIA_NEOPLASIA, Linfoma difuso de células grandes B ( LCGB ) tipo centrogerminal is a MORFOLOGIA_NEOPLASIA
909_task0
Sentence: Anamnesis Antecedentes familiares: tío materno fallecido por cáncer de próstata con más de 70 años y otro por neoplasia faríngea. Tío paterno fallecido por cáncer de pulmón. Antecedentes personales: sin alergias medicamentosas conocidas. Exfumador desde hace 20 años (20 paquetes-año). Diabetes mellitus tipo II desde 2004, insulinodependiente desde hace 3 años. Hipercolesterolemia. Trabajador de una bodega. Niega consumo de tóxicos. Tratamiento habitual: simvastatina 20 mg, omeprazol 20 mg, naproxeno si tiene dolor, cinitaprida 10 mg antes de las comidas. Su historia oncológica comienza el 03/12/16, cuando el paciente acudió a Urgencias por fiebre de hasta 38,5ºC, pérdida de ponderal cuantificada en 7 kg en el último mes, disfagia a sólidos y a líquidos, con sensación de plenitud gástrica precoz, astenia intensa y dolor abdominal hipogástrico. Se realizó ecografía y TC abdominal urgente con contraste objetivando tumoración centro-abdominal de 17,2 x 7,7 x 7,5 cm, con importante componente hidroaéreo, engrosamiento mural marcado e irregular, contactando con asas de intestino delgado, probablemente en relación a GIST complicado. Se decidió realización de laparotomía exploradora urgente por sospecha de perforación intestinal, que objetiva cloaca centro abdominal, realizándose resección de tumoral con varias asas intestinales, y anastomosis laterolateral mecánica. Cirugía subóptima por bordes afectos. El informe anatomopatológico objetivó hallazgos compatibles con fibromatosis mesentérica de tipo desmoide, con estudio inmunohistoquímico positivo para actina de músculo liso y beta-catenina; y negativo para desmina, CD34, S100, CD117(C-KIT) y DOG1. Valorado por primera vez en consultas de Oncología Médica el 16/01/2017, se decidió seguimiento estrecho con control radiológico en 4 meses, así como colonoscopia por la asociación conocida de los tumores desmoides y la poliposis adenomatosa familiar (PAF). Un mes después de la intervención, acudió a Urgencias por dolor en fosa renal derecha con irradiación, realizándose TC abdominal que mostró ureterohidronefrosis derecha moderada y múltiples implantes peritoneales, compatibles con recidiva tumoral. Se desestimó nueva intervención por parte de Urología y Cirugía, por lo que ingresó en Oncología para completar estudio y se procedió a la colocación de nefrostomía percutánea derecha sin complicaciones. Previa al alta, se realizó colonoscopia descartándose PAF. Ante la discordancia clínico-patológica (necrosis tumoral, implantes peritoneales, evolución clínica, etc.) se solicitó una nueva revisión histológica en centro de referencia de tumores de partes blandas, emitiéndose un diagnóstico de linfoma B difuso de células grandes, inmunofenotipo germinal con inmunoexpresión positiva para BCL-6 y negativos para MUM-1, CD5, CD10, cMYC y EBER con un índice proliferativo (Ki67) del 80 %. Por consiguiente, el paciente continuó su evolución a cargo del Servicio de Hematología. Tras aparición de fiebre junto a ataxia, alteraciones del sensorio y síndrome emético, se realizó RMN cerebral que descartó afectación a este nivel. Se decidió realización de punción lumbar, detectándose antígeno Cryptococcus (+); iniciándose anfotericina liposomal y fludrocortisona (fecha de inicio del tratamiento: 17/03/17). A las 48 horas, se informó de serología para VIH (+) con viremia de 684.000c/ml y recuento de LCD4 en 38/ul. El paciente presentó evolución favorable, siendo el cultivo de control (-) y tras completar ciclo, se realizó desescalada a fluconazol oral. Tras cuatro semanas de tratamiento antifúngico, se inició tratamiento antirretroviral con raltegravir + FTC + TDF con buena tolerancia. Se completó estudio con PET que informó de extensa afectación a nivel abdominal y pulmonar, biopsia ósea (sin infiltración) y ecocardiograma con fracción de eyección conservada. En situación estable, se inició ciclo R-CHOP con buena tolerancia y respuesta. Exploración física ECOG 2. Boca seca sin aftas. Marcada caquexia. A nivel abdominal, destacó empastamiento en hemiabdomen derecho, así como dudoso en flanco izquierdo con dolor a la palpación de epigastrio e hipocondrio derecho. El resto, anodino. Pruebas complementarias » TC con contraste I.V. de abdomen (13/02/2017): progresión de la enfermedad con múltiples masas intraperitoneales compatibles con implantes metastásicos. Uno de ellos obstruye al uréter derecho y otro infiltra a un asa de delegado en la fosa iliaca izquierda. » LCR (17/03/17): 30 leucocitos (10 % PMN, 30 % MN), 0 hematíes, 97 glucosa, 125 proteínas, 22,3 ADA. Abundantes linfocitos. IF: sólo 4 % linfocitos B monoclonales, resto linfocitos T. Se detecta antígeno Cryptococcus. » Serologías (20/03/17): VIH (+), VHB y VHC (-), CMV IgG(+), VEB(-), VHS IgG(+),Sífilis (-), toxoplasma IgG(+). B2- microglobulina (21/04/17): 4,52, LDH: 473. » PET (24/04/17): informa de extensa afectación supra e infradiafragmática con predominio de grandes masas a nivel abdominal, así como pulmonar y sin hallazgos en el resto. Diagnóstico » Linfoma difuso de células grandes B (LCGB) tipo centrogerminal. » Infección por VIH categoría C3 (sida). » Meningitis criptocócica. Tratamiento Tras presentar el caso en sesión multidisciplinar, se decidió inicio de tratamiento con anfotericina liposomal y fludrocortisona, pasando a fluconazol vía oral. Pasadas 4 semanas, se instauró tratamiento antirretroviral con raltegravir + FTC + TDF y, por último, se inició quimioterapia sistémica según esquema R-CHOP. Evolución Paciente con los antecedentes descritos previamente, estable en el momento actual, en seguimiento por la Unidad de Hematología en Consultas Externas. Buena respuesta y tolerancia tras tercer ciclo de R-CHOP. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: MORFOLOGIA_NEOPLASIA
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Anamnesis Antecedentes familiares: tío materno fallecido por cáncer de próstata con más de 70 años y otro por neoplasia faríngea. Tío paterno fallecido por cáncer de pulmón. Antecedentes personales: sin alergias medicamentosas conocidas. Exfumador desde hace 20 años (20 paquetes-año). Diabetes mellitus tipo II desde 2004, insulinodependiente desde hace 3 años. Hipercolesterolemia. Trabajador de una bodega. Niega consumo de tóxicos. Tratamiento habitual: simvastatina 20 mg, omeprazol 20 mg, naproxeno si tiene dolor, cinitaprida 10 mg antes de las comidas. Su historia oncológica comienza el 03/12/16, cuando el paciente acudió a Urgencias por fiebre de hasta 38,5ºC, pérdida de ponderal cuantificada en 7 kg en el último mes, disfagia a sólidos y a líquidos, con sensación de plenitud gástrica precoz, astenia intensa y dolor abdominal hipogástrico. Se realizó ecografía y TC abdominal urgente con contraste objetivando tumoración centro-abdominal de 17,2 x 7,7 x 7,5 cm, con importante componente hidroaéreo, engrosamiento mural marcado e irregular, contactando con asas de intestino delgado, probablemente en relación a GIST complicado. Se decidió realización de laparotomía exploradora urgente por sospecha de perforación intestinal, que objetiva cloaca centro abdominal, realizándose resección de tumoral con varias asas intestinales, y anastomosis laterolateral mecánica. Cirugía subóptima por bordes afectos. El informe anatomopatológico objetivó hallazgos compatibles con fibromatosis mesentérica de tipo desmoide, con estudio inmunohistoquímico positivo para actina de músculo liso y beta-catenina; y negativo para desmina, CD34, S100, CD117(C-KIT) y DOG1. Valorado por primera vez en consultas de Oncología Médica el 16/01/2017, se decidió seguimiento estrecho con control radiológico en 4 meses, así como colonoscopia por la asociación conocida de los tumores desmoides y la poliposis adenomatosa familiar (PAF). Un mes después de la intervención, acudió a Urgencias por dolor en fosa renal derecha con irradiación, realizándose TC abdominal que mostró ureterohidronefrosis derecha moderada y múltiples implantes peritoneales, compatibles con recidiva tumoral. Se desestimó nueva intervención por parte de Urología y Cirugía, por lo que ingresó en Oncología para completar estudio y se procedió a la colocación de nefrostomía percutánea derecha sin complicaciones. Previa al alta, se realizó colonoscopia descartándose PAF. Ante la discordancia clínico-patológica (necrosis tumoral, implantes peritoneales, evolución clínica, etc.) se solicitó una nueva revisión histológica en centro de referencia de tumores de partes blandas, emitiéndose un diagnóstico de linfoma B difuso de células grandes, inmunofenotipo germinal con inmunoexpresión positiva para BCL-6 y negativos para MUM-1, CD5, CD10, cMYC y EBER con un índice proliferativo (Ki67) del 80 %. Por consiguiente, el paciente continuó su evolución a cargo del Servicio de Hematología. Tras aparición de fiebre junto a ataxia, alteraciones del sensorio y síndrome emético, se realizó RMN cerebral que descartó afectación a este nivel. Se decidió realización de punción lumbar, detectándose antígeno Cryptococcus (+); iniciándose anfotericina liposomal y fludrocortisona (fecha de inicio del tratamiento: 17/03/17). A las 48 horas, se informó de serología para VIH (+) con viremia de 684.000c/ml y recuento de LCD4 en 38/ul. El paciente presentó evolución favorable, siendo el cultivo de control (-) y tras completar ciclo, se realizó desescalada a fluconazol oral. Tras cuatro semanas de tratamiento antifúngico, se inició tratamiento antirretroviral con raltegravir + FTC + TDF con buena tolerancia. Se completó estudio con PET que informó de extensa afectación a nivel abdominal y pulmonar, biopsia ósea (sin infiltración) y ecocardiograma con fracción de eyección conservada. En situación estable, se inició ciclo R-CHOP con buena tolerancia y respuesta. Exploración física ECOG 2. Boca seca sin aftas. Marcada caquexia. A nivel abdominal, destacó empastamiento en hemiabdomen derecho, así como dudoso en flanco izquierdo con dolor a la palpación de epigastrio e hipocondrio derecho. El resto, anodino. Pruebas complementarias » TC con contraste I.V. de abdomen (13/02/2017): progresión de la enfermedad con múltiples masas intraperitoneales compatibles con implantes metastásicos. Uno de ellos obstruye al uréter derecho y otro infiltra a un asa de delegado en la fosa iliaca izquierda. » LCR (17/03/17): 30 leucocitos (10 % PMN, 30 % MN), 0 hematíes, 97 glucosa, 125 proteínas, 22,3 ADA. Abundantes linfocitos. IF: sólo 4 % linfocitos B monoclonales, resto linfocitos T. Se detecta antígeno Cryptococcus. » Serologías (20/03/17): VIH (+), VHB y VHC (-), CMV IgG(+), VEB(-), VHS IgG(+),Sífilis (-), toxoplasma IgG(+). B2- microglobulina (21/04/17): 4,52, LDH: 473. » PET (24/04/17): informa de extensa afectación supra e infradiafragmática con predominio de grandes masas a nivel abdominal, así como pulmonar y sin hallazgos en el resto. Diagnóstico » Linfoma difuso de células grandes B (LCGB) tipo centrogerminal. » Infección por VIH categoría C3 (sida). » Meningitis criptocócica. Tratamiento Tras presentar el caso en sesión multidisciplinar, se decidió inicio de tratamiento con anfotericina liposomal y fludrocortisona, pasando a fluconazol vía oral. Pasadas 4 semanas, se instauró tratamiento antirretroviral con raltegravir + FTC + TDF y, por último, se inició quimioterapia sistémica según esquema R-CHOP. Evolución Paciente con los antecedentes descritos previamente, estable en el momento actual, en seguimiento por la Unidad de Hematología en Consultas Externas. Buena respuesta y tolerancia tras tercer ciclo de R-CHOP.
[ "Anamnesis", "\n", "Antecedentes", "familiares", ":", "tío", "materno", "fallecido", "por", "cáncer", "de", "próstata", "con", "más", "de", "70", "años", "y", "otro", "por", "neoplasia", "faríngea", ".", "Tío", "paterno", "fallecido", "por", "cáncer", "de", "pulmón", ".", "\n", "Antecedentes", "personales", ":", "sin", "alergias", "medicamentosas", "conocidas", ".", "Exfumador", "desde", "hace", "20", "años", "(", "20", "paquetes", "-", "año", ")", ".", "Diabetes", "mellitus", "tipo", "II", "desde", "2004", ",", "insulinodependiente", "desde", "hace", "3", "años", ".", "\n", "Hipercolesterolemia", ".", "Trabajador", "de", "una", "bodega", ".", "Niega", "consumo", "de", "tóxicos", ".", "Tratamiento", "habitual", ":", "simvastatina", "20", "mg", ",", "omeprazol", "20", "mg", ",", "naproxeno", "si", "tiene", "dolor", ",", "cinitaprida", "10", "mg", "antes", "de", "las", "comidas", ".", "\n", "Su", "historia", "oncológica", "comienza", "el", "03/12/16", ",", "cuando", "el", "paciente", "acudió", "a", "Urgencias", "por", "fiebre", "de", "hasta", "38,5ºC", ",", "pérdida", "de", "ponderal", "cuantificada", "en", "7", "kg", "en", "el", "último", "mes", ",", "disfagia", "a", "sólidos", "y", "a", "líquidos", ",", "con", "sensación", "de", "plenitud", "gástrica", "precoz", ",", "astenia", "intensa", "y", "dolor", "abdominal", "hipogástrico", ".", "\n", "Se", "realizó", "ecografía", "y", "TC", "abdominal", "urgente", "con", "contraste", "objetivando", "tumoración", "centro", "-", "abdominal", "de", "17,2", "x", "7,7", "x", "7,5", "cm", ",", "con", "importante", "componente", "hidroaéreo", ",", "engrosamiento", "mural", "marcado", "e", "irregular", ",", "contactando", "con", "asas", "de", "intestino", "delgado", ",", "probablemente", "en", "relación", "a", "GIST", "complicado", ".", "Se", "decidió", "realización", "de", "laparotomía", "exploradora", "urgente", "por", "sospecha", "de", "perforación", "intestinal", ",", "que", "objetiva", "cloaca", "centro", "abdominal", ",", "realizándose", "resección", "de", "tumoral", "con", "varias", "asas", "intestinales", ",", "y", "anastomosis", "laterolateral", "mecánica", ".", "Cirugía", "subóptima", "por", "bordes", "afectos", ".", "\n", "El", "informe", "anatomopatológico", "objetivó", "hallazgos", "compatibles", "con", "fibromatosis", "mesentérica", "de", "tipo", "desmoide", ",", "con", "estudio", "inmunohistoquímico", "positivo", "para", "actina", "de", "músculo", "liso", "y", "beta", "-", "catenina", ";", "y", "negativo", "para", "desmina", ",", "CD34", ",", "S100", ",", "CD117(C", "-", "KIT", ")", "y", "DOG1", ".", "\n", "Valorado", "por", "primera", "vez", "en", "consultas", "de", "Oncología", "Médica", "el", "16/01/2017", ",", "se", "decidió", "seguimiento", "estrecho", "con", "control", "radiológico", "en", "4", "meses", ",", "así", "como", "colonoscopia", "por", "la", "asociación", "conocida", "de", "los", "tumores", "desmoides", "y", "la", "poliposis", "adenomatosa", "familiar", "(", "PAF", ")", ".", "\n", "Un", "mes", "después", "de", "la", "intervención", ",", "acudió", "a", "Urgencias", "por", "dolor", "en", "fosa", "renal", "derecha", "con", "irradiación", ",", "realizándose", "TC", "abdominal", "que", "mostró", "ureterohidronefrosis", "derecha", "moderada", "y", "múltiples", "implantes", "peritoneales", ",", "compatibles", "con", "recidiva", "tumoral", ".", "Se", "desestimó", "nueva", "intervención", "por", "parte", "de", "Urología", "y", "Cirugía", ",", "por", "lo", "que", "ingresó", "en", "Oncología", "para", "completar", "estudio", "y", "se", "procedió", "a", "la", "colocación", "de", "nefrostomía", "percutánea", "derecha", "sin", "complicaciones", ".", "\n", "Previa", "al", "alta", ",", "se", "realizó", "colonoscopia", "descartándose", "PAF", ".", "Ante", "la", "discordancia", "clínico", "-", "patológica", "(", "necrosis", "tumoral", ",", "implantes", "peritoneales", ",", "evolución", "clínica", ",", "etc", ".", ")", "se", "solicitó", "una", "nueva", "revisión", "histológica", "en", "centro", "de", "referencia", "de", "tumores", "de", "partes", "blandas", ",", "emitiéndose", "un", "diagnóstico", "de", "linfoma", "B", "difuso", "de", "células", "grandes", ",", "inmunofenotipo", "germinal", "con", "inmunoexpresión", "positiva", "para", "BCL-6", "y", "negativos", "para", "MUM-1", ",", "CD5", ",", "CD10", ",", "cMYC", "y", "EBER", "con", "un", "índice", "proliferativo", "(", "Ki67", ")", "del", "80", "%", ".", "Por", "consiguiente", ",", "el", "paciente", "continuó", "su", "evolución", "a", "cargo", "del", "Servicio", "de", "Hematología", ".", "\n", "Tras", "aparición", "de", "fiebre", "junto", "a", "ataxia", ",", "alteraciones", "del", "sensorio", "y", "síndrome", "emético", ",", "se", "realizó", "RMN", "cerebral", "que", "descartó", "afectación", "a", "este", "nivel", ".", "Se", "decidió", "realización", "de", "punción", "lumbar", ",", "detectándose", "antígeno", "Cryptococcus", "(", "+", ")", ";", "iniciándose", "anfotericina", "liposomal", "y", "fludrocortisona", "(", "fecha", "de", "inicio", "del", "tratamiento", ":", "17/03/17", ")", ".", "A", "las", "48", "horas", ",", "se", "informó", "de", "serología", "para", "VIH", "(", "+", ")", "con", "viremia", "de", "684.000c", "/", "ml", "y", "recuento", "de", "LCD4", "en", "38", "/", "ul", ".", "\n", "El", "paciente", "presentó", "evolución", "favorable", ",", "siendo", "el", "cultivo", "de", "control", "(", "-", ")", "y", "tras", "completar", "ciclo", ",", "se", "realizó", "desescalada", "a", "fluconazol", "oral", ".", "Tras", "cuatro", "semanas", "de", "tratamiento", "antifúngico", ",", "se", "inició", "tratamiento", "antirretroviral", "con", "raltegravir", "+", "FTC", "+", "TDF", "con", "buena", "tolerancia", ".", "\n", "Se", "completó", "estudio", "con", "PET", "que", "informó", "de", "extensa", "afectación", "a", "nivel", "abdominal", "y", "pulmonar", ",", "biopsia", "ósea", "(", "sin", "infiltración", ")", "y", "ecocardiograma", "con", "fracción", "de", "eyección", "conservada", ".", "En", "situación", "estable", ",", "se", "inició", "ciclo", "R", "-", "CHOP", "con", "buena", "tolerancia", "y", "respuesta", ".", "\n\n", "Exploración", "física", "\n", "ECOG", "2", ".", "Boca", "seca", "sin", "aftas", ".", "Marcada", "caquexia", ".", "A", "nivel", "abdominal", ",", "destacó", "empastamiento", "en", "hemiabdomen", "derecho", ",", "así", "como", "dudoso", "en", "flanco", "izquierdo", "con", "dolor", "a", "la", "palpación", "de", "epigastrio", "e", "hipocondrio", "derecho", ".", "El", "resto", ",", "anodino", ".", "\n\n", "Pruebas", "complementarias", "\n", "»", "TC", "con", "contraste", "I.V.", "de", "abdomen", "(", "13/02/2017", "):", "progresión", "de", "la", "enfermedad", "con", "múltiples", "masas", "intraperitoneales", "compatibles", "con", "implantes", "metastásicos", ".", "Uno", "de", "ellos", "obstruye", "al", "uréter", "derecho", "y", "otro", "infiltra", "a", "un", "asa", "de", "delegado", "en", "la", "fosa", "iliaca", "izquierda", ".", "\n", "»", "LCR", "(", "17/03/17", "):", "30", "leucocitos", "(", "10", "%", "PMN", ",", "30", "%", "MN", ")", ",", "0", "hematíes", ",", "97", "glucosa", ",", "125", "proteínas", ",", "22,3", "ADA", ".", "Abundantes", "linfocitos", ".", "IF", ":", "sólo", "4", "%", "linfocitos", "B", "monoclonales", ",", "resto", "linfocitos", "T.", "Se", "detecta", "antígeno", "Cryptococcus", ".", "\n", "»", "Serologías", "(", "20/03/17", "):", "VIH", "(", "+", ")", ",", "VHB", "y", "VHC", "(", "-", ")", ",", "CMV", "IgG(+", ")", ",", "VEB(-", ")", ",", "VHS", "IgG(+),Sífilis", "(", "-", ")", ",", "toxoplasma", "IgG(+", ")", ".", "B2-", "microglobulina", "(", "21/04/17", "):", "4,52", ",", "LDH", ":", "473", ".", "\n", "»", "PET", "(", "24/04/17", "):", "informa", "de", "extensa", "afectación", "supra", "e", "infradiafragmática", "con", "predominio", "de", "grandes", "masas", "a", "nivel", "abdominal", ",", "así", "como", "pulmonar", "y", "sin", "hallazgos", "en", "el", "resto", ".", "\n\n", "Diagnóstico", "\n", "»", "Linfoma", "difuso", "de", "células", "grandes", "B", "(", "LCGB", ")", "tipo", "centrogerminal", ".", "\n", "»", "Infección", "por", "VIH", "categoría", "C3", "(", "sida", ")", ".", "\n", "»", "Meningitis", "criptocócica", ".", "\n\n", "Tratamiento", "\n", "Tras", "presentar", "el", "caso", "en", "sesión", "multidisciplinar", ",", "se", "decidió", "inicio", "de", "tratamiento", "con", "anfotericina", "liposomal", "y", "fludrocortisona", ",", "pasando", "a", "fluconazol", "vía", "oral", ".", "Pasadas", "4", "semanas", ",", "se", "instauró", "tratamiento", "antirretroviral", "con", "raltegravir", "+", "FTC", "+", "TDF", "y", ",", "por", "último", ",", "se", "inició", "quimioterapia", "sistémica", "según", "esquema", "R", "-", "CHOP", ".", "\n\n", "Evolución", "\n", "Paciente", "con", "los", "antecedentes", "descritos", "previamente", ",", "estable", "en", "el", "momento", "actual", ",", "en", "seguimiento", "por", "la", "Unidad", "de", "Hematología", "en", "Consultas", "Externas", ".", "Buena", "respuesta", "y", "tolerancia", "tras", "tercer", "ciclo", "de", "R", "-", "CHOP", "." ]
[ "MORFOLOGIA_NEOPLASIA" ]
cáncer is a MORFOLOGIA_NEOPLASIA, neoplasia is a MORFOLOGIA_NEOPLASIA, cáncer is a MORFOLOGIA_NEOPLASIA, tumoración is a MORFOLOGIA_NEOPLASIA, GIST is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, fibromatosis mesentérica de tipo desmoide is a MORFOLOGIA_NEOPLASIA, tumores desmoides is a MORFOLOGIA_NEOPLASIA, poliposis adenomatosa familiar is a MORFOLOGIA_NEOPLASIA, PAF is a MORFOLOGIA_NEOPLASIA, implantes peritoneales is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, PAF is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, implantes peritoneales is a MORFOLOGIA_NEOPLASIA, linfoma B difuso de células grandes , inmunofenotipo germinal is a MORFOLOGIA_NEOPLASIA, afectación a nivel abdominal is a MORFOLOGIA_NEOPLASIA, masas intraperitoneales is a MORFOLOGIA_NEOPLASIA, metastásicos is a MORFOLOGIA_NEOPLASIA, masas a nivel abdominal is a MORFOLOGIA_NEOPLASIA, Linfoma difuso de células grandes B ( LCGB ) tipo centrogerminal is a MORFOLOGIA_NEOPLASIA
909_task1
Sentence: Anamnesis Antecedentes familiares: tío materno fallecido por cáncer de próstata con más de 70 años y otro por neoplasia faríngea. Tío paterno fallecido por cáncer de pulmón. Antecedentes personales: sin alergias medicamentosas conocidas. Exfumador desde hace 20 años (20 paquetes-año). Diabetes mellitus tipo II desde 2004, insulinodependiente desde hace 3 años. Hipercolesterolemia. Trabajador de una bodega. Niega consumo de tóxicos. Tratamiento habitual: simvastatina 20 mg, omeprazol 20 mg, naproxeno si tiene dolor, cinitaprida 10 mg antes de las comidas. Su historia oncológica comienza el 03/12/16, cuando el paciente acudió a Urgencias por fiebre de hasta 38,5ºC, pérdida de ponderal cuantificada en 7 kg en el último mes, disfagia a sólidos y a líquidos, con sensación de plenitud gástrica precoz, astenia intensa y dolor abdominal hipogástrico. Se realizó ecografía y TC abdominal urgente con contraste objetivando tumoración centro-abdominal de 17,2 x 7,7 x 7,5 cm, con importante componente hidroaéreo, engrosamiento mural marcado e irregular, contactando con asas de intestino delgado, probablemente en relación a GIST complicado. Se decidió realización de laparotomía exploradora urgente por sospecha de perforación intestinal, que objetiva cloaca centro abdominal, realizándose resección de tumoral con varias asas intestinales, y anastomosis laterolateral mecánica. Cirugía subóptima por bordes afectos. El informe anatomopatológico objetivó hallazgos compatibles con fibromatosis mesentérica de tipo desmoide, con estudio inmunohistoquímico positivo para actina de músculo liso y beta-catenina; y negativo para desmina, CD34, S100, CD117(C-KIT) y DOG1. Valorado por primera vez en consultas de Oncología Médica el 16/01/2017, se decidió seguimiento estrecho con control radiológico en 4 meses, así como colonoscopia por la asociación conocida de los tumores desmoides y la poliposis adenomatosa familiar (PAF). Un mes después de la intervención, acudió a Urgencias por dolor en fosa renal derecha con irradiación, realizándose TC abdominal que mostró ureterohidronefrosis derecha moderada y múltiples implantes peritoneales, compatibles con recidiva tumoral. Se desestimó nueva intervención por parte de Urología y Cirugía, por lo que ingresó en Oncología para completar estudio y se procedió a la colocación de nefrostomía percutánea derecha sin complicaciones. Previa al alta, se realizó colonoscopia descartándose PAF. Ante la discordancia clínico-patológica (necrosis tumoral, implantes peritoneales, evolución clínica, etc.) se solicitó una nueva revisión histológica en centro de referencia de tumores de partes blandas, emitiéndose un diagnóstico de linfoma B difuso de células grandes, inmunofenotipo germinal con inmunoexpresión positiva para BCL-6 y negativos para MUM-1, CD5, CD10, cMYC y EBER con un índice proliferativo (Ki67) del 80 %. Por consiguiente, el paciente continuó su evolución a cargo del Servicio de Hematología. Tras aparición de fiebre junto a ataxia, alteraciones del sensorio y síndrome emético, se realizó RMN cerebral que descartó afectación a este nivel. Se decidió realización de punción lumbar, detectándose antígeno Cryptococcus (+); iniciándose anfotericina liposomal y fludrocortisona (fecha de inicio del tratamiento: 17/03/17). A las 48 horas, se informó de serología para VIH (+) con viremia de 684.000c/ml y recuento de LCD4 en 38/ul. El paciente presentó evolución favorable, siendo el cultivo de control (-) y tras completar ciclo, se realizó desescalada a fluconazol oral. Tras cuatro semanas de tratamiento antifúngico, se inició tratamiento antirretroviral con raltegravir + FTC + TDF con buena tolerancia. Se completó estudio con PET que informó de extensa afectación a nivel abdominal y pulmonar, biopsia ósea (sin infiltración) y ecocardiograma con fracción de eyección conservada. En situación estable, se inició ciclo R-CHOP con buena tolerancia y respuesta. Exploración física ECOG 2. Boca seca sin aftas. Marcada caquexia. A nivel abdominal, destacó empastamiento en hemiabdomen derecho, así como dudoso en flanco izquierdo con dolor a la palpación de epigastrio e hipocondrio derecho. El resto, anodino. Pruebas complementarias » TC con contraste I.V. de abdomen (13/02/2017): progresión de la enfermedad con múltiples masas intraperitoneales compatibles con implantes metastásicos. Uno de ellos obstruye al uréter derecho y otro infiltra a un asa de delegado en la fosa iliaca izquierda. » LCR (17/03/17): 30 leucocitos (10 % PMN, 30 % MN), 0 hematíes, 97 glucosa, 125 proteínas, 22,3 ADA. Abundantes linfocitos. IF: sólo 4 % linfocitos B monoclonales, resto linfocitos T. Se detecta antígeno Cryptococcus. » Serologías (20/03/17): VIH (+), VHB y VHC (-), CMV IgG(+), VEB(-), VHS IgG(+),Sífilis (-), toxoplasma IgG(+). B2- microglobulina (21/04/17): 4,52, LDH: 473. » PET (24/04/17): informa de extensa afectación supra e infradiafragmática con predominio de grandes masas a nivel abdominal, así como pulmonar y sin hallazgos en el resto. Diagnóstico » Linfoma difuso de células grandes B (LCGB) tipo centrogerminal. » Infección por VIH categoría C3 (sida). » Meningitis criptocócica. Tratamiento Tras presentar el caso en sesión multidisciplinar, se decidió inicio de tratamiento con anfotericina liposomal y fludrocortisona, pasando a fluconazol vía oral. Pasadas 4 semanas, se instauró tratamiento antirretroviral con raltegravir + FTC + TDF y, por último, se inició quimioterapia sistémica según esquema R-CHOP. Evolución Paciente con los antecedentes descritos previamente, estable en el momento actual, en seguimiento por la Unidad de Hematología en Consultas Externas. Buena respuesta y tolerancia tras tercer ciclo de R-CHOP. Instructions: please typing these entity words according to sentence: cáncer, neoplasia, cáncer, tumoración, GIST, tumoral, fibromatosis mesentérica de tipo desmoide, tumores desmoides, poliposis adenomatosa familiar, PAF, implantes peritoneales, tumoral, PAF, tumoral, implantes peritoneales, linfoma B difuso de células grandes , inmunofenotipo germinal, afectación a nivel abdominal, masas intraperitoneales, metastásicos, masas a nivel abdominal, Linfoma difuso de células grandes B ( LCGB ) tipo centrogerminal Options: MORFOLOGIA_NEOPLASIA
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Anamnesis Antecedentes familiares: tío materno fallecido por cáncer de próstata con más de 70 años y otro por neoplasia faríngea. Tío paterno fallecido por cáncer de pulmón. Antecedentes personales: sin alergias medicamentosas conocidas. Exfumador desde hace 20 años (20 paquetes-año). Diabetes mellitus tipo II desde 2004, insulinodependiente desde hace 3 años. Hipercolesterolemia. Trabajador de una bodega. Niega consumo de tóxicos. Tratamiento habitual: simvastatina 20 mg, omeprazol 20 mg, naproxeno si tiene dolor, cinitaprida 10 mg antes de las comidas. Su historia oncológica comienza el 03/12/16, cuando el paciente acudió a Urgencias por fiebre de hasta 38,5ºC, pérdida de ponderal cuantificada en 7 kg en el último mes, disfagia a sólidos y a líquidos, con sensación de plenitud gástrica precoz, astenia intensa y dolor abdominal hipogástrico. Se realizó ecografía y TC abdominal urgente con contraste objetivando tumoración centro-abdominal de 17,2 x 7,7 x 7,5 cm, con importante componente hidroaéreo, engrosamiento mural marcado e irregular, contactando con asas de intestino delgado, probablemente en relación a GIST complicado. Se decidió realización de laparotomía exploradora urgente por sospecha de perforación intestinal, que objetiva cloaca centro abdominal, realizándose resección de tumoral con varias asas intestinales, y anastomosis laterolateral mecánica. Cirugía subóptima por bordes afectos. El informe anatomopatológico objetivó hallazgos compatibles con fibromatosis mesentérica de tipo desmoide, con estudio inmunohistoquímico positivo para actina de músculo liso y beta-catenina; y negativo para desmina, CD34, S100, CD117(C-KIT) y DOG1. Valorado por primera vez en consultas de Oncología Médica el 16/01/2017, se decidió seguimiento estrecho con control radiológico en 4 meses, así como colonoscopia por la asociación conocida de los tumores desmoides y la poliposis adenomatosa familiar (PAF). Un mes después de la intervención, acudió a Urgencias por dolor en fosa renal derecha con irradiación, realizándose TC abdominal que mostró ureterohidronefrosis derecha moderada y múltiples implantes peritoneales, compatibles con recidiva tumoral. Se desestimó nueva intervención por parte de Urología y Cirugía, por lo que ingresó en Oncología para completar estudio y se procedió a la colocación de nefrostomía percutánea derecha sin complicaciones. Previa al alta, se realizó colonoscopia descartándose PAF. Ante la discordancia clínico-patológica (necrosis tumoral, implantes peritoneales, evolución clínica, etc.) se solicitó una nueva revisión histológica en centro de referencia de tumores de partes blandas, emitiéndose un diagnóstico de linfoma B difuso de células grandes, inmunofenotipo germinal con inmunoexpresión positiva para BCL-6 y negativos para MUM-1, CD5, CD10, cMYC y EBER con un índice proliferativo (Ki67) del 80 %. Por consiguiente, el paciente continuó su evolución a cargo del Servicio de Hematología. Tras aparición de fiebre junto a ataxia, alteraciones del sensorio y síndrome emético, se realizó RMN cerebral que descartó afectación a este nivel. Se decidió realización de punción lumbar, detectándose antígeno Cryptococcus (+); iniciándose anfotericina liposomal y fludrocortisona (fecha de inicio del tratamiento: 17/03/17). A las 48 horas, se informó de serología para VIH (+) con viremia de 684.000c/ml y recuento de LCD4 en 38/ul. El paciente presentó evolución favorable, siendo el cultivo de control (-) y tras completar ciclo, se realizó desescalada a fluconazol oral. Tras cuatro semanas de tratamiento antifúngico, se inició tratamiento antirretroviral con raltegravir + FTC + TDF con buena tolerancia. Se completó estudio con PET que informó de extensa afectación a nivel abdominal y pulmonar, biopsia ósea (sin infiltración) y ecocardiograma con fracción de eyección conservada. En situación estable, se inició ciclo R-CHOP con buena tolerancia y respuesta. Exploración física ECOG 2. Boca seca sin aftas. Marcada caquexia. A nivel abdominal, destacó empastamiento en hemiabdomen derecho, así como dudoso en flanco izquierdo con dolor a la palpación de epigastrio e hipocondrio derecho. El resto, anodino. Pruebas complementarias » TC con contraste I.V. de abdomen (13/02/2017): progresión de la enfermedad con múltiples masas intraperitoneales compatibles con implantes metastásicos. Uno de ellos obstruye al uréter derecho y otro infiltra a un asa de delegado en la fosa iliaca izquierda. » LCR (17/03/17): 30 leucocitos (10 % PMN, 30 % MN), 0 hematíes, 97 glucosa, 125 proteínas, 22,3 ADA. Abundantes linfocitos. IF: sólo 4 % linfocitos B monoclonales, resto linfocitos T. Se detecta antígeno Cryptococcus. » Serologías (20/03/17): VIH (+), VHB y VHC (-), CMV IgG(+), VEB(-), VHS IgG(+),Sífilis (-), toxoplasma IgG(+). B2- microglobulina (21/04/17): 4,52, LDH: 473. » PET (24/04/17): informa de extensa afectación supra e infradiafragmática con predominio de grandes masas a nivel abdominal, así como pulmonar y sin hallazgos en el resto. Diagnóstico » Linfoma difuso de células grandes B (LCGB) tipo centrogerminal. » Infección por VIH categoría C3 (sida). » Meningitis criptocócica. Tratamiento Tras presentar el caso en sesión multidisciplinar, se decidió inicio de tratamiento con anfotericina liposomal y fludrocortisona, pasando a fluconazol vía oral. Pasadas 4 semanas, se instauró tratamiento antirretroviral con raltegravir + FTC + TDF y, por último, se inició quimioterapia sistémica según esquema R-CHOP. Evolución Paciente con los antecedentes descritos previamente, estable en el momento actual, en seguimiento por la Unidad de Hematología en Consultas Externas. Buena respuesta y tolerancia tras tercer ciclo de R-CHOP.
[ "Anamnesis", "\n", "Antecedentes", "familiares", ":", "tío", "materno", "fallecido", "por", "cáncer", "de", "próstata", "con", "más", "de", "70", "años", "y", "otro", "por", "neoplasia", "faríngea", ".", "Tío", "paterno", "fallecido", "por", "cáncer", "de", "pulmón", ".", "\n", "Antecedentes", "personales", ":", "sin", "alergias", "medicamentosas", "conocidas", ".", "Exfumador", "desde", "hace", "20", "años", "(", "20", "paquetes", "-", "año", ")", ".", "Diabetes", "mellitus", "tipo", "II", "desde", "2004", ",", "insulinodependiente", "desde", "hace", "3", "años", ".", "\n", "Hipercolesterolemia", ".", "Trabajador", "de", "una", "bodega", ".", "Niega", "consumo", "de", "tóxicos", ".", "Tratamiento", "habitual", ":", "simvastatina", "20", "mg", ",", "omeprazol", "20", "mg", ",", "naproxeno", "si", "tiene", "dolor", ",", "cinitaprida", "10", "mg", "antes", "de", "las", "comidas", ".", "\n", "Su", "historia", "oncológica", "comienza", "el", "03/12/16", ",", "cuando", "el", "paciente", "acudió", "a", "Urgencias", "por", "fiebre", "de", "hasta", "38,5ºC", ",", "pérdida", "de", "ponderal", "cuantificada", "en", "7", "kg", "en", "el", "último", "mes", ",", "disfagia", "a", "sólidos", "y", "a", "líquidos", ",", "con", "sensación", "de", "plenitud", "gástrica", "precoz", ",", "astenia", "intensa", "y", "dolor", "abdominal", "hipogástrico", ".", "\n", "Se", "realizó", "ecografía", "y", "TC", "abdominal", "urgente", "con", "contraste", "objetivando", "tumoración", "centro", "-", "abdominal", "de", "17,2", "x", "7,7", "x", "7,5", "cm", ",", "con", "importante", "componente", "hidroaéreo", ",", "engrosamiento", "mural", "marcado", "e", "irregular", ",", "contactando", "con", "asas", "de", "intestino", "delgado", ",", "probablemente", "en", "relación", "a", "GIST", "complicado", ".", "Se", "decidió", "realización", "de", "laparotomía", "exploradora", "urgente", "por", "sospecha", "de", "perforación", "intestinal", ",", "que", "objetiva", "cloaca", "centro", "abdominal", ",", "realizándose", "resección", "de", "tumoral", "con", "varias", "asas", "intestinales", ",", "y", "anastomosis", "laterolateral", "mecánica", ".", "Cirugía", "subóptima", "por", "bordes", "afectos", ".", "\n", "El", "informe", "anatomopatológico", "objetivó", "hallazgos", "compatibles", "con", "fibromatosis", "mesentérica", "de", "tipo", "desmoide", ",", "con", "estudio", "inmunohistoquímico", "positivo", "para", "actina", "de", "músculo", "liso", "y", "beta", "-", "catenina", ";", "y", "negativo", "para", "desmina", ",", "CD34", ",", "S100", ",", "CD117(C", "-", "KIT", ")", "y", "DOG1", ".", "\n", "Valorado", "por", "primera", "vez", "en", "consultas", "de", "Oncología", "Médica", "el", "16/01/2017", ",", "se", "decidió", "seguimiento", "estrecho", "con", "control", "radiológico", "en", "4", "meses", ",", "así", "como", "colonoscopia", "por", "la", "asociación", "conocida", "de", "los", "tumores", "desmoides", "y", "la", "poliposis", "adenomatosa", "familiar", "(", "PAF", ")", ".", "\n", "Un", "mes", "después", "de", "la", "intervención", ",", "acudió", "a", "Urgencias", "por", "dolor", "en", "fosa", "renal", "derecha", "con", "irradiación", ",", "realizándose", "TC", "abdominal", "que", "mostró", "ureterohidronefrosis", "derecha", "moderada", "y", "múltiples", "implantes", "peritoneales", ",", "compatibles", "con", "recidiva", "tumoral", ".", "Se", "desestimó", "nueva", "intervención", "por", "parte", "de", "Urología", "y", "Cirugía", ",", "por", "lo", "que", "ingresó", "en", "Oncología", "para", "completar", "estudio", "y", "se", "procedió", "a", "la", "colocación", "de", "nefrostomía", "percutánea", "derecha", "sin", "complicaciones", ".", "\n", "Previa", "al", "alta", ",", "se", "realizó", "colonoscopia", "descartándose", "PAF", ".", "Ante", "la", "discordancia", "clínico", "-", "patológica", "(", "necrosis", "tumoral", ",", "implantes", "peritoneales", ",", "evolución", "clínica", ",", "etc", ".", ")", "se", "solicitó", "una", "nueva", "revisión", "histológica", "en", "centro", "de", "referencia", "de", "tumores", "de", "partes", "blandas", ",", "emitiéndose", "un", "diagnóstico", "de", "linfoma", "B", "difuso", "de", "células", "grandes", ",", "inmunofenotipo", "germinal", "con", "inmunoexpresión", "positiva", "para", "BCL-6", "y", "negativos", "para", "MUM-1", ",", "CD5", ",", "CD10", ",", "cMYC", "y", "EBER", "con", "un", "índice", "proliferativo", "(", "Ki67", ")", "del", "80", "%", ".", "Por", "consiguiente", ",", "el", "paciente", "continuó", "su", "evolución", "a", "cargo", "del", "Servicio", "de", "Hematología", ".", "\n", "Tras", "aparición", "de", "fiebre", "junto", "a", "ataxia", ",", "alteraciones", "del", "sensorio", "y", "síndrome", "emético", ",", "se", "realizó", "RMN", "cerebral", "que", "descartó", "afectación", "a", "este", "nivel", ".", "Se", "decidió", "realización", "de", "punción", "lumbar", ",", "detectándose", "antígeno", "Cryptococcus", "(", "+", ")", ";", "iniciándose", "anfotericina", "liposomal", "y", "fludrocortisona", "(", "fecha", "de", "inicio", "del", "tratamiento", ":", "17/03/17", ")", ".", "A", "las", "48", "horas", ",", "se", "informó", "de", "serología", "para", "VIH", "(", "+", ")", "con", "viremia", "de", "684.000c", "/", "ml", "y", "recuento", "de", "LCD4", "en", "38", "/", "ul", ".", "\n", "El", "paciente", "presentó", "evolución", "favorable", ",", "siendo", "el", "cultivo", "de", "control", "(", "-", ")", "y", "tras", "completar", "ciclo", ",", "se", "realizó", "desescalada", "a", "fluconazol", "oral", ".", "Tras", "cuatro", "semanas", "de", "tratamiento", "antifúngico", ",", "se", "inició", "tratamiento", "antirretroviral", "con", "raltegravir", "+", "FTC", "+", "TDF", "con", "buena", "tolerancia", ".", "\n", "Se", "completó", "estudio", "con", "PET", "que", "informó", "de", "extensa", "afectación", "a", "nivel", "abdominal", "y", "pulmonar", ",", "biopsia", "ósea", "(", "sin", "infiltración", ")", "y", "ecocardiograma", "con", "fracción", "de", "eyección", "conservada", ".", "En", "situación", "estable", ",", "se", "inició", "ciclo", "R", "-", "CHOP", "con", "buena", "tolerancia", "y", "respuesta", ".", "\n\n", "Exploración", "física", "\n", "ECOG", "2", ".", "Boca", "seca", "sin", "aftas", ".", "Marcada", "caquexia", ".", "A", "nivel", "abdominal", ",", "destacó", "empastamiento", "en", "hemiabdomen", "derecho", ",", "así", "como", "dudoso", "en", "flanco", "izquierdo", "con", "dolor", "a", "la", "palpación", "de", "epigastrio", "e", "hipocondrio", "derecho", ".", "El", "resto", ",", "anodino", ".", "\n\n", "Pruebas", "complementarias", "\n", "»", "TC", "con", "contraste", "I.V.", "de", "abdomen", "(", "13/02/2017", "):", "progresión", "de", "la", "enfermedad", "con", "múltiples", "masas", "intraperitoneales", "compatibles", "con", "implantes", "metastásicos", ".", "Uno", "de", "ellos", "obstruye", "al", "uréter", "derecho", "y", "otro", "infiltra", "a", "un", "asa", "de", "delegado", "en", "la", "fosa", "iliaca", "izquierda", ".", "\n", "»", "LCR", "(", "17/03/17", "):", "30", "leucocitos", "(", "10", "%", "PMN", ",", "30", "%", "MN", ")", ",", "0", "hematíes", ",", "97", "glucosa", ",", "125", "proteínas", ",", "22,3", "ADA", ".", "Abundantes", "linfocitos", ".", "IF", ":", "sólo", "4", "%", "linfocitos", "B", "monoclonales", ",", "resto", "linfocitos", "T.", "Se", "detecta", "antígeno", "Cryptococcus", ".", "\n", "»", "Serologías", "(", "20/03/17", "):", "VIH", "(", "+", ")", ",", "VHB", "y", "VHC", "(", "-", ")", ",", "CMV", "IgG(+", ")", ",", "VEB(-", ")", ",", "VHS", "IgG(+),Sífilis", "(", "-", ")", ",", "toxoplasma", "IgG(+", ")", ".", "B2-", "microglobulina", "(", "21/04/17", "):", "4,52", ",", "LDH", ":", "473", ".", "\n", "»", "PET", "(", "24/04/17", "):", "informa", "de", "extensa", "afectación", "supra", "e", "infradiafragmática", "con", "predominio", "de", "grandes", "masas", "a", "nivel", "abdominal", ",", "así", "como", "pulmonar", "y", "sin", "hallazgos", "en", "el", "resto", ".", "\n\n", "Diagnóstico", "\n", "»", "Linfoma", "difuso", "de", "células", "grandes", "B", "(", "LCGB", ")", "tipo", "centrogerminal", ".", "\n", "»", "Infección", "por", "VIH", "categoría", "C3", "(", "sida", ")", ".", "\n", "»", "Meningitis", "criptocócica", ".", "\n\n", "Tratamiento", "\n", "Tras", "presentar", "el", "caso", "en", "sesión", "multidisciplinar", ",", "se", "decidió", "inicio", "de", "tratamiento", "con", "anfotericina", "liposomal", "y", "fludrocortisona", ",", "pasando", "a", "fluconazol", "vía", "oral", ".", "Pasadas", "4", "semanas", ",", "se", "instauró", "tratamiento", "antirretroviral", "con", "raltegravir", "+", "FTC", "+", "TDF", "y", ",", "por", "último", ",", "se", "inició", "quimioterapia", "sistémica", "según", "esquema", "R", "-", "CHOP", ".", "\n\n", "Evolución", "\n", "Paciente", "con", "los", "antecedentes", "descritos", "previamente", ",", "estable", "en", "el", "momento", "actual", ",", "en", "seguimiento", "por", "la", "Unidad", "de", "Hematología", "en", "Consultas", "Externas", ".", "Buena", "respuesta", "y", "tolerancia", "tras", "tercer", "ciclo", "de", "R", "-", "CHOP", "." ]
[ "MORFOLOGIA_NEOPLASIA" ]
cáncer, neoplasia, cáncer, tumoración, GIST, tumoral, fibromatosis mesentérica de tipo desmoide, tumores desmoides, poliposis adenomatosa familiar, PAF, implantes peritoneales, tumoral, PAF, tumoral, implantes peritoneales, linfoma B difuso de células grandes , inmunofenotipo germinal, afectación a nivel abdominal, masas intraperitoneales, metastásicos, masas a nivel abdominal, Linfoma difuso de células grandes B ( LCGB ) tipo centrogerminal
909_task2
Sentence: Anamnesis Antecedentes familiares: tío materno fallecido por cáncer de próstata con más de 70 años y otro por neoplasia faríngea. Tío paterno fallecido por cáncer de pulmón. Antecedentes personales: sin alergias medicamentosas conocidas. Exfumador desde hace 20 años (20 paquetes-año). Diabetes mellitus tipo II desde 2004, insulinodependiente desde hace 3 años. Hipercolesterolemia. Trabajador de una bodega. Niega consumo de tóxicos. Tratamiento habitual: simvastatina 20 mg, omeprazol 20 mg, naproxeno si tiene dolor, cinitaprida 10 mg antes de las comidas. Su historia oncológica comienza el 03/12/16, cuando el paciente acudió a Urgencias por fiebre de hasta 38,5ºC, pérdida de ponderal cuantificada en 7 kg en el último mes, disfagia a sólidos y a líquidos, con sensación de plenitud gástrica precoz, astenia intensa y dolor abdominal hipogástrico. Se realizó ecografía y TC abdominal urgente con contraste objetivando tumoración centro-abdominal de 17,2 x 7,7 x 7,5 cm, con importante componente hidroaéreo, engrosamiento mural marcado e irregular, contactando con asas de intestino delgado, probablemente en relación a GIST complicado. Se decidió realización de laparotomía exploradora urgente por sospecha de perforación intestinal, que objetiva cloaca centro abdominal, realizándose resección de tumoral con varias asas intestinales, y anastomosis laterolateral mecánica. Cirugía subóptima por bordes afectos. El informe anatomopatológico objetivó hallazgos compatibles con fibromatosis mesentérica de tipo desmoide, con estudio inmunohistoquímico positivo para actina de músculo liso y beta-catenina; y negativo para desmina, CD34, S100, CD117(C-KIT) y DOG1. Valorado por primera vez en consultas de Oncología Médica el 16/01/2017, se decidió seguimiento estrecho con control radiológico en 4 meses, así como colonoscopia por la asociación conocida de los tumores desmoides y la poliposis adenomatosa familiar (PAF). Un mes después de la intervención, acudió a Urgencias por dolor en fosa renal derecha con irradiación, realizándose TC abdominal que mostró ureterohidronefrosis derecha moderada y múltiples implantes peritoneales, compatibles con recidiva tumoral. Se desestimó nueva intervención por parte de Urología y Cirugía, por lo que ingresó en Oncología para completar estudio y se procedió a la colocación de nefrostomía percutánea derecha sin complicaciones. Previa al alta, se realizó colonoscopia descartándose PAF. Ante la discordancia clínico-patológica (necrosis tumoral, implantes peritoneales, evolución clínica, etc.) se solicitó una nueva revisión histológica en centro de referencia de tumores de partes blandas, emitiéndose un diagnóstico de linfoma B difuso de células grandes, inmunofenotipo germinal con inmunoexpresión positiva para BCL-6 y negativos para MUM-1, CD5, CD10, cMYC y EBER con un índice proliferativo (Ki67) del 80 %. Por consiguiente, el paciente continuó su evolución a cargo del Servicio de Hematología. Tras aparición de fiebre junto a ataxia, alteraciones del sensorio y síndrome emético, se realizó RMN cerebral que descartó afectación a este nivel. Se decidió realización de punción lumbar, detectándose antígeno Cryptococcus (+); iniciándose anfotericina liposomal y fludrocortisona (fecha de inicio del tratamiento: 17/03/17). A las 48 horas, se informó de serología para VIH (+) con viremia de 684.000c/ml y recuento de LCD4 en 38/ul. El paciente presentó evolución favorable, siendo el cultivo de control (-) y tras completar ciclo, se realizó desescalada a fluconazol oral. Tras cuatro semanas de tratamiento antifúngico, se inició tratamiento antirretroviral con raltegravir + FTC + TDF con buena tolerancia. Se completó estudio con PET que informó de extensa afectación a nivel abdominal y pulmonar, biopsia ósea (sin infiltración) y ecocardiograma con fracción de eyección conservada. En situación estable, se inició ciclo R-CHOP con buena tolerancia y respuesta. Exploración física ECOG 2. Boca seca sin aftas. Marcada caquexia. A nivel abdominal, destacó empastamiento en hemiabdomen derecho, así como dudoso en flanco izquierdo con dolor a la palpación de epigastrio e hipocondrio derecho. El resto, anodino. Pruebas complementarias » TC con contraste I.V. de abdomen (13/02/2017): progresión de la enfermedad con múltiples masas intraperitoneales compatibles con implantes metastásicos. Uno de ellos obstruye al uréter derecho y otro infiltra a un asa de delegado en la fosa iliaca izquierda. » LCR (17/03/17): 30 leucocitos (10 % PMN, 30 % MN), 0 hematíes, 97 glucosa, 125 proteínas, 22,3 ADA. Abundantes linfocitos. IF: sólo 4 % linfocitos B monoclonales, resto linfocitos T. Se detecta antígeno Cryptococcus. » Serologías (20/03/17): VIH (+), VHB y VHC (-), CMV IgG(+), VEB(-), VHS IgG(+),Sífilis (-), toxoplasma IgG(+). B2- microglobulina (21/04/17): 4,52, LDH: 473. » PET (24/04/17): informa de extensa afectación supra e infradiafragmática con predominio de grandes masas a nivel abdominal, así como pulmonar y sin hallazgos en el resto. Diagnóstico » Linfoma difuso de células grandes B (LCGB) tipo centrogerminal. » Infección por VIH categoría C3 (sida). » Meningitis criptocócica. Tratamiento Tras presentar el caso en sesión multidisciplinar, se decidió inicio de tratamiento con anfotericina liposomal y fludrocortisona, pasando a fluconazol vía oral. Pasadas 4 semanas, se instauró tratamiento antirretroviral con raltegravir + FTC + TDF y, por último, se inició quimioterapia sistémica según esquema R-CHOP. Evolución Paciente con los antecedentes descritos previamente, estable en el momento actual, en seguimiento por la Unidad de Hematología en Consultas Externas. Buena respuesta y tolerancia tras tercer ciclo de R-CHOP. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Anamnesis Antecedentes familiares: tío materno fallecido por cáncer de próstata con más de 70 años y otro por neoplasia faríngea. Tío paterno fallecido por cáncer de pulmón. Antecedentes personales: sin alergias medicamentosas conocidas. Exfumador desde hace 20 años (20 paquetes-año). Diabetes mellitus tipo II desde 2004, insulinodependiente desde hace 3 años. Hipercolesterolemia. Trabajador de una bodega. Niega consumo de tóxicos. Tratamiento habitual: simvastatina 20 mg, omeprazol 20 mg, naproxeno si tiene dolor, cinitaprida 10 mg antes de las comidas. Su historia oncológica comienza el 03/12/16, cuando el paciente acudió a Urgencias por fiebre de hasta 38,5ºC, pérdida de ponderal cuantificada en 7 kg en el último mes, disfagia a sólidos y a líquidos, con sensación de plenitud gástrica precoz, astenia intensa y dolor abdominal hipogástrico. Se realizó ecografía y TC abdominal urgente con contraste objetivando tumoración centro-abdominal de 17,2 x 7,7 x 7,5 cm, con importante componente hidroaéreo, engrosamiento mural marcado e irregular, contactando con asas de intestino delgado, probablemente en relación a GIST complicado. Se decidió realización de laparotomía exploradora urgente por sospecha de perforación intestinal, que objetiva cloaca centro abdominal, realizándose resección de tumoral con varias asas intestinales, y anastomosis laterolateral mecánica. Cirugía subóptima por bordes afectos. El informe anatomopatológico objetivó hallazgos compatibles con fibromatosis mesentérica de tipo desmoide, con estudio inmunohistoquímico positivo para actina de músculo liso y beta-catenina; y negativo para desmina, CD34, S100, CD117(C-KIT) y DOG1. Valorado por primera vez en consultas de Oncología Médica el 16/01/2017, se decidió seguimiento estrecho con control radiológico en 4 meses, así como colonoscopia por la asociación conocida de los tumores desmoides y la poliposis adenomatosa familiar (PAF). Un mes después de la intervención, acudió a Urgencias por dolor en fosa renal derecha con irradiación, realizándose TC abdominal que mostró ureterohidronefrosis derecha moderada y múltiples implantes peritoneales, compatibles con recidiva tumoral. Se desestimó nueva intervención por parte de Urología y Cirugía, por lo que ingresó en Oncología para completar estudio y se procedió a la colocación de nefrostomía percutánea derecha sin complicaciones. Previa al alta, se realizó colonoscopia descartándose PAF. Ante la discordancia clínico-patológica (necrosis tumoral, implantes peritoneales, evolución clínica, etc.) se solicitó una nueva revisión histológica en centro de referencia de tumores de partes blandas, emitiéndose un diagnóstico de linfoma B difuso de células grandes, inmunofenotipo germinal con inmunoexpresión positiva para BCL-6 y negativos para MUM-1, CD5, CD10, cMYC y EBER con un índice proliferativo (Ki67) del 80 %. Por consiguiente, el paciente continuó su evolución a cargo del Servicio de Hematología. Tras aparición de fiebre junto a ataxia, alteraciones del sensorio y síndrome emético, se realizó RMN cerebral que descartó afectación a este nivel. Se decidió realización de punción lumbar, detectándose antígeno Cryptococcus (+); iniciándose anfotericina liposomal y fludrocortisona (fecha de inicio del tratamiento: 17/03/17). A las 48 horas, se informó de serología para VIH (+) con viremia de 684.000c/ml y recuento de LCD4 en 38/ul. El paciente presentó evolución favorable, siendo el cultivo de control (-) y tras completar ciclo, se realizó desescalada a fluconazol oral. Tras cuatro semanas de tratamiento antifúngico, se inició tratamiento antirretroviral con raltegravir + FTC + TDF con buena tolerancia. Se completó estudio con PET que informó de extensa afectación a nivel abdominal y pulmonar, biopsia ósea (sin infiltración) y ecocardiograma con fracción de eyección conservada. En situación estable, se inició ciclo R-CHOP con buena tolerancia y respuesta. Exploración física ECOG 2. Boca seca sin aftas. Marcada caquexia. A nivel abdominal, destacó empastamiento en hemiabdomen derecho, así como dudoso en flanco izquierdo con dolor a la palpación de epigastrio e hipocondrio derecho. El resto, anodino. Pruebas complementarias » TC con contraste I.V. de abdomen (13/02/2017): progresión de la enfermedad con múltiples masas intraperitoneales compatibles con implantes metastásicos. Uno de ellos obstruye al uréter derecho y otro infiltra a un asa de delegado en la fosa iliaca izquierda. » LCR (17/03/17): 30 leucocitos (10 % PMN, 30 % MN), 0 hematíes, 97 glucosa, 125 proteínas, 22,3 ADA. Abundantes linfocitos. IF: sólo 4 % linfocitos B monoclonales, resto linfocitos T. Se detecta antígeno Cryptococcus. » Serologías (20/03/17): VIH (+), VHB y VHC (-), CMV IgG(+), VEB(-), VHS IgG(+),Sífilis (-), toxoplasma IgG(+). B2- microglobulina (21/04/17): 4,52, LDH: 473. » PET (24/04/17): informa de extensa afectación supra e infradiafragmática con predominio de grandes masas a nivel abdominal, así como pulmonar y sin hallazgos en el resto. Diagnóstico » Linfoma difuso de células grandes B (LCGB) tipo centrogerminal. » Infección por VIH categoría C3 (sida). » Meningitis criptocócica. Tratamiento Tras presentar el caso en sesión multidisciplinar, se decidió inicio de tratamiento con anfotericina liposomal y fludrocortisona, pasando a fluconazol vía oral. Pasadas 4 semanas, se instauró tratamiento antirretroviral con raltegravir + FTC + TDF y, por último, se inició quimioterapia sistémica según esquema R-CHOP. Evolución Paciente con los antecedentes descritos previamente, estable en el momento actual, en seguimiento por la Unidad de Hematología en Consultas Externas. Buena respuesta y tolerancia tras tercer ciclo de R-CHOP.
[ "Anamnesis", "\n", "Antecedentes", "familiares", ":", "tío", "materno", "fallecido", "por", "cáncer", "de", "próstata", "con", "más", "de", "70", "años", "y", "otro", "por", "neoplasia", "faríngea", ".", "Tío", "paterno", "fallecido", "por", "cáncer", "de", "pulmón", ".", "\n", "Antecedentes", "personales", ":", "sin", "alergias", "medicamentosas", "conocidas", ".", "Exfumador", "desde", "hace", "20", "años", "(", "20", "paquetes", "-", "año", ")", ".", "Diabetes", "mellitus", "tipo", "II", "desde", "2004", ",", "insulinodependiente", "desde", "hace", "3", "años", ".", "\n", "Hipercolesterolemia", ".", "Trabajador", "de", "una", "bodega", ".", "Niega", "consumo", "de", "tóxicos", ".", "Tratamiento", "habitual", ":", "simvastatina", "20", "mg", ",", "omeprazol", "20", "mg", ",", "naproxeno", "si", "tiene", "dolor", ",", "cinitaprida", "10", "mg", "antes", "de", "las", "comidas", ".", "\n", "Su", "historia", "oncológica", "comienza", "el", "03/12/16", ",", "cuando", "el", "paciente", "acudió", "a", "Urgencias", "por", "fiebre", "de", "hasta", "38,5ºC", ",", "pérdida", "de", "ponderal", "cuantificada", "en", "7", "kg", "en", "el", "último", "mes", ",", "disfagia", "a", "sólidos", "y", "a", "líquidos", ",", "con", "sensación", "de", "plenitud", "gástrica", "precoz", ",", "astenia", "intensa", "y", "dolor", "abdominal", "hipogástrico", ".", "\n", "Se", "realizó", "ecografía", "y", "TC", "abdominal", "urgente", "con", "contraste", "objetivando", "tumoración", "centro", "-", "abdominal", "de", "17,2", "x", "7,7", "x", "7,5", "cm", ",", "con", "importante", "componente", "hidroaéreo", ",", "engrosamiento", "mural", "marcado", "e", "irregular", ",", "contactando", "con", "asas", "de", "intestino", "delgado", ",", "probablemente", "en", "relación", "a", "GIST", "complicado", ".", "Se", "decidió", "realización", "de", "laparotomía", "exploradora", "urgente", "por", "sospecha", "de", "perforación", "intestinal", ",", "que", "objetiva", "cloaca", "centro", "abdominal", ",", "realizándose", "resección", "de", "tumoral", "con", "varias", "asas", "intestinales", ",", "y", "anastomosis", "laterolateral", "mecánica", ".", "Cirugía", "subóptima", "por", "bordes", "afectos", ".", "\n", "El", "informe", "anatomopatológico", "objetivó", "hallazgos", "compatibles", "con", "fibromatosis", "mesentérica", "de", "tipo", "desmoide", ",", "con", "estudio", "inmunohistoquímico", "positivo", "para", "actina", "de", "músculo", "liso", "y", "beta", "-", "catenina", ";", "y", "negativo", "para", "desmina", ",", "CD34", ",", "S100", ",", "CD117(C", "-", "KIT", ")", "y", "DOG1", ".", "\n", "Valorado", "por", "primera", "vez", "en", "consultas", "de", "Oncología", "Médica", "el", "16/01/2017", ",", "se", "decidió", "seguimiento", "estrecho", "con", "control", "radiológico", "en", "4", "meses", ",", "así", "como", "colonoscopia", "por", "la", "asociación", "conocida", "de", "los", "tumores", "desmoides", "y", "la", "poliposis", "adenomatosa", "familiar", "(", "PAF", ")", ".", "\n", "Un", "mes", "después", "de", "la", "intervención", ",", "acudió", "a", "Urgencias", "por", "dolor", "en", "fosa", "renal", "derecha", "con", "irradiación", ",", "realizándose", "TC", "abdominal", "que", "mostró", "ureterohidronefrosis", "derecha", "moderada", "y", "múltiples", "implantes", "peritoneales", ",", "compatibles", "con", "recidiva", "tumoral", ".", "Se", "desestimó", "nueva", "intervención", "por", "parte", "de", "Urología", "y", "Cirugía", ",", "por", "lo", "que", "ingresó", "en", "Oncología", "para", "completar", "estudio", "y", "se", "procedió", "a", "la", "colocación", "de", "nefrostomía", "percutánea", "derecha", "sin", "complicaciones", ".", "\n", "Previa", "al", "alta", ",", "se", "realizó", "colonoscopia", "descartándose", "PAF", ".", "Ante", "la", "discordancia", "clínico", "-", "patológica", "(", "necrosis", "tumoral", ",", "implantes", "peritoneales", ",", "evolución", "clínica", ",", "etc", ".", ")", "se", "solicitó", "una", "nueva", "revisión", "histológica", "en", "centro", "de", "referencia", "de", "tumores", "de", "partes", "blandas", ",", "emitiéndose", "un", "diagnóstico", "de", "linfoma", "B", "difuso", "de", "células", "grandes", ",", "inmunofenotipo", "germinal", "con", "inmunoexpresión", "positiva", "para", "BCL-6", "y", "negativos", "para", "MUM-1", ",", "CD5", ",", "CD10", ",", "cMYC", "y", "EBER", "con", "un", "índice", "proliferativo", "(", "Ki67", ")", "del", "80", "%", ".", "Por", "consiguiente", ",", "el", "paciente", "continuó", "su", "evolución", "a", "cargo", "del", "Servicio", "de", "Hematología", ".", "\n", "Tras", "aparición", "de", "fiebre", "junto", "a", "ataxia", ",", "alteraciones", "del", "sensorio", "y", "síndrome", "emético", ",", "se", "realizó", "RMN", "cerebral", "que", "descartó", "afectación", "a", "este", "nivel", ".", "Se", "decidió", "realización", "de", "punción", "lumbar", ",", "detectándose", "antígeno", "Cryptococcus", "(", "+", ")", ";", "iniciándose", "anfotericina", "liposomal", "y", "fludrocortisona", "(", "fecha", "de", "inicio", "del", "tratamiento", ":", "17/03/17", ")", ".", "A", "las", "48", "horas", ",", "se", "informó", "de", "serología", "para", "VIH", "(", "+", ")", "con", "viremia", "de", "684.000c", "/", "ml", "y", "recuento", "de", "LCD4", "en", "38", "/", "ul", ".", "\n", "El", "paciente", "presentó", "evolución", "favorable", ",", "siendo", "el", "cultivo", "de", "control", "(", "-", ")", "y", "tras", "completar", "ciclo", ",", "se", "realizó", "desescalada", "a", "fluconazol", "oral", ".", "Tras", "cuatro", "semanas", "de", "tratamiento", "antifúngico", ",", "se", "inició", "tratamiento", "antirretroviral", "con", "raltegravir", "+", "FTC", "+", "TDF", "con", "buena", "tolerancia", ".", "\n", "Se", "completó", "estudio", "con", "PET", "que", "informó", "de", "extensa", "afectación", "a", "nivel", "abdominal", "y", "pulmonar", ",", "biopsia", "ósea", "(", "sin", "infiltración", ")", "y", "ecocardiograma", "con", "fracción", "de", "eyección", "conservada", ".", "En", "situación", "estable", ",", "se", "inició", "ciclo", "R", "-", "CHOP", "con", "buena", "tolerancia", "y", "respuesta", ".", "\n\n", "Exploración", "física", "\n", "ECOG", "2", ".", "Boca", "seca", "sin", "aftas", ".", "Marcada", "caquexia", ".", "A", "nivel", "abdominal", ",", "destacó", "empastamiento", "en", "hemiabdomen", "derecho", ",", "así", "como", "dudoso", "en", "flanco", "izquierdo", "con", "dolor", "a", "la", "palpación", "de", "epigastrio", "e", "hipocondrio", "derecho", ".", "El", "resto", ",", "anodino", ".", "\n\n", "Pruebas", "complementarias", "\n", "»", "TC", "con", "contraste", "I.V.", "de", "abdomen", "(", "13/02/2017", "):", "progresión", "de", "la", "enfermedad", "con", "múltiples", "masas", "intraperitoneales", "compatibles", "con", "implantes", "metastásicos", ".", "Uno", "de", "ellos", "obstruye", "al", "uréter", "derecho", "y", "otro", "infiltra", "a", "un", "asa", "de", "delegado", "en", "la", "fosa", "iliaca", "izquierda", ".", "\n", "»", "LCR", "(", "17/03/17", "):", "30", "leucocitos", "(", "10", "%", "PMN", ",", "30", "%", "MN", ")", ",", "0", "hematíes", ",", "97", "glucosa", ",", "125", "proteínas", ",", "22,3", "ADA", ".", "Abundantes", "linfocitos", ".", "IF", ":", "sólo", "4", "%", "linfocitos", "B", "monoclonales", ",", "resto", "linfocitos", "T.", "Se", "detecta", "antígeno", "Cryptococcus", ".", "\n", "»", "Serologías", "(", "20/03/17", "):", "VIH", "(", "+", ")", ",", "VHB", "y", "VHC", "(", "-", ")", ",", "CMV", "IgG(+", ")", ",", "VEB(-", ")", ",", "VHS", "IgG(+),Sífilis", "(", "-", ")", ",", "toxoplasma", "IgG(+", ")", ".", "B2-", "microglobulina", "(", "21/04/17", "):", "4,52", ",", "LDH", ":", "473", ".", "\n", "»", "PET", "(", "24/04/17", "):", "informa", "de", "extensa", "afectación", "supra", "e", "infradiafragmática", "con", "predominio", "de", "grandes", "masas", "a", "nivel", "abdominal", ",", "así", "como", "pulmonar", "y", "sin", "hallazgos", "en", "el", "resto", ".", "\n\n", "Diagnóstico", "\n", "»", "Linfoma", "difuso", "de", "células", "grandes", "B", "(", "LCGB", ")", "tipo", "centrogerminal", ".", "\n", "»", "Infección", "por", "VIH", "categoría", "C3", "(", "sida", ")", ".", "\n", "»", "Meningitis", "criptocócica", ".", "\n\n", "Tratamiento", "\n", "Tras", "presentar", "el", "caso", "en", "sesión", "multidisciplinar", ",", "se", "decidió", "inicio", "de", "tratamiento", "con", "anfotericina", "liposomal", "y", "fludrocortisona", ",", "pasando", "a", "fluconazol", "vía", "oral", ".", "Pasadas", "4", "semanas", ",", "se", "instauró", "tratamiento", "antirretroviral", "con", "raltegravir", "+", "FTC", "+", "TDF", "y", ",", "por", "último", ",", "se", "inició", "quimioterapia", "sistémica", "según", "esquema", "R", "-", "CHOP", ".", "\n\n", "Evolución", "\n", "Paciente", "con", "los", "antecedentes", "descritos", "previamente", ",", "estable", "en", "el", "momento", "actual", ",", "en", "seguimiento", "por", "la", "Unidad", "de", "Hematología", "en", "Consultas", "Externas", ".", "Buena", "respuesta", "y", "tolerancia", "tras", "tercer", "ciclo", "de", "R", "-", "CHOP", "." ]
[ "MORFOLOGIA_NEOPLASIA" ]
Blutung is an umlsterm, Praxis is an umlsterm, Blutung is an umlsterm, Karzinom is an umlsterm, Behandlung is an umlsterm, Blutung is an umlsterm, Blutung is an umlsterm
DerGynaekologe.00330659.ger.abstr_task0
Sentence: Die vaginale und uterine Blutung ist ein haeufig anzutreffendes Symptom in der gynaekologischen Praxis . Jede vaginale Blutung sollte abgeklaert werden , um ein Karzinom als Ursache auszuschliessen . Bei der Behandlung der akuten Blutung muss zuerst die Kreislaufsituation der Patientin stabilisiert werden . In Abhaengigkeit von der Kreislaufsituation kann bei Stabilitaet der Lage eine diagnostische Abklaerung der Genese der Blutung bzw. des Primaertumors erfolgen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]
Die vaginale und uterine Blutung ist ein haeufig anzutreffendes Symptom in der gynaekologischen Praxis . Jede vaginale Blutung sollte abgeklaert werden , um ein Karzinom als Ursache auszuschliessen . Bei der Behandlung der akuten Blutung muss zuerst die Kreislaufsituation der Patientin stabilisiert werden . In Abhaengigkeit von der Kreislaufsituation kann bei Stabilitaet der Lage eine diagnostische Abklaerung der Genese der Blutung bzw. des Primaertumors erfolgen .
[ "Die", "vaginale", "und", "uterine", "Blutung", "ist", "ein", "haeufig", "anzutreffendes", "Symptom", "in", "der", "gynaekologischen", "Praxis", ".", "Jede", "vaginale", "Blutung", "sollte", "abgeklaert", "werden", ",", "um", "ein", "Karzinom", "als", "Ursache", "auszuschliessen", ".", "Bei", "der", "Behandlung", "der", "akuten", "Blutung", "muss", "zuerst", "die", "Kreislaufsituation", "der", "Patientin", "stabilisiert", "werden", ".", "In", "Abhaengigkeit", "von", "der", "Kreislaufsituation", "kann", "bei", "Stabilitaet", "der", "Lage", "eine", "diagnostische", "Abklaerung", "der", "Genese", "der", "Blutung", "bzw", ".", "des", "Primaertumors", "erfolgen", "." ]
[ "umlsterm" ]
Blutung is an umlsterm, Praxis is an umlsterm, Blutung is an umlsterm, Karzinom is an umlsterm, Behandlung is an umlsterm, Blutung is an umlsterm, Blutung is an umlsterm
DerGynaekologe.00330659.ger.abstr_task1
Sentence: Die vaginale und uterine Blutung ist ein haeufig anzutreffendes Symptom in der gynaekologischen Praxis . Jede vaginale Blutung sollte abgeklaert werden , um ein Karzinom als Ursache auszuschliessen . Bei der Behandlung der akuten Blutung muss zuerst die Kreislaufsituation der Patientin stabilisiert werden . In Abhaengigkeit von der Kreislaufsituation kann bei Stabilitaet der Lage eine diagnostische Abklaerung der Genese der Blutung bzw. des Primaertumors erfolgen . Instructions: please typing these entity words according to sentence: Blutung, Praxis, Blutung, Karzinom, Behandlung, Blutung, Blutung Options: umlsterm
[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]
Die vaginale und uterine Blutung ist ein haeufig anzutreffendes Symptom in der gynaekologischen Praxis . Jede vaginale Blutung sollte abgeklaert werden , um ein Karzinom als Ursache auszuschliessen . Bei der Behandlung der akuten Blutung muss zuerst die Kreislaufsituation der Patientin stabilisiert werden . In Abhaengigkeit von der Kreislaufsituation kann bei Stabilitaet der Lage eine diagnostische Abklaerung der Genese der Blutung bzw. des Primaertumors erfolgen .
[ "Die", "vaginale", "und", "uterine", "Blutung", "ist", "ein", "haeufig", "anzutreffendes", "Symptom", "in", "der", "gynaekologischen", "Praxis", ".", "Jede", "vaginale", "Blutung", "sollte", "abgeklaert", "werden", ",", "um", "ein", "Karzinom", "als", "Ursache", "auszuschliessen", ".", "Bei", "der", "Behandlung", "der", "akuten", "Blutung", "muss", "zuerst", "die", "Kreislaufsituation", "der", "Patientin", "stabilisiert", "werden", ".", "In", "Abhaengigkeit", "von", "der", "Kreislaufsituation", "kann", "bei", "Stabilitaet", "der", "Lage", "eine", "diagnostische", "Abklaerung", "der", "Genese", "der", "Blutung", "bzw", ".", "des", "Primaertumors", "erfolgen", "." ]
[ "umlsterm" ]
Blutung, Praxis, Blutung, Karzinom, Behandlung, Blutung, Blutung
DerGynaekologe.00330659.ger.abstr_task2
Sentence: Die vaginale und uterine Blutung ist ein haeufig anzutreffendes Symptom in der gynaekologischen Praxis . Jede vaginale Blutung sollte abgeklaert werden , um ein Karzinom als Ursache auszuschliessen . Bei der Behandlung der akuten Blutung muss zuerst die Kreislaufsituation der Patientin stabilisiert werden . In Abhaengigkeit von der Kreislaufsituation kann bei Stabilitaet der Lage eine diagnostische Abklaerung der Genese der Blutung bzw. des Primaertumors erfolgen . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]
Die vaginale und uterine Blutung ist ein haeufig anzutreffendes Symptom in der gynaekologischen Praxis . Jede vaginale Blutung sollte abgeklaert werden , um ein Karzinom als Ursache auszuschliessen . Bei der Behandlung der akuten Blutung muss zuerst die Kreislaufsituation der Patientin stabilisiert werden . In Abhaengigkeit von der Kreislaufsituation kann bei Stabilitaet der Lage eine diagnostische Abklaerung der Genese der Blutung bzw. des Primaertumors erfolgen .
[ "Die", "vaginale", "und", "uterine", "Blutung", "ist", "ein", "haeufig", "anzutreffendes", "Symptom", "in", "der", "gynaekologischen", "Praxis", ".", "Jede", "vaginale", "Blutung", "sollte", "abgeklaert", "werden", ",", "um", "ein", "Karzinom", "als", "Ursache", "auszuschliessen", ".", "Bei", "der", "Behandlung", "der", "akuten", "Blutung", "muss", "zuerst", "die", "Kreislaufsituation", "der", "Patientin", "stabilisiert", "werden", ".", "In", "Abhaengigkeit", "von", "der", "Kreislaufsituation", "kann", "bei", "Stabilitaet", "der", "Lage", "eine", "diagnostische", "Abklaerung", "der", "Genese", "der", "Blutung", "bzw", ".", "des", "Primaertumors", "erfolgen", "." ]
[ "umlsterm" ]
journal is an umlsterm, survey is an umlsterm, Working is an umlsterm, Association is an umlsterm, Intensive Care is an umlsterm, Medicine is an umlsterm, analysis is an umlsterm, intensive care units is an umlsterm, beds is an umlsterm, intensive care units is an umlsterm, beds is an umlsterm, intensive care units is an umlsterm, ventilation is an umlsterm, equipment is an umlsterm, beds is an umlsterm, training is an umlsterm, physicians is an umlsterm, nurses is an umlsterm, equipment is an umlsterm, apparatus is an umlsterm, neurosurgery is an umlsterm, measures is an umlsterm, medicine is an umlsterm, hand is an umlsterm, ventilation is an umlsterm, treatment is an umlsterm, hand is an umlsterm, frequency is an umlsterm, diagnosis is an umlsterm, patients is an umlsterm, intensive care units is an umlsterm, development is an umlsterm, intensive care is an umlsterm, intensive care is an umlsterm, standard is an umlsterm, single is an umlsterm, physician is an umlsterm, beds is an umlsterm, beds is an umlsterm, ventilation is an umlsterm, ventilator is an umlsterm, overall is an umlsterm, time is an umlsterm, ventilation is an umlsterm, intensive care is an umlsterm
DerNervenarzt.80691123.eng.abstr_task0
Sentence: In 1994 this journal published the results of a survey undertaken on behalf of the Working Association for Neurological Intensive Care Medicine ( ANIM ) in the winter of 1992/93 . In the winter of 1996/97 a continuation of this analysis was performed . With the help of a questionaire the data of 62 intensive care units with a total of 420 beds were established . This is 11 intensive care units and 83 beds more than 1992/93 . The intensive care units were again classified into three groups ( ventilation units , monitoring units , interdisciplinary units ) relating to their equipment and structure . The questions concerned structural organisation , such as the number of beds , type of clinic , number and training of physicians and nurses , technical equipment and availability of large and high-tech apparatus or access to other facilities , such as neurosurgery . Of great interest were data about whether and to what extent special measures of intensive medicine can be taken on the one hand and performance parameter data e.g. days of ventilation and duration of in-patient treatment on the other hand . Detailed data were provided concerning the frequency of each diagnosis of patients treated in those intensive care units . Evaluating the data a positive development in the last four years of the neurological intensive care can be found in most of the areas investigated . It has also been found that neurological intensive care in the new lander has reached equal standard both in quality and quantity . Now a single physician is responsible for 2,3 beds compared to 3,6 . Today 78 per cent of the beds in ventilation units are equiped with a ventilator . The overall time of ventilation increased to 48 per cent . Overall there are , however , considerable differences between individual units as well as regions . The data presented can serve as a means to monitor the quality of neurological intensive care . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]
In 1994 this journal published the results of a survey undertaken on behalf of the Working Association for Neurological Intensive Care Medicine ( ANIM ) in the winter of 1992/93 . In the winter of 1996/97 a continuation of this analysis was performed . With the help of a questionaire the data of 62 intensive care units with a total of 420 beds were established . This is 11 intensive care units and 83 beds more than 1992/93 . The intensive care units were again classified into three groups ( ventilation units , monitoring units , interdisciplinary units ) relating to their equipment and structure . The questions concerned structural organisation , such as the number of beds , type of clinic , number and training of physicians and nurses , technical equipment and availability of large and high-tech apparatus or access to other facilities , such as neurosurgery . Of great interest were data about whether and to what extent special measures of intensive medicine can be taken on the one hand and performance parameter data e.g. days of ventilation and duration of in-patient treatment on the other hand . Detailed data were provided concerning the frequency of each diagnosis of patients treated in those intensive care units . Evaluating the data a positive development in the last four years of the neurological intensive care can be found in most of the areas investigated . It has also been found that neurological intensive care in the new lander has reached equal standard both in quality and quantity . Now a single physician is responsible for 2,3 beds compared to 3,6 . Today 78 per cent of the beds in ventilation units are equiped with a ventilator . The overall time of ventilation increased to 48 per cent . Overall there are , however , considerable differences between individual units as well as regions . The data presented can serve as a means to monitor the quality of neurological intensive care .
[ "In", "1994", "this", "journal", "published", "the", "results", "of", "a", "survey", "undertaken", "on", "behalf", "of", "the", "Working", "Association", "for", "Neurological", "Intensive", "Care", "Medicine", "(", "ANIM", ")", "in", "the", "winter", "of", "1992/93", ".", "In", "the", "winter", "of", "1996/97", "a", "continuation", "of", "this", "analysis", "was", "performed", ".", "With", "the", "help", "of", "a", "questionaire", "the", "data", "of", "62", "intensive", "care", "units", "with", "a", "total", "of", "420", "beds", "were", "established", ".", "This", "is", "11", "intensive", "care", "units", "and", "83", "beds", "more", "than", "1992/93", ".", "The", "intensive", "care", "units", "were", "again", "classified", "into", "three", "groups", "(", "ventilation", "units", ",", "monitoring", "units", ",", "interdisciplinary", "units", ")", "relating", "to", "their", "equipment", "and", "structure", ".", "The", "questions", "concerned", "structural", "organisation", ",", "such", "as", "the", "number", "of", "beds", ",", "type", "of", "clinic", ",", "number", "and", "training", "of", "physicians", "and", "nurses", ",", "technical", "equipment", "and", "availability", "of", "large", "and", "high", "-", "tech", "apparatus", "or", "access", "to", "other", "facilities", ",", "such", "as", "neurosurgery", ".", "Of", "great", "interest", "were", "data", "about", "whether", "and", "to", "what", "extent", "special", "measures", "of", "intensive", "medicine", "can", "be", "taken", "on", "the", "one", "hand", "and", "performance", "parameter", "data", "e.g", ".", "days", "of", "ventilation", "and", "duration", "of", "in", "-", "patient", "treatment", "on", "the", "other", "hand", ".", "Detailed", "data", "were", "provided", "concerning", "the", "frequency", "of", "each", "diagnosis", "of", "patients", "treated", "in", "those", "intensive", "care", "units", ".", "Evaluating", "the", "data", "a", "positive", "development", "in", "the", "last", "four", "years", "of", "the", "neurological", "intensive", "care", "can", "be", "found", "in", "most", "of", "the", "areas", "investigated", ".", "It", "has", "also", "been", "found", "that", "neurological", "intensive", "care", "in", "the", "new", "lander", "has", "reached", "equal", "standard", "both", "in", "quality", "and", "quantity", ".", "Now", "a", "single", "physician", "is", "responsible", "for", "2,3", "beds", "compared", "to", "3,6", ".", "Today", "78", "per", "cent", "of", "the", "beds", "in", "ventilation", "units", "are", "equiped", "with", "a", "ventilator", ".", "The", "overall", "time", "of", "ventilation", "increased", "to", "48", "per", "cent", ".", "Overall", "there", "are", ",", "however", ",", "considerable", "differences", "between", "individual", "units", "as", "well", "as", "regions", ".", "The", "data", "presented", "can", "serve", "as", "a", "means", "to", "monitor", "the", "quality", "of", "neurological", "intensive", "care", "." ]
[ "umlsterm" ]
journal is an umlsterm, survey is an umlsterm, Working is an umlsterm, Association is an umlsterm, Intensive Care is an umlsterm, Medicine is an umlsterm, analysis is an umlsterm, intensive care units is an umlsterm, beds is an umlsterm, intensive care units is an umlsterm, beds is an umlsterm, intensive care units is an umlsterm, ventilation is an umlsterm, equipment is an umlsterm, beds is an umlsterm, training is an umlsterm, physicians is an umlsterm, nurses is an umlsterm, equipment is an umlsterm, apparatus is an umlsterm, neurosurgery is an umlsterm, measures is an umlsterm, medicine is an umlsterm, hand is an umlsterm, ventilation is an umlsterm, treatment is an umlsterm, hand is an umlsterm, frequency is an umlsterm, diagnosis is an umlsterm, patients is an umlsterm, intensive care units is an umlsterm, development is an umlsterm, intensive care is an umlsterm, intensive care is an umlsterm, standard is an umlsterm, single is an umlsterm, physician is an umlsterm, beds is an umlsterm, beds is an umlsterm, ventilation is an umlsterm, ventilator is an umlsterm, overall is an umlsterm, time is an umlsterm, ventilation is an umlsterm, intensive care is an umlsterm
DerNervenarzt.80691123.eng.abstr_task1
Sentence: In 1994 this journal published the results of a survey undertaken on behalf of the Working Association for Neurological Intensive Care Medicine ( ANIM ) in the winter of 1992/93 . In the winter of 1996/97 a continuation of this analysis was performed . With the help of a questionaire the data of 62 intensive care units with a total of 420 beds were established . This is 11 intensive care units and 83 beds more than 1992/93 . The intensive care units were again classified into three groups ( ventilation units , monitoring units , interdisciplinary units ) relating to their equipment and structure . The questions concerned structural organisation , such as the number of beds , type of clinic , number and training of physicians and nurses , technical equipment and availability of large and high-tech apparatus or access to other facilities , such as neurosurgery . Of great interest were data about whether and to what extent special measures of intensive medicine can be taken on the one hand and performance parameter data e.g. days of ventilation and duration of in-patient treatment on the other hand . Detailed data were provided concerning the frequency of each diagnosis of patients treated in those intensive care units . Evaluating the data a positive development in the last four years of the neurological intensive care can be found in most of the areas investigated . It has also been found that neurological intensive care in the new lander has reached equal standard both in quality and quantity . Now a single physician is responsible for 2,3 beds compared to 3,6 . Today 78 per cent of the beds in ventilation units are equiped with a ventilator . The overall time of ventilation increased to 48 per cent . Overall there are , however , considerable differences between individual units as well as regions . The data presented can serve as a means to monitor the quality of neurological intensive care . Instructions: please typing these entity words according to sentence: journal, survey, Working, Association, Intensive Care, Medicine, analysis, intensive care units, beds, intensive care units, beds, intensive care units, ventilation, equipment, beds, training, physicians, nurses, equipment, apparatus, neurosurgery, measures, medicine, hand, ventilation, treatment, hand, frequency, diagnosis, patients, intensive care units, development, intensive care, intensive care, standard, single, physician, beds, beds, ventilation, ventilator, overall, time, ventilation, intensive care Options: umlsterm
[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]
In 1994 this journal published the results of a survey undertaken on behalf of the Working Association for Neurological Intensive Care Medicine ( ANIM ) in the winter of 1992/93 . In the winter of 1996/97 a continuation of this analysis was performed . With the help of a questionaire the data of 62 intensive care units with a total of 420 beds were established . This is 11 intensive care units and 83 beds more than 1992/93 . The intensive care units were again classified into three groups ( ventilation units , monitoring units , interdisciplinary units ) relating to their equipment and structure . The questions concerned structural organisation , such as the number of beds , type of clinic , number and training of physicians and nurses , technical equipment and availability of large and high-tech apparatus or access to other facilities , such as neurosurgery . Of great interest were data about whether and to what extent special measures of intensive medicine can be taken on the one hand and performance parameter data e.g. days of ventilation and duration of in-patient treatment on the other hand . Detailed data were provided concerning the frequency of each diagnosis of patients treated in those intensive care units . Evaluating the data a positive development in the last four years of the neurological intensive care can be found in most of the areas investigated . It has also been found that neurological intensive care in the new lander has reached equal standard both in quality and quantity . Now a single physician is responsible for 2,3 beds compared to 3,6 . Today 78 per cent of the beds in ventilation units are equiped with a ventilator . The overall time of ventilation increased to 48 per cent . Overall there are , however , considerable differences between individual units as well as regions . The data presented can serve as a means to monitor the quality of neurological intensive care .
[ "In", "1994", "this", "journal", "published", "the", "results", "of", "a", "survey", "undertaken", "on", "behalf", "of", "the", "Working", "Association", "for", "Neurological", "Intensive", "Care", "Medicine", "(", "ANIM", ")", "in", "the", "winter", "of", "1992/93", ".", "In", "the", "winter", "of", "1996/97", "a", "continuation", "of", "this", "analysis", "was", "performed", ".", "With", "the", "help", "of", "a", "questionaire", "the", "data", "of", "62", "intensive", "care", "units", "with", "a", "total", "of", "420", "beds", "were", "established", ".", "This", "is", "11", "intensive", "care", "units", "and", "83", "beds", "more", "than", "1992/93", ".", "The", "intensive", "care", "units", "were", "again", "classified", "into", "three", "groups", "(", "ventilation", "units", ",", "monitoring", "units", ",", "interdisciplinary", "units", ")", "relating", "to", "their", "equipment", "and", "structure", ".", "The", "questions", "concerned", "structural", "organisation", ",", "such", "as", "the", "number", "of", "beds", ",", "type", "of", "clinic", ",", "number", "and", "training", "of", "physicians", "and", "nurses", ",", "technical", "equipment", "and", "availability", "of", "large", "and", "high", "-", "tech", "apparatus", "or", "access", "to", "other", "facilities", ",", "such", "as", "neurosurgery", ".", "Of", "great", "interest", "were", "data", "about", "whether", "and", "to", "what", "extent", "special", "measures", "of", "intensive", "medicine", "can", "be", "taken", "on", "the", "one", "hand", "and", "performance", "parameter", "data", "e.g", ".", "days", "of", "ventilation", "and", "duration", "of", "in", "-", "patient", "treatment", "on", "the", "other", "hand", ".", "Detailed", "data", "were", "provided", "concerning", "the", "frequency", "of", "each", "diagnosis", "of", "patients", "treated", "in", "those", "intensive", "care", "units", ".", "Evaluating", "the", "data", "a", "positive", "development", "in", "the", "last", "four", "years", "of", "the", "neurological", "intensive", "care", "can", "be", "found", "in", "most", "of", "the", "areas", "investigated", ".", "It", "has", "also", "been", "found", "that", "neurological", "intensive", "care", "in", "the", "new", "lander", "has", "reached", "equal", "standard", "both", "in", "quality", "and", "quantity", ".", "Now", "a", "single", "physician", "is", "responsible", "for", "2,3", "beds", "compared", "to", "3,6", ".", "Today", "78", "per", "cent", "of", "the", "beds", "in", "ventilation", "units", "are", "equiped", "with", "a", "ventilator", ".", "The", "overall", "time", "of", "ventilation", "increased", "to", "48", "per", "cent", ".", "Overall", "there", "are", ",", "however", ",", "considerable", "differences", "between", "individual", "units", "as", "well", "as", "regions", ".", "The", "data", "presented", "can", "serve", "as", "a", "means", "to", "monitor", "the", "quality", "of", "neurological", "intensive", "care", "." ]
[ "umlsterm" ]
journal, survey, Working, Association, Intensive Care, Medicine, analysis, intensive care units, beds, intensive care units, beds, intensive care units, ventilation, equipment, beds, training, physicians, nurses, equipment, apparatus, neurosurgery, measures, medicine, hand, ventilation, treatment, hand, frequency, diagnosis, patients, intensive care units, development, intensive care, intensive care, standard, single, physician, beds, beds, ventilation, ventilator, overall, time, ventilation, intensive care
DerNervenarzt.80691123.eng.abstr_task2
Sentence: In 1994 this journal published the results of a survey undertaken on behalf of the Working Association for Neurological Intensive Care Medicine ( ANIM ) in the winter of 1992/93 . In the winter of 1996/97 a continuation of this analysis was performed . With the help of a questionaire the data of 62 intensive care units with a total of 420 beds were established . This is 11 intensive care units and 83 beds more than 1992/93 . The intensive care units were again classified into three groups ( ventilation units , monitoring units , interdisciplinary units ) relating to their equipment and structure . The questions concerned structural organisation , such as the number of beds , type of clinic , number and training of physicians and nurses , technical equipment and availability of large and high-tech apparatus or access to other facilities , such as neurosurgery . Of great interest were data about whether and to what extent special measures of intensive medicine can be taken on the one hand and performance parameter data e.g. days of ventilation and duration of in-patient treatment on the other hand . Detailed data were provided concerning the frequency of each diagnosis of patients treated in those intensive care units . Evaluating the data a positive development in the last four years of the neurological intensive care can be found in most of the areas investigated . It has also been found that neurological intensive care in the new lander has reached equal standard both in quality and quantity . Now a single physician is responsible for 2,3 beds compared to 3,6 . Today 78 per cent of the beds in ventilation units are equiped with a ventilator . The overall time of ventilation increased to 48 per cent . Overall there are , however , considerable differences between individual units as well as regions . The data presented can serve as a means to monitor the quality of neurological intensive care . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]
In 1994 this journal published the results of a survey undertaken on behalf of the Working Association for Neurological Intensive Care Medicine ( ANIM ) in the winter of 1992/93 . In the winter of 1996/97 a continuation of this analysis was performed . With the help of a questionaire the data of 62 intensive care units with a total of 420 beds were established . This is 11 intensive care units and 83 beds more than 1992/93 . The intensive care units were again classified into three groups ( ventilation units , monitoring units , interdisciplinary units ) relating to their equipment and structure . The questions concerned structural organisation , such as the number of beds , type of clinic , number and training of physicians and nurses , technical equipment and availability of large and high-tech apparatus or access to other facilities , such as neurosurgery . Of great interest were data about whether and to what extent special measures of intensive medicine can be taken on the one hand and performance parameter data e.g. days of ventilation and duration of in-patient treatment on the other hand . Detailed data were provided concerning the frequency of each diagnosis of patients treated in those intensive care units . Evaluating the data a positive development in the last four years of the neurological intensive care can be found in most of the areas investigated . It has also been found that neurological intensive care in the new lander has reached equal standard both in quality and quantity . Now a single physician is responsible for 2,3 beds compared to 3,6 . Today 78 per cent of the beds in ventilation units are equiped with a ventilator . The overall time of ventilation increased to 48 per cent . Overall there are , however , considerable differences between individual units as well as regions . The data presented can serve as a means to monitor the quality of neurological intensive care .
[ "In", "1994", "this", "journal", "published", "the", "results", "of", "a", "survey", "undertaken", "on", "behalf", "of", "the", "Working", "Association", "for", "Neurological", "Intensive", "Care", "Medicine", "(", "ANIM", ")", "in", "the", "winter", "of", "1992/93", ".", "In", "the", "winter", "of", "1996/97", "a", "continuation", "of", "this", "analysis", "was", "performed", ".", "With", "the", "help", "of", "a", "questionaire", "the", "data", "of", "62", "intensive", "care", "units", "with", "a", "total", "of", "420", "beds", "were", "established", ".", "This", "is", "11", "intensive", "care", "units", "and", "83", "beds", "more", "than", "1992/93", ".", "The", "intensive", "care", "units", "were", "again", "classified", "into", "three", "groups", "(", "ventilation", "units", ",", "monitoring", "units", ",", "interdisciplinary", "units", ")", "relating", "to", "their", "equipment", "and", "structure", ".", "The", "questions", "concerned", "structural", "organisation", ",", "such", "as", "the", "number", "of", "beds", ",", "type", "of", "clinic", ",", "number", "and", "training", "of", "physicians", "and", "nurses", ",", "technical", "equipment", "and", "availability", "of", "large", "and", "high", "-", "tech", "apparatus", "or", "access", "to", "other", "facilities", ",", "such", "as", "neurosurgery", ".", "Of", "great", "interest", "were", "data", "about", "whether", "and", "to", "what", "extent", "special", "measures", "of", "intensive", "medicine", "can", "be", "taken", "on", "the", "one", "hand", "and", "performance", "parameter", "data", "e.g", ".", "days", "of", "ventilation", "and", "duration", "of", "in", "-", "patient", "treatment", "on", "the", "other", "hand", ".", "Detailed", "data", "were", "provided", "concerning", "the", "frequency", "of", "each", "diagnosis", "of", "patients", "treated", "in", "those", "intensive", "care", "units", ".", "Evaluating", "the", "data", "a", "positive", "development", "in", "the", "last", "four", "years", "of", "the", "neurological", "intensive", "care", "can", "be", "found", "in", "most", "of", "the", "areas", "investigated", ".", "It", "has", "also", "been", "found", "that", "neurological", "intensive", "care", "in", "the", "new", "lander", "has", "reached", "equal", "standard", "both", "in", "quality", "and", "quantity", ".", "Now", "a", "single", "physician", "is", "responsible", "for", "2,3", "beds", "compared", "to", "3,6", ".", "Today", "78", "per", "cent", "of", "the", "beds", "in", "ventilation", "units", "are", "equiped", "with", "a", "ventilator", ".", "The", "overall", "time", "of", "ventilation", "increased", "to", "48", "per", "cent", ".", "Overall", "there", "are", ",", "however", ",", "considerable", "differences", "between", "individual", "units", "as", "well", "as", "regions", ".", "The", "data", "presented", "can", "serve", "as", "a", "means", "to", "monitor", "the", "quality", "of", "neurological", "intensive", "care", "." ]
[ "umlsterm" ]
Skotome is an umlsterm, Gesichtsfelddefekte is an umlsterm, Methode is an umlsterm, Eignung is an umlsterm, Rundfunk is an umlsterm, Arzt- is an umlsterm, Patientenfragebogens is an umlsterm, gesehenen is an umlsterm, Personen is an umlsterm, augenaerztlichen is an umlsterm, Gesichtsfelddefekte is an umlsterm
DerOpthalmologe.60930604.ger.abstr_task0
Sentence: Mit Hilfe der Rauschfeldkampimetrie ist es moeglich , typischerweise meist negative ( unsichtbare ) Skotome in unmittelbar fuer den Betroffenen wahrnehmbare Gesichtsfelddefekte zu ueberfuehren . Da diese Untersuchung ohnehin auf einem Monitor ablaeuft , lag es nahe , diese Methode hinsichtlich ihrer Eignung als Fernseh-Screening-Test zu ueberpruefen . In Zusammenarbeit mit dem Sueddeutschen Rundfunk ( SDR ) und der AOK Baden-Wuerttemberg ( nebst anderen RVO-Kassen ) wurden daher im Rahmen einer lokalen Fernsehsendung schaetzungsweise 300 000 Zuschauer nach kurzer Information und Instruktion mit einem eingespielten Rauschfeldreiz konfrontiert . Es gingen 531 postalische Anfragen von Fernsehzuschauern ein , die um Zusendung eines Arzt- bzw. Patientenfragebogens baten . Dies geschah in den meisten Faellen , um einen im Rauschfeld gesehenen Defekt von einem Augenarzt weiter abklaeren zu lassen . Laut 127 eingegangener , auswertbarer Untersuchungsboegen lagen in 78 Faellen keine relevanten ophthalmologischen Erkrankungen , insbesondere keine Sehbahnlaesionen , vor . Bei 49 Personen hingegen konnten die augenaerztlichen Kollegen ophthalmologisch abklaerungsbeduerftige Pathologika nachweisen ; hiervon waren in 20 Faellen die Gesichtsfelddefekte dem Augenarzt noch nicht bekannt . Am haeufigsten wurden glaukomatoese Optikusneuropathien sowie Makulopathien diagnostiziert . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Mit Hilfe der Rauschfeldkampimetrie ist es moeglich , typischerweise meist negative ( unsichtbare ) Skotome in unmittelbar fuer den Betroffenen wahrnehmbare Gesichtsfelddefekte zu ueberfuehren . Da diese Untersuchung ohnehin auf einem Monitor ablaeuft , lag es nahe , diese Methode hinsichtlich ihrer Eignung als Fernseh-Screening-Test zu ueberpruefen . In Zusammenarbeit mit dem Sueddeutschen Rundfunk ( SDR ) und der AOK Baden-Wuerttemberg ( nebst anderen RVO-Kassen ) wurden daher im Rahmen einer lokalen Fernsehsendung schaetzungsweise 300 000 Zuschauer nach kurzer Information und Instruktion mit einem eingespielten Rauschfeldreiz konfrontiert . Es gingen 531 postalische Anfragen von Fernsehzuschauern ein , die um Zusendung eines Arzt- bzw. Patientenfragebogens baten . Dies geschah in den meisten Faellen , um einen im Rauschfeld gesehenen Defekt von einem Augenarzt weiter abklaeren zu lassen . Laut 127 eingegangener , auswertbarer Untersuchungsboegen lagen in 78 Faellen keine relevanten ophthalmologischen Erkrankungen , insbesondere keine Sehbahnlaesionen , vor . Bei 49 Personen hingegen konnten die augenaerztlichen Kollegen ophthalmologisch abklaerungsbeduerftige Pathologika nachweisen ; hiervon waren in 20 Faellen die Gesichtsfelddefekte dem Augenarzt noch nicht bekannt . Am haeufigsten wurden glaukomatoese Optikusneuropathien sowie Makulopathien diagnostiziert .
[ "Mit", "Hilfe", "der", "Rauschfeldkampimetrie", "ist", "es", "moeglich", ",", "typischerweise", "meist", "negative", "(", "unsichtbare", ")", "Skotome", "in", "unmittelbar", "fuer", "den", "Betroffenen", "wahrnehmbare", "Gesichtsfelddefekte", "zu", "ueberfuehren", ".", "Da", "diese", "Untersuchung", "ohnehin", "auf", "einem", "Monitor", "ablaeuft", ",", "lag", "es", "nahe", ",", "diese", "Methode", "hinsichtlich", "ihrer", "Eignung", "als", "Fernseh", "-", "Screening", "-", "Test", "zu", "ueberpruefen", ".", "In", "Zusammenarbeit", "mit", "dem", "Sueddeutschen", "Rundfunk", "(", "SDR", ")", "und", "der", "AOK", "Baden", "-", "Wuerttemberg", "(", "nebst", "anderen", "RVO", "-", "Kassen", ")", "wurden", "daher", "im", "Rahmen", "einer", "lokalen", "Fernsehsendung", "schaetzungsweise", "300", "000", "Zuschauer", "nach", "kurzer", "Information", "und", "Instruktion", "mit", "einem", "eingespielten", "Rauschfeldreiz", "konfrontiert", ".", "Es", "gingen", "531", "postalische", "Anfragen", "von", "Fernsehzuschauern", "ein", ",", "die", "um", "Zusendung", "eines", "Arzt-", "bzw", ".", "Patientenfragebogens", "baten", ".", "Dies", "geschah", "in", "den", "meisten", "Faellen", ",", "um", "einen", "im", "Rauschfeld", "gesehenen", "Defekt", "von", "einem", "Augenarzt", "weiter", "abklaeren", "zu", "lassen", ".", "Laut", "127", "eingegangener", ",", "auswertbarer", "Untersuchungsboegen", "lagen", "in", "78", "Faellen", "keine", "relevanten", "ophthalmologischen", "Erkrankungen", ",", "insbesondere", "keine", "Sehbahnlaesionen", ",", "vor", ".", "Bei", "49", "Personen", "hingegen", "konnten", "die", "augenaerztlichen", "Kollegen", "ophthalmologisch", "abklaerungsbeduerftige", "Pathologika", "nachweisen", ";", "hiervon", "waren", "in", "20", "Faellen", "die", "Gesichtsfelddefekte", "dem", "Augenarzt", "noch", "nicht", "bekannt", ".", "Am", "haeufigsten", "wurden", "glaukomatoese", "Optikusneuropathien", "sowie", "Makulopathien", "diagnostiziert", "." ]
[ "umlsterm" ]
Skotome is an umlsterm, Gesichtsfelddefekte is an umlsterm, Methode is an umlsterm, Eignung is an umlsterm, Rundfunk is an umlsterm, Arzt- is an umlsterm, Patientenfragebogens is an umlsterm, gesehenen is an umlsterm, Personen is an umlsterm, augenaerztlichen is an umlsterm, Gesichtsfelddefekte is an umlsterm
DerOpthalmologe.60930604.ger.abstr_task1
Sentence: Mit Hilfe der Rauschfeldkampimetrie ist es moeglich , typischerweise meist negative ( unsichtbare ) Skotome in unmittelbar fuer den Betroffenen wahrnehmbare Gesichtsfelddefekte zu ueberfuehren . Da diese Untersuchung ohnehin auf einem Monitor ablaeuft , lag es nahe , diese Methode hinsichtlich ihrer Eignung als Fernseh-Screening-Test zu ueberpruefen . In Zusammenarbeit mit dem Sueddeutschen Rundfunk ( SDR ) und der AOK Baden-Wuerttemberg ( nebst anderen RVO-Kassen ) wurden daher im Rahmen einer lokalen Fernsehsendung schaetzungsweise 300 000 Zuschauer nach kurzer Information und Instruktion mit einem eingespielten Rauschfeldreiz konfrontiert . Es gingen 531 postalische Anfragen von Fernsehzuschauern ein , die um Zusendung eines Arzt- bzw. Patientenfragebogens baten . Dies geschah in den meisten Faellen , um einen im Rauschfeld gesehenen Defekt von einem Augenarzt weiter abklaeren zu lassen . Laut 127 eingegangener , auswertbarer Untersuchungsboegen lagen in 78 Faellen keine relevanten ophthalmologischen Erkrankungen , insbesondere keine Sehbahnlaesionen , vor . Bei 49 Personen hingegen konnten die augenaerztlichen Kollegen ophthalmologisch abklaerungsbeduerftige Pathologika nachweisen ; hiervon waren in 20 Faellen die Gesichtsfelddefekte dem Augenarzt noch nicht bekannt . Am haeufigsten wurden glaukomatoese Optikusneuropathien sowie Makulopathien diagnostiziert . Instructions: please typing these entity words according to sentence: Skotome, Gesichtsfelddefekte, Methode, Eignung, Rundfunk, Arzt-, Patientenfragebogens, gesehenen, Personen, augenaerztlichen, Gesichtsfelddefekte Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Mit Hilfe der Rauschfeldkampimetrie ist es moeglich , typischerweise meist negative ( unsichtbare ) Skotome in unmittelbar fuer den Betroffenen wahrnehmbare Gesichtsfelddefekte zu ueberfuehren . Da diese Untersuchung ohnehin auf einem Monitor ablaeuft , lag es nahe , diese Methode hinsichtlich ihrer Eignung als Fernseh-Screening-Test zu ueberpruefen . In Zusammenarbeit mit dem Sueddeutschen Rundfunk ( SDR ) und der AOK Baden-Wuerttemberg ( nebst anderen RVO-Kassen ) wurden daher im Rahmen einer lokalen Fernsehsendung schaetzungsweise 300 000 Zuschauer nach kurzer Information und Instruktion mit einem eingespielten Rauschfeldreiz konfrontiert . Es gingen 531 postalische Anfragen von Fernsehzuschauern ein , die um Zusendung eines Arzt- bzw. Patientenfragebogens baten . Dies geschah in den meisten Faellen , um einen im Rauschfeld gesehenen Defekt von einem Augenarzt weiter abklaeren zu lassen . Laut 127 eingegangener , auswertbarer Untersuchungsboegen lagen in 78 Faellen keine relevanten ophthalmologischen Erkrankungen , insbesondere keine Sehbahnlaesionen , vor . Bei 49 Personen hingegen konnten die augenaerztlichen Kollegen ophthalmologisch abklaerungsbeduerftige Pathologika nachweisen ; hiervon waren in 20 Faellen die Gesichtsfelddefekte dem Augenarzt noch nicht bekannt . Am haeufigsten wurden glaukomatoese Optikusneuropathien sowie Makulopathien diagnostiziert .
[ "Mit", "Hilfe", "der", "Rauschfeldkampimetrie", "ist", "es", "moeglich", ",", "typischerweise", "meist", "negative", "(", "unsichtbare", ")", "Skotome", "in", "unmittelbar", "fuer", "den", "Betroffenen", "wahrnehmbare", "Gesichtsfelddefekte", "zu", "ueberfuehren", ".", "Da", "diese", "Untersuchung", "ohnehin", "auf", "einem", "Monitor", "ablaeuft", ",", "lag", "es", "nahe", ",", "diese", "Methode", "hinsichtlich", "ihrer", "Eignung", "als", "Fernseh", "-", "Screening", "-", "Test", "zu", "ueberpruefen", ".", "In", "Zusammenarbeit", "mit", "dem", "Sueddeutschen", "Rundfunk", "(", "SDR", ")", "und", "der", "AOK", "Baden", "-", "Wuerttemberg", "(", "nebst", "anderen", "RVO", "-", "Kassen", ")", "wurden", "daher", "im", "Rahmen", "einer", "lokalen", "Fernsehsendung", "schaetzungsweise", "300", "000", "Zuschauer", "nach", "kurzer", "Information", "und", "Instruktion", "mit", "einem", "eingespielten", "Rauschfeldreiz", "konfrontiert", ".", "Es", "gingen", "531", "postalische", "Anfragen", "von", "Fernsehzuschauern", "ein", ",", "die", "um", "Zusendung", "eines", "Arzt-", "bzw", ".", "Patientenfragebogens", "baten", ".", "Dies", "geschah", "in", "den", "meisten", "Faellen", ",", "um", "einen", "im", "Rauschfeld", "gesehenen", "Defekt", "von", "einem", "Augenarzt", "weiter", "abklaeren", "zu", "lassen", ".", "Laut", "127", "eingegangener", ",", "auswertbarer", "Untersuchungsboegen", "lagen", "in", "78", "Faellen", "keine", "relevanten", "ophthalmologischen", "Erkrankungen", ",", "insbesondere", "keine", "Sehbahnlaesionen", ",", "vor", ".", "Bei", "49", "Personen", "hingegen", "konnten", "die", "augenaerztlichen", "Kollegen", "ophthalmologisch", "abklaerungsbeduerftige", "Pathologika", "nachweisen", ";", "hiervon", "waren", "in", "20", "Faellen", "die", "Gesichtsfelddefekte", "dem", "Augenarzt", "noch", "nicht", "bekannt", ".", "Am", "haeufigsten", "wurden", "glaukomatoese", "Optikusneuropathien", "sowie", "Makulopathien", "diagnostiziert", "." ]
[ "umlsterm" ]
Skotome, Gesichtsfelddefekte, Methode, Eignung, Rundfunk, Arzt-, Patientenfragebogens, gesehenen, Personen, augenaerztlichen, Gesichtsfelddefekte
DerOpthalmologe.60930604.ger.abstr_task2
Sentence: Mit Hilfe der Rauschfeldkampimetrie ist es moeglich , typischerweise meist negative ( unsichtbare ) Skotome in unmittelbar fuer den Betroffenen wahrnehmbare Gesichtsfelddefekte zu ueberfuehren . Da diese Untersuchung ohnehin auf einem Monitor ablaeuft , lag es nahe , diese Methode hinsichtlich ihrer Eignung als Fernseh-Screening-Test zu ueberpruefen . In Zusammenarbeit mit dem Sueddeutschen Rundfunk ( SDR ) und der AOK Baden-Wuerttemberg ( nebst anderen RVO-Kassen ) wurden daher im Rahmen einer lokalen Fernsehsendung schaetzungsweise 300 000 Zuschauer nach kurzer Information und Instruktion mit einem eingespielten Rauschfeldreiz konfrontiert . Es gingen 531 postalische Anfragen von Fernsehzuschauern ein , die um Zusendung eines Arzt- bzw. Patientenfragebogens baten . Dies geschah in den meisten Faellen , um einen im Rauschfeld gesehenen Defekt von einem Augenarzt weiter abklaeren zu lassen . Laut 127 eingegangener , auswertbarer Untersuchungsboegen lagen in 78 Faellen keine relevanten ophthalmologischen Erkrankungen , insbesondere keine Sehbahnlaesionen , vor . Bei 49 Personen hingegen konnten die augenaerztlichen Kollegen ophthalmologisch abklaerungsbeduerftige Pathologika nachweisen ; hiervon waren in 20 Faellen die Gesichtsfelddefekte dem Augenarzt noch nicht bekannt . Am haeufigsten wurden glaukomatoese Optikusneuropathien sowie Makulopathien diagnostiziert . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Mit Hilfe der Rauschfeldkampimetrie ist es moeglich , typischerweise meist negative ( unsichtbare ) Skotome in unmittelbar fuer den Betroffenen wahrnehmbare Gesichtsfelddefekte zu ueberfuehren . Da diese Untersuchung ohnehin auf einem Monitor ablaeuft , lag es nahe , diese Methode hinsichtlich ihrer Eignung als Fernseh-Screening-Test zu ueberpruefen . In Zusammenarbeit mit dem Sueddeutschen Rundfunk ( SDR ) und der AOK Baden-Wuerttemberg ( nebst anderen RVO-Kassen ) wurden daher im Rahmen einer lokalen Fernsehsendung schaetzungsweise 300 000 Zuschauer nach kurzer Information und Instruktion mit einem eingespielten Rauschfeldreiz konfrontiert . Es gingen 531 postalische Anfragen von Fernsehzuschauern ein , die um Zusendung eines Arzt- bzw. Patientenfragebogens baten . Dies geschah in den meisten Faellen , um einen im Rauschfeld gesehenen Defekt von einem Augenarzt weiter abklaeren zu lassen . Laut 127 eingegangener , auswertbarer Untersuchungsboegen lagen in 78 Faellen keine relevanten ophthalmologischen Erkrankungen , insbesondere keine Sehbahnlaesionen , vor . Bei 49 Personen hingegen konnten die augenaerztlichen Kollegen ophthalmologisch abklaerungsbeduerftige Pathologika nachweisen ; hiervon waren in 20 Faellen die Gesichtsfelddefekte dem Augenarzt noch nicht bekannt . Am haeufigsten wurden glaukomatoese Optikusneuropathien sowie Makulopathien diagnostiziert .
[ "Mit", "Hilfe", "der", "Rauschfeldkampimetrie", "ist", "es", "moeglich", ",", "typischerweise", "meist", "negative", "(", "unsichtbare", ")", "Skotome", "in", "unmittelbar", "fuer", "den", "Betroffenen", "wahrnehmbare", "Gesichtsfelddefekte", "zu", "ueberfuehren", ".", "Da", "diese", "Untersuchung", "ohnehin", "auf", "einem", "Monitor", "ablaeuft", ",", "lag", "es", "nahe", ",", "diese", "Methode", "hinsichtlich", "ihrer", "Eignung", "als", "Fernseh", "-", "Screening", "-", "Test", "zu", "ueberpruefen", ".", "In", "Zusammenarbeit", "mit", "dem", "Sueddeutschen", "Rundfunk", "(", "SDR", ")", "und", "der", "AOK", "Baden", "-", "Wuerttemberg", "(", "nebst", "anderen", "RVO", "-", "Kassen", ")", "wurden", "daher", "im", "Rahmen", "einer", "lokalen", "Fernsehsendung", "schaetzungsweise", "300", "000", "Zuschauer", "nach", "kurzer", "Information", "und", "Instruktion", "mit", "einem", "eingespielten", "Rauschfeldreiz", "konfrontiert", ".", "Es", "gingen", "531", "postalische", "Anfragen", "von", "Fernsehzuschauern", "ein", ",", "die", "um", "Zusendung", "eines", "Arzt-", "bzw", ".", "Patientenfragebogens", "baten", ".", "Dies", "geschah", "in", "den", "meisten", "Faellen", ",", "um", "einen", "im", "Rauschfeld", "gesehenen", "Defekt", "von", "einem", "Augenarzt", "weiter", "abklaeren", "zu", "lassen", ".", "Laut", "127", "eingegangener", ",", "auswertbarer", "Untersuchungsboegen", "lagen", "in", "78", "Faellen", "keine", "relevanten", "ophthalmologischen", "Erkrankungen", ",", "insbesondere", "keine", "Sehbahnlaesionen", ",", "vor", ".", "Bei", "49", "Personen", "hingegen", "konnten", "die", "augenaerztlichen", "Kollegen", "ophthalmologisch", "abklaerungsbeduerftige", "Pathologika", "nachweisen", ";", "hiervon", "waren", "in", "20", "Faellen", "die", "Gesichtsfelddefekte", "dem", "Augenarzt", "noch", "nicht", "bekannt", ".", "Am", "haeufigsten", "wurden", "glaukomatoese", "Optikusneuropathien", "sowie", "Makulopathien", "diagnostiziert", "." ]
[ "umlsterm" ]
neoformación is a MORFOLOGIA_NEOPLASIA, nódulos hipodensos hepáticos is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, lesión hepática is a MORFOLOGIA_NEOPLASIA, metástasis de adenocarcinoma is a MORFOLOGIA_NEOPLASIA, carcinoma is a MORFOLOGIA_NEOPLASIA, nódulos hipodensos en ambos lóbulos hepáticos is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, lesiones hepáticas is a MORFOLOGIA_NEOPLASIA, lesiones focales hepáticas is a MORFOLOGIA_NEOPLASIA, lesiones focales hepáticas is a MORFOLOGIA_NEOPLASIA, Adenocarcinoma is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA
97_task0
Sentence: Anamnesis Se presenta el caso de un varón de 75 años que debuta con un cuadro de diabetes mellitus en noviembre de 2013. Como antecedentes personales destacaba dislipemia controlada con simvastatina 20 mg, alergia a la penicilina y había sido intervenido de apendicectomía con 40 años de edad. No era ni había sido fumador o bebedor, mantenía buena calidad de vida, independiente para actividades básicas de la vida diaria, jubilado actualmente, había ejercido como mecánico. No describe antecedentes familiares oncológicos de interés. En control analítico rutinario por su médico de Atención Primaria se objetivan cifras de glicemia en torno a 210 mg/dL (valores normales, VN, 75-105 mg/dL). Además, el paciente refiere poliuria, nicturia y polidipsia de tres meses de evolución, por lo que es diagnosticado de diabetes mellitus tipo 2. Inicia tratamiento con metformina 850 mg diarios con buen control de cifras de glicemia. En marzo de 2014, acude a Servicio de Urgencias por cuadro de dolor abdominal centrado en el mesogastrio-fosa iliaca derecha, meteorismo y cuadro de pérdida ponderal de peso (>15 kg en los últimos cinco meses), que motiva ingreso en Medicina Interna para estudio. Se solicita estudio de imagen con TC de abdomen1, hallándose una neoformación en la cabeza-cuerpo de páncreas junto con adenopatías patológicas y múltiples nódulos hipodensos hepáticos bilobares compatibles con metástasis. Dados los resultados, se presenta el caso en Comité Multidisciplinar de tumores hepatobiliares y se decide realizar biopsia percutánea de la lesión hepática. Esta se lleva a cabo en abril de 2104. El diagnóstico histológico fue compatible con metástasis de adenocarcinoma, compatible con origen pancreático. Exploración física IK: 80%, PS:1. Destaca dolor abdominal a la palpación en el mesogastrio y el hipocondrio derecho. Resto de la exploración dentro de la normalidad. Pruebas complementarias » TC con contraste IV de tórax, abdomen y pelvis (marzo/2014): Masa en cuerpo-cabeza pancreáticos de aprox 3,7 x 2,2 cm, de centro hipodenso y bordes mal delimitados, compatible con carcinoma pancreático. Engrosamiento nodular en cola de páncreas de 1,9 cm. Se observan múltiples nódulos hipodensos en ambos lóbulos hepáticos, el mayor en LHI de 1,6 cm, compatibles con metástasis. Adenopatías patológicas gastrohepáticas, paraaórticas, interaortocava y retrocrurales. Resto de estudio sin otros hallazgos reseñables. » Analítica (mayo/2014) destaca: Hb 9,8 g/dL; leucocitos 13.640 con 10.250 PMN; plaquetas: 223.000; FA 153 U/L (VN 34-104 U/L); GGT 195 U/L (VN: 5-85 U/L); Ca 19.9: 198 U/ml (VN 0,00-37,00U/mL). » TC con contraste IV de tórax, abdomen y pelvis (mayo/2014): comparativamente con estudio previo las lesiones hepáticas son mucho más numerosas y de mayor tamaño. Resto sin cambios significativos. » Analítica (junio/2014) destaca: GOT 95 U/L (VN 15-37 U/L); GPT 113 U/L (VN 12-78 U/L); GGT 799 U/L; bilirrubina total 0,3 mg/dL (VN 0,00-1,00 mg/dL). » Analítica (septiembre/2014) destaca: GGT 61 U/L; GOT 23 U/L. » TC con contraste IV de tórax, abdomen y pelvis (septiembre/2014): nódulo retrocrural derecho que en la actualidad presenta un diámetro de 13,4 mm (previo 19,3 mm). Las lesiones focales hepáticas en ambos lóbulos han disminuido tanto en número como en tamaño. Disminución del tamaño de la adenopatía paraaórtica izquierda que presenta unos diámetros aproximados de 9 x 17 mm (previo 29 x 16 mm). Resto sin cambios significativos respecto al estudio previo. » Analítica (febrero/2015) destaca: GGT 26 U/L; GOT 30 U/L; GPT 45 U/L; Ca 19.9 4,80. » TC con contraste IV de tórax, abdomen y pelvis (febrero/2015): disminución de tamaño del nódulo retrocrural derecho (en la actualidad diámetro de 8,5 mm, previo 13,4 mm). Persisten numerosas lesiones focales hepáticas en ambos lóbulos, aunque han disminuido tanto en número como en tamaño. Disminución del tamaño de la adenopatía paraaórtica izquierda (diámetro de 6.5 x 15 mm, previo 9 x 17 mm). Resto sin cambios significativos respecto al estudio previo. Diagnóstico Adenocarcinoma de cabeza-cuerpo de páncreas estadio IV. TVP de MII (mayo de 2014) anticoagulado con HBPM. Tratamiento Tras descartarse la cirugía, dada la extensión de la enfermedad, el paciente es derivado a Consultas Externas de Oncología Médica (mayo de 2014), solicitándose nuevo estudio de extensión. Lo volvemos a ver a finales de mayo, ya que ha estado ingresado por un cuadro de neumonía bilateral. Se encuentra más deteriorado (IK 50%-PS 2-3). Refiere astenia severa que limita su calidad de vida de forma importante (vida cama-sillón en las últimas dos semanas). En la exploraciones objetivamos aumento del perímetro del miembro inferior izquierdo (MII) con empastamiento a nivel de pantorrilla, por lo que solicitamos eco-coppler urgente que confirma la sospecha de trombosis venosa profunda (TVP) que afecta al segmento femoral y poplíteo del MII. Iniciamos tratamiento con heparina de bajo peso molecular (HBPM) a dosis terapéutica y reajustamos tratamiento sintomático. El estudio solicitado en la visita previa confirma progresión de enfermedad. Acude de nuevo a revisión en junio de 2014. Se encuentra mejor, ha recuperado autonomía, sale a la calle solo (IK 70% PS 2). Únicamente refiere astenia grado 2. A la exploración física solo destacar signos de síndrome posflebítico en MII y a nivel analítico destaca elevación de transaminasas. Ante la situación actual, proponemos tratamiento de quimioterapia con esquema gemcitabina 1.000 mg/m2 más nab-paclitaxel 125 mg/m2 días 1, 8 y 15 cada 28 días4. Pautamos primer ciclo con reducción del 20% de la dosis. Monitorizamos tolerancia y toxicidad con carácter semanal, de manera que escalamos dosis y tras dos semanas pautamos la tercera dosis al 100%. Tras el primer ciclo completo, el paciente presenta beneficio clínico evidente con mejoría de la situación funcional (PS 1) y reducción de la analgesia. Como efectos adversos objetivamos astenia, alopecia y anemia grado 1. Evolución En septiembre de 2014, tras tres meses de quimioterapia a dosis plenas, persiste el beneficio clínico (IK 90% PS 1). No refiere dolor, mantiene apetito y prosigue con astenia grado 1. Además, existe respuesta bioquímica, con descenso de los valores de transaminasas, y respuesta radiológica parcial con disminución en número y tamaño de las adenopatías y metástasis hepáticas. En diciembre de 2014, tras cinco ciclos, el paciente refiere como única toxicidad parestesias plantares grado 1. En reevaluación, tras seis meses de quimioterapia (febrero/2015) persiste el beneficio clínico. El paciente hace vida activa y refiere mínima astenia. Como toxicidad al tratamiento presenta alopecia grado 2, parestesias palmo-plantar grado 1-2 y anemia grado 1. A nivel bioquímico, continúa la normalización de las cifras de transaminasas y Ca 19.9; y a nivel radiológico, persiste reducción del número y tamaño de las metástasis hepáticas objetivándose una respuesta parcial mayor. Tras ocho ciclos, ha precisado reducción de dosis de nab-paclitaxel (100 mg/m2 ) por neuropatía grado 2 mantenida. Actualmente, ha completado nueve meses de tratamiento, hace su vida normal, dice encontrarse "muy bien" con buena tolerancia al tratamiento y desea continuar con el mismo. En última reevaluación (abril/2015) mantiene el beneficio clínico, bioquímico y respuesta radiológica. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: MORFOLOGIA_NEOPLASIA
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Anamnesis Se presenta el caso de un varón de 75 años que debuta con un cuadro de diabetes mellitus en noviembre de 2013. Como antecedentes personales destacaba dislipemia controlada con simvastatina 20 mg, alergia a la penicilina y había sido intervenido de apendicectomía con 40 años de edad. No era ni había sido fumador o bebedor, mantenía buena calidad de vida, independiente para actividades básicas de la vida diaria, jubilado actualmente, había ejercido como mecánico. No describe antecedentes familiares oncológicos de interés. En control analítico rutinario por su médico de Atención Primaria se objetivan cifras de glicemia en torno a 210 mg/dL (valores normales, VN, 75-105 mg/dL). Además, el paciente refiere poliuria, nicturia y polidipsia de tres meses de evolución, por lo que es diagnosticado de diabetes mellitus tipo 2. Inicia tratamiento con metformina 850 mg diarios con buen control de cifras de glicemia. En marzo de 2014, acude a Servicio de Urgencias por cuadro de dolor abdominal centrado en el mesogastrio-fosa iliaca derecha, meteorismo y cuadro de pérdida ponderal de peso (>15 kg en los últimos cinco meses), que motiva ingreso en Medicina Interna para estudio. Se solicita estudio de imagen con TC de abdomen1, hallándose una neoformación en la cabeza-cuerpo de páncreas junto con adenopatías patológicas y múltiples nódulos hipodensos hepáticos bilobares compatibles con metástasis. Dados los resultados, se presenta el caso en Comité Multidisciplinar de tumores hepatobiliares y se decide realizar biopsia percutánea de la lesión hepática. Esta se lleva a cabo en abril de 2104. El diagnóstico histológico fue compatible con metástasis de adenocarcinoma, compatible con origen pancreático. Exploración física IK: 80%, PS:1. Destaca dolor abdominal a la palpación en el mesogastrio y el hipocondrio derecho. Resto de la exploración dentro de la normalidad. Pruebas complementarias » TC con contraste IV de tórax, abdomen y pelvis (marzo/2014): Masa en cuerpo-cabeza pancreáticos de aprox 3,7 x 2,2 cm, de centro hipodenso y bordes mal delimitados, compatible con carcinoma pancreático. Engrosamiento nodular en cola de páncreas de 1,9 cm. Se observan múltiples nódulos hipodensos en ambos lóbulos hepáticos, el mayor en LHI de 1,6 cm, compatibles con metástasis. Adenopatías patológicas gastrohepáticas, paraaórticas, interaortocava y retrocrurales. Resto de estudio sin otros hallazgos reseñables. » Analítica (mayo/2014) destaca: Hb 9,8 g/dL; leucocitos 13.640 con 10.250 PMN; plaquetas: 223.000; FA 153 U/L (VN 34-104 U/L); GGT 195 U/L (VN: 5-85 U/L); Ca 19.9: 198 U/ml (VN 0,00-37,00U/mL). » TC con contraste IV de tórax, abdomen y pelvis (mayo/2014): comparativamente con estudio previo las lesiones hepáticas son mucho más numerosas y de mayor tamaño. Resto sin cambios significativos. » Analítica (junio/2014) destaca: GOT 95 U/L (VN 15-37 U/L); GPT 113 U/L (VN 12-78 U/L); GGT 799 U/L; bilirrubina total 0,3 mg/dL (VN 0,00-1,00 mg/dL). » Analítica (septiembre/2014) destaca: GGT 61 U/L; GOT 23 U/L. » TC con contraste IV de tórax, abdomen y pelvis (septiembre/2014): nódulo retrocrural derecho que en la actualidad presenta un diámetro de 13,4 mm (previo 19,3 mm). Las lesiones focales hepáticas en ambos lóbulos han disminuido tanto en número como en tamaño. Disminución del tamaño de la adenopatía paraaórtica izquierda que presenta unos diámetros aproximados de 9 x 17 mm (previo 29 x 16 mm). Resto sin cambios significativos respecto al estudio previo. » Analítica (febrero/2015) destaca: GGT 26 U/L; GOT 30 U/L; GPT 45 U/L; Ca 19.9 4,80. » TC con contraste IV de tórax, abdomen y pelvis (febrero/2015): disminución de tamaño del nódulo retrocrural derecho (en la actualidad diámetro de 8,5 mm, previo 13,4 mm). Persisten numerosas lesiones focales hepáticas en ambos lóbulos, aunque han disminuido tanto en número como en tamaño. Disminución del tamaño de la adenopatía paraaórtica izquierda (diámetro de 6.5 x 15 mm, previo 9 x 17 mm). Resto sin cambios significativos respecto al estudio previo. Diagnóstico Adenocarcinoma de cabeza-cuerpo de páncreas estadio IV. TVP de MII (mayo de 2014) anticoagulado con HBPM. Tratamiento Tras descartarse la cirugía, dada la extensión de la enfermedad, el paciente es derivado a Consultas Externas de Oncología Médica (mayo de 2014), solicitándose nuevo estudio de extensión. Lo volvemos a ver a finales de mayo, ya que ha estado ingresado por un cuadro de neumonía bilateral. Se encuentra más deteriorado (IK 50%-PS 2-3). Refiere astenia severa que limita su calidad de vida de forma importante (vida cama-sillón en las últimas dos semanas). En la exploraciones objetivamos aumento del perímetro del miembro inferior izquierdo (MII) con empastamiento a nivel de pantorrilla, por lo que solicitamos eco-coppler urgente que confirma la sospecha de trombosis venosa profunda (TVP) que afecta al segmento femoral y poplíteo del MII. Iniciamos tratamiento con heparina de bajo peso molecular (HBPM) a dosis terapéutica y reajustamos tratamiento sintomático. El estudio solicitado en la visita previa confirma progresión de enfermedad. Acude de nuevo a revisión en junio de 2014. Se encuentra mejor, ha recuperado autonomía, sale a la calle solo (IK 70% PS 2). Únicamente refiere astenia grado 2. A la exploración física solo destacar signos de síndrome posflebítico en MII y a nivel analítico destaca elevación de transaminasas. Ante la situación actual, proponemos tratamiento de quimioterapia con esquema gemcitabina 1.000 mg/m2 más nab-paclitaxel 125 mg/m2 días 1, 8 y 15 cada 28 días4. Pautamos primer ciclo con reducción del 20% de la dosis. Monitorizamos tolerancia y toxicidad con carácter semanal, de manera que escalamos dosis y tras dos semanas pautamos la tercera dosis al 100%. Tras el primer ciclo completo, el paciente presenta beneficio clínico evidente con mejoría de la situación funcional (PS 1) y reducción de la analgesia. Como efectos adversos objetivamos astenia, alopecia y anemia grado 1. Evolución En septiembre de 2014, tras tres meses de quimioterapia a dosis plenas, persiste el beneficio clínico (IK 90% PS 1). No refiere dolor, mantiene apetito y prosigue con astenia grado 1. Además, existe respuesta bioquímica, con descenso de los valores de transaminasas, y respuesta radiológica parcial con disminución en número y tamaño de las adenopatías y metástasis hepáticas. En diciembre de 2014, tras cinco ciclos, el paciente refiere como única toxicidad parestesias plantares grado 1. En reevaluación, tras seis meses de quimioterapia (febrero/2015) persiste el beneficio clínico. El paciente hace vida activa y refiere mínima astenia. Como toxicidad al tratamiento presenta alopecia grado 2, parestesias palmo-plantar grado 1-2 y anemia grado 1. A nivel bioquímico, continúa la normalización de las cifras de transaminasas y Ca 19.9; y a nivel radiológico, persiste reducción del número y tamaño de las metástasis hepáticas objetivándose una respuesta parcial mayor. Tras ocho ciclos, ha precisado reducción de dosis de nab-paclitaxel (100 mg/m2 ) por neuropatía grado 2 mantenida. Actualmente, ha completado nueve meses de tratamiento, hace su vida normal, dice encontrarse "muy bien" con buena tolerancia al tratamiento y desea continuar con el mismo. En última reevaluación (abril/2015) mantiene el beneficio clínico, bioquímico y respuesta radiológica.
[ "Anamnesis", "\n", "Se", "presenta", "el", "caso", "de", "un", "varón", "de", "75", "años", "que", "debuta", "con", "un", "cuadro", "de", "diabetes", "mellitus", "en", "noviembre", "de", "2013", ".", "\n\n", "Como", "antecedentes", "personales", "destacaba", "dislipemia", "controlada", "con", "simvastatina", "20", "mg", ",", "alergia", "a", "la", "penicilina", "y", "había", "sido", "intervenido", "de", "apendicectomía", "con", "40", "años", "de", "edad", ".", "No", "era", "ni", "había", "sido", "fumador", "o", "bebedor", ",", "mantenía", "buena", "calidad", "de", "vida", ",", "independiente", "para", "actividades", "básicas", "de", "la", "vida", "diaria", ",", "jubilado", "actualmente", ",", "había", "ejercido", "como", "mecánico", ".", "No", "describe", "antecedentes", "familiares", "oncológicos", "de", "interés", ".", "\n\n", "En", "control", "analítico", "rutinario", "por", "su", "médico", "de", "Atención", "Primaria", "se", "objetivan", "cifras", "de", "glicemia", "en", "torno", "a", "210", "mg", "/", "dL", "(", "valores", "normales", ",", "VN", ",", "75", "-", "105", "mg", "/", "dL", ")", ".", "Además", ",", "el", "paciente", "refiere", "poliuria", ",", "nicturia", "y", "polidipsia", "de", "tres", "meses", "de", "evolución", ",", "por", "lo", "que", "es", "diagnosticado", "de", "diabetes", "mellitus", "tipo", "2", ".", "Inicia", "tratamiento", "con", "metformina", "850", "mg", "diarios", "con", "buen", "control", "de", "cifras", "de", "glicemia", ".", "\n\n", "En", "marzo", "de", "2014", ",", "acude", "a", "Servicio", "de", "Urgencias", "por", "cuadro", "de", "dolor", "abdominal", "centrado", "en", "el", "mesogastrio", "-", "fosa", "iliaca", "derecha", ",", "meteorismo", "y", "cuadro", "de", "pérdida", "ponderal", "de", "peso", "(", ">", "15", "kg", "en", "los", "últimos", "cinco", "meses", ")", ",", "que", "motiva", "ingreso", "en", "Medicina", "Interna", "para", "estudio", ".", "Se", "solicita", "estudio", "de", "imagen", "con", "TC", "de", "abdomen1", ",", "hallándose", "una", "neoformación", "en", "la", "cabeza", "-", "cuerpo", "de", "páncreas", "junto", "con", "adenopatías", "patológicas", "y", "múltiples", "nódulos", "hipodensos", "hepáticos", "bilobares", "compatibles", "con", "metástasis", ".", "\n\n", "Dados", "los", "resultados", ",", "se", "presenta", "el", "caso", "en", "Comité", "Multidisciplinar", "de", "tumores", "hepatobiliares", "y", "se", "decide", "realizar", "biopsia", "percutánea", "de", "la", "lesión", "hepática", ".", "Esta", "se", "lleva", "a", "cabo", "en", "abril", "de", "2104", ".", "El", "diagnóstico", "histológico", "fue", "compatible", "con", "metástasis", "de", "adenocarcinoma", ",", "compatible", "con", "origen", "pancreático", ".", "\n\n", "Exploración", "física", "\n", "IK", ":", "80", "%", ",", "PS:1", ".", "Destaca", "dolor", "abdominal", "a", "la", "palpación", "en", "el", "mesogastrio", "y", "el", "hipocondrio", "derecho", ".", "\n", "Resto", "de", "la", "exploración", "dentro", "de", "la", "normalidad", ".", "\n\n", "Pruebas", "complementarias", "\n", "»", "TC", "con", "contraste", "IV", "de", "tórax", ",", "abdomen", "y", "pelvis", "(", "marzo/2014", "):", "Masa", "en", "cuerpo", "-", "cabeza", "pancreáticos", "de", "aprox", "3,7", "x", "2,2", "cm", ",", "de", "centro", "hipodenso", "y", "bordes", "mal", "delimitados", ",", "compatible", "con", "carcinoma", "pancreático", ".", "Engrosamiento", "nodular", "en", "cola", "de", "páncreas", "de", "1,9", "cm", ".", "Se", "observan", "múltiples", "nódulos", "hipodensos", "en", "ambos", "lóbulos", "hepáticos", ",", "el", "mayor", "en", "LHI", "de", "1,6", "cm", ",", "compatibles", "con", "metástasis", ".", "Adenopatías", "patológicas", "gastrohepáticas", ",", "paraaórticas", ",", "interaortocava", "y", "retrocrurales", ".", "\n\n", "Resto", "de", "estudio", "sin", "otros", "hallazgos", "reseñables", ".", "\n", "»", "Analítica", "(", "mayo/2014", ")", "destaca", ":", "Hb", "9,8", "g", "/", "dL", ";", "leucocitos", "13.640", "con", "10.250", "PMN", ";", "plaquetas", ":", "223.000", ";", "FA", "153", "U", "/", "L", "(", "VN", "34", "-", "104", "U", "/", "L", ")", ";", "GGT", "195", "U", "/", "L", "(", "VN", ":", "5", "-", "85", "U", "/", "L", ")", ";", "Ca", "19.9", ":", "198", "U", "/", "ml", "(", "VN", "0,00", "-", "37,00U", "/", "mL", ")", ".", "\n", "»", "TC", "con", "contraste", "IV", "de", "tórax", ",", "abdomen", "y", "pelvis", "(", "mayo/2014", "):", "comparativamente", "con", "estudio", "previo", "las", "lesiones", "hepáticas", "son", "mucho", "más", "numerosas", "y", "de", "mayor", "tamaño", ".", "Resto", "sin", "cambios", "significativos", ".", "\n", "»", "Analítica", "(", "junio/2014", ")", "destaca", ":", "GOT", "95", "U", "/", "L", "(", "VN", "15", "-", "37", "U", "/", "L", ")", ";", "GPT", "113", "U", "/", "L", "(", "VN", "12", "-", "78", "U", "/", "L", ")", ";", "GGT", "799", "U", "/", "L", ";", "bilirrubina", "total", "0,3", "mg", "/", "dL", "(", "VN", "0,00", "-", "1,00", "mg", "/", "dL", ")", ".", "\n", "»", "Analítica", "(", "septiembre/2014", ")", "destaca", ":", "GGT", "61", "U", "/", "L", ";", "GOT", "23", "U", "/", "L.", "\n", "»", "TC", "con", "contraste", "IV", "de", "tórax", ",", "abdomen", "y", "pelvis", "(", "septiembre/2014", "):", "nódulo", "retrocrural", "derecho", "que", "en", "la", "actualidad", "presenta", "un", "diámetro", "de", "13,4", "mm", "(", "previo", "19,3", "mm", ")", ".", "Las", "lesiones", "focales", "hepáticas", "en", "ambos", "lóbulos", "han", "disminuido", "tanto", "en", "número", "como", "en", "tamaño", ".", "Disminución", "del", "tamaño", "de", "la", "adenopatía", "paraaórtica", "izquierda", "que", "presenta", "unos", "diámetros", "aproximados", "de", "9", "x", "17", "mm", "(", "previo", "29", "x", "16", "mm", ")", ".", "Resto", "sin", "cambios", "significativos", "respecto", "al", "estudio", "previo", ".", "\n", "»", "Analítica", "(", "febrero/2015", ")", "destaca", ":", "GGT", "26", "U", "/", "L", ";", "GOT", "30", "U", "/", "L", ";", "GPT", "45", "U", "/", "L", ";", "Ca", "19.9", "4,80", ".", "\n", "»", "TC", "con", "contraste", "IV", "de", "tórax", ",", "abdomen", "y", "pelvis", "(", "febrero/2015", "):", "disminución", "de", "tamaño", "del", "nódulo", "retrocrural", "derecho", "(", "en", "la", "actualidad", "diámetro", "de", "8,5", "mm", ",", "previo", "13,4", "mm", ")", ".", "Persisten", "numerosas", "lesiones", "focales", "hepáticas", "en", "ambos", "lóbulos", ",", "aunque", "han", "disminuido", "tanto", "en", "número", "como", "en", "tamaño", ".", "Disminución", "del", "tamaño", "de", "la", "adenopatía", "paraaórtica", "izquierda", "(", "diámetro", "de", "6.5", "x", "15", "mm", ",", "previo", "9", "x", "17", "mm", ")", ".", "Resto", "sin", "cambios", "significativos", "respecto", "al", "estudio", "previo", ".", "\n\n", "Diagnóstico", "\n", "Adenocarcinoma", "de", "cabeza", "-", "cuerpo", "de", "páncreas", "estadio", "IV", ".", "\n", "TVP", "de", "MII", "(", "mayo", "de", "2014", ")", "anticoagulado", "con", "HBPM", ".", "\n\n", "Tratamiento", "\n", "Tras", "descartarse", "la", "cirugía", ",", "dada", "la", "extensión", "de", "la", "enfermedad", ",", "el", "paciente", "es", "derivado", "a", "Consultas", "Externas", "de", "Oncología", "Médica", "(", "mayo", "de", "2014", ")", ",", "solicitándose", "nuevo", "estudio", "de", "extensión", ".", "\n\n", "Lo", "volvemos", "a", "ver", "a", "finales", "de", "mayo", ",", "ya", "que", "ha", "estado", "ingresado", "por", "un", "cuadro", "de", "neumonía", "bilateral", ".", "Se", "encuentra", "más", "deteriorado", "(", "IK", "50%-PS", "2", "-", "3", ")", ".", "Refiere", "astenia", "severa", "que", "limita", "su", "calidad", "de", "vida", "de", "forma", "importante", "(", "vida", "cama", "-", "sillón", "en", "las", "últimas", "dos", "semanas", ")", ".", "En", "la", "exploraciones", "objetivamos", "aumento", "del", "perímetro", "del", "miembro", "inferior", "izquierdo", "(", "MII", ")", "con", "empastamiento", "a", "nivel", "de", "pantorrilla", ",", "por", "lo", "que", "solicitamos", "eco", "-", "coppler", "urgente", "que", "confirma", "la", "sospecha", "de", "trombosis", "venosa", "profunda", "(", "TVP", ")", "que", "afecta", "al", "segmento", "femoral", "y", "poplíteo", "del", "MII", ".", "Iniciamos", "tratamiento", "con", "heparina", "de", "bajo", "peso", "molecular", "(", "HBPM", ")", "a", "dosis", "terapéutica", "y", "reajustamos", "tratamiento", "sintomático", ".", "El", "estudio", "solicitado", "en", "la", "visita", "previa", "confirma", "progresión", "de", "enfermedad", ".", "\n\n", "Acude", "de", "nuevo", "a", "revisión", "en", "junio", "de", "2014", ".", "Se", "encuentra", "mejor", ",", "ha", "recuperado", "autonomía", ",", "sale", "a", "la", "calle", "solo", "(", "IK", "70", "%", "PS", "2", ")", ".", "Únicamente", "refiere", "astenia", "grado", "2", ".", "A", "la", "exploración", "física", "solo", "destacar", "signos", "de", "síndrome", "posflebítico", "en", "MII", "y", "a", "nivel", "analítico", "destaca", "elevación", "de", "transaminasas", ".", "Ante", "la", "situación", "actual", ",", "proponemos", "tratamiento", "de", "quimioterapia", "con", "esquema", "gemcitabina", "1.000", "mg", "/", "m2", "más", "nab", "-", "paclitaxel", "125", "mg", "/", "m2", "días", "1", ",", "8", "y", "15", "cada", "28", "días4", ".", "Pautamos", "primer", "ciclo", "con", "reducción", "del", "20", "%", "de", "la", "dosis", ".", "Monitorizamos", "tolerancia", "y", "toxicidad", "con", "carácter", "semanal", ",", "de", "manera", "que", "escalamos", "dosis", "y", "tras", "dos", "semanas", "pautamos", "la", "tercera", "dosis", "al", "100", "%", ".", "Tras", "el", "primer", "ciclo", "completo", ",", "el", "paciente", "presenta", "beneficio", "clínico", "evidente", "con", "mejoría", "de", "la", "situación", "funcional", "(", "PS", "1", ")", "y", "reducción", "de", "la", "analgesia", ".", "Como", "efectos", "adversos", "objetivamos", "astenia", ",", "alopecia", "y", "anemia", "grado", "1", ".", "\n\n", "Evolución", "\n", "En", "septiembre", "de", "2014", ",", "tras", "tres", "meses", "de", "quimioterapia", "a", "dosis", "plenas", ",", "persiste", "el", "beneficio", "clínico", "(", "IK", "90", "%", "PS", "1", ")", ".", "No", "refiere", "dolor", ",", "mantiene", "apetito", "y", "prosigue", "con", "astenia", "grado", "1", ".", "Además", ",", "existe", "respuesta", "bioquímica", ",", "con", "descenso", "de", "los", "valores", "de", "transaminasas", ",", "y", "respuesta", "radiológica", "parcial", "con", "disminución", "en", "número", "y", "tamaño", "de", "las", "adenopatías", "y", "metástasis", "hepáticas", ".", "En", "diciembre", "de", "2014", ",", "tras", "cinco", "ciclos", ",", "el", "paciente", "refiere", "como", "única", "toxicidad", "parestesias", "plantares", "grado", "1", ".", "\n\n", "En", "reevaluación", ",", "tras", "seis", "meses", "de", "quimioterapia", "(", "febrero/2015", ")", "persiste", "el", "beneficio", "clínico", ".", "El", "paciente", "hace", "vida", "activa", "y", "refiere", "mínima", "astenia", ".", "Como", "toxicidad", "al", "tratamiento", "presenta", "alopecia", "grado", "2", ",", "parestesias", "palmo", "-", "plantar", "grado", "1", "-", "2", "y", "anemia", "grado", "1", ".", "A", "nivel", "bioquímico", ",", "continúa", "la", "normalización", "de", "las", "cifras", "de", "transaminasas", "y", "Ca", "19.9", ";", "y", "a", "nivel", "radiológico", ",", "persiste", "reducción", "del", "número", "y", "tamaño", "de", "las", "metástasis", "hepáticas", "objetivándose", "una", "respuesta", "parcial", "mayor", ".", "\n\n", "Tras", "ocho", "ciclos", ",", "ha", "precisado", "reducción", "de", "dosis", "de", "nab", "-", "paclitaxel", "(", "100", "mg", "/", "m2", ")", "por", "neuropatía", "grado", "2", "mantenida", ".", "Actualmente", ",", "ha", "completado", "nueve", "meses", "de", "tratamiento", ",", "hace", "su", "vida", "normal", ",", "dice", "encontrarse", "\"", "muy", "bien", "\"", "con", "buena", "tolerancia", "al", "tratamiento", "y", "desea", "continuar", "con", "el", "mismo", ".", "En", "última", "reevaluación", "(", "abril/2015", ")", "mantiene", "el", "beneficio", "clínico", ",", "bioquímico", "y", "respuesta", "radiológica", "." ]
[ "MORFOLOGIA_NEOPLASIA" ]
neoformación is a MORFOLOGIA_NEOPLASIA, nódulos hipodensos hepáticos is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, lesión hepática is a MORFOLOGIA_NEOPLASIA, metástasis de adenocarcinoma is a MORFOLOGIA_NEOPLASIA, carcinoma is a MORFOLOGIA_NEOPLASIA, nódulos hipodensos en ambos lóbulos hepáticos is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, lesiones hepáticas is a MORFOLOGIA_NEOPLASIA, lesiones focales hepáticas is a MORFOLOGIA_NEOPLASIA, lesiones focales hepáticas is a MORFOLOGIA_NEOPLASIA, Adenocarcinoma is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA
97_task1
Sentence: Anamnesis Se presenta el caso de un varón de 75 años que debuta con un cuadro de diabetes mellitus en noviembre de 2013. Como antecedentes personales destacaba dislipemia controlada con simvastatina 20 mg, alergia a la penicilina y había sido intervenido de apendicectomía con 40 años de edad. No era ni había sido fumador o bebedor, mantenía buena calidad de vida, independiente para actividades básicas de la vida diaria, jubilado actualmente, había ejercido como mecánico. No describe antecedentes familiares oncológicos de interés. En control analítico rutinario por su médico de Atención Primaria se objetivan cifras de glicemia en torno a 210 mg/dL (valores normales, VN, 75-105 mg/dL). Además, el paciente refiere poliuria, nicturia y polidipsia de tres meses de evolución, por lo que es diagnosticado de diabetes mellitus tipo 2. Inicia tratamiento con metformina 850 mg diarios con buen control de cifras de glicemia. En marzo de 2014, acude a Servicio de Urgencias por cuadro de dolor abdominal centrado en el mesogastrio-fosa iliaca derecha, meteorismo y cuadro de pérdida ponderal de peso (>15 kg en los últimos cinco meses), que motiva ingreso en Medicina Interna para estudio. Se solicita estudio de imagen con TC de abdomen1, hallándose una neoformación en la cabeza-cuerpo de páncreas junto con adenopatías patológicas y múltiples nódulos hipodensos hepáticos bilobares compatibles con metástasis. Dados los resultados, se presenta el caso en Comité Multidisciplinar de tumores hepatobiliares y se decide realizar biopsia percutánea de la lesión hepática. Esta se lleva a cabo en abril de 2104. El diagnóstico histológico fue compatible con metástasis de adenocarcinoma, compatible con origen pancreático. Exploración física IK: 80%, PS:1. Destaca dolor abdominal a la palpación en el mesogastrio y el hipocondrio derecho. Resto de la exploración dentro de la normalidad. Pruebas complementarias » TC con contraste IV de tórax, abdomen y pelvis (marzo/2014): Masa en cuerpo-cabeza pancreáticos de aprox 3,7 x 2,2 cm, de centro hipodenso y bordes mal delimitados, compatible con carcinoma pancreático. Engrosamiento nodular en cola de páncreas de 1,9 cm. Se observan múltiples nódulos hipodensos en ambos lóbulos hepáticos, el mayor en LHI de 1,6 cm, compatibles con metástasis. Adenopatías patológicas gastrohepáticas, paraaórticas, interaortocava y retrocrurales. Resto de estudio sin otros hallazgos reseñables. » Analítica (mayo/2014) destaca: Hb 9,8 g/dL; leucocitos 13.640 con 10.250 PMN; plaquetas: 223.000; FA 153 U/L (VN 34-104 U/L); GGT 195 U/L (VN: 5-85 U/L); Ca 19.9: 198 U/ml (VN 0,00-37,00U/mL). » TC con contraste IV de tórax, abdomen y pelvis (mayo/2014): comparativamente con estudio previo las lesiones hepáticas son mucho más numerosas y de mayor tamaño. Resto sin cambios significativos. » Analítica (junio/2014) destaca: GOT 95 U/L (VN 15-37 U/L); GPT 113 U/L (VN 12-78 U/L); GGT 799 U/L; bilirrubina total 0,3 mg/dL (VN 0,00-1,00 mg/dL). » Analítica (septiembre/2014) destaca: GGT 61 U/L; GOT 23 U/L. » TC con contraste IV de tórax, abdomen y pelvis (septiembre/2014): nódulo retrocrural derecho que en la actualidad presenta un diámetro de 13,4 mm (previo 19,3 mm). Las lesiones focales hepáticas en ambos lóbulos han disminuido tanto en número como en tamaño. Disminución del tamaño de la adenopatía paraaórtica izquierda que presenta unos diámetros aproximados de 9 x 17 mm (previo 29 x 16 mm). Resto sin cambios significativos respecto al estudio previo. » Analítica (febrero/2015) destaca: GGT 26 U/L; GOT 30 U/L; GPT 45 U/L; Ca 19.9 4,80. » TC con contraste IV de tórax, abdomen y pelvis (febrero/2015): disminución de tamaño del nódulo retrocrural derecho (en la actualidad diámetro de 8,5 mm, previo 13,4 mm). Persisten numerosas lesiones focales hepáticas en ambos lóbulos, aunque han disminuido tanto en número como en tamaño. Disminución del tamaño de la adenopatía paraaórtica izquierda (diámetro de 6.5 x 15 mm, previo 9 x 17 mm). Resto sin cambios significativos respecto al estudio previo. Diagnóstico Adenocarcinoma de cabeza-cuerpo de páncreas estadio IV. TVP de MII (mayo de 2014) anticoagulado con HBPM. Tratamiento Tras descartarse la cirugía, dada la extensión de la enfermedad, el paciente es derivado a Consultas Externas de Oncología Médica (mayo de 2014), solicitándose nuevo estudio de extensión. Lo volvemos a ver a finales de mayo, ya que ha estado ingresado por un cuadro de neumonía bilateral. Se encuentra más deteriorado (IK 50%-PS 2-3). Refiere astenia severa que limita su calidad de vida de forma importante (vida cama-sillón en las últimas dos semanas). En la exploraciones objetivamos aumento del perímetro del miembro inferior izquierdo (MII) con empastamiento a nivel de pantorrilla, por lo que solicitamos eco-coppler urgente que confirma la sospecha de trombosis venosa profunda (TVP) que afecta al segmento femoral y poplíteo del MII. Iniciamos tratamiento con heparina de bajo peso molecular (HBPM) a dosis terapéutica y reajustamos tratamiento sintomático. El estudio solicitado en la visita previa confirma progresión de enfermedad. Acude de nuevo a revisión en junio de 2014. Se encuentra mejor, ha recuperado autonomía, sale a la calle solo (IK 70% PS 2). Únicamente refiere astenia grado 2. A la exploración física solo destacar signos de síndrome posflebítico en MII y a nivel analítico destaca elevación de transaminasas. Ante la situación actual, proponemos tratamiento de quimioterapia con esquema gemcitabina 1.000 mg/m2 más nab-paclitaxel 125 mg/m2 días 1, 8 y 15 cada 28 días4. Pautamos primer ciclo con reducción del 20% de la dosis. Monitorizamos tolerancia y toxicidad con carácter semanal, de manera que escalamos dosis y tras dos semanas pautamos la tercera dosis al 100%. Tras el primer ciclo completo, el paciente presenta beneficio clínico evidente con mejoría de la situación funcional (PS 1) y reducción de la analgesia. Como efectos adversos objetivamos astenia, alopecia y anemia grado 1. Evolución En septiembre de 2014, tras tres meses de quimioterapia a dosis plenas, persiste el beneficio clínico (IK 90% PS 1). No refiere dolor, mantiene apetito y prosigue con astenia grado 1. Además, existe respuesta bioquímica, con descenso de los valores de transaminasas, y respuesta radiológica parcial con disminución en número y tamaño de las adenopatías y metástasis hepáticas. En diciembre de 2014, tras cinco ciclos, el paciente refiere como única toxicidad parestesias plantares grado 1. En reevaluación, tras seis meses de quimioterapia (febrero/2015) persiste el beneficio clínico. El paciente hace vida activa y refiere mínima astenia. Como toxicidad al tratamiento presenta alopecia grado 2, parestesias palmo-plantar grado 1-2 y anemia grado 1. A nivel bioquímico, continúa la normalización de las cifras de transaminasas y Ca 19.9; y a nivel radiológico, persiste reducción del número y tamaño de las metástasis hepáticas objetivándose una respuesta parcial mayor. Tras ocho ciclos, ha precisado reducción de dosis de nab-paclitaxel (100 mg/m2 ) por neuropatía grado 2 mantenida. Actualmente, ha completado nueve meses de tratamiento, hace su vida normal, dice encontrarse "muy bien" con buena tolerancia al tratamiento y desea continuar con el mismo. En última reevaluación (abril/2015) mantiene el beneficio clínico, bioquímico y respuesta radiológica. Instructions: please typing these entity words according to sentence: neoformación, nódulos hipodensos hepáticos, metástasis, lesión hepática, metástasis de adenocarcinoma, carcinoma, nódulos hipodensos en ambos lóbulos hepáticos, metástasis, lesiones hepáticas, lesiones focales hepáticas, lesiones focales hepáticas, Adenocarcinoma, metástasis, metástasis Options: MORFOLOGIA_NEOPLASIA
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Anamnesis Se presenta el caso de un varón de 75 años que debuta con un cuadro de diabetes mellitus en noviembre de 2013. Como antecedentes personales destacaba dislipemia controlada con simvastatina 20 mg, alergia a la penicilina y había sido intervenido de apendicectomía con 40 años de edad. No era ni había sido fumador o bebedor, mantenía buena calidad de vida, independiente para actividades básicas de la vida diaria, jubilado actualmente, había ejercido como mecánico. No describe antecedentes familiares oncológicos de interés. En control analítico rutinario por su médico de Atención Primaria se objetivan cifras de glicemia en torno a 210 mg/dL (valores normales, VN, 75-105 mg/dL). Además, el paciente refiere poliuria, nicturia y polidipsia de tres meses de evolución, por lo que es diagnosticado de diabetes mellitus tipo 2. Inicia tratamiento con metformina 850 mg diarios con buen control de cifras de glicemia. En marzo de 2014, acude a Servicio de Urgencias por cuadro de dolor abdominal centrado en el mesogastrio-fosa iliaca derecha, meteorismo y cuadro de pérdida ponderal de peso (>15 kg en los últimos cinco meses), que motiva ingreso en Medicina Interna para estudio. Se solicita estudio de imagen con TC de abdomen1, hallándose una neoformación en la cabeza-cuerpo de páncreas junto con adenopatías patológicas y múltiples nódulos hipodensos hepáticos bilobares compatibles con metástasis. Dados los resultados, se presenta el caso en Comité Multidisciplinar de tumores hepatobiliares y se decide realizar biopsia percutánea de la lesión hepática. Esta se lleva a cabo en abril de 2104. El diagnóstico histológico fue compatible con metástasis de adenocarcinoma, compatible con origen pancreático. Exploración física IK: 80%, PS:1. Destaca dolor abdominal a la palpación en el mesogastrio y el hipocondrio derecho. Resto de la exploración dentro de la normalidad. Pruebas complementarias » TC con contraste IV de tórax, abdomen y pelvis (marzo/2014): Masa en cuerpo-cabeza pancreáticos de aprox 3,7 x 2,2 cm, de centro hipodenso y bordes mal delimitados, compatible con carcinoma pancreático. Engrosamiento nodular en cola de páncreas de 1,9 cm. Se observan múltiples nódulos hipodensos en ambos lóbulos hepáticos, el mayor en LHI de 1,6 cm, compatibles con metástasis. Adenopatías patológicas gastrohepáticas, paraaórticas, interaortocava y retrocrurales. Resto de estudio sin otros hallazgos reseñables. » Analítica (mayo/2014) destaca: Hb 9,8 g/dL; leucocitos 13.640 con 10.250 PMN; plaquetas: 223.000; FA 153 U/L (VN 34-104 U/L); GGT 195 U/L (VN: 5-85 U/L); Ca 19.9: 198 U/ml (VN 0,00-37,00U/mL). » TC con contraste IV de tórax, abdomen y pelvis (mayo/2014): comparativamente con estudio previo las lesiones hepáticas son mucho más numerosas y de mayor tamaño. Resto sin cambios significativos. » Analítica (junio/2014) destaca: GOT 95 U/L (VN 15-37 U/L); GPT 113 U/L (VN 12-78 U/L); GGT 799 U/L; bilirrubina total 0,3 mg/dL (VN 0,00-1,00 mg/dL). » Analítica (septiembre/2014) destaca: GGT 61 U/L; GOT 23 U/L. » TC con contraste IV de tórax, abdomen y pelvis (septiembre/2014): nódulo retrocrural derecho que en la actualidad presenta un diámetro de 13,4 mm (previo 19,3 mm). Las lesiones focales hepáticas en ambos lóbulos han disminuido tanto en número como en tamaño. Disminución del tamaño de la adenopatía paraaórtica izquierda que presenta unos diámetros aproximados de 9 x 17 mm (previo 29 x 16 mm). Resto sin cambios significativos respecto al estudio previo. » Analítica (febrero/2015) destaca: GGT 26 U/L; GOT 30 U/L; GPT 45 U/L; Ca 19.9 4,80. » TC con contraste IV de tórax, abdomen y pelvis (febrero/2015): disminución de tamaño del nódulo retrocrural derecho (en la actualidad diámetro de 8,5 mm, previo 13,4 mm). Persisten numerosas lesiones focales hepáticas en ambos lóbulos, aunque han disminuido tanto en número como en tamaño. Disminución del tamaño de la adenopatía paraaórtica izquierda (diámetro de 6.5 x 15 mm, previo 9 x 17 mm). Resto sin cambios significativos respecto al estudio previo. Diagnóstico Adenocarcinoma de cabeza-cuerpo de páncreas estadio IV. TVP de MII (mayo de 2014) anticoagulado con HBPM. Tratamiento Tras descartarse la cirugía, dada la extensión de la enfermedad, el paciente es derivado a Consultas Externas de Oncología Médica (mayo de 2014), solicitándose nuevo estudio de extensión. Lo volvemos a ver a finales de mayo, ya que ha estado ingresado por un cuadro de neumonía bilateral. Se encuentra más deteriorado (IK 50%-PS 2-3). Refiere astenia severa que limita su calidad de vida de forma importante (vida cama-sillón en las últimas dos semanas). En la exploraciones objetivamos aumento del perímetro del miembro inferior izquierdo (MII) con empastamiento a nivel de pantorrilla, por lo que solicitamos eco-coppler urgente que confirma la sospecha de trombosis venosa profunda (TVP) que afecta al segmento femoral y poplíteo del MII. Iniciamos tratamiento con heparina de bajo peso molecular (HBPM) a dosis terapéutica y reajustamos tratamiento sintomático. El estudio solicitado en la visita previa confirma progresión de enfermedad. Acude de nuevo a revisión en junio de 2014. Se encuentra mejor, ha recuperado autonomía, sale a la calle solo (IK 70% PS 2). Únicamente refiere astenia grado 2. A la exploración física solo destacar signos de síndrome posflebítico en MII y a nivel analítico destaca elevación de transaminasas. Ante la situación actual, proponemos tratamiento de quimioterapia con esquema gemcitabina 1.000 mg/m2 más nab-paclitaxel 125 mg/m2 días 1, 8 y 15 cada 28 días4. Pautamos primer ciclo con reducción del 20% de la dosis. Monitorizamos tolerancia y toxicidad con carácter semanal, de manera que escalamos dosis y tras dos semanas pautamos la tercera dosis al 100%. Tras el primer ciclo completo, el paciente presenta beneficio clínico evidente con mejoría de la situación funcional (PS 1) y reducción de la analgesia. Como efectos adversos objetivamos astenia, alopecia y anemia grado 1. Evolución En septiembre de 2014, tras tres meses de quimioterapia a dosis plenas, persiste el beneficio clínico (IK 90% PS 1). No refiere dolor, mantiene apetito y prosigue con astenia grado 1. Además, existe respuesta bioquímica, con descenso de los valores de transaminasas, y respuesta radiológica parcial con disminución en número y tamaño de las adenopatías y metástasis hepáticas. En diciembre de 2014, tras cinco ciclos, el paciente refiere como única toxicidad parestesias plantares grado 1. En reevaluación, tras seis meses de quimioterapia (febrero/2015) persiste el beneficio clínico. El paciente hace vida activa y refiere mínima astenia. Como toxicidad al tratamiento presenta alopecia grado 2, parestesias palmo-plantar grado 1-2 y anemia grado 1. A nivel bioquímico, continúa la normalización de las cifras de transaminasas y Ca 19.9; y a nivel radiológico, persiste reducción del número y tamaño de las metástasis hepáticas objetivándose una respuesta parcial mayor. Tras ocho ciclos, ha precisado reducción de dosis de nab-paclitaxel (100 mg/m2 ) por neuropatía grado 2 mantenida. Actualmente, ha completado nueve meses de tratamiento, hace su vida normal, dice encontrarse "muy bien" con buena tolerancia al tratamiento y desea continuar con el mismo. En última reevaluación (abril/2015) mantiene el beneficio clínico, bioquímico y respuesta radiológica.
[ "Anamnesis", "\n", "Se", "presenta", "el", "caso", "de", "un", "varón", "de", "75", "años", "que", "debuta", "con", "un", "cuadro", "de", "diabetes", "mellitus", "en", "noviembre", "de", "2013", ".", "\n\n", "Como", "antecedentes", "personales", "destacaba", "dislipemia", "controlada", "con", "simvastatina", "20", "mg", ",", "alergia", "a", "la", "penicilina", "y", "había", "sido", "intervenido", "de", "apendicectomía", "con", "40", "años", "de", "edad", ".", "No", "era", "ni", "había", "sido", "fumador", "o", "bebedor", ",", "mantenía", "buena", "calidad", "de", "vida", ",", "independiente", "para", "actividades", "básicas", "de", "la", "vida", "diaria", ",", "jubilado", "actualmente", ",", "había", "ejercido", "como", "mecánico", ".", "No", "describe", "antecedentes", "familiares", "oncológicos", "de", "interés", ".", "\n\n", "En", "control", "analítico", "rutinario", "por", "su", "médico", "de", "Atención", "Primaria", "se", "objetivan", "cifras", "de", "glicemia", "en", "torno", "a", "210", "mg", "/", "dL", "(", "valores", "normales", ",", "VN", ",", "75", "-", "105", "mg", "/", "dL", ")", ".", "Además", ",", "el", "paciente", "refiere", "poliuria", ",", "nicturia", "y", "polidipsia", "de", "tres", "meses", "de", "evolución", ",", "por", "lo", "que", "es", "diagnosticado", "de", "diabetes", "mellitus", "tipo", "2", ".", "Inicia", "tratamiento", "con", "metformina", "850", "mg", "diarios", "con", "buen", "control", "de", "cifras", "de", "glicemia", ".", "\n\n", "En", "marzo", "de", "2014", ",", "acude", "a", "Servicio", "de", "Urgencias", "por", "cuadro", "de", "dolor", "abdominal", "centrado", "en", "el", "mesogastrio", "-", "fosa", "iliaca", "derecha", ",", "meteorismo", "y", "cuadro", "de", "pérdida", "ponderal", "de", "peso", "(", ">", "15", "kg", "en", "los", "últimos", "cinco", "meses", ")", ",", "que", "motiva", "ingreso", "en", "Medicina", "Interna", "para", "estudio", ".", "Se", "solicita", "estudio", "de", "imagen", "con", "TC", "de", "abdomen1", ",", "hallándose", "una", "neoformación", "en", "la", "cabeza", "-", "cuerpo", "de", "páncreas", "junto", "con", "adenopatías", "patológicas", "y", "múltiples", "nódulos", "hipodensos", "hepáticos", "bilobares", "compatibles", "con", "metástasis", ".", "\n\n", "Dados", "los", "resultados", ",", "se", "presenta", "el", "caso", "en", "Comité", "Multidisciplinar", "de", "tumores", "hepatobiliares", "y", "se", "decide", "realizar", "biopsia", "percutánea", "de", "la", "lesión", "hepática", ".", "Esta", "se", "lleva", "a", "cabo", "en", "abril", "de", "2104", ".", "El", "diagnóstico", "histológico", "fue", "compatible", "con", "metástasis", "de", "adenocarcinoma", ",", "compatible", "con", "origen", "pancreático", ".", "\n\n", "Exploración", "física", "\n", "IK", ":", "80", "%", ",", "PS:1", ".", "Destaca", "dolor", "abdominal", "a", "la", "palpación", "en", "el", "mesogastrio", "y", "el", "hipocondrio", "derecho", ".", "\n", "Resto", "de", "la", "exploración", "dentro", "de", "la", "normalidad", ".", "\n\n", "Pruebas", "complementarias", "\n", "»", "TC", "con", "contraste", "IV", "de", "tórax", ",", "abdomen", "y", "pelvis", "(", "marzo/2014", "):", "Masa", "en", "cuerpo", "-", "cabeza", "pancreáticos", "de", "aprox", "3,7", "x", "2,2", "cm", ",", "de", "centro", "hipodenso", "y", "bordes", "mal", "delimitados", ",", "compatible", "con", "carcinoma", "pancreático", ".", "Engrosamiento", "nodular", "en", "cola", "de", "páncreas", "de", "1,9", "cm", ".", "Se", "observan", "múltiples", "nódulos", "hipodensos", "en", "ambos", "lóbulos", "hepáticos", ",", "el", "mayor", "en", "LHI", "de", "1,6", "cm", ",", "compatibles", "con", "metástasis", ".", "Adenopatías", "patológicas", "gastrohepáticas", ",", "paraaórticas", ",", "interaortocava", "y", "retrocrurales", ".", "\n\n", "Resto", "de", "estudio", "sin", "otros", "hallazgos", "reseñables", ".", "\n", "»", "Analítica", "(", "mayo/2014", ")", "destaca", ":", "Hb", "9,8", "g", "/", "dL", ";", "leucocitos", "13.640", "con", "10.250", "PMN", ";", "plaquetas", ":", "223.000", ";", "FA", "153", "U", "/", "L", "(", "VN", "34", "-", "104", "U", "/", "L", ")", ";", "GGT", "195", "U", "/", "L", "(", "VN", ":", "5", "-", "85", "U", "/", "L", ")", ";", "Ca", "19.9", ":", "198", "U", "/", "ml", "(", "VN", "0,00", "-", "37,00U", "/", "mL", ")", ".", "\n", "»", "TC", "con", "contraste", "IV", "de", "tórax", ",", "abdomen", "y", "pelvis", "(", "mayo/2014", "):", "comparativamente", "con", "estudio", "previo", "las", "lesiones", "hepáticas", "son", "mucho", "más", "numerosas", "y", "de", "mayor", "tamaño", ".", "Resto", "sin", "cambios", "significativos", ".", "\n", "»", "Analítica", "(", "junio/2014", ")", "destaca", ":", "GOT", "95", "U", "/", "L", "(", "VN", "15", "-", "37", "U", "/", "L", ")", ";", "GPT", "113", "U", "/", "L", "(", "VN", "12", "-", "78", "U", "/", "L", ")", ";", "GGT", "799", "U", "/", "L", ";", "bilirrubina", "total", "0,3", "mg", "/", "dL", "(", "VN", "0,00", "-", "1,00", "mg", "/", "dL", ")", ".", "\n", "»", "Analítica", "(", "septiembre/2014", ")", "destaca", ":", "GGT", "61", "U", "/", "L", ";", "GOT", "23", "U", "/", "L.", "\n", "»", "TC", "con", "contraste", "IV", "de", "tórax", ",", "abdomen", "y", "pelvis", "(", "septiembre/2014", "):", "nódulo", "retrocrural", "derecho", "que", "en", "la", "actualidad", "presenta", "un", "diámetro", "de", "13,4", "mm", "(", "previo", "19,3", "mm", ")", ".", "Las", "lesiones", "focales", "hepáticas", "en", "ambos", "lóbulos", "han", "disminuido", "tanto", "en", "número", "como", "en", "tamaño", ".", "Disminución", "del", "tamaño", "de", "la", "adenopatía", "paraaórtica", "izquierda", "que", "presenta", "unos", "diámetros", "aproximados", "de", "9", "x", "17", "mm", "(", "previo", "29", "x", "16", "mm", ")", ".", "Resto", "sin", "cambios", "significativos", "respecto", "al", "estudio", "previo", ".", "\n", "»", "Analítica", "(", "febrero/2015", ")", "destaca", ":", "GGT", "26", "U", "/", "L", ";", "GOT", "30", "U", "/", "L", ";", "GPT", "45", "U", "/", "L", ";", "Ca", "19.9", "4,80", ".", "\n", "»", "TC", "con", "contraste", "IV", "de", "tórax", ",", "abdomen", "y", "pelvis", "(", "febrero/2015", "):", "disminución", "de", "tamaño", "del", "nódulo", "retrocrural", "derecho", "(", "en", "la", "actualidad", "diámetro", "de", "8,5", "mm", ",", "previo", "13,4", "mm", ")", ".", "Persisten", "numerosas", "lesiones", "focales", "hepáticas", "en", "ambos", "lóbulos", ",", "aunque", "han", "disminuido", "tanto", "en", "número", "como", "en", "tamaño", ".", "Disminución", "del", "tamaño", "de", "la", "adenopatía", "paraaórtica", "izquierda", "(", "diámetro", "de", "6.5", "x", "15", "mm", ",", "previo", "9", "x", "17", "mm", ")", ".", "Resto", "sin", "cambios", "significativos", "respecto", "al", "estudio", "previo", ".", "\n\n", "Diagnóstico", "\n", "Adenocarcinoma", "de", "cabeza", "-", "cuerpo", "de", "páncreas", "estadio", "IV", ".", "\n", "TVP", "de", "MII", "(", "mayo", "de", "2014", ")", "anticoagulado", "con", "HBPM", ".", "\n\n", "Tratamiento", "\n", "Tras", "descartarse", "la", "cirugía", ",", "dada", "la", "extensión", "de", "la", "enfermedad", ",", "el", "paciente", "es", "derivado", "a", "Consultas", "Externas", "de", "Oncología", "Médica", "(", "mayo", "de", "2014", ")", ",", "solicitándose", "nuevo", "estudio", "de", "extensión", ".", "\n\n", "Lo", "volvemos", "a", "ver", "a", "finales", "de", "mayo", ",", "ya", "que", "ha", "estado", "ingresado", "por", "un", "cuadro", "de", "neumonía", "bilateral", ".", "Se", "encuentra", "más", "deteriorado", "(", "IK", "50%-PS", "2", "-", "3", ")", ".", "Refiere", "astenia", "severa", "que", "limita", "su", "calidad", "de", "vida", "de", "forma", "importante", "(", "vida", "cama", "-", "sillón", "en", "las", "últimas", "dos", "semanas", ")", ".", "En", "la", "exploraciones", "objetivamos", "aumento", "del", "perímetro", "del", "miembro", "inferior", "izquierdo", "(", "MII", ")", "con", "empastamiento", "a", "nivel", "de", "pantorrilla", ",", "por", "lo", "que", "solicitamos", "eco", "-", "coppler", "urgente", "que", "confirma", "la", "sospecha", "de", "trombosis", "venosa", "profunda", "(", "TVP", ")", "que", "afecta", "al", "segmento", "femoral", "y", "poplíteo", "del", "MII", ".", "Iniciamos", "tratamiento", "con", "heparina", "de", "bajo", "peso", "molecular", "(", "HBPM", ")", "a", "dosis", "terapéutica", "y", "reajustamos", "tratamiento", "sintomático", ".", "El", "estudio", "solicitado", "en", "la", "visita", "previa", "confirma", "progresión", "de", "enfermedad", ".", "\n\n", "Acude", "de", "nuevo", "a", "revisión", "en", "junio", "de", "2014", ".", "Se", "encuentra", "mejor", ",", "ha", "recuperado", "autonomía", ",", "sale", "a", "la", "calle", "solo", "(", "IK", "70", "%", "PS", "2", ")", ".", "Únicamente", "refiere", "astenia", "grado", "2", ".", "A", "la", "exploración", "física", "solo", "destacar", "signos", "de", "síndrome", "posflebítico", "en", "MII", "y", "a", "nivel", "analítico", "destaca", "elevación", "de", "transaminasas", ".", "Ante", "la", "situación", "actual", ",", "proponemos", "tratamiento", "de", "quimioterapia", "con", "esquema", "gemcitabina", "1.000", "mg", "/", "m2", "más", "nab", "-", "paclitaxel", "125", "mg", "/", "m2", "días", "1", ",", "8", "y", "15", "cada", "28", "días4", ".", "Pautamos", "primer", "ciclo", "con", "reducción", "del", "20", "%", "de", "la", "dosis", ".", "Monitorizamos", "tolerancia", "y", "toxicidad", "con", "carácter", "semanal", ",", "de", "manera", "que", "escalamos", "dosis", "y", "tras", "dos", "semanas", "pautamos", "la", "tercera", "dosis", "al", "100", "%", ".", "Tras", "el", "primer", "ciclo", "completo", ",", "el", "paciente", "presenta", "beneficio", "clínico", "evidente", "con", "mejoría", "de", "la", "situación", "funcional", "(", "PS", "1", ")", "y", "reducción", "de", "la", "analgesia", ".", "Como", "efectos", "adversos", "objetivamos", "astenia", ",", "alopecia", "y", "anemia", "grado", "1", ".", "\n\n", "Evolución", "\n", "En", "septiembre", "de", "2014", ",", "tras", "tres", "meses", "de", "quimioterapia", "a", "dosis", "plenas", ",", "persiste", "el", "beneficio", "clínico", "(", "IK", "90", "%", "PS", "1", ")", ".", "No", "refiere", "dolor", ",", "mantiene", "apetito", "y", "prosigue", "con", "astenia", "grado", "1", ".", "Además", ",", "existe", "respuesta", "bioquímica", ",", "con", "descenso", "de", "los", "valores", "de", "transaminasas", ",", "y", "respuesta", "radiológica", "parcial", "con", "disminución", "en", "número", "y", "tamaño", "de", "las", "adenopatías", "y", "metástasis", "hepáticas", ".", "En", "diciembre", "de", "2014", ",", "tras", "cinco", "ciclos", ",", "el", "paciente", "refiere", "como", "única", "toxicidad", "parestesias", "plantares", "grado", "1", ".", "\n\n", "En", "reevaluación", ",", "tras", "seis", "meses", "de", "quimioterapia", "(", "febrero/2015", ")", "persiste", "el", "beneficio", "clínico", ".", "El", "paciente", "hace", "vida", "activa", "y", "refiere", "mínima", "astenia", ".", "Como", "toxicidad", "al", "tratamiento", "presenta", "alopecia", "grado", "2", ",", "parestesias", "palmo", "-", "plantar", "grado", "1", "-", "2", "y", "anemia", "grado", "1", ".", "A", "nivel", "bioquímico", ",", "continúa", "la", "normalización", "de", "las", "cifras", "de", "transaminasas", "y", "Ca", "19.9", ";", "y", "a", "nivel", "radiológico", ",", "persiste", "reducción", "del", "número", "y", "tamaño", "de", "las", "metástasis", "hepáticas", "objetivándose", "una", "respuesta", "parcial", "mayor", ".", "\n\n", "Tras", "ocho", "ciclos", ",", "ha", "precisado", "reducción", "de", "dosis", "de", "nab", "-", "paclitaxel", "(", "100", "mg", "/", "m2", ")", "por", "neuropatía", "grado", "2", "mantenida", ".", "Actualmente", ",", "ha", "completado", "nueve", "meses", "de", "tratamiento", ",", "hace", "su", "vida", "normal", ",", "dice", "encontrarse", "\"", "muy", "bien", "\"", "con", "buena", "tolerancia", "al", "tratamiento", "y", "desea", "continuar", "con", "el", "mismo", ".", "En", "última", "reevaluación", "(", "abril/2015", ")", "mantiene", "el", "beneficio", "clínico", ",", "bioquímico", "y", "respuesta", "radiológica", "." ]
[ "MORFOLOGIA_NEOPLASIA" ]
neoformación, nódulos hipodensos hepáticos, metástasis, lesión hepática, metástasis de adenocarcinoma, carcinoma, nódulos hipodensos en ambos lóbulos hepáticos, metástasis, lesiones hepáticas, lesiones focales hepáticas, lesiones focales hepáticas, Adenocarcinoma, metástasis, metástasis
97_task2
Sentence: Anamnesis Se presenta el caso de un varón de 75 años que debuta con un cuadro de diabetes mellitus en noviembre de 2013. Como antecedentes personales destacaba dislipemia controlada con simvastatina 20 mg, alergia a la penicilina y había sido intervenido de apendicectomía con 40 años de edad. No era ni había sido fumador o bebedor, mantenía buena calidad de vida, independiente para actividades básicas de la vida diaria, jubilado actualmente, había ejercido como mecánico. No describe antecedentes familiares oncológicos de interés. En control analítico rutinario por su médico de Atención Primaria se objetivan cifras de glicemia en torno a 210 mg/dL (valores normales, VN, 75-105 mg/dL). Además, el paciente refiere poliuria, nicturia y polidipsia de tres meses de evolución, por lo que es diagnosticado de diabetes mellitus tipo 2. Inicia tratamiento con metformina 850 mg diarios con buen control de cifras de glicemia. En marzo de 2014, acude a Servicio de Urgencias por cuadro de dolor abdominal centrado en el mesogastrio-fosa iliaca derecha, meteorismo y cuadro de pérdida ponderal de peso (>15 kg en los últimos cinco meses), que motiva ingreso en Medicina Interna para estudio. Se solicita estudio de imagen con TC de abdomen1, hallándose una neoformación en la cabeza-cuerpo de páncreas junto con adenopatías patológicas y múltiples nódulos hipodensos hepáticos bilobares compatibles con metástasis. Dados los resultados, se presenta el caso en Comité Multidisciplinar de tumores hepatobiliares y se decide realizar biopsia percutánea de la lesión hepática. Esta se lleva a cabo en abril de 2104. El diagnóstico histológico fue compatible con metástasis de adenocarcinoma, compatible con origen pancreático. Exploración física IK: 80%, PS:1. Destaca dolor abdominal a la palpación en el mesogastrio y el hipocondrio derecho. Resto de la exploración dentro de la normalidad. Pruebas complementarias » TC con contraste IV de tórax, abdomen y pelvis (marzo/2014): Masa en cuerpo-cabeza pancreáticos de aprox 3,7 x 2,2 cm, de centro hipodenso y bordes mal delimitados, compatible con carcinoma pancreático. Engrosamiento nodular en cola de páncreas de 1,9 cm. Se observan múltiples nódulos hipodensos en ambos lóbulos hepáticos, el mayor en LHI de 1,6 cm, compatibles con metástasis. Adenopatías patológicas gastrohepáticas, paraaórticas, interaortocava y retrocrurales. Resto de estudio sin otros hallazgos reseñables. » Analítica (mayo/2014) destaca: Hb 9,8 g/dL; leucocitos 13.640 con 10.250 PMN; plaquetas: 223.000; FA 153 U/L (VN 34-104 U/L); GGT 195 U/L (VN: 5-85 U/L); Ca 19.9: 198 U/ml (VN 0,00-37,00U/mL). » TC con contraste IV de tórax, abdomen y pelvis (mayo/2014): comparativamente con estudio previo las lesiones hepáticas son mucho más numerosas y de mayor tamaño. Resto sin cambios significativos. » Analítica (junio/2014) destaca: GOT 95 U/L (VN 15-37 U/L); GPT 113 U/L (VN 12-78 U/L); GGT 799 U/L; bilirrubina total 0,3 mg/dL (VN 0,00-1,00 mg/dL). » Analítica (septiembre/2014) destaca: GGT 61 U/L; GOT 23 U/L. » TC con contraste IV de tórax, abdomen y pelvis (septiembre/2014): nódulo retrocrural derecho que en la actualidad presenta un diámetro de 13,4 mm (previo 19,3 mm). Las lesiones focales hepáticas en ambos lóbulos han disminuido tanto en número como en tamaño. Disminución del tamaño de la adenopatía paraaórtica izquierda que presenta unos diámetros aproximados de 9 x 17 mm (previo 29 x 16 mm). Resto sin cambios significativos respecto al estudio previo. » Analítica (febrero/2015) destaca: GGT 26 U/L; GOT 30 U/L; GPT 45 U/L; Ca 19.9 4,80. » TC con contraste IV de tórax, abdomen y pelvis (febrero/2015): disminución de tamaño del nódulo retrocrural derecho (en la actualidad diámetro de 8,5 mm, previo 13,4 mm). Persisten numerosas lesiones focales hepáticas en ambos lóbulos, aunque han disminuido tanto en número como en tamaño. Disminución del tamaño de la adenopatía paraaórtica izquierda (diámetro de 6.5 x 15 mm, previo 9 x 17 mm). Resto sin cambios significativos respecto al estudio previo. Diagnóstico Adenocarcinoma de cabeza-cuerpo de páncreas estadio IV. TVP de MII (mayo de 2014) anticoagulado con HBPM. Tratamiento Tras descartarse la cirugía, dada la extensión de la enfermedad, el paciente es derivado a Consultas Externas de Oncología Médica (mayo de 2014), solicitándose nuevo estudio de extensión. Lo volvemos a ver a finales de mayo, ya que ha estado ingresado por un cuadro de neumonía bilateral. Se encuentra más deteriorado (IK 50%-PS 2-3). Refiere astenia severa que limita su calidad de vida de forma importante (vida cama-sillón en las últimas dos semanas). En la exploraciones objetivamos aumento del perímetro del miembro inferior izquierdo (MII) con empastamiento a nivel de pantorrilla, por lo que solicitamos eco-coppler urgente que confirma la sospecha de trombosis venosa profunda (TVP) que afecta al segmento femoral y poplíteo del MII. Iniciamos tratamiento con heparina de bajo peso molecular (HBPM) a dosis terapéutica y reajustamos tratamiento sintomático. El estudio solicitado en la visita previa confirma progresión de enfermedad. Acude de nuevo a revisión en junio de 2014. Se encuentra mejor, ha recuperado autonomía, sale a la calle solo (IK 70% PS 2). Únicamente refiere astenia grado 2. A la exploración física solo destacar signos de síndrome posflebítico en MII y a nivel analítico destaca elevación de transaminasas. Ante la situación actual, proponemos tratamiento de quimioterapia con esquema gemcitabina 1.000 mg/m2 más nab-paclitaxel 125 mg/m2 días 1, 8 y 15 cada 28 días4. Pautamos primer ciclo con reducción del 20% de la dosis. Monitorizamos tolerancia y toxicidad con carácter semanal, de manera que escalamos dosis y tras dos semanas pautamos la tercera dosis al 100%. Tras el primer ciclo completo, el paciente presenta beneficio clínico evidente con mejoría de la situación funcional (PS 1) y reducción de la analgesia. Como efectos adversos objetivamos astenia, alopecia y anemia grado 1. Evolución En septiembre de 2014, tras tres meses de quimioterapia a dosis plenas, persiste el beneficio clínico (IK 90% PS 1). No refiere dolor, mantiene apetito y prosigue con astenia grado 1. Además, existe respuesta bioquímica, con descenso de los valores de transaminasas, y respuesta radiológica parcial con disminución en número y tamaño de las adenopatías y metástasis hepáticas. En diciembre de 2014, tras cinco ciclos, el paciente refiere como única toxicidad parestesias plantares grado 1. En reevaluación, tras seis meses de quimioterapia (febrero/2015) persiste el beneficio clínico. El paciente hace vida activa y refiere mínima astenia. Como toxicidad al tratamiento presenta alopecia grado 2, parestesias palmo-plantar grado 1-2 y anemia grado 1. A nivel bioquímico, continúa la normalización de las cifras de transaminasas y Ca 19.9; y a nivel radiológico, persiste reducción del número y tamaño de las metástasis hepáticas objetivándose una respuesta parcial mayor. Tras ocho ciclos, ha precisado reducción de dosis de nab-paclitaxel (100 mg/m2 ) por neuropatía grado 2 mantenida. Actualmente, ha completado nueve meses de tratamiento, hace su vida normal, dice encontrarse "muy bien" con buena tolerancia al tratamiento y desea continuar con el mismo. En última reevaluación (abril/2015) mantiene el beneficio clínico, bioquímico y respuesta radiológica. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Anamnesis Se presenta el caso de un varón de 75 años que debuta con un cuadro de diabetes mellitus en noviembre de 2013. Como antecedentes personales destacaba dislipemia controlada con simvastatina 20 mg, alergia a la penicilina y había sido intervenido de apendicectomía con 40 años de edad. No era ni había sido fumador o bebedor, mantenía buena calidad de vida, independiente para actividades básicas de la vida diaria, jubilado actualmente, había ejercido como mecánico. No describe antecedentes familiares oncológicos de interés. En control analítico rutinario por su médico de Atención Primaria se objetivan cifras de glicemia en torno a 210 mg/dL (valores normales, VN, 75-105 mg/dL). Además, el paciente refiere poliuria, nicturia y polidipsia de tres meses de evolución, por lo que es diagnosticado de diabetes mellitus tipo 2. Inicia tratamiento con metformina 850 mg diarios con buen control de cifras de glicemia. En marzo de 2014, acude a Servicio de Urgencias por cuadro de dolor abdominal centrado en el mesogastrio-fosa iliaca derecha, meteorismo y cuadro de pérdida ponderal de peso (>15 kg en los últimos cinco meses), que motiva ingreso en Medicina Interna para estudio. Se solicita estudio de imagen con TC de abdomen1, hallándose una neoformación en la cabeza-cuerpo de páncreas junto con adenopatías patológicas y múltiples nódulos hipodensos hepáticos bilobares compatibles con metástasis. Dados los resultados, se presenta el caso en Comité Multidisciplinar de tumores hepatobiliares y se decide realizar biopsia percutánea de la lesión hepática. Esta se lleva a cabo en abril de 2104. El diagnóstico histológico fue compatible con metástasis de adenocarcinoma, compatible con origen pancreático. Exploración física IK: 80%, PS:1. Destaca dolor abdominal a la palpación en el mesogastrio y el hipocondrio derecho. Resto de la exploración dentro de la normalidad. Pruebas complementarias » TC con contraste IV de tórax, abdomen y pelvis (marzo/2014): Masa en cuerpo-cabeza pancreáticos de aprox 3,7 x 2,2 cm, de centro hipodenso y bordes mal delimitados, compatible con carcinoma pancreático. Engrosamiento nodular en cola de páncreas de 1,9 cm. Se observan múltiples nódulos hipodensos en ambos lóbulos hepáticos, el mayor en LHI de 1,6 cm, compatibles con metástasis. Adenopatías patológicas gastrohepáticas, paraaórticas, interaortocava y retrocrurales. Resto de estudio sin otros hallazgos reseñables. » Analítica (mayo/2014) destaca: Hb 9,8 g/dL; leucocitos 13.640 con 10.250 PMN; plaquetas: 223.000; FA 153 U/L (VN 34-104 U/L); GGT 195 U/L (VN: 5-85 U/L); Ca 19.9: 198 U/ml (VN 0,00-37,00U/mL). » TC con contraste IV de tórax, abdomen y pelvis (mayo/2014): comparativamente con estudio previo las lesiones hepáticas son mucho más numerosas y de mayor tamaño. Resto sin cambios significativos. » Analítica (junio/2014) destaca: GOT 95 U/L (VN 15-37 U/L); GPT 113 U/L (VN 12-78 U/L); GGT 799 U/L; bilirrubina total 0,3 mg/dL (VN 0,00-1,00 mg/dL). » Analítica (septiembre/2014) destaca: GGT 61 U/L; GOT 23 U/L. » TC con contraste IV de tórax, abdomen y pelvis (septiembre/2014): nódulo retrocrural derecho que en la actualidad presenta un diámetro de 13,4 mm (previo 19,3 mm). Las lesiones focales hepáticas en ambos lóbulos han disminuido tanto en número como en tamaño. Disminución del tamaño de la adenopatía paraaórtica izquierda que presenta unos diámetros aproximados de 9 x 17 mm (previo 29 x 16 mm). Resto sin cambios significativos respecto al estudio previo. » Analítica (febrero/2015) destaca: GGT 26 U/L; GOT 30 U/L; GPT 45 U/L; Ca 19.9 4,80. » TC con contraste IV de tórax, abdomen y pelvis (febrero/2015): disminución de tamaño del nódulo retrocrural derecho (en la actualidad diámetro de 8,5 mm, previo 13,4 mm). Persisten numerosas lesiones focales hepáticas en ambos lóbulos, aunque han disminuido tanto en número como en tamaño. Disminución del tamaño de la adenopatía paraaórtica izquierda (diámetro de 6.5 x 15 mm, previo 9 x 17 mm). Resto sin cambios significativos respecto al estudio previo. Diagnóstico Adenocarcinoma de cabeza-cuerpo de páncreas estadio IV. TVP de MII (mayo de 2014) anticoagulado con HBPM. Tratamiento Tras descartarse la cirugía, dada la extensión de la enfermedad, el paciente es derivado a Consultas Externas de Oncología Médica (mayo de 2014), solicitándose nuevo estudio de extensión. Lo volvemos a ver a finales de mayo, ya que ha estado ingresado por un cuadro de neumonía bilateral. Se encuentra más deteriorado (IK 50%-PS 2-3). Refiere astenia severa que limita su calidad de vida de forma importante (vida cama-sillón en las últimas dos semanas). En la exploraciones objetivamos aumento del perímetro del miembro inferior izquierdo (MII) con empastamiento a nivel de pantorrilla, por lo que solicitamos eco-coppler urgente que confirma la sospecha de trombosis venosa profunda (TVP) que afecta al segmento femoral y poplíteo del MII. Iniciamos tratamiento con heparina de bajo peso molecular (HBPM) a dosis terapéutica y reajustamos tratamiento sintomático. El estudio solicitado en la visita previa confirma progresión de enfermedad. Acude de nuevo a revisión en junio de 2014. Se encuentra mejor, ha recuperado autonomía, sale a la calle solo (IK 70% PS 2). Únicamente refiere astenia grado 2. A la exploración física solo destacar signos de síndrome posflebítico en MII y a nivel analítico destaca elevación de transaminasas. Ante la situación actual, proponemos tratamiento de quimioterapia con esquema gemcitabina 1.000 mg/m2 más nab-paclitaxel 125 mg/m2 días 1, 8 y 15 cada 28 días4. Pautamos primer ciclo con reducción del 20% de la dosis. Monitorizamos tolerancia y toxicidad con carácter semanal, de manera que escalamos dosis y tras dos semanas pautamos la tercera dosis al 100%. Tras el primer ciclo completo, el paciente presenta beneficio clínico evidente con mejoría de la situación funcional (PS 1) y reducción de la analgesia. Como efectos adversos objetivamos astenia, alopecia y anemia grado 1. Evolución En septiembre de 2014, tras tres meses de quimioterapia a dosis plenas, persiste el beneficio clínico (IK 90% PS 1). No refiere dolor, mantiene apetito y prosigue con astenia grado 1. Además, existe respuesta bioquímica, con descenso de los valores de transaminasas, y respuesta radiológica parcial con disminución en número y tamaño de las adenopatías y metástasis hepáticas. En diciembre de 2014, tras cinco ciclos, el paciente refiere como única toxicidad parestesias plantares grado 1. En reevaluación, tras seis meses de quimioterapia (febrero/2015) persiste el beneficio clínico. El paciente hace vida activa y refiere mínima astenia. Como toxicidad al tratamiento presenta alopecia grado 2, parestesias palmo-plantar grado 1-2 y anemia grado 1. A nivel bioquímico, continúa la normalización de las cifras de transaminasas y Ca 19.9; y a nivel radiológico, persiste reducción del número y tamaño de las metástasis hepáticas objetivándose una respuesta parcial mayor. Tras ocho ciclos, ha precisado reducción de dosis de nab-paclitaxel (100 mg/m2 ) por neuropatía grado 2 mantenida. Actualmente, ha completado nueve meses de tratamiento, hace su vida normal, dice encontrarse "muy bien" con buena tolerancia al tratamiento y desea continuar con el mismo. En última reevaluación (abril/2015) mantiene el beneficio clínico, bioquímico y respuesta radiológica.
[ "Anamnesis", "\n", "Se", "presenta", "el", "caso", "de", "un", "varón", "de", "75", "años", "que", "debuta", "con", "un", "cuadro", "de", "diabetes", "mellitus", "en", "noviembre", "de", "2013", ".", "\n\n", "Como", "antecedentes", "personales", "destacaba", "dislipemia", "controlada", "con", "simvastatina", "20", "mg", ",", "alergia", "a", "la", "penicilina", "y", "había", "sido", "intervenido", "de", "apendicectomía", "con", "40", "años", "de", "edad", ".", "No", "era", "ni", "había", "sido", "fumador", "o", "bebedor", ",", "mantenía", "buena", "calidad", "de", "vida", ",", "independiente", "para", "actividades", "básicas", "de", "la", "vida", "diaria", ",", "jubilado", "actualmente", ",", "había", "ejercido", "como", "mecánico", ".", "No", "describe", "antecedentes", "familiares", "oncológicos", "de", "interés", ".", "\n\n", "En", "control", "analítico", "rutinario", "por", "su", "médico", "de", "Atención", "Primaria", "se", "objetivan", "cifras", "de", "glicemia", "en", "torno", "a", "210", "mg", "/", "dL", "(", "valores", "normales", ",", "VN", ",", "75", "-", "105", "mg", "/", "dL", ")", ".", "Además", ",", "el", "paciente", "refiere", "poliuria", ",", "nicturia", "y", "polidipsia", "de", "tres", "meses", "de", "evolución", ",", "por", "lo", "que", "es", "diagnosticado", "de", "diabetes", "mellitus", "tipo", "2", ".", "Inicia", "tratamiento", "con", "metformina", "850", "mg", "diarios", "con", "buen", "control", "de", "cifras", "de", "glicemia", ".", "\n\n", "En", "marzo", "de", "2014", ",", "acude", "a", "Servicio", "de", "Urgencias", "por", "cuadro", "de", "dolor", "abdominal", "centrado", "en", "el", "mesogastrio", "-", "fosa", "iliaca", "derecha", ",", "meteorismo", "y", "cuadro", "de", "pérdida", "ponderal", "de", "peso", "(", ">", "15", "kg", "en", "los", "últimos", "cinco", "meses", ")", ",", "que", "motiva", "ingreso", "en", "Medicina", "Interna", "para", "estudio", ".", "Se", "solicita", "estudio", "de", "imagen", "con", "TC", "de", "abdomen1", ",", "hallándose", "una", "neoformación", "en", "la", "cabeza", "-", "cuerpo", "de", "páncreas", "junto", "con", "adenopatías", "patológicas", "y", "múltiples", "nódulos", "hipodensos", "hepáticos", "bilobares", "compatibles", "con", "metástasis", ".", "\n\n", "Dados", "los", "resultados", ",", "se", "presenta", "el", "caso", "en", "Comité", "Multidisciplinar", "de", "tumores", "hepatobiliares", "y", "se", "decide", "realizar", "biopsia", "percutánea", "de", "la", "lesión", "hepática", ".", "Esta", "se", "lleva", "a", "cabo", "en", "abril", "de", "2104", ".", "El", "diagnóstico", "histológico", "fue", "compatible", "con", "metástasis", "de", "adenocarcinoma", ",", "compatible", "con", "origen", "pancreático", ".", "\n\n", "Exploración", "física", "\n", "IK", ":", "80", "%", ",", "PS:1", ".", "Destaca", "dolor", "abdominal", "a", "la", "palpación", "en", "el", "mesogastrio", "y", "el", "hipocondrio", "derecho", ".", "\n", "Resto", "de", "la", "exploración", "dentro", "de", "la", "normalidad", ".", "\n\n", "Pruebas", "complementarias", "\n", "»", "TC", "con", "contraste", "IV", "de", "tórax", ",", "abdomen", "y", "pelvis", "(", "marzo/2014", "):", "Masa", "en", "cuerpo", "-", "cabeza", "pancreáticos", "de", "aprox", "3,7", "x", "2,2", "cm", ",", "de", "centro", "hipodenso", "y", "bordes", "mal", "delimitados", ",", "compatible", "con", "carcinoma", "pancreático", ".", "Engrosamiento", "nodular", "en", "cola", "de", "páncreas", "de", "1,9", "cm", ".", "Se", "observan", "múltiples", "nódulos", "hipodensos", "en", "ambos", "lóbulos", "hepáticos", ",", "el", "mayor", "en", "LHI", "de", "1,6", "cm", ",", "compatibles", "con", "metástasis", ".", "Adenopatías", "patológicas", "gastrohepáticas", ",", "paraaórticas", ",", "interaortocava", "y", "retrocrurales", ".", "\n\n", "Resto", "de", "estudio", "sin", "otros", "hallazgos", "reseñables", ".", "\n", "»", "Analítica", "(", "mayo/2014", ")", "destaca", ":", "Hb", "9,8", "g", "/", "dL", ";", "leucocitos", "13.640", "con", "10.250", "PMN", ";", "plaquetas", ":", "223.000", ";", "FA", "153", "U", "/", "L", "(", "VN", "34", "-", "104", "U", "/", "L", ")", ";", "GGT", "195", "U", "/", "L", "(", "VN", ":", "5", "-", "85", "U", "/", "L", ")", ";", "Ca", "19.9", ":", "198", "U", "/", "ml", "(", "VN", "0,00", "-", "37,00U", "/", "mL", ")", ".", "\n", "»", "TC", "con", "contraste", "IV", "de", "tórax", ",", "abdomen", "y", "pelvis", "(", "mayo/2014", "):", "comparativamente", "con", "estudio", "previo", "las", "lesiones", "hepáticas", "son", "mucho", "más", "numerosas", "y", "de", "mayor", "tamaño", ".", "Resto", "sin", "cambios", "significativos", ".", "\n", "»", "Analítica", "(", "junio/2014", ")", "destaca", ":", "GOT", "95", "U", "/", "L", "(", "VN", "15", "-", "37", "U", "/", "L", ")", ";", "GPT", "113", "U", "/", "L", "(", "VN", "12", "-", "78", "U", "/", "L", ")", ";", "GGT", "799", "U", "/", "L", ";", "bilirrubina", "total", "0,3", "mg", "/", "dL", "(", "VN", "0,00", "-", "1,00", "mg", "/", "dL", ")", ".", "\n", "»", "Analítica", "(", "septiembre/2014", ")", "destaca", ":", "GGT", "61", "U", "/", "L", ";", "GOT", "23", "U", "/", "L.", "\n", "»", "TC", "con", "contraste", "IV", "de", "tórax", ",", "abdomen", "y", "pelvis", "(", "septiembre/2014", "):", "nódulo", "retrocrural", "derecho", "que", "en", "la", "actualidad", "presenta", "un", "diámetro", "de", "13,4", "mm", "(", "previo", "19,3", "mm", ")", ".", "Las", "lesiones", "focales", "hepáticas", "en", "ambos", "lóbulos", "han", "disminuido", "tanto", "en", "número", "como", "en", "tamaño", ".", "Disminución", "del", "tamaño", "de", "la", "adenopatía", "paraaórtica", "izquierda", "que", "presenta", "unos", "diámetros", "aproximados", "de", "9", "x", "17", "mm", "(", "previo", "29", "x", "16", "mm", ")", ".", "Resto", "sin", "cambios", "significativos", "respecto", "al", "estudio", "previo", ".", "\n", "»", "Analítica", "(", "febrero/2015", ")", "destaca", ":", "GGT", "26", "U", "/", "L", ";", "GOT", "30", "U", "/", "L", ";", "GPT", "45", "U", "/", "L", ";", "Ca", "19.9", "4,80", ".", "\n", "»", "TC", "con", "contraste", "IV", "de", "tórax", ",", "abdomen", "y", "pelvis", "(", "febrero/2015", "):", "disminución", "de", "tamaño", "del", "nódulo", "retrocrural", "derecho", "(", "en", "la", "actualidad", "diámetro", "de", "8,5", "mm", ",", "previo", "13,4", "mm", ")", ".", "Persisten", "numerosas", "lesiones", "focales", "hepáticas", "en", "ambos", "lóbulos", ",", "aunque", "han", "disminuido", "tanto", "en", "número", "como", "en", "tamaño", ".", "Disminución", "del", "tamaño", "de", "la", "adenopatía", "paraaórtica", "izquierda", "(", "diámetro", "de", "6.5", "x", "15", "mm", ",", "previo", "9", "x", "17", "mm", ")", ".", "Resto", "sin", "cambios", "significativos", "respecto", "al", "estudio", "previo", ".", "\n\n", "Diagnóstico", "\n", "Adenocarcinoma", "de", "cabeza", "-", "cuerpo", "de", "páncreas", "estadio", "IV", ".", "\n", "TVP", "de", "MII", "(", "mayo", "de", "2014", ")", "anticoagulado", "con", "HBPM", ".", "\n\n", "Tratamiento", "\n", "Tras", "descartarse", "la", "cirugía", ",", "dada", "la", "extensión", "de", "la", "enfermedad", ",", "el", "paciente", "es", "derivado", "a", "Consultas", "Externas", "de", "Oncología", "Médica", "(", "mayo", "de", "2014", ")", ",", "solicitándose", "nuevo", "estudio", "de", "extensión", ".", "\n\n", "Lo", "volvemos", "a", "ver", "a", "finales", "de", "mayo", ",", "ya", "que", "ha", "estado", "ingresado", "por", "un", "cuadro", "de", "neumonía", "bilateral", ".", "Se", "encuentra", "más", "deteriorado", "(", "IK", "50%-PS", "2", "-", "3", ")", ".", "Refiere", "astenia", "severa", "que", "limita", "su", "calidad", "de", "vida", "de", "forma", "importante", "(", "vida", "cama", "-", "sillón", "en", "las", "últimas", "dos", "semanas", ")", ".", "En", "la", "exploraciones", "objetivamos", "aumento", "del", "perímetro", "del", "miembro", "inferior", "izquierdo", "(", "MII", ")", "con", "empastamiento", "a", "nivel", "de", "pantorrilla", ",", "por", "lo", "que", "solicitamos", "eco", "-", "coppler", "urgente", "que", "confirma", "la", "sospecha", "de", "trombosis", "venosa", "profunda", "(", "TVP", ")", "que", "afecta", "al", "segmento", "femoral", "y", "poplíteo", "del", "MII", ".", "Iniciamos", "tratamiento", "con", "heparina", "de", "bajo", "peso", "molecular", "(", "HBPM", ")", "a", "dosis", "terapéutica", "y", "reajustamos", "tratamiento", "sintomático", ".", "El", "estudio", "solicitado", "en", "la", "visita", "previa", "confirma", "progresión", "de", "enfermedad", ".", "\n\n", "Acude", "de", "nuevo", "a", "revisión", "en", "junio", "de", "2014", ".", "Se", "encuentra", "mejor", ",", "ha", "recuperado", "autonomía", ",", "sale", "a", "la", "calle", "solo", "(", "IK", "70", "%", "PS", "2", ")", ".", "Únicamente", "refiere", "astenia", "grado", "2", ".", "A", "la", "exploración", "física", "solo", "destacar", "signos", "de", "síndrome", "posflebítico", "en", "MII", "y", "a", "nivel", "analítico", "destaca", "elevación", "de", "transaminasas", ".", "Ante", "la", "situación", "actual", ",", "proponemos", "tratamiento", "de", "quimioterapia", "con", "esquema", "gemcitabina", "1.000", "mg", "/", "m2", "más", "nab", "-", "paclitaxel", "125", "mg", "/", "m2", "días", "1", ",", "8", "y", "15", "cada", "28", "días4", ".", "Pautamos", "primer", "ciclo", "con", "reducción", "del", "20", "%", "de", "la", "dosis", ".", "Monitorizamos", "tolerancia", "y", "toxicidad", "con", "carácter", "semanal", ",", "de", "manera", "que", "escalamos", "dosis", "y", "tras", "dos", "semanas", "pautamos", "la", "tercera", "dosis", "al", "100", "%", ".", "Tras", "el", "primer", "ciclo", "completo", ",", "el", "paciente", "presenta", "beneficio", "clínico", "evidente", "con", "mejoría", "de", "la", "situación", "funcional", "(", "PS", "1", ")", "y", "reducción", "de", "la", "analgesia", ".", "Como", "efectos", "adversos", "objetivamos", "astenia", ",", "alopecia", "y", "anemia", "grado", "1", ".", "\n\n", "Evolución", "\n", "En", "septiembre", "de", "2014", ",", "tras", "tres", "meses", "de", "quimioterapia", "a", "dosis", "plenas", ",", "persiste", "el", "beneficio", "clínico", "(", "IK", "90", "%", "PS", "1", ")", ".", "No", "refiere", "dolor", ",", "mantiene", "apetito", "y", "prosigue", "con", "astenia", "grado", "1", ".", "Además", ",", "existe", "respuesta", "bioquímica", ",", "con", "descenso", "de", "los", "valores", "de", "transaminasas", ",", "y", "respuesta", "radiológica", "parcial", "con", "disminución", "en", "número", "y", "tamaño", "de", "las", "adenopatías", "y", "metástasis", "hepáticas", ".", "En", "diciembre", "de", "2014", ",", "tras", "cinco", "ciclos", ",", "el", "paciente", "refiere", "como", "única", "toxicidad", "parestesias", "plantares", "grado", "1", ".", "\n\n", "En", "reevaluación", ",", "tras", "seis", "meses", "de", "quimioterapia", "(", "febrero/2015", ")", "persiste", "el", "beneficio", "clínico", ".", "El", "paciente", "hace", "vida", "activa", "y", "refiere", "mínima", "astenia", ".", "Como", "toxicidad", "al", "tratamiento", "presenta", "alopecia", "grado", "2", ",", "parestesias", "palmo", "-", "plantar", "grado", "1", "-", "2", "y", "anemia", "grado", "1", ".", "A", "nivel", "bioquímico", ",", "continúa", "la", "normalización", "de", "las", "cifras", "de", "transaminasas", "y", "Ca", "19.9", ";", "y", "a", "nivel", "radiológico", ",", "persiste", "reducción", "del", "número", "y", "tamaño", "de", "las", "metástasis", "hepáticas", "objetivándose", "una", "respuesta", "parcial", "mayor", ".", "\n\n", "Tras", "ocho", "ciclos", ",", "ha", "precisado", "reducción", "de", "dosis", "de", "nab", "-", "paclitaxel", "(", "100", "mg", "/", "m2", ")", "por", "neuropatía", "grado", "2", "mantenida", ".", "Actualmente", ",", "ha", "completado", "nueve", "meses", "de", "tratamiento", ",", "hace", "su", "vida", "normal", ",", "dice", "encontrarse", "\"", "muy", "bien", "\"", "con", "buena", "tolerancia", "al", "tratamiento", "y", "desea", "continuar", "con", "el", "mismo", ".", "En", "última", "reevaluación", "(", "abril/2015", ")", "mantiene", "el", "beneficio", "clínico", ",", "bioquímico", "y", "respuesta", "radiológica", "." ]
[ "MORFOLOGIA_NEOPLASIA" ]
atopic dermatitis - like skin lesions is a DISEASE, Atopic dermatitis is a DISEASE, AD is a DISEASE, chronic inflammatory skin disease is a DISEASE, skin inflammation is a DISEASE, AD - like skin lesions is a DISEASE, AD - like skin lesions is a DISEASE, ear swelling is a DISEASE, skin inflammation is a DISEASE, AD is a DISEASE, inflammatory skin diseases is a DISEASE
example-207_task0
Sentence: Inhibition of atopic dermatitis-like skin lesions by topical application of a novel ceramide derivative, K6PC-9p, in NC/Nga mice. Atopic dermatitis (AD) is a chronic inflammatory skin disease that commonly begins in childhood. K6PC-9p (N-(Ethyl dihydrogenphosphate)-2-hexyl-3-oxo-decanamide) is a synthetic ceramide derivative of PC-9S (N-Ethanol-2-mirystyl-3-oxo-staramide), which was known to be effective in atopic patients. In this study, we examined the effect of topical application of K6PC-9p on skin inflammation and AD-like skin lesions in mouse models. K6PC-9p dose-dependently inhibited phorbol ester-induced increase in ear thickness in BALB/c mice. Moreover, topical application of K6PC-9p suppressed dust mite extract-induced AD-like skin lesions in NC/Nga mice. Histopathological analysis revealed that both ear swelling and leucocyte infiltration were suppressed by K6PC-9p treatment. K6PC-9p also suppressed IL-4 and TNF-alpha expression in the ears and mast cell infiltration into the ears in NC/Nga mice. Further study demonstrated that K6PC-9p inhibited ConA-induced IL-4 secretion and LPS-induced macrophage activation. Taken together, our results showed that topical application of K6PC-9p exerts beneficial effects in animal model of skin inflammation and AD, suggesting that K6PC-9p might be a promising topical agent for the treatment of inflammatory skin diseases. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: DISEASE
[ "O", "O", "B-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "I-DISEASE", "O", "B-DISEASE", "O", "O", "O", "B-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "I-DISEASE", "O", "B-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "I-DISEASE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "I-DISEASE", "O", "B-DISEASE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "I-DISEASE", "I-DISEASE", "O" ]
Inhibition of atopic dermatitis-like skin lesions by topical application of a novel ceramide derivative, K6PC-9p, in NC/Nga mice. Atopic dermatitis (AD) is a chronic inflammatory skin disease that commonly begins in childhood. K6PC-9p (N-(Ethyl dihydrogenphosphate)-2-hexyl-3-oxo-decanamide) is a synthetic ceramide derivative of PC-9S (N-Ethanol-2-mirystyl-3-oxo-staramide), which was known to be effective in atopic patients. In this study, we examined the effect of topical application of K6PC-9p on skin inflammation and AD-like skin lesions in mouse models. K6PC-9p dose-dependently inhibited phorbol ester-induced increase in ear thickness in BALB/c mice. Moreover, topical application of K6PC-9p suppressed dust mite extract-induced AD-like skin lesions in NC/Nga mice. Histopathological analysis revealed that both ear swelling and leucocyte infiltration were suppressed by K6PC-9p treatment. K6PC-9p also suppressed IL-4 and TNF-alpha expression in the ears and mast cell infiltration into the ears in NC/Nga mice. Further study demonstrated that K6PC-9p inhibited ConA-induced IL-4 secretion and LPS-induced macrophage activation. Taken together, our results showed that topical application of K6PC-9p exerts beneficial effects in animal model of skin inflammation and AD, suggesting that K6PC-9p might be a promising topical agent for the treatment of inflammatory skin diseases.
[ "Inhibition", "of", "atopic", "dermatitis", "-", "like", "skin", "lesions", "by", "topical", "application", "of", "a", "novel", "ceramide", "derivative", ",", "K6PC-9p", ",", "in", "NC", "/", "Nga", "mice", ".", " ", "Atopic", "dermatitis", "(", "AD", ")", "is", "a", "chronic", "inflammatory", "skin", "disease", "that", "commonly", "begins", "in", "childhood", ".", "K6PC-9p", "(", "N-(Ethyl", "dihydrogenphosphate)-2-hexyl-3-oxo", "-", "decanamide", ")", "is", "a", "synthetic", "ceramide", "derivative", "of", "PC-9S", "(", "N", "-", "Ethanol-2-mirystyl-3-oxo", "-", "staramide", ")", ",", "which", "was", "known", "to", "be", "effective", "in", "atopic", "patients", ".", "In", "this", "study", ",", "we", "examined", "the", "effect", "of", "topical", "application", "of", "K6PC-9p", "on", "skin", "inflammation", "and", "AD", "-", "like", "skin", "lesions", "in", "mouse", "models", ".", "K6PC-9p", "dose", "-", "dependently", "inhibited", "phorbol", "ester", "-", "induced", "increase", "in", "ear", "thickness", "in", "BALB", "/", "c", "mice", ".", "Moreover", ",", "topical", "application", "of", "K6PC-9p", "suppressed", "dust", "mite", "extract", "-", "induced", "AD", "-", "like", "skin", "lesions", "in", "NC", "/", "Nga", "mice", ".", "Histopathological", "analysis", "revealed", "that", "both", "ear", "swelling", "and", "leucocyte", "infiltration", "were", "suppressed", "by", "K6PC-9p", "treatment", ".", "K6PC-9p", "also", "suppressed", "IL-4", "and", "TNF", "-", "alpha", "expression", "in", "the", "ears", "and", "mast", "cell", "infiltration", "into", "the", "ears", "in", "NC", "/", "Nga", "mice", ".", "Further", "study", "demonstrated", "that", "K6PC-9p", "inhibited", "ConA", "-", "induced", "IL-4", "secretion", "and", "LPS", "-", "induced", "macrophage", "activation", ".", "Taken", "together", ",", "our", "results", "showed", "that", "topical", "application", "of", "K6PC-9p", "exerts", "beneficial", "effects", "in", "animal", "model", "of", "skin", "inflammation", "and", "AD", ",", "suggesting", "that", "K6PC-9p", "might", "be", "a", "promising", "topical", "agent", "for", "the", "treatment", "of", "inflammatory", "skin", "diseases", "." ]
[ "DISEASE" ]